_MEMBER_MyList,_LogP_MyList,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,-3.1,GO:0007051,spindle organization,M1,1,0
1,-2.9,M14728,BROWNE HCMV INFECTION 6HR UP,M1,1,0
1,-6.6,M18299,YANG BREAST CANCER ESR1 UP,M1,1,0
1,-7.6,WP3584,MECP2 and associated Rett syndrome,M1,1,0
1,-2.3,WP4324,Mitochondrial complex I assembly model OXPHOS system,M1,1,0
1,-2.1,GO:0072210,metanephric nephron development,M1,1,0
1,-3.1,M9700,GSE44732 UNSTIM VS IL27 STIM IMATURE DC DN,M1,1,0
1,-13,GO:0010948,negative regulation of cell cycle process,M1,1,0
1,-5.2,M3835,BENPORATH SOX2 TARGETS,M1,1,0
1,-5,GO:0007611,learning or memory,M1,1,0
1,-29,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M1,1,0
1,-2,M2226,PILON KLF1 TARGETS UP,M1,1,0
1,-3,M9848,GSE46606 IRF4HIGH VS WT CD40L IL2 IL5 DAY1 STIMULATED BCELL DN,M1,1,0
1,-23,hsa01524,Platinum drug resistance,M1,1,0
1,-5.2,R-HSA-6781827,Transcription-Coupled Nucleotide Excision Repair (TC-NER),M1,1,0
1,-3.1,M2715,SNF5 DN.V1 DN,M1,1,0
1,-3,GO:0032757,positive regulation of interleukin-8 production,M1,1,0
1,-2.6,M34027,BLANCO MELO BRONCHIAL EPITHELIAL CELLS INFLUENZA A DEL NS1 INFECTION DN,M1,1,0
1,-4,M828,MASSARWEH TAMOXIFEN RESISTANCE DN,M1,1,0
1,-4.8,GO:0017111,ribonucleoside triphosphate phosphatase activity,M1,1,0
1,-5.1,GO:0033148,positive regulation of intracellular estrogen receptor signaling pathway,M1,1,0
1,-3.6,GO:0006164,purine nucleotide biosynthetic process,M1,1,0
1,-2.3,M19695,FLECHNER BIOPSY KIDNEY TRANSPLANT REJECTED VS OK UP,M1,1,0
1,-2.6,GO:0010837,regulation of keratinocyte proliferation,M1,1,0
1,-12,hsa04915,Estrogen signaling pathway,M1,1,0
1,-13,M231,PID KIT PATHWAY,M1,1,0
1,-6.5,GO:0072657,protein localization to membrane,M1,1,0
1,-3.8,M12224,MARTINEZ RB1 TARGETS UP,M1,1,0
1,-2.9,GO:0021510,spinal cord development,M1,1,0
1,-2.6,GO:0045540,regulation of cholesterol biosynthetic process,M1,1,0
1,-2.5,M19744,GRAHAM CML QUIESCENT VS CML DIVIDING UP,M1,1,0
1,-2.2,GO:0098586,cellular response to virus,M1,1,0
1,-2.4,M2468,KRIEG KDM3A TARGETS NOT HYPOXIA,M1,1,0
1,-2.5,M3982,GSE17721 LPS VS CPG 0.5H BMDC UP,M1,1,0
1,-3,M4133,GSE17721 12H VS 24H CPG BMDC DN,M1,1,0
1,-3.1,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M1,1,0
1,-16,WP4630,Measles virus infection,M1,1,0
1,-9.4,GO:0006366,transcription by RNA polymerase II,M1,1,0
1,-3.6,GO:0040013,negative regulation of locomotion,M1,1,0
1,-3.1,M3299,GSE13485 DAY1 VS DAY21 YF17D VACCINE PBMC DN,M1,1,0
1,-5.4,GO:0006140,regulation of nucleotide metabolic process,M1,1,0
1,-2.4,M3508,GSE14769 UNSTIM VS 240MIN LPS BMDM DN,M1,1,0
1,-5.8,GO:2001239,regulation of extrinsic apoptotic signaling pathway in absence of ligand,M1,1,0
1,-3.2,WP2363,Gastric cancer network 2,M1,1,0
1,-2.4,M3431,GSE1448 ANTI VALPHA2 VS VBETA5 DP THYMOCYTE UP,M1,1,0
1,-3,M3481,GSE1460 CORD VS ADULT BLOOD NAIVE CD4 TCELL DN,M1,1,0
1,-3.6,M3238,SMID BREAST CANCER RELAPSE IN BONE UP,M1,1,0
1,-2.3,M2586,SMIRNOV RESPONSE TO IR 2HR DN,M1,1,0
1,-3,R-HSA-9671793,Diseases of hemostasis,M1,1,0
1,-2.3,hsa04392,Hippo signaling pathway - multiple species,M1,1,0
1,-4.4,M5837,GSE9650 EFFECTOR VS MEMORY CD8 TCELL DN,M1,1,0
1,-2.1,GO:0002889,regulation of immunoglobulin mediated immune response,M1,1,0
1,-3.3,M6857,GSE7768 OVA ALONE VS OVA WITH MPL IMMUNIZED MOUSE WHOLE SPLEEN 6H UP,M1,1,0
1,-4.7,R-HSA-9682385,FLT3 signaling in disease,M1,1,0
1,-6.4,GO:0010631,epithelial cell migration,M1,1,0
1,-3.6,GO:0005272,sodium channel activity,M1,1,0
1,-11,M40,PID E2F PATHWAY,M1,1,0
1,-2.3,GO:0060037,pharyngeal system development,M1,1,0
1,-5.4,WP3617,Photodynamic therapy-induced NF-kB survival signaling,M1,1,0
1,-2.1,GO:0006354,DNA-templated transcription elongation,M1,1,0
1,-35,hsa05212,Pancreatic cancer,M1,1,0
1,-5.8,M9576,GSE42021 TREG PLN VS CD24INT TREG THYMUS DN,M1,1,0
1,-5.8,M9598,GSE42021 TCONV PLN VS CD24HI TCONV THYMUS UP,M1,1,0
1,-2.9,GO:0046982,protein heterodimerization activity,M1,1,0
1,-13,GO:0019902,phosphatase binding,M1,1,0
1,-11,M84,PID ATM PATHWAY,M1,1,0
1,-8.2,M5547,LU AGING BRAIN UP,M1,1,0
1,-2.1,GO:0101002,ficolin-1-rich granule,M1,1,0
1,-3.7,M3770,GSE17721 CTRL VS CPG 12H BMDC DN,M1,1,0
1,-4,GO:0038134,ERBB2-EGFR signaling pathway,M1,1,0
1,-2.6,M1981,ONO FOXP3 TARGETS UP,M1,1,0
1,-2.6,GO:2000573,positive regulation of DNA biosynthetic process,M1,1,0
1,-2.3,GO:0071320,cellular response to cAMP,M1,1,0
1,-5.3,GO:0060525,prostate glandular acinus development,M1,1,0
1,-9.7,M58,PID AR PATHWAY,M1,1,0
1,-2,GO:0042401,cellular biogenic amine biosynthetic process,M1,1,0
1,-8,GO:0048511,rhythmic process,M1,1,0
1,-9.3,GO:0050767,regulation of neurogenesis,M1,1,0
1,-4.3,GO:0140296,general transcription initiation factor binding,M1,1,0
1,-2.7,GO:0006356,regulation of transcription by RNA polymerase I,M1,1,0
1,-2.4,M3818,GSE17721 LPS VS POLYIC 16H BMDC UP,M1,1,0
1,-2.4,GO:0051496,positive regulation of stress fiber assembly,M1,1,0
1,-2.8,M7775,EHLERS ANEUPLOIDY UP,M1,1,0
1,-4.2,R-HSA-187687,Signalling to ERKs,M1,1,0
1,-2.8,GO:0045740,positive regulation of DNA replication,M1,1,0
1,-2.7,R-HSA-6807070,PTEN Regulation,M1,1,0
1,-6.4,GO:0060149,negative regulation of post-transcriptional gene silencing,M1,1,0
1,-4.7,GO:0005902,microvillus,M1,1,0
1,-11,R-HSA-9634638,Estrogen-dependent nuclear events downstream of ESR-membrane signaling,M1,1,0
1,-5.1,M4131,GSE17721 4 VS 24H CPG BMDC DN,M1,1,0
1,-2.1,M16774,WILCOX RESPONSE TO PROGESTERONE DN,M1,1,0
1,-3,M8318,GSE28726 NAIVE VS ACTIVATED NKTCELL UP,M1,1,0
1,-3.7,M3594,GSE15930 NAIVE VS 24H IN VITRO STIM INFAB CD8 TCELL DN,M1,1,0
1,-8.6,GO:0021987,cerebral cortex development,M1,1,0
1,-3.7,R-HSA-110056,MAPK3 (ERK1) activation,M1,1,0
1,-6.1,GO:0031983,vesicle lumen,M1,1,0
1,-3.7,GO:0000012,single strand break repair,M1,1,0
1,-2.9,GO:0001750,photoreceptor outer segment,M1,1,0
1,-7.8,GO:0051090,regulation of DNA-binding transcription factor activity,M1,1,0
1,-3.1,M8408,GSE29949 CD8 POS DC SPLEEN VS DC BRAIN DN,M1,1,0
1,-4.3,GO:0098562,cytoplasmic side of membrane,M1,1,0
1,-11,GO:0006625,protein targeting to peroxisome,M1,1,0
1,-2.6,GO:0002053,positive regulation of mesenchymal cell proliferation,M1,1,0
1,-2.5,M6211,GSE2405 0H VS 1.5H A PHAGOCYTOPHILUM STIM NEUTROPHIL DN,M1,1,0
1,-12,M15,PID LYSOPHOSPHOLIPID PATHWAY,M1,1,0
1,-10,GO:0007596,blood coagulation,M1,1,0
1,-3.8,GO:0044283,small molecule biosynthetic process,M1,1,0
1,-4.2,GO:2001242,regulation of intrinsic apoptotic signaling pathway,M1,1,0
1,-2.7,GO:1904037,positive regulation of epithelial cell apoptotic process,M1,1,0
1,-8.1,GO:1902532,negative regulation of intracellular signal transduction,M1,1,0
1,-2.6,M4479,TURASHVILI BREAST DUCTAL CARCINOMA VS LOBULAR NORMAL UP,M1,1,0
1,-4.7,GO:0086019,cell-cell signaling involved in cardiac conduction,M1,1,0
1,-6.4,GO:0030036,actin cytoskeleton organization,M1,1,0
1,-2.7,M2428,WELCSH BRCA1 TARGETS DN,M1,1,0
1,-12,M145,PID P53 DOWNSTREAM PATHWAY,M1,1,0
1,-2.1,GO:0006984,ER-nucleus signaling pathway,M1,1,0
1,-6.4,GO:0098659,inorganic cation import across plasma membrane,M1,1,0
1,-4.2,M854,LINDGREN BLADDER CANCER CLUSTER 3 UP,M1,1,0
1,-6.1,R-HSA-5576893,Phase 2 - plateau phase,M1,1,0
1,-3.2,R-HSA-9027284,Erythropoietin activates RAS,M1,1,0
1,-3.7,M19927,TOYOTA TARGETS OF MIR34B AND MIR34C,M1,1,0
1,-8.5,R-HSA-9671555,Signaling by PDGFR in disease,M1,1,0
1,-11,M1,PID FANCONI PATHWAY,M1,1,0
1,-2.6,GO:0048259,regulation of receptor-mediated endocytosis,M1,1,0
1,-25,R-HSA-1257604,PIP3 activates AKT signaling,M1,1,0
1,-3,M6207,GSE2405 S AUREUS VS A PHAGOCYTOPHILUM NEUTROPHIL UP,M1,1,0
1,-3,GO:0016307,phosphatidylinositol phosphate kinase activity,M1,1,0
1,-3,M6417,GSE8921 UNSTIM VS TLR1 2 STIM MONOCYTE 6H DN,M1,1,0
1,-3.1,R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,M1,1,0
1,-3.2,GO:2000181,negative regulation of blood vessel morphogenesis,M1,1,0
1,-2.4,M3676,GSE17580 UNINFECTED VS S MANSONI INF TEFF DN,M1,1,0
1,-3.3,GO:0001676,long-chain fatty acid metabolic process,M1,1,0
1,-5.4,GO:0060205,cytoplasmic vesicle lumen,M1,1,0
1,-6.5,GO:0010960,magnesium ion homeostasis,M1,1,0
1,-23,hsa05213,Endometrial cancer,M1,1,0
1,-2.2,M2248,BRUINS UVC RESPONSE EARLY LATE,M1,1,0
1,-9.5,R-HSA-69481,G2/M Checkpoints,M1,1,0
1,-2.5,R-HSA-9020702,Interleukin-1 signaling,M1,1,0
1,-2.4,GO:0007204,positive regulation of cytosolic calcium ion concentration,M1,1,0
1,-19,hsa05160,Hepatitis C,M1,1,0
1,-8.3,GO:0016558,protein import into peroxisome matrix,M1,1,0
1,-3.1,M4228,GSE17974 IL4 AND ANTI IL12 VS UNTREATED 48H ACT CD4 TCELL UP,M1,1,0
1,-4,GO:2000146,negative regulation of cell motility,M1,1,0
1,-3,GO:0090218,positive regulation of lipid kinase activity,M1,1,0
1,-7.5,GO:0060170,ciliary membrane,M1,1,0
1,-21,GO:0040007,growth,M1,1,0
1,-5.1,M3207,GSE13229 IMM VS MATURE NKCELL DN,M1,1,0
1,-3.2,CORUM:713,BRG1-SIN3A complex,M1,1,0
1,-2.8,WP1545,miRNAs involved in DNA damage response,M1,1,0
1,-6,GO:0008083,growth factor activity,M1,1,0
1,-3.7,M7222,GSE19198 CTRL VS IL21 TREATED TCELL 1H DN,M1,1,0
1,-2.8,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M1,1,0
1,-4.7,GO:0001945,lymph vessel development,M1,1,0
1,-4.9,GO:0030425,dendrite,M1,1,0
1,-5.4,GO:2000677,regulation of transcription regulatory region DNA binding,M1,1,0
1,-2.4,M1604,JACKSON DNMT1 TARGETS UP,M1,1,0
1,-3.3,M286,PID TGFBR PATHWAY,M1,1,0
1,-5.6,GO:0060966,regulation of gene silencing by RNA,M1,1,0
1,-4.2,GO:0021782,glial cell development,M1,1,0
1,-2.8,GO:0050803,regulation of synapse structure or activity,M1,1,0
1,-3.2,GO:0051302,regulation of cell division,M1,1,0
1,-9.5,GO:0003712,transcription coregulator activity,M1,1,0
1,-21,GO:1901652,response to peptide,M1,1,0
1,-2.9,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M1,1,0
1,-11,M2879,BLUM RESPONSE TO SALIRASIB DN,M1,1,0
1,-2.5,M5222,GSE360 HIGH VS LOW DOSE B MALAYI DC UP,M1,1,0
1,-4.8,CORUM:1004,RC complex during S-phase of cell cycle,M1,1,0
1,-4.6,GO:0055021,regulation of cardiac muscle tissue growth,M1,1,0
1,-6.4,hsa04750,Inflammatory mediator regulation of TRP channels,M1,1,0
1,-11,M1718,SIG IL4RECEPTOR IN B LYPHOCYTES,M1,1,0
1,-3,M6619,GSE5589 LPS VS LPS AND IL10 STIM IL6 KO MACROPHAGE 45MIN DN,M1,1,0
1,-5.1,CORUM:2787,BRCA1 C complex,M1,1,0
1,-4.3,GO:0010565,regulation of cellular ketone metabolic process,M1,1,0
1,-7,GO:0032787,monocarboxylic acid metabolic process,M1,1,0
1,-7.7,R-HSA-5655302,Signaling by FGFR1 in disease,M1,1,0
1,-10,GO:0048753,pigment granule organization,M1,1,0
1,-2.2,M4306,ONDER CDH1 TARGETS 2 DN,M1,1,0
1,-3.4,GO:1904019,epithelial cell apoptotic process,M1,1,0
1,-7,WP2112,IL-17 signaling pathway,M1,1,0
1,-2.5,GO:0004529,exodeoxyribonuclease activity,M1,1,0
1,-2.5,M8111,GSE19941 UNSTIM VS LPS STIM IL10 KO NFKBP50 KO MACROPHAGE DN,M1,1,0
1,-5.6,M4960,SMID BREAST CANCER BASAL DN,M1,1,0
1,-4.6,GO:1900542,regulation of purine nucleotide metabolic process,M1,1,0
1,-2.4,GO:0060038,cardiac muscle cell proliferation,M1,1,0
1,-5.6,M1373,GOTZMANN EPITHELIAL TO MESENCHYMAL TRANSITION UP,M1,1,0
1,-2.1,GO:0070542,response to fatty acid,M1,1,0
1,-5.4,GO:0002688,regulation of leukocyte chemotaxis,M1,1,0
1,-4.3,GO:1903532,positive regulation of secretion by cell,M1,1,0
1,-5.1,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M1,1,0
1,-3.4,R-HSA-9664420,Killing mechanisms,M1,1,0
1,-3.3,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M1,1,0
1,-2.4,M7981,GSE25088 IL4 VS IL4 AND ROSIGLITAZONE STIM MACROPHAGE DAY10 UP,M1,1,0
1,-3.8,CORUM:1237,BAF complex,M1,1,0
1,-2.6,R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,M1,1,0
1,-3.2,GO:0032940,secretion by cell,M1,1,0
1,-3.8,WP4864,Host-pathogen interaction of human coronaviruses - apoptosis,M1,1,0
1,-7.5,R-HSA-5576890,Phase 3 - rapid repolarisation,M1,1,0
1,-2.3,M8520,SHEDDEN LUNG CANCER POOR SURVIVAL A6,M1,1,0
1,-9.1,WP3935,Leptin-insulin signaling overlap,M1,1,0
1,-24,GO:0008134,transcription factor binding,M1,1,0
1,-5.5,GO:0009206,purine ribonucleoside triphosphate biosynthetic process,M1,1,0
1,-3.8,GO:1904375,regulation of protein localization to cell periphery,M1,1,0
1,-2.1,M11028,ROVERSI GLIOMA COPY NUMBER UP,M1,1,0
1,-2.9,GO:0032042,mitochondrial DNA metabolic process,M1,1,0
1,-5.3,GO:0022804,active transmembrane transporter activity,M1,1,0
1,-3.5,M6189,ELVIDGE HIF1A AND HIF2A TARGETS DN,M1,1,0
1,-2.4,GO:0032816,positive regulation of natural killer cell activation,M1,1,0
1,-2.2,M4572,LOCKWOOD AMPLIFIED IN LUNG CANCER,M1,1,0
1,-4.8,M1117,CAIRO PML TARGETS BOUND BY MYC DN,M1,1,0
1,-7,R-HSA-9614085,FOXO-mediated transcription,M1,1,0
1,-3.7,M9749,GSE43863 TFH VS LY6C INT CXCR5POS EFFECTOR CD4 TCELL DN,M1,1,0
1,-4.8,GO:0001709,cell fate determination,M1,1,0
1,-3.1,WP1601,Fluoropyrimidine activity,M1,1,0
1,-3.3,M6364,HEIDENBLAD AMPLIFIED IN SOFT TISSUE CANCER,M1,1,0
1,-5,GO:0019898,extrinsic component of membrane,M1,1,0
1,-2.4,GO:0030507,spectrin binding,M1,1,0
1,-3,M4865,GSE27786 NKTCELL VS ERYTHROBLAST UP,M1,1,0
1,-5,GO:0022037,metencephalon development,M1,1,0
1,-4.2,M2461,DELACROIX RARG BOUND MEF,M1,1,0
1,-6.1,GO:0098857,membrane microdomain,M1,1,0
1,-2.4,M9793,GSE42724 NAIVE VS MEMORY BCELL DN,M1,1,0
1,-2.4,M3861,GSE17721 PAM3CSK4 VS CPG 4H BMDC DN,M1,1,0
1,-2.4,GO:0030159,signaling receptor complex adaptor activity,M1,1,0
1,-2.4,M9609,GSE42021 CD24LO TREG VS CD24LO TCONV THYMUS DN,M1,1,0
1,-2.4,GO:0035188,hatching,M1,1,0
1,-3.3,M19391,LIU PROSTATE CANCER DN,M1,1,0
1,-2.4,GO:0010970,transport along microtubule,M1,1,0
1,-3.7,M2635,ERBB2 UP.V1 DN,M1,1,0
1,-2.4,M6542,GSE5542 IFNG VS IFNA TREATED EPITHELIAL CELLS 6H UP,M1,1,0
1,-5,R-HSA-9027276,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),M1,1,0
1,-6.7,M16718,DING LUNG CANCER MUTATED FREQUENTLY,M1,1,0
1,-4.1,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,M1,1,0
1,-16,hsa04620,Toll-like receptor signaling pathway,M1,1,0
1,-2.4,GO:0089717,spanning component of membrane,M1,1,0
1,-8.2,WP2848,Pluripotent stem cell differentiation pathway,M1,1,0
1,-4.5,GO:0045725,positive regulation of glycogen biosynthetic process,M1,1,0
1,-13,WP4803,Ciliopathies,M1,1,0
1,-5,M6816,GSE7509 UNSTIM VS IFNA STIM IMMATURE DC DN,M1,1,0
1,-7.1,WP3878,ATM signaling in development and disease,M1,1,0
1,-4,R-HSA-8876384,Listeria monocytogenes entry into host cells,M1,1,0
1,-2.7,M4621,ROSS AML OF FAB M7 TYPE,M1,1,0
1,-3.9,R-HSA-445144,Signal transduction by L1,M1,1,0
1,-5,GO:0021954,central nervous system neuron development,M1,1,0
1,-7.6,hsa04350,TGF-beta signaling pathway,M1,1,0
1,-3.2,GO:0043552,positive regulation of phosphatidylinositol 3-kinase activity,M1,1,0
1,-3.5,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,M1,1,0
1,-2.1,R-HSA-1839126,FGFR2 mutant receptor activation,M1,1,0
1,-5.8,M234,PID IL2 STAT5 PATHWAY,M1,1,0
1,-4.7,GO:0033598,mammary gland epithelial cell proliferation,M1,1,0
1,-13,R-HSA-9675108,Nervous system development,M1,1,0
1,-3.3,M66,PID MYC ACTIV PATHWAY,M1,1,0
1,-4.8,GO:0007088,regulation of mitotic nuclear division,M1,1,0
1,-2.4,M3682,FLECHNER PBL KIDNEY TRANSPLANT REJECTED VS OK DN,M1,1,0
1,-3,M6646,GSE5589 WT VS IL6 KO LPS AND IL6 STIM MACROPHAGE 45MIN DN,M1,1,0
1,-2.1,GO:0002269,leukocyte activation involved in inflammatory response,M1,1,0
1,-2.3,GO:0060079,excitatory postsynaptic potential,M1,1,0
1,-13,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M1,1,0
1,-3,M9610,GSE42021 TREG PLN VS CD24HI TREG THYMUS UP,M1,1,0
1,-4,R-HSA-167044,Signalling to RAS,M1,1,0
1,-2.2,GO:0000323,lytic vacuole,M1,1,0
1,-3,GO:0072521,purine-containing compound metabolic process,M1,1,0
1,-3.9,GO:0070316,regulation of G0 to G1 transition,M1,1,0
1,-4,R-HSA-164944,Nef and signal transduction,M1,1,0
1,-3.8,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M1,1,0
1,-8.6,GO:0031960,response to corticosteroid,M1,1,0
1,-20,hsa04660,T cell receptor signaling pathway,M1,1,0
1,-3.7,M3907,GSE17721 LPS VS PAM3CSK4 0.5H BMDC DN,M1,1,0
1,-6.3,GO:0032204,regulation of telomere maintenance,M1,1,0
1,-3.8,GO:0072311,glomerular epithelial cell differentiation,M1,1,0
1,-19,hsa04935,"Growth hormone synthesis, secretion and action",M1,1,0
1,-2.2,M447,GSE12963 UNINF VS ENV AND NEF AND VPR DEFICIENT HIV1 INF CD4 TCELL UP,M1,1,0
1,-28,hsa01521,EGFR tyrosine kinase inhibitor resistance,M1,1,0
1,-3.3,GO:0006163,purine nucleotide metabolic process,M1,1,0
1,-2.1,GO:1903846,positive regulation of cellular response to transforming growth factor beta stimulus,M1,1,0
1,-6.4,GO:0002200,somatic diversification of immune receptors,M1,1,0
1,-2.4,M7992,GSE25123 ROSIGLITAZONE VS IL4 AND ROSIGLITAZONE STIM PPARG KO MACROPHAGE DAY10 DN,M1,1,0
1,-3.8,GO:0009152,purine ribonucleotide biosynthetic process,M1,1,0
1,-6.7,GO:0048485,sympathetic nervous system development,M1,1,0
1,-4.1,R-HSA-5621481,C-type lectin receptors (CLRs),M1,1,0
1,-3,M4142,GSE17721 0.5H VS 8H GARDIQUIMOD BMDC DN,M1,1,0
1,-3.5,GO:0032732,positive regulation of interleukin-1 production,M1,1,0
1,-3.7,WP4963,p53 transcriptional gene network,M1,1,0
1,-4.5,GO:0019439,aromatic compound catabolic process,M1,1,0
1,-4.9,M11038,GEORGES CELL CYCLE MIR192 TARGETS,M1,1,0
1,-3.1,M5295,GSE36476 CTRL VS TSST ACT 16H MEMORY CD4 TCELL OLD UP,M1,1,0
1,-5.1,M1938,MEISSNER BRAIN HCP WITH H3K27ME3,M1,1,0
1,-9.1,GO:0035265,organ growth,M1,1,0
1,-4.4,GO:0051100,negative regulation of binding,M1,1,0
1,-3,GO:0016241,regulation of macroautophagy,M1,1,0
1,-2.9,R-HSA-5619102,SLC transporter disorders,M1,1,0
1,-2.7,GO:0001836,release of cytochrome c from mitochondria,M1,1,0
1,-6,M672,CHIN BREAST CANCER COPY NUMBER UP,M1,1,0
1,-2.5,M1638,ZAMORA NOS2 TARGETS DN,M1,1,0
1,-7.5,GO:0043536,positive regulation of blood vessel endothelial cell migration,M1,1,0
1,-3.9,GO:0072112,podocyte differentiation,M1,1,0
1,-9.6,GO:0006261,DNA-templated DNA replication,M1,1,0
1,-2.4,M5851,GSE9988 ANTI TREM1 VS CTRL TREATED MONOCYTES DN,M1,1,0
1,-2,M6748,GSE6259 FLT3L INDUCED 33D1 POS DC VS CD8 TCELL UP,M1,1,0
1,-3.5,GO:0046677,response to antibiotic,M1,1,0
1,-2.3,M15171,SASAKI ADULT T CELL LEUKEMIA,M1,1,0
1,-24,hsa04510,Focal adhesion,M1,1,0
1,-3.3,M10319,WALLACE PROSTATE CANCER RACE UP,M1,1,0
1,-3,GO:0032271,regulation of protein polymerization,M1,1,0
1,-17,hsa04960,Aldosterone-regulated sodium reabsorption,M1,1,0
1,-2.4,M1741,ZHENG BOUND BY FOXP3,M1,1,0
1,-17,WP304,Kit receptor signaling pathway,M1,1,0
1,-3.4,M15801,SCHLOSSER SERUM RESPONSE AUGMENTED BY MYC,M1,1,0
1,-2.4,GO:0030705,cytoskeleton-dependent intracellular transport,M1,1,0
1,-4.9,GO:0000280,nuclear division,M1,1,0
1,-2.5,GO:0019867,outer membrane,M1,1,0
1,-4.4,GO:0098794,postsynapse,M1,1,0
1,-4.4,GO:0043491,protein kinase B signaling,M1,1,0
1,-4.4,GO:0040018,positive regulation of multicellular organism growth,M1,1,0
1,-14,GO:0005667,transcription regulator complex,M1,1,0
1,-3,M2398,SERVITJA LIVER HNF1A TARGETS DN,M1,1,0
1,-7.1,M12,PID RHOA PATHWAY,M1,1,0
1,-5.2,GO:0071276,cellular response to cadmium ion,M1,1,0
1,-2.8,WP4707,Aspirin and miRNAs,M1,1,0
1,-5.5,GO:1903530,regulation of secretion by cell,M1,1,0
1,-2.2,hsa04730,Long-term depression,M1,1,0
1,-3,M7709,GSE22527 ANTI CD3 INVIVO VS UNTREATED MOUSE TREG DN,M1,1,0
1,-2.9,R-HSA-111465,Apoptotic cleavage of cellular proteins,M1,1,0
1,-14,GO:0050673,epithelial cell proliferation,M1,1,0
1,-2.7,M7061,CROMER METASTASIS UP,M1,1,0
1,-26,GO:0006974,cellular response to DNA damage stimulus,M1,1,0
1,-4.5,GO:0071902,positive regulation of protein serine/threonine kinase activity,M1,1,0
1,-5.2,GO:0051301,cell division,M1,1,0
1,-2.2,GO:0019058,viral life cycle,M1,1,0
1,-3.1,M1595,BARRIER CANCER RELAPSE NORMAL SAMPLE UP,M1,1,0
1,-2.4,M3734,GSE17721 CTRL VS PAM3CSK4 2H BMDC DN,M1,1,0
1,-14,hsa05221,Acute myeloid leukemia,M1,1,0
1,-2.7,GO:0023061,signal release,M1,1,0
1,-2.5,M7451,GSE21670 IL6 VS TGFB AND IL6 TREATED STAT3 KO CD4 TCELL DN,M1,1,0
1,-3.3,GO:0120034,positive regulation of plasma membrane bounded cell projection assembly,M1,1,0
1,-2.3,GO:0032420,stereocilium,M1,1,0
1,-11,WP244,Alpha 6 beta 4 signaling pathway,M1,1,0
1,-3.6,GO:0034332,adherens junction organization,M1,1,0
1,-2.6,GO:0001658,branching involved in ureteric bud morphogenesis,M1,1,0
1,-11,GO:0010332,response to gamma radiation,M1,1,0
1,-7.6,GO:2000628,regulation of miRNA metabolic process,M1,1,0
1,-2.4,M7473,GSE21670 IL6 VS TGFB AND IL6 TREATED CD4 TCELL DN,M1,1,0
1,-4,WP15,Selenium micronutrient network,M1,1,0
1,-12,GO:0051904,pigment granule transport,M1,1,0
1,-2.5,M7468,GSE21670 STAT3 KO VS WT CD4 TCELL UP,M1,1,0
1,-2.7,R-HSA-6803204,TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,M1,1,0
1,-2.7,R-HSA-1474228,Degradation of the extracellular matrix,M1,1,0
1,-3.5,GO:0009150,purine ribonucleotide metabolic process,M1,1,0
1,-7.8,GO:0021761,limbic system development,M1,1,0
1,-3,M9608,GSE42021 CD24LO TREG VS CD24LO TCONV THYMUS UP,M1,1,0
1,-3.8,GO:0048704,embryonic skeletal system morphogenesis,M1,1,0
1,-2.9,GO:1901387,positive regulation of voltage-gated calcium channel activity,M1,1,0
1,-3.7,WP2815,Mammary gland development pathway - Involution (Stage 4 of 4),M1,1,0
1,-4,hsa05340,Primary immunodeficiency,M1,1,0
1,-7.5,M5160,GSE360 CTRL VS L MAJOR MAC UP,M1,1,0
1,-16,WP2332,Interleukin-11 signaling pathway,M1,1,0
1,-2.4,M3633,GSE15930 STIM VS STIM AND IFNAB 48H CD8 T CELL UP,M1,1,0
1,-3.7,GO:0048703,embryonic viscerocranium morphogenesis,M1,1,0
1,-3.7,M8869,GSE37301 COMMON LYMPHOID PROGENITOR VS CD4 TCELL DN,M1,1,0
1,-10,R-HSA-9603798,Class I peroxisomal membrane protein import,M1,1,0
1,-2,M13453,DER IFN BETA RESPONSE UP,M1,1,0
1,-2.3,R-HSA-446728,Cell junction organization,M1,1,0
1,-5.1,R-HSA-1059683,Interleukin-6 signaling,M1,1,0
1,-10,WP2882,Nuclear receptors meta-pathway,M1,1,0
1,-3.1,R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,M1,1,0
1,-2.7,M11383,BROWNE HCMV INFECTION 16HR UP,M1,1,0
1,-3.6,GO:0010677,negative regulation of cellular carbohydrate metabolic process,M1,1,0
1,-5.6,R-HSA-202403,TCR signaling,M1,1,0
1,-9.2,R-HSA-5620920,Cargo trafficking to the periciliary membrane,M1,1,0
1,-12,GO:0030001,metal ion transport,M1,1,0
1,-15,M7,PID FCER1 PATHWAY,M1,1,0
1,-2.1,GO:1903050,regulation of proteolysis involved in protein catabolic process,M1,1,0
1,-2.4,M1804,WANG SMARCE1 TARGETS UP,M1,1,0
1,-6.3,GO:0007622,rhythmic behavior,M1,1,0
1,-2.3,M2395,SERVITJA ISLET HNF1A TARGETS UP,M1,1,0
1,-22,WP4396,Nonalcoholic fatty liver disease,M1,1,0
1,-2.7,GO:0098743,cell aggregation,M1,1,0
1,-4.3,M17572,SMID BREAST CANCER LUMINAL B DN,M1,1,0
1,-3.2,GO:0045820,negative regulation of glycolytic process,M1,1,0
1,-4,M15693,GENTILE UV RESPONSE CLUSTER D8,M1,1,0
1,-5.1,M16458,RIZ ERYTHROID DIFFERENTIATION,M1,1,0
1,-18,R-HSA-5693538,Homology Directed Repair,M1,1,0
1,-5,hsa04310,Wnt signaling pathway,M1,1,0
1,-2,hsa04720,Long-term potentiation,M1,1,0
1,-2.6,M14594,LASTOWSKA NEUROBLASTOMA COPY NUMBER DN,M1,1,0
1,-6,R-HSA-1295596,Spry regulation of FGF signaling,M1,1,0
1,-3.8,GO:0003170,heart valve development,M1,1,0
1,-3.8,GO:0030321,transepithelial chloride transport,M1,1,0
1,-3,M9165,GSE40274 GATA1 VS FOXP3 AND GATA1 TRANSDUCED ACTIVATED CD4 TCELL DN,M1,1,0
1,-8.3,WP185,Integrin-mediated cell adhesion,M1,1,0
1,-2.9,GO:0072376,protein activation cascade,M1,1,0
1,-10,WP2840,Hair follicle development: cytodifferentiation - part 3 of 3,M1,1,0
1,-2.9,GO:0002093,auditory receptor cell morphogenesis,M1,1,0
1,-3.8,GO:0030020,extracellular matrix structural constituent conferring tensile strength,M1,1,0
1,-2.2,M2397,SERVITJA LIVER HNF1A TARGETS UP,M1,1,0
1,-4.4,GO:1902751,positive regulation of cell cycle G2/M phase transition,M1,1,0
1,-9.7,GO:0046777,protein autophosphorylation,M1,1,0
1,-7.5,GO:0005943,"phosphatidylinositol 3-kinase complex, class IA",M1,1,0
1,-3.1,M6165,GSE1791 CTRL VS NEUROMEDINU IN T CELL LINE 0.8H UP,M1,1,0
1,-3.3,GO:0051155,positive regulation of striated muscle cell differentiation,M1,1,0
1,-2.2,R-HSA-5602358,Diseases associated with the TLR signaling cascade,M1,1,0
1,-3.2,GO:0035019,somatic stem cell population maintenance,M1,1,0
1,-2.2,GO:0030296,protein tyrosine kinase activator activity,M1,1,0
1,-6.4,GO:0002687,positive regulation of leukocyte migration,M1,1,0
1,-4.4,M8978,GSE37534 UNTREATED VS GW1929 TREATED CD4 TCELL PPARG1 AND FOXP3 TRASDUCED UP,M1,1,0
1,-4.5,GO:2000379,positive regulation of reactive oxygen species metabolic process,M1,1,0
1,-2.1,M15068,NOUZOVA TRETINOIN AND H4 ACETYLATION,M1,1,0
1,-2.4,M9437,GSE35543 IN VITRO ITREG VS CONVERTED EX ITREG UP,M1,1,0
1,-6.9,GO:1904062,regulation of cation transmembrane transport,M1,1,0
1,-2.1,GO:0090022,regulation of neutrophil chemotaxis,M1,1,0
1,-4.4,R-HSA-5626467,RHO GTPases activate IQGAPs,M1,1,0
1,-14,GO:0007610,behavior,M1,1,0
1,-2.1,GO:0090313,regulation of protein targeting to membrane,M1,1,0
1,-3.2,GO:0071564,npBAF complex,M1,1,0
1,-2.6,M2238,JOHNSTONE PARVB TARGETS 2 UP,M1,1,0
1,-9.9,GO:0042633,hair cycle,M1,1,0
1,-2.7,GO:0014823,response to activity,M1,1,0
1,-9.7,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M1,1,0
1,-2.1,GO:0050699,WW domain binding,M1,1,0
1,-2.8,GO:0031645,negative regulation of nervous system process,M1,1,0
1,-4.7,CORUM:6601,BBS1-BBS4-BBS5-PKD1-TTC8 complex,M1,1,0
1,-4.9,M254,PID MYC REPRESS PATHWAY,M1,1,0
1,-2.5,M5259,GSE360 T GONDII VS M TUBERCULOSIS MAC DN,M1,1,0
1,-24,WP2034,Leptin signaling pathway,M1,1,0
1,-5.6,GO:0044818,mitotic G2/M transition checkpoint,M1,1,0
1,-4.3,WP5088,Prostaglandin signaling,M1,1,0
1,-2.4,M7688,GSE22033 UNTREATED VS MRL24 TREATED MEF UP,M1,1,0
1,-36,hsa05215,Prostate cancer,M1,1,0
1,-2.6,GO:0015711,organic anion transport,M1,1,0
1,-5.5,M7404,FRIDMAN IMMORTALIZATION DN,M1,1,0
1,-4.7,R-HSA-8941856,RUNX3 regulates NOTCH signaling,M1,1,0
1,-8.3,M223,PID BETA CATENIN NUC PATHWAY,M1,1,0
1,-4,R-HSA-1474244,Extracellular matrix organization,M1,1,0
1,-7.7,R-HSA-9609507,Protein localization,M1,1,0
1,-3.9,M438,GSE12507 PDC CELL LINE VS IMMATUE T CELL LINE UP,M1,1,0
1,-4.4,GO:0045046,protein import into peroxisome membrane,M1,1,0
1,-5.7,GO:0048569,post-embryonic animal organ development,M1,1,0
1,-5.2,GO:0002253,activation of immune response,M1,1,0
1,-2.7,hsa05014,Amyotrophic lateral sclerosis,M1,1,0
1,-3,GO:0060841,venous blood vessel development,M1,1,0
1,-2.6,GO:0010888,negative regulation of lipid storage,M1,1,0
1,-4.2,GO:0016817,"hydrolase activity, acting on acid anhydrides",M1,1,0
1,-2,GO:0071346,cellular response to interferon-gamma,M1,1,0
1,-2.5,M8984,GSE37534 UNTREATED VS ROSIGLITAZONE TREATED CD4 TCELL PPARG1 AND FOXP3 TRASDUCED DN,M1,1,0
1,-8.5,WP179,Cell cycle,M1,1,0
1,-9.2,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M1,1,0
1,-6.2,GO:0045739,positive regulation of DNA repair,M1,1,0
1,-5,GO:0045599,negative regulation of fat cell differentiation,M1,1,0
1,-4,GO:0022904,respiratory electron transport chain,M1,1,0
1,-2.2,GO:0070160,tight junction,M1,1,0
1,-4.6,GO:0031641,regulation of myelination,M1,1,0
1,-3.5,WP4971,Phosphoinositides metabolism,M1,1,0
1,-6.5,GO:0045860,positive regulation of protein kinase activity,M1,1,0
1,-2.4,M4472,GSE22886 DC VS MONOCYTE DN,M1,1,0
1,-31,R-HSA-199418,Negative regulation of the PI3K/AKT network,M1,1,0
1,-2.9,R-HSA-6804114,TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,M1,1,0
1,-7,GO:0051321,meiotic cell cycle,M1,1,0
1,-2.1,GO:0050771,negative regulation of axonogenesis,M1,1,0
1,-4.5,M1421,PEART HDAC PROLIFERATION CLUSTER DN,M1,1,0
1,-3.3,GO:0030004,cellular monovalent inorganic cation homeostasis,M1,1,0
1,-3,GO:0010390,histone monoubiquitination,M1,1,0
1,-2.5,M8399,GSE29949 MICROGLIA VS DC BRAIN UP,M1,1,0
1,-2.7,GO:0002066,columnar/cuboidal epithelial cell development,M1,1,0
1,-5.1,GO:0046661,male sex differentiation,M1,1,0
1,-3.7,M9675,GSE43955 1H VS 10H ACT CD4 TCELL WITH TGFB IL6 DN,M1,1,0
1,-4.7,M69,PID REELIN PATHWAY,M1,1,0
1,-2.4,M7452,GSE21670 STAT3 KO VS WT CD4 TCELL TGFB IL6 TREATED UP,M1,1,0
1,-2.2,M12338,GERY CEBP TARGETS,M1,1,0
1,-5,GO:0033145,positive regulation of intracellular steroid hormone receptor signaling pathway,M1,1,0
1,-3.1,GO:0015081,sodium ion transmembrane transporter activity,M1,1,0
1,-2.1,GO:0045428,regulation of nitric oxide biosynthetic process,M1,1,0
1,-4.9,GO:0050136,NADH dehydrogenase (quinone) activity,M1,1,0
1,-5.8,R-HSA-9659787,Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects,M1,1,0
1,-25,hsa05210,Colorectal cancer,M1,1,0
1,-3.9,M103,PID S1P S1P1 PATHWAY,M1,1,0
1,-2.1,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M1,1,0
1,-3.3,WP3301,MFAP5-mediated ovarian cancer cell motility and invasiveness,M1,1,0
1,-5.6,GO:0035148,tube formation,M1,1,0
1,-2.3,M7371,LOPES METHYLATED IN COLON CANCER UP,M1,1,0
1,-4.1,GO:0051783,regulation of nuclear division,M1,1,0
1,-9.4,M22,PID GMCSF PATHWAY,M1,1,0
1,-3.7,GO:0038095,Fc-epsilon receptor signaling pathway,M1,1,0
1,-6.7,WP2059,Alzheimer's disease and miRNA effects,M1,1,0
1,-4.8,GO:0016050,vesicle organization,M1,1,0
1,-18,R-HSA-73894,DNA Repair,M1,1,0
1,-12,M161,PID IFNG PATHWAY,M1,1,0
1,-3,M3729,GSE17721 CTRL VS PAM3CSK4 0.5H BMDC DN,M1,1,0
1,-2.5,M8419,GSE29949 DC BRAIN VS MONOCYTE BONE MARROW DN,M1,1,0
1,-3.5,GO:0072015,podocyte development,M1,1,0
1,-7.5,GO:0009617,response to bacterium,M1,1,0
1,-4,GO:0043406,positive regulation of MAP kinase activity,M1,1,0
1,-2.4,M9686,GSE43955 10H VS 60H ACT CD4 TCELL WITH TGFB IL6 UP,M1,1,0
1,-4.2,GO:0016462,pyrophosphatase activity,M1,1,0
1,-6.5,GO:0099625,ventricular cardiac muscle cell membrane repolarization,M1,1,0
1,-2.6,M2613,ZWANG CLASS 3 TRANSIENTLY INDUCED BY EGF,M1,1,0
1,-16,hsa04662,B cell receptor signaling pathway,M1,1,0
1,-3.1,M9520,GSE41867 DAY6 VS DAY15 LCMV ARMSTRONG EFFECTOR CD8 TCELL UP,M1,1,0
1,-2.8,M19745,TARTE PLASMA CELL VS PLASMABLAST DN,M1,1,0
1,-2.3,GO:0045830,positive regulation of isotype switching,M1,1,0
1,-5.4,GO:0060041,retina development in camera-type eye,M1,1,0
1,-6,GO:0010906,regulation of glucose metabolic process,M1,1,0
1,-2.5,M3485,MONNIER POSTRADIATION TUMOR ESCAPE DN,M1,1,0
1,-3.8,GO:0098862,cluster of actin-based cell projections,M1,1,0
1,-2.3,GO:0031965,nuclear membrane,M1,1,0
1,-5.1,GO:0003205,cardiac chamber development,M1,1,0
1,-4.3,M3063,DEBIASI APOPTOSIS BY REOVIRUS INFECTION DN,M1,1,0
1,-2.4,M9625,GSE43957 UNTREATED VS NACL TREATED ANTI CD3 CD28 STIM CD4 TCELL DN,M1,1,0
1,-8.5,R-HSA-5693565,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,M1,1,0
1,-2.6,GO:0032526,response to retinoic acid,M1,1,0
1,-4.5,GO:0060560,developmental growth involved in morphogenesis,M1,1,0
1,-5.3,GO:0048705,skeletal system morphogenesis,M1,1,0
1,-2.7,M12459,CHIBA RESPONSE TO TSA DN,M1,1,0
1,-3.7,M9595,GSE42021 CD24HI VS CD24LOW TCONV THYMUS DN,M1,1,0
1,-4.5,R-HSA-9012852,Signaling by NOTCH3,M1,1,0
1,-2.4,M3822,GSE17721 POLYIC VS PAM3CSK4 0.5H BMDC UP,M1,1,0
1,-2.4,GO:0099172,presynapse organization,M1,1,0
1,-11,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M1,1,0
1,-9.1,R-HSA-9034015,Signaling by NTRK3 (TRKC),M1,1,0
1,-3.8,GO:0042776,proton motive force-driven mitochondrial ATP synthesis,M1,1,0
1,-4,GO:0071482,cellular response to light stimulus,M1,1,0
1,-3.7,GO:0060193,positive regulation of lipase activity,M1,1,0
1,-2.4,M6411,GSE8921 UNSTIM 0H VS TLR1 2 STIM MONOCYTE 24H DN,M1,1,0
1,-4.8,WP2881,Estrogen receptor pathway,M1,1,0
1,-3,GO:0050891,multicellular organismal water homeostasis,M1,1,0
1,-11,WP4657,22q11.2 copy number variation syndrome,M1,1,0
1,-4.6,GO:0005746,mitochondrial respirasome,M1,1,0
1,-5.8,M15351,SUZUKI AMPLIFIED IN ORAL CANCER,M1,1,0
1,-5.4,GO:0048730,epidermis morphogenesis,M1,1,0
1,-3.3,WP2406,Cardiac progenitor differentiation,M1,1,0
1,-3,GO:0030071,regulation of mitotic metaphase/anaphase transition,M1,1,0
1,-3.6,GO:0072010,glomerular epithelium development,M1,1,0
1,-3.3,GO:0010543,regulation of platelet activation,M1,1,0
1,-3.3,GO:0007283,spermatogenesis,M1,1,0
1,-5.1,GO:0051216,cartilage development,M1,1,0
1,-7.2,GO:0044819,mitotic G1/S transition checkpoint signaling,M1,1,0
1,-3,GO:0072330,monocarboxylic acid biosynthetic process,M1,1,0
1,-13,GO:0009416,response to light stimulus,M1,1,0
1,-2.5,M7520,GSE21546 WT VS ELK1 KO DP THYMOCYTES UP,M1,1,0
1,-3.6,GO:0008047,enzyme activator activity,M1,1,0
1,-5.7,WP4204,Tumor suppressor activity of SMARCB1,M1,1,0
1,-6.4,GO:0005925,focal adhesion,M1,1,0
1,-7,M236,PID DELTA NP63 PATHWAY,M1,1,0
1,-3.6,M14134,TURASHVILI BREAST DUCTAL CARCINOMA VS DUCTAL NORMAL DN,M1,1,0
1,-2.4,GO:0001704,formation of primary germ layer,M1,1,0
1,-2.3,R-HSA-9013409,RHOJ GTPase cycle,M1,1,0
1,-11,M279,PID RB 1PATHWAY,M1,1,0
1,-3.4,R-HSA-8866907,Activation of the TFAP2 (AP-2) family of transcription factors,M1,1,0
1,-4.8,R-HSA-179812,GRB2 events in EGFR signaling,M1,1,0
1,-15,hsa04211,Longevity regulating pathway,M1,1,0
1,-4.4,M3588,GSE15930 NAIVE VS 24H IN VITRO STIM CD8 TCELL DN,M1,1,0
1,-11,GO:0035315,hair cell differentiation,M1,1,0
1,-4.9,GO:0009142,nucleoside triphosphate biosynthetic process,M1,1,0
1,-2.4,M5129,GSE339 EX VIVO VS IN CULTURE CD4POS DC UP,M1,1,0
1,-21,hsa05214,Glioma,M1,1,0
1,-2.7,M19432,MCBRYAN PUBERTAL BREAST 4 5WK UP,M1,1,0
1,-3,M8979,GSE37534 UNTREATED VS GW1929 TREATED CD4 TCELL PPARG1 AND FOXP3 TRASDUCED DN,M1,1,0
1,-4.2,GO:0030235,nitric-oxide synthase regulator activity,M1,1,0
1,-5.3,GO:0044403,biological process involved in symbiotic interaction,M1,1,0
1,-2.9,GO:0019229,regulation of vasoconstriction,M1,1,0
1,-11,R-HSA-69620,Cell Cycle Checkpoints,M1,1,0
1,-4.9,WP3668,Hypothesized pathways in pathogenesis of cardiovascular disease,M1,1,0
1,-2.3,M15671,WALLACE PROSTATE CANCER RACE DN,M1,1,0
1,-8.2,GO:0048483,autonomic nervous system development,M1,1,0
1,-6.5,GO:0045598,regulation of fat cell differentiation,M1,1,0
1,-18,R-HSA-9701192,Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function,M1,1,0
1,-5.6,M275,PID ALPHA SYNUCLEIN PATHWAY,M1,1,0
1,-4.4,M14019,DING LUNG CANCER MUTATED RECURRENTLY,M1,1,0
1,-2.1,GO:0009648,photoperiodism,M1,1,0
1,-5.5,M8239,GSE27241 WT VS RORGT KO TH17 POLARIZED CD4 TCELL TREATED WITH DIGOXIN UP,M1,1,0
1,-4.7,R-HSA-350054,Notch-HLH transcription pathway,M1,1,0
1,-2.7,WP4961,STING pathway in Kawasaki-like disease and COVID-19,M1,1,0
1,-2.9,R-HSA-196299,Beta-catenin phosphorylation cascade,M1,1,0
1,-4.5,GO:0045271,respiratory chain complex I,M1,1,0
1,-3.8,WP4480,Altered glycosylation of MUC1 in tumor microenvironment,M1,1,0
1,-2,M16574,PACHER TARGETS OF IGF1 AND IGF2 UP,M1,1,0
1,-6.2,GO:0019887,protein kinase regulator activity,M1,1,0
1,-3.5,M41739,RIEGE DELTANP63 DIRECT TARGETS UP,M1,1,0
1,-3,M9178,GSE40277 GATA1 AND SATB1 TRANSDUCED VS CTRL CD4 TCELL DN,M1,1,0
1,-8.5,GO:0005777,peroxisome,M1,1,0
1,-3.4,GO:0090276,regulation of peptide hormone secretion,M1,1,0
1,-5.5,GO:0045926,negative regulation of growth,M1,1,0
1,-23,R-HSA-3700989,Transcriptional Regulation by TP53,M1,1,0
1,-10,GO:0045165,cell fate commitment,M1,1,0
1,-9.4,M4151,HINATA NFKB TARGETS FIBROBLAST UP,M1,1,0
1,-3.9,R-HSA-373760,L1CAM interactions,M1,1,0
1,-6.9,GO:0044344,cellular response to fibroblast growth factor stimulus,M1,1,0
1,-7.4,GO:0006813,potassium ion transport,M1,1,0
1,-2.9,GO:0016202,regulation of striated muscle tissue development,M1,1,0
1,-3.5,GO:0002286,T cell activation involved in immune response,M1,1,0
1,-8.4,M9372,KAUFFMANN DNA REPLICATION GENES,M1,1,0
1,-5.7,GO:0099094,ligand-gated cation channel activity,M1,1,0
1,-9.9,hsa05145,Toxoplasmosis,M1,1,0
1,-9,GO:0048565,digestive tract development,M1,1,0
1,-10,GO:0032402,melanosome transport,M1,1,0
1,-2.1,M433,GSE12484 HEALTHY VS PERIDONTITIS NEUTROPHILS UP,M1,1,0
1,-6.5,CORUM:2738,BLM complex II,M1,1,0
1,-9.1,GO:0098687,chromosomal region,M1,1,0
1,-3.9,GO:0030331,nuclear estrogen receptor binding,M1,1,0
1,-2.4,M11197,HSIAO HOUSEKEEPING GENES,M1,1,0
1,-2.3,GO:0090025,regulation of monocyte chemotaxis,M1,1,0
1,-3.1,hsa04217,Necroptosis,M1,1,0
1,-4.6,hsa04622,RIG-I-like receptor signaling pathway,M1,1,0
1,-3.5,GO:1902882,regulation of response to oxidative stress,M1,1,0
1,-3.8,GO:0043274,phospholipase binding,M1,1,0
1,-5.2,M6767,POOLA INVASIVE BREAST CANCER DN,M1,1,0
1,-6.6,M4389,RIZ ERYTHROID DIFFERENTIATION 12HR,M1,1,0
1,-4.1,R-HSA-1483257,Phospholipid metabolism,M1,1,0
1,-12,R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,M1,1,0
1,-4.9,GO:0036336,dendritic cell migration,M1,1,0
1,-3.4,M8655,DAIRKEE CANCER PRONE RESPONSE BPA,M1,1,0
1,-5.4,R-HSA-2559580,Oxidative Stress Induced Senescence,M1,1,0
1,-11,R-HSA-1227990,Signaling by ERBB2 in Cancer,M1,1,0
1,-2.1,GO:0035282,segmentation,M1,1,0
1,-2.2,R-HSA-110314,Recognition of DNA damage by PCNA-containing replication complex,M1,1,0
1,-3,M3943,GSE17721 POLYIC VS CPG 6H BMDC UP,M1,1,0
1,-4.3,GO:0000400,four-way junction DNA binding,M1,1,0
1,-3.3,GO:0032210,regulation of telomere maintenance via telomerase,M1,1,0
1,-5.1,GO:0032105,negative regulation of response to extracellular stimulus,M1,1,0
1,-3.7,M3895,GSE17721 CPG VS GARDIQUIMOD 12H BMDC DN,M1,1,0
1,-3.5,M17693,GARY CD5 TARGETS UP,M1,1,0
1,-2.7,GO:0007033,vacuole organization,M1,1,0
1,-2.4,M8203,GSE27092 WT VS HDAC7 PHOSPHO DEFICIENT CD8 TCELL UP,M1,1,0
1,-2.6,WP4942,15q13.3 copy number variation syndrome,M1,1,0
1,-3.1,R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,M1,1,0
1,-2.6,M1590,LEE AGING NEOCORTEX UP,M1,1,0
1,-2.1,GO:0010596,negative regulation of endothelial cell migration,M1,1,0
1,-2.7,GO:0031063,regulation of histone deacetylation,M1,1,0
1,-8.1,R-HSA-5654695,PI-3K cascade:FGFR2,M1,1,0
1,-2.4,GO:0030901,midbrain development,M1,1,0
1,-3.3,GO:0032651,regulation of interleukin-1 beta production,M1,1,0
1,-3.7,M3662,GSE16522 MEMORY VS NAIVE ANTI CD3CD28 STIM CD8 TCELL DN,M1,1,0
1,-2.5,M2317,KASLER HDAC7 TARGETS 1 UP,M1,1,0
1,-6.4,R-HSA-1655829,Regulation of cholesterol biosynthesis by SREBP (SREBF),M1,1,0
1,-4.2,GO:1901137,carbohydrate derivative biosynthetic process,M1,1,0
1,-5.7,GO:0048285,organelle fission,M1,1,0
1,-2.3,GO:0010559,regulation of glycoprotein biosynthetic process,M1,1,0
1,-2.6,R-HSA-8956321,Nucleotide salvage,M1,1,0
1,-8.5,GO:0098751,bone cell development,M1,1,0
1,-3,M6848,GSE7348 UNSTIM VS TOLERIZED AND LPS STIM MACROPHAGE DN,M1,1,0
1,-2.9,GO:0072078,nephron tubule morphogenesis,M1,1,0
1,-19,GO:0009410,response to xenobiotic stimulus,M1,1,0
1,-4.4,M6602,GSE5589 UNSTIM VS 45MIN LPS AND IL10 STIM MACROPHAGE UP,M1,1,0
1,-2.2,GO:0051048,negative regulation of secretion,M1,1,0
1,-16,GO:0001894,tissue homeostasis,M1,1,0
1,-3.1,GO:0050974,detection of mechanical stimulus involved in sensory perception,M1,1,0
1,-3,M3059,GSE10239 MEMORY VS KLRG1INT EFF CD8 TCELL DN,M1,1,0
1,-2.6,M9871,GSE46606 DAY1 VS DAY3 CD40L IL2 IL5 STIMULATED BCELL UP,M1,1,0
1,-2.7,WP5220,Metabolic reprogramming in pancreatic cancer,M1,1,0
1,-9.9,hsa04658,Th1 and Th2 cell differentiation,M1,1,0
1,-17,WP3888,VEGFA-VEGFR2 signaling pathway,M1,1,0
1,-3.6,GO:0032652,regulation of interleukin-1 production,M1,1,0
1,-2.4,R-HSA-180786,Extension of Telomeres,M1,1,0
1,-2.5,M14242,BYSTRYKH HEMATOPOIESIS STEM CELL AND BRAIN QTL TRANS,M1,1,0
1,-2.4,M14958,PRAMOONJAGO SOX4 TARGETS UP,M1,1,0
1,-7,GO:2001252,positive regulation of chromosome organization,M1,1,0
1,-9.7,GO:0042110,T cell activation,M1,1,0
1,-9.8,GO:0051960,regulation of nervous system development,M1,1,0
1,-4.7,GO:0002208,somatic diversification of immunoglobulins involved in immune response,M1,1,0
1,-19,GO:0150063,visual system development,M1,1,0
1,-5.4,GO:0061377,mammary gland lobule development,M1,1,0
1,-5.2,M1459,PETROVA ENDOTHELIUM LYMPHATIC VS BLOOD DN,M1,1,0
1,-19,M105,PID TELOMERASE PATHWAY,M1,1,0
1,-2.8,GO:0010950,positive regulation of endopeptidase activity,M1,1,0
1,-3,M4407,GSE22886 NAIVE CD8 TCELL VS MEMORY TCELL DN,M1,1,0
1,-3.9,hsa04540,Gap junction,M1,1,0
1,-2.6,M2895,MARKEY RB1 CHRONIC LOF UP,M1,1,0
1,-5.6,M6897,NATSUME RESPONSE TO INTERFERON BETA UP,M1,1,0
1,-2.7,GO:0031674,I band,M1,1,0
1,-27,hsa05161,Hepatitis B,M1,1,0
1,-4.4,GO:0098813,nuclear chromosome segregation,M1,1,0
1,-7.5,GO:1901615,organic hydroxy compound metabolic process,M1,1,0
1,-3.8,GO:0050804,modulation of chemical synaptic transmission,M1,1,0
1,-8.2,GO:0071900,regulation of protein serine/threonine kinase activity,M1,1,0
1,-2.4,M9321,GSE11961 MARGINAL ZONE BCELL VS GERMINAL CENTER BCELL DAY7 DN,M1,1,0
1,-2.6,WP4141,PI3K/AKT/mTOR - vitamin D3 signaling,M1,1,0
1,-10,R-HSA-400253,Circadian Clock,M1,1,0
1,-2.3,GO:0071624,positive regulation of granulocyte chemotaxis,M1,1,0
1,-3,R-HSA-9651496,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),M1,1,0
1,-4.2,R-HSA-112412,SOS-mediated signalling,M1,1,0
1,-3.7,M5292,GSE36476 CTRL VS TSST ACT 40H MEMORY CD4 TCELL YOUNG DN,M1,1,0
1,-5.1,M17,PID NOTCH PATHWAY,M1,1,0
1,-3.7,GO:0043025,neuronal cell body,M1,1,0
1,-9,GO:0032990,cell part morphogenesis,M1,1,0
1,-4,M15150,ZHANG BREAST CANCER PROGENITORS UP,M1,1,0
1,-9.6,GO:0048812,neuron projection morphogenesis,M1,1,0
1,-6,GO:0006275,regulation of DNA replication,M1,1,0
1,-6.8,GO:0010817,regulation of hormone levels,M1,1,0
1,-4.2,CORUM:2529,"LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated",M1,1,0
1,-5.5,GO:0050821,protein stabilization,M1,1,0
1,-5.3,GO:0051896,regulation of protein kinase B signaling,M1,1,0
1,-5.6,R-HSA-8951936,RUNX3 regulates p14-ARF,M1,1,0
1,-20,GO:0030855,epithelial cell differentiation,M1,1,0
1,-6.1,R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,M1,1,0
1,-8.1,GO:0016605,PML body,M1,1,0
1,-3.4,GO:0001941,postsynaptic membrane organization,M1,1,0
1,-2.5,GO:0031345,negative regulation of cell projection organization,M1,1,0
1,-8.3,WP2038,Microtubule cytoskeleton regulation,M1,1,0
1,-3.8,GO:0060421,positive regulation of heart growth,M1,1,0
1,-4.1,M16010,KOBAYASHI EGFR SIGNALING 24HR DN,M1,1,0
1,-2.1,M2500,PHONG TNF RESPONSE VIA P38 COMPLETE,M1,1,0
1,-3.6,GO:0007179,transforming growth factor beta receptor signaling pathway,M1,1,0
1,-11,GO:0097659,nucleic acid-templated transcription,M1,1,0
1,-2.6,GO:0051131,chaperone-mediated protein complex assembly,M1,1,0
1,-2.6,GO:1903169,regulation of calcium ion transmembrane transport,M1,1,0
1,-4.9,M17026,RIZKI TUMOR INVASIVENESS 3D UP,M1,1,0
1,-3,GO:0048813,dendrite morphogenesis,M1,1,0
1,-3.1,M17753,BENPORATH MYC MAX TARGETS,M1,1,0
1,-5.7,GO:0031069,hair follicle morphogenesis,M1,1,0
1,-4.3,GO:0051962,positive regulation of nervous system development,M1,1,0
1,-16,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M1,1,0
1,-4,GO:0022029,telencephalon cell migration,M1,1,0
1,-4,GO:0050708,regulation of protein secretion,M1,1,0
1,-6.7,M2631,FARMER BREAST CANCER APOCRINE VS BASAL,M1,1,0
1,-11,R-HSA-6806003,Regulation of TP53 Expression and Degradation,M1,1,0
1,-3.4,GO:0046875,ephrin receptor binding,M1,1,0
1,-2.3,GO:0005253,anion channel activity,M1,1,0
1,-2,GO:0033559,unsaturated fatty acid metabolic process,M1,1,0
1,-2.5,M4698,GSE2706 UNSTIM VS 8H LPS DC UP,M1,1,0
1,-2.5,M5379,GSE3982 MEMORY CD4 TCELL VS TH1 DN,M1,1,0
1,-4.7,GO:0071356,cellular response to tumor necrosis factor,M1,1,0
1,-3,GO:0097154,GABAergic neuron differentiation,M1,1,0
1,-3,M8574,GSE26030 TH1 VS TH17 RESTIMULATED DAY5 POST POLARIZATION DN,M1,1,0
1,-6,R-HSA-9033241,Peroxisomal protein import,M1,1,0
1,-3.2,GO:0006606,protein import into nucleus,M1,1,0
1,-2.1,GO:0000209,protein polyubiquitination,M1,1,0
1,-4.3,M8661,GSE35825 UNTREATED VS IFNA STIM MACROPHAGE DN,M1,1,0
1,-3.1,hsa04330,Notch signaling pathway,M1,1,0
1,-4.9,GO:0002831,regulation of response to biotic stimulus,M1,1,0
1,-4.2,GO:2001251,negative regulation of chromosome organization,M1,1,0
1,-3.1,WP4241,Type 2 papillary renal cell carcinoma,M1,1,0
1,-3.8,GO:0098644,complex of collagen trimers,M1,1,0
1,-2.5,M11572,BROWNE HCMV INFECTION 12HR UP,M1,1,0
1,-5,GO:0005126,cytokine receptor binding,M1,1,0
1,-7.8,GO:0009855,determination of bilateral symmetry,M1,1,0
1,-20,GO:0000902,cell morphogenesis,M1,1,0
1,-2.2,GO:0015833,peptide transport,M1,1,0
1,-2.7,WP466,DNA replication,M1,1,0
1,-3,M9554,GSE41978 WT VS BIM KO KLRG1 LOW EFFECTOR CD8 TCELL DN,M1,1,0
1,-7.3,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M1,1,0
1,-7.3,GO:0022890,inorganic cation transmembrane transporter activity,M1,1,0
1,-2.4,GO:0019209,kinase activator activity,M1,1,0
1,-3.9,GO:0050994,regulation of lipid catabolic process,M1,1,0
1,-4.3,GO:0007143,female meiotic nuclear division,M1,1,0
1,-11,GO:0042475,odontogenesis of dentin-containing tooth,M1,1,0
1,-2.1,M2994,GSE13547 WT VS ZFX KO BCELL ANTI IGM STIM 2H UP,M1,1,0
1,-4.4,M6486,GSE4748 CTRL VS CYANOBACTERIUM LPSLIKE STIM DC 1H UP,M1,1,0
1,-4,GO:0040016,embryonic cleavage,M1,1,0
1,-4.7,M71,PID ILK PATHWAY,M1,1,0
1,-3.8,GO:0097733,photoreceptor cell cilium,M1,1,0
1,-8.6,M11961,PUJANA CHEK2 PCC NETWORK,M1,1,0
1,-6.2,R-HSA-9664422,FCGR3A-mediated phagocytosis,M1,1,0
1,-2.2,GO:0006475,internal protein amino acid acetylation,M1,1,0
1,-2.3,M4399,MOHANKUMAR HOXA1 TARGETS UP,M1,1,0
1,-3.7,M4135,GSE17721 0.5H VS 12H GARDIQUIMOD BMDC UP,M1,1,0
1,-2.7,GO:0019724,B cell mediated immunity,M1,1,0
1,-4.7,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M1,1,0
1,-2.7,GO:0090026,positive regulation of monocyte chemotaxis,M1,1,0
1,-2.2,GO:0006575,cellular modified amino acid metabolic process,M1,1,0
1,-2.4,M5477,GSE3982 DC VS CENT MEMORY CD4 TCELL DN,M1,1,0
1,-2.1,GO:1903018,regulation of glycoprotein metabolic process,M1,1,0
1,-2.4,M8433,GSE23321 CENTRAL VS EFFECTOR MEMORY CD8 TCELL UP,M1,1,0
1,-3.7,GO:0051224,negative regulation of protein transport,M1,1,0
1,-3.1,GO:0034655,nucleobase-containing compound catabolic process,M1,1,0
1,-4.4,M2256,MIYAGAWA TARGETS OF EWSR1 ETS FUSIONS DN,M1,1,0
1,-2.7,GO:1902259,regulation of delayed rectifier potassium channel activity,M1,1,0
1,-3.1,M4676,GSE26928 NAIVE VS EFF MEMORY CD4 TCELL DN,M1,1,0
1,-22,hsa05207,Chemical carcinogenesis - receptor activation,M1,1,0
1,-2.4,GO:0044786,cell cycle DNA replication,M1,1,0
1,-10,R-HSA-5654738,Signaling by FGFR2,M1,1,0
1,-10,GO:0044057,regulation of system process,M1,1,0
1,-17,hsa04931,Insulin resistance,M1,1,0
1,-6.2,M1919,COLINA TARGETS OF 4EBP1 AND 4EBP2,M1,1,0
1,-5.5,GO:0071496,cellular response to external stimulus,M1,1,0
1,-2.8,M16859,SENESE HDAC3 TARGETS DN,M1,1,0
1,-26,hsa04151,PI3K-Akt signaling pathway,M1,1,0
1,-3.1,M7316,GSE19888 ADENOSINE A3R ACT VS A3R ACT WITH A3R INH PRETREATMENT IN MAST CELL UP,M1,1,0
1,-3.8,GO:0002250,adaptive immune response,M1,1,0
1,-21,GO:0051052,regulation of DNA metabolic process,M1,1,0
1,-2.8,GO:0006337,nucleosome disassembly,M1,1,0
1,-4.2,CORUM:3137,MASH1 promoter-coactivator complex,M1,1,0
1,-4.1,GO:0000217,DNA secondary structure binding,M1,1,0
1,-3.6,M60,PID NFAT TFPATHWAY,M1,1,0
1,-6.4,GO:0032103,positive regulation of response to external stimulus,M1,1,0
1,-5.1,M6140,GSE1112 OT1 VS HY CD8AB THYMOCYTE RTOC CULTURE UP,M1,1,0
1,-6.6,M3955,GU PDEF TARGETS UP,M1,1,0
1,-2.4,GO:0010460,positive regulation of heart rate,M1,1,0
1,-14,R-HSA-5673001,RAF/MAP kinase cascade,M1,1,0
1,-2.4,WP26,S1P receptor signal transduction,M1,1,0
1,-3.4,GO:0002706,regulation of lymphocyte mediated immunity,M1,1,0
1,-2,GO:0032228,"regulation of synaptic transmission, GABAergic",M1,1,0
1,-5,WP3941,Oxidative damage response,M1,1,0
1,-4,WP524,G13 signaling pathway,M1,1,0
1,-7.4,GO:0061695,"transferase complex, transferring phosphorus-containing groups",M1,1,0
1,-3.6,GO:0000152,nuclear ubiquitin ligase complex,M1,1,0
1,-3.4,WP3965,Lipid metabolism pathway,M1,1,0
1,-3.6,R-HSA-372790,Signaling by GPCR,M1,1,0
1,-2.2,WP4304,"Oligodendrocyte specification and differentiation, leading to myelin components for CNS",M1,1,0
1,-2.9,WP2849,Hematopoietic stem cell differentiation,M1,1,0
1,-7.7,GO:0001764,neuron migration,M1,1,0
1,-4.3,R-HSA-397014,Muscle contraction,M1,1,0
1,-3.3,GO:0016514,SWI/SNF complex,M1,1,0
1,-7.8,GO:0051385,response to mineralocorticoid,M1,1,0
1,-3.4,GO:0046606,negative regulation of centrosome cycle,M1,1,0
1,-8.9,WP4564,Neural crest cell migration during development,M1,1,0
1,-22,hsa05220,Chronic myeloid leukemia,M1,1,0
1,-2.7,M17772,MACLACHLAN BRCA1 TARGETS UP,M1,1,0
1,-2.2,R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,M1,1,0
1,-12,WP4539,Synaptic signaling pathways associated with autism spectrum disorder,M1,1,0
1,-4.7,R-HSA-5693571,Nonhomologous End-Joining (NHEJ),M1,1,0
1,-5.1,M12112,VART KSHV INFECTION ANGIOGENIC MARKERS UP,M1,1,0
1,-2.9,GO:0055017,cardiac muscle tissue growth,M1,1,0
1,-2.9,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M1,1,0
1,-2.1,M14447,MASSARWEH RESPONSE TO ESTRADIOL,M1,1,0
1,-2.2,R-HSA-5260271,Diseases of Immune System,M1,1,0
1,-2.5,GO:0062023,collagen-containing extracellular matrix,M1,1,0
1,-3.1,WP5117,Cohesin complex - Cornelia de Lange syndrome,M1,1,0
1,-5.2,GO:0071560,cellular response to transforming growth factor beta stimulus,M1,1,0
1,-4.1,GO:0070661,leukocyte proliferation,M1,1,0
1,-20,hsa05231,Choline metabolism in cancer,M1,1,0
1,-3.1,M8309,GSE28726 NAIVE VS ACTIVATED VA24NEG NKTCELL DN,M1,1,0
1,-5,GO:0000793,condensed chromosome,M1,1,0
1,-5.1,WP5181,Roles of ceramides in the development of insulin resistance,M1,1,0
1,-4.4,M5834,GSE9650 EFFECTOR VS EXHAUSTED CD8 TCELL DN,M1,1,0
1,-9.7,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M1,1,0
1,-2,M9507,GSE41867 NAIVE VS DAY15 LCMV CONE13 EFFECTOR CD8 TCELL UP,M1,1,0
1,-2,GO:1990778,protein localization to cell periphery,M1,1,0
1,-3.3,GO:0060045,positive regulation of cardiac muscle cell proliferation,M1,1,0
1,-2.2,GO:0019882,antigen processing and presentation,M1,1,0
1,-3.9,GO:0060612,adipose tissue development,M1,1,0
1,-4.4,GO:0005938,cell cortex,M1,1,0
1,-4.7,GO:0038094,Fc-gamma receptor signaling pathway,M1,1,0
1,-6.1,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M1,1,0
1,-7.6,WP3937,Microglia pathogen phagocytosis pathway,M1,1,0
1,-7.4,hsa05140,Leishmaniasis,M1,1,0
1,-22,hsa04014,Ras signaling pathway,M1,1,0
1,-6.3,GO:0071466,cellular response to xenobiotic stimulus,M1,1,0
1,-2.1,M34018,BLANCO MELO COVID19 SARS COV 2 INFECTION A594 ACE2 EXPRESSING CELLS RUXOLITINIB UP,M1,1,0
1,-4.8,WP4136,Fibrin complement receptor 3 signaling pathway,M1,1,0
1,-5.3,GO:0003266,regulation of secondary heart field cardioblast proliferation,M1,1,0
1,-2.5,GO:0018210,peptidyl-threonine modification,M1,1,0
1,-12,GO:0050865,regulation of cell activation,M1,1,0
1,-2.9,M1671,KYNG RESPONSE TO H2O2,M1,1,0
1,-3.5,GO:0000109,nucleotide-excision repair complex,M1,1,0
1,-4.9,GO:0016651,"oxidoreductase activity, acting on NAD(P)H",M1,1,0
1,-2.4,GO:1902930,regulation of alcohol biosynthetic process,M1,1,0
1,-28,WP5087,Malignant pleural mesothelioma,M1,1,0
1,-6.5,GO:0098915,membrane repolarization during ventricular cardiac muscle cell action potential,M1,1,0
1,-11,GO:0051129,negative regulation of cellular component organization,M1,1,0
1,-2.5,M3486,GSE1460 NAIVE CD4 TCELL CORD BLOOD VS THYMIC STROMAL CELL DN,M1,1,0
1,-3,M5118,GSE339 CD8POS VS CD4CD8DN DC DN,M1,1,0
1,-4.8,GO:0016247,channel regulator activity,M1,1,0
1,-6,GO:0033077,T cell differentiation in thymus,M1,1,0
1,-8.4,GO:0022803,passive transmembrane transporter activity,M1,1,0
1,-3,M7789,GSE22103 UNSTIM VS GMCSF AND IFNG STIM NEUTROPHIL UP,M1,1,0
1,-3.8,hsa03430,Mismatch repair,M1,1,0
1,-4.2,GO:0045619,regulation of lymphocyte differentiation,M1,1,0
1,-3,GO:0060135,maternal process involved in female pregnancy,M1,1,0
1,-2.3,M17163,CAIRO LIVER DEVELOPMENT UP,M1,1,0
1,-2.4,M6774,GSE6259 DEC205 POS DC VS CD4 TCELL DN,M1,1,0
1,-7,GO:0050890,cognition,M1,1,0
1,-3.3,GO:0050671,positive regulation of lymphocyte proliferation,M1,1,0
1,-2.5,M2899,LINDGREN BLADDER CANCER HIGH RECURRENCE,M1,1,0
1,-3.7,GO:0090317,negative regulation of intracellular protein transport,M1,1,0
1,-13,GO:0043065,positive regulation of apoptotic process,M1,1,0
1,-3.8,M6663,HOLLMANN APOPTOSIS VIA CD40 DN,M1,1,0
1,-4.9,GO:0001892,embryonic placenta development,M1,1,0
1,-3.8,M11682,BONCI TARGETS OF MIR15A AND MIR16 1,M1,1,0
1,-15,hsa04668,TNF signaling pathway,M1,1,0
1,-2.9,GO:0031396,regulation of protein ubiquitination,M1,1,0
1,-7.1,GO:0071354,cellular response to interleukin-6,M1,1,0
1,-2.7,R-HSA-5696395,Formation of Incision Complex in GG-NER,M1,1,0
1,-2.6,GO:0106118,regulation of sterol biosynthetic process,M1,1,0
1,-25,GO:1901699,cellular response to nitrogen compound,M1,1,0
1,-4.1,CORUM:778,LARC complex (LCR-associated remodeling complex),M1,1,0
1,-5.1,CORUM:246,BLM complex III,M1,1,0
1,-2.1,M5664,GSE6269 STAPH AUREUS VS STREP PNEUMO INF PBMC DN,M1,1,0
1,-4,GO:1990814,DNA/DNA annealing activity,M1,1,0
1,-4.9,GO:0051384,response to glucocorticoid,M1,1,0
1,-2.1,M15382,BROWNE HCMV INFECTION 10HR UP,M1,1,0
1,-2.3,M2447,PLASARI NFIC TARGETS BASAL UP,M1,1,0
1,-3,GO:0045995,regulation of embryonic development,M1,1,0
1,-2.5,M2019,MIKKELSEN MEF HCP WITH H3K27ME3,M1,1,0
1,-5.7,CORUM:12,BLOC-2 (biogenesis of lysosome-related organelles complex 2),M1,1,0
1,-6.8,GO:0002443,leukocyte mediated immunity,M1,1,0
1,-3.5,GO:0006360,transcription by RNA polymerase I,M1,1,0
1,-7.2,R-HSA-556833,Metabolism of lipids,M1,1,0
1,-2.1,M7429,BANDRES RESPONSE TO CARMUSTIN MGMT 24HR DN,M1,1,0
1,-2.6,WP268,Notch signaling,M1,1,0
1,-2.5,M1610,CUI TCF21 TARGETS 2 UP,M1,1,0
1,-6.5,GO:1902745,positive regulation of lamellipodium organization,M1,1,0
1,-4.5,GO:0009060,aerobic respiration,M1,1,0
1,-19,GO:1901653,cellular response to peptide,M1,1,0
1,-3.1,GO:1902554,serine/threonine protein kinase complex,M1,1,0
1,-3.8,M9527,GSE41087 WT VS FOXP3 MUT ANTI CD3 CD28 STIM CD4 TCELL UP,M1,1,0
1,-3,GO:0000038,very long-chain fatty acid metabolic process,M1,1,0
1,-2.6,GO:0140747,regulation of ncRNA transcription,M1,1,0
1,-3.1,CORUM:714,BRM-SIN3A complex,M1,1,0
1,-4,CORUM:3142,CAMK2-delta-MASH1 promoter-coactivator complex,M1,1,0
1,-3.5,M1999,WONG ADULT TISSUE STEM MODULE,M1,1,0
1,-10,R-HSA-5654741,Signaling by FGFR3,M1,1,0
1,-3.6,M9197,ELVIDGE HYPOXIA BY DMOG UP,M1,1,0
1,-13,GO:0032868,response to insulin,M1,1,0
1,-5.6,GO:0051051,negative regulation of transport,M1,1,0
1,-10,R-HSA-1474165,Reproduction,M1,1,0
1,-3.6,GO:2000241,regulation of reproductive process,M1,1,0
1,-19,GO:1901987,regulation of cell cycle phase transition,M1,1,0
1,-2.2,GO:0009798,axis specification,M1,1,0
1,-4.3,GO:0060122,inner ear receptor cell stereocilium organization,M1,1,0
1,-2.5,M8396,GSE29949 MICROGLIA BRAIN VS CD8 POS DC SPLEEN UP,M1,1,0
1,-2,M6510,PASQUALUCCI LYMPHOMA BY GC STAGE UP,M1,1,0
1,-2.4,M3236,GSE13306 RA VS UNTREATED MEM CD4 TCELL UP,M1,1,0
1,-2.1,hsa00310,Lysine degradation,M1,1,0
1,-5.3,GO:2000179,positive regulation of neural precursor cell proliferation,M1,1,0
1,-4.4,M9940,HONRADO BREAST CANCER BRCA1 VS BRCA2,M1,1,0
1,-4.7,R-HSA-5358565,Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),M1,1,0
1,-7.4,GO:0002685,regulation of leukocyte migration,M1,1,0
1,-4.5,WP4561,Cell migration and invasion through p75NTR,M1,1,0
1,-2.5,M5569,GSE3982 EFF MEMORY VS CENT MEMORY CD4 TCELL UP,M1,1,0
1,-19,M186,PID PDGFRB PATHWAY,M1,1,0
1,-4.5,hsa05012,Parkinson disease,M1,1,0
1,-4.6,GO:0051492,regulation of stress fiber assembly,M1,1,0
1,-2.9,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,M1,1,0
1,-17,hsa05206,MicroRNAs in cancer,M1,1,0
1,-5.3,M12676,FOSTER TOLERANT MACROPHAGE DN,M1,1,0
1,-6.1,GO:0030330,"DNA damage response, signal transduction by p53 class mediator",M1,1,0
1,-5.8,GO:1904064,positive regulation of cation transmembrane transport,M1,1,0
1,-2.6,M8457,GSE27291 0H VS 7D STIM GAMMADELTA TCELL DN,M1,1,0
1,-3.8,M5543,GSE3982 BCELL VS EFF MEMORY CD4 TCELL DN,M1,1,0
1,-6.5,GO:0046326,positive regulation of glucose import,M1,1,0
1,-7.1,R-HSA-6804760,Regulation of TP53 Activity through Methylation,M1,1,0
1,-6.2,M18077,ABRAHAM ALPC VS MULTIPLE MYELOMA UP,M1,1,0
1,-8.2,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M1,1,0
1,-6.3,GO:0030324,lung development,M1,1,0
1,-4.2,GO:0006875,cellular metal ion homeostasis,M1,1,0
1,-4.4,M8312,GSE28726 ACT CD4 TCELL VS ACT NKTCELL UP,M1,1,0
1,-2.9,GO:0007064,mitotic sister chromatid cohesion,M1,1,0
1,-2.1,M1263,WANG RESPONSE TO BEXAROTENE UP,M1,1,0
1,-6.9,WP2817,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4),M1,1,0
1,-2.6,GO:0043414,macromolecule methylation,M1,1,0
1,-2.7,R-HSA-622312,Inflammasomes,M1,1,0
1,-3.9,GO:0009165,nucleotide biosynthetic process,M1,1,0
1,-3.3,GO:0001824,blastocyst development,M1,1,0
1,-4.4,M9066,BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 48HR DN,M1,1,0
1,-3.5,M10783,HOFMANN CELL LYMPHOMA UP,M1,1,0
1,-11,WP4816,TGF-beta receptor signaling in skeletal dysplasias,M1,1,0
1,-3.2,R-HSA-6804116,TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,M1,1,0
1,-4.7,hsa04621,NOD-like receptor signaling pathway,M1,1,0
1,-4.5,M17859,KIM WT1 TARGETS DN,M1,1,0
1,-2.6,GO:0090199,regulation of release of cytochrome c from mitochondria,M1,1,0
1,-2.8,M8451,SENESE HDAC3 TARGETS UP,M1,1,0
1,-13,GO:0019904,protein domain specific binding,M1,1,0
1,-2.3,M2513,ELVIDGE HIF1A TARGETS DN,M1,1,0
1,-4.5,GO:0046626,regulation of insulin receptor signaling pathway,M1,1,0
1,-5.5,GO:1904888,cranial skeletal system development,M1,1,0
1,-2.1,GO:0045335,phagocytic vesicle,M1,1,0
1,-2.6,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M1,1,0
1,-2.9,GO:0004708,MAP kinase kinase activity,M1,1,0
1,-7.8,GO:0048854,brain morphogenesis,M1,1,0
1,-2,GO:0009309,amine biosynthetic process,M1,1,0
1,-2.3,GO:0010883,regulation of lipid storage,M1,1,0
1,-9,WP585,Interferon type I signaling pathways,M1,1,0
1,-3.6,GO:0002381,immunoglobulin production involved in immunoglobulin-mediated immune response,M1,1,0
1,-2.9,GO:0050807,regulation of synapse organization,M1,1,0
1,-14,R-HSA-187037,Signaling by NTRK1 (TRKA),M1,1,0
1,-3,GO:1901099,negative regulation of signal transduction in absence of ligand,M1,1,0
1,-2.4,M6424,GSE8921 3H VS 24H TLR1 2 STIM MONOCYTE UP,M1,1,0
1,-7.4,GO:0060253,negative regulation of glial cell proliferation,M1,1,0
1,-2.3,M1411,LAU APOPTOSIS CDKN2A UP,M1,1,0
1,-5.3,GO:0051345,positive regulation of hydrolase activity,M1,1,0
1,-9,R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",M1,1,0
1,-3.1,M2351,TORCHIA TARGETS OF EWSR1 FLI1 FUSION DN,M1,1,0
1,-3.2,M19982,WAMUNYOKOLI OVARIAN CANCER LMP UP,M1,1,0
1,-10,GO:0060271,cilium assembly,M1,1,0
1,-3,GO:2000352,negative regulation of endothelial cell apoptotic process,M1,1,0
1,-3.7,M5286,GSE36392 MAC VS NEUTROPHIL IL25 TREATED LUNG DN,M1,1,0
1,-2.2,GO:0010574,regulation of vascular endothelial growth factor production,M1,1,0
1,-6.6,GO:1905332,positive regulation of morphogenesis of an epithelium,M1,1,0
1,-2.5,M5765,GSE8515 CTRL VS IL6 4H STIM MAC DN,M1,1,0
1,-2.3,GO:0055001,muscle cell development,M1,1,0
1,-4.1,M347,WEIGEL OXIDATIVE STRESS BY HNE AND H2O2,M1,1,0
1,-2.8,GO:0070301,cellular response to hydrogen peroxide,M1,1,0
1,-2.9,M12144,BROWNE HCMV INFECTION 48HR DN,M1,1,0
1,-2.9,GO:0051145,smooth muscle cell differentiation,M1,1,0
1,-3.8,R-HSA-112409,RAF-independent MAPK1/3 activation,M1,1,0
1,-4.2,M1376,GOTZMANN EPITHELIAL TO MESENCHYMAL TRANSITION DN,M1,1,0
1,-6.5,CORUM:2222,BLM complex II,M1,1,0
1,-5.1,M107,FISCHER G1 S CELL CYCLE,M1,1,0
1,-3.1,GO:0035066,positive regulation of histone acetylation,M1,1,0
1,-2.1,M19245,COULOUARN TEMPORAL TGFB1 SIGNATURE DN,M1,1,0
1,-3.3,GO:0071285,cellular response to lithium ion,M1,1,0
1,-7.6,GO:1901342,regulation of vasculature development,M1,1,0
1,-3.2,GO:0008156,negative regulation of DNA replication,M1,1,0
1,-5.5,GO:0008585,female gonad development,M1,1,0
1,-13,R-HSA-186797,Signaling by PDGF,M1,1,0
1,-5.9,GO:0010592,positive regulation of lamellipodium assembly,M1,1,0
1,-9,WP3998,Prader-Willi and Angelman syndrome,M1,1,0
1,-5.7,CORUM:2818,BRCA1-BARD1-BRCA2-DNA damage complex III,M1,1,0
1,-19,hsa05418,Fluid shear stress and atherosclerosis,M1,1,0
1,-3.5,GO:0060020,Bergmann glial cell differentiation,M1,1,0
1,-3,M7665,GSE19401 UNSTIM VS RETINOIC ACID AND PAM2CSK4 STIM FOLLICULAR DC UP,M1,1,0
1,-3.9,GO:0034644,cellular response to UV,M1,1,0
1,-5.7,GO:0050670,regulation of lymphocyte proliferation,M1,1,0
1,-2.3,hsa04340,Hedgehog signaling pathway,M1,1,0
1,-4.4,GO:0005168,neurotrophin TRKA receptor binding,M1,1,0
1,-2.2,GO:0048665,neuron fate specification,M1,1,0
1,-2.3,GO:0006914,autophagy,M1,1,0
1,-5.1,WP531,DNA mismatch repair,M1,1,0
1,-7.6,CORUM:6165,BBSome core complex,M1,1,0
1,-5.9,R-HSA-5654732,Negative regulation of FGFR3 signaling,M1,1,0
1,-2.3,M7621,GSE21360 SECONDARY VS TERTIARY MEMORY CD8 TCELL DN,M1,1,0
1,-6.3,M1819,MATZUK MEIOTIC AND DNA REPAIR,M1,1,0
1,-20,WP4205,MET in type 1 papillary renal cell carcinoma,M1,1,0
1,-2.9,M1954,MIKKELSEN MCV6 HCP WITH H3K27ME3,M1,1,0
1,-5.8,GO:0034502,protein localization to chromosome,M1,1,0
1,-2.6,GO:0009268,response to pH,M1,1,0
1,-2.6,GO:0005740,mitochondrial envelope,M1,1,0
1,-2.5,M5513,GSE3982 MAC VS TH2 UP,M1,1,0
1,-2.5,M4404,GSE22886 CD8 VS CD4 NAIVE TCELL DN,M1,1,0
1,-4,GO:2000617,positive regulation of histone H3-K9 acetylation,M1,1,0
1,-3.6,R-HSA-9734009,Defective Intrinsic Pathway for Apoptosis,M1,1,0
1,-24,WP4172,PI3K-Akt signaling pathway,M1,1,0
1,-5.1,GO:0034329,cell junction assembly,M1,1,0
1,-3.8,R-HSA-8875878,MET promotes cell motility,M1,1,0
1,-3.1,R-HSA-2644603,Signaling by NOTCH1 in Cancer,M1,1,0
1,-5.4,GO:0048018,receptor ligand activity,M1,1,0
1,-3.2,M308,TSAI RESPONSE TO RADIATION THERAPY,M1,1,0
1,-11,hsa05132,Salmonella infection,M1,1,0
1,-4.2,GO:0007095,mitotic G2 DNA damage checkpoint signaling,M1,1,0
1,-3,M328,GSE8685 IL2 STARVED VS IL21 ACT IL2 STARVED CD4 TCELL UP,M1,1,0
1,-4.5,M1157,KONG E2F3 TARGETS,M1,1,0
1,-2.8,GO:0035272,exocrine system development,M1,1,0
1,-7.6,M62,PID EPHB FWD PATHWAY,M1,1,0
1,-5.4,GO:0000729,DNA double-strand break processing,M1,1,0
1,-4.9,GO:0046660,female sex differentiation,M1,1,0
1,-3.1,GO:0048489,synaptic vesicle transport,M1,1,0
1,-3,GO:0010661,positive regulation of muscle cell apoptotic process,M1,1,0
1,-2.9,GO:0043516,"regulation of DNA damage response, signal transduction by p53 class mediator",M1,1,0
1,-3.7,M5382,GSE3982 MEMORY CD4 TCELL VS TH2 DN,M1,1,0
1,-2.9,M9334,VALK AML CLUSTER 11,M1,1,0
1,-4,GO:0043586,tongue development,M1,1,0
1,-2.6,M9206,YAMASHITA LIVER CANCER STEM CELL DN,M1,1,0
1,-9.5,GO:0032400,melanosome localization,M1,1,0
1,-5.8,WP22,IL-9 signaling pathway,M1,1,0
1,-12,hsa04810,Regulation of actin cytoskeleton,M1,1,0
1,-5.1,GO:0032108,negative regulation of response to nutrient levels,M1,1,0
1,-7.1,GO:0006954,inflammatory response,M1,1,0
1,-5.9,GO:1901381,positive regulation of potassium ion transmembrane transport,M1,1,0
1,-2.4,M7040,GSE15330 WT VS IKAROS KO HSC UP,M1,1,0
1,-4.5,GO:0051147,regulation of muscle cell differentiation,M1,1,0
1,-2.4,M385,GSE7219 WT VS NIK NFKB2 KO LPS AND ANTI CD40 STIM DC UP,M1,1,0
1,-5.7,GO:0043550,regulation of lipid kinase activity,M1,1,0
1,-2.5,M5397,GSE3982 EOSINOPHIL VS MAST CELL UP,M1,1,0
1,-3.3,GO:0002429,immune response-activating cell surface receptor signaling pathway,M1,1,0
1,-4.8,M182,PID IL3 PATHWAY,M1,1,0
1,-15,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M1,1,0
1,-2.8,GO:0045346,regulation of MHC class II biosynthetic process,M1,1,0
1,-2.2,R-HSA-4641262,Disassembly of the destruction complex and recruitment of AXIN to the membrane,M1,1,0
1,-3.5,R-HSA-9020956,Interleukin-27 signaling,M1,1,0
1,-3.3,GO:0072332,intrinsic apoptotic signaling pathway by p53 class mediator,M1,1,0
1,-3,GO:0031330,negative regulation of cellular catabolic process,M1,1,0
1,-3,M9289,GSE36078 UNTREATED VS AD5 INF MOUSE LUNG DC UP,M1,1,0
1,-3,M4060,GSE17721 LPS VS GARDIQUIMOD 16H BMDC UP,M1,1,0
1,-20,WP706,Sudden infant death syndrome (SIDS) susceptibility pathways,M1,1,0
1,-2.9,WP3874,Canonical and non-canonical TGF-B signaling,M1,1,0
1,-3.9,GO:2000047,regulation of cell-cell adhesion mediated by cadherin,M1,1,0
1,-4.8,CORUM:178,"Respiratory chain complex I (holoenzyme), mitochondrial",M1,1,0
1,-5.5,GO:0002761,regulation of myeloid leukocyte differentiation,M1,1,0
1,-3,M3962,GSE17721 PAM3CSK4 VS GADIQUIMOD 1H BMDC UP,M1,1,0
1,-3.5,GO:0035112,genitalia morphogenesis,M1,1,0
1,-7.6,GO:0001223,transcription coactivator binding,M1,1,0
1,-7.2,M3456,FERNANDEZ BOUND BY MYC,M1,1,0
1,-10,GO:0005813,centrosome,M1,1,0
1,-6.3,GO:0098739,import across plasma membrane,M1,1,0
1,-6.6,GO:0030027,lamellipodium,M1,1,0
1,-4.7,GO:0060443,mammary gland morphogenesis,M1,1,0
1,-3.7,R-HSA-8948216,Collagen chain trimerization,M1,1,0
1,-2.7,M1967,MIKKELSEN IPS WITH HCP H3K27ME3,M1,1,0
1,-2.6,GO:0031065,positive regulation of histone deacetylation,M1,1,0
1,-5.3,GO:0044743,protein transmembrane import into intracellular organelle,M1,1,0
1,-3.5,GO:0045661,regulation of myoblast differentiation,M1,1,0
1,-3.4,GO:2000819,regulation of nucleotide-excision repair,M1,1,0
1,-7.6,R-HSA-109606,Intrinsic Pathway for Apoptosis,M1,1,0
1,-3,GO:0004402,histone acetyltransferase activity,M1,1,0
1,-3.1,GO:0002040,sprouting angiogenesis,M1,1,0
1,-33,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M1,1,0
1,-10,GO:0043524,negative regulation of neuron apoptotic process,M1,1,0
1,-6.3,M1475,FLECHNER BIOPSY KIDNEY TRANSPLANT REJECTED VS OK DN,M1,1,0
1,-3,M5073,GSE32423 MEMORY VS NAIVE CD8 TCELL DN,M1,1,0
1,-5,WP3865,Novel intracellular components of RIG-I-like receptor pathway,M1,1,0
1,-4.4,M227,GRYDER PAX3FOXO1 ENHANCERS KO DOWN,M1,1,0
1,-2.4,M7334,GSE19888 CTRL VS T CELL MEMBRANES ACT MAST CELL DN,M1,1,0
1,-4.8,M36,PID IL27 PATHWAY,M1,1,0
1,-2.2,M2832,PDGF UP.V1 DN,M1,1,0
1,-5.5,GO:0045912,negative regulation of carbohydrate metabolic process,M1,1,0
1,-6.1,R-HSA-5576891,Cardiac conduction,M1,1,0
1,-2.4,M18806,TOOKER GEMCITABINE RESISTANCE DN,M1,1,0
1,-7.8,GO:0048146,positive regulation of fibroblast proliferation,M1,1,0
1,-11,GO:0006109,regulation of carbohydrate metabolic process,M1,1,0
1,-3,M6950,GSE7831 CPG VS INFLUENZA STIM PDC 1H UP,M1,1,0
1,-9.4,GO:0007162,negative regulation of cell adhesion,M1,1,0
1,-3.8,M11,PID PRL SIGNALING EVENTS PATHWAY,M1,1,0
1,-3.2,GO:0019395,fatty acid oxidation,M1,1,0
1,-5.2,GO:0071453,cellular response to oxygen levels,M1,1,0
1,-12,GO:0050954,sensory perception of mechanical stimulus,M1,1,0
1,-2.2,GO:0008637,apoptotic mitochondrial changes,M1,1,0
1,-6,GO:0007623,circadian rhythm,M1,1,0
1,-3.4,M283,OISHI CHOLANGIOMA STEM CELL LIKE UP,M1,1,0
1,-3.9,GO:1903844,regulation of cellular response to transforming growth factor beta stimulus,M1,1,0
1,-21,GO:0048589,developmental growth,M1,1,0
1,-3.3,GO:0010962,regulation of glucan biosynthetic process,M1,1,0
1,-11,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M1,1,0
1,-12,M151,PID AR TF PATHWAY,M1,1,0
1,-15,WP3651,Pathways affected in adenoid cystic carcinoma,M1,1,0
1,-6.2,R-HSA-186712,Regulation of beta-cell development,M1,1,0
1,-5,GO:0043062,extracellular structure organization,M1,1,0
1,-14,GO:0022407,regulation of cell-cell adhesion,M1,1,0
1,-9.4,WP45,G1 to S cell cycle control,M1,1,0
1,-5.8,M255,PID HIF1 TFPATHWAY,M1,1,0
1,-6.9,GO:0060742,epithelial cell differentiation involved in prostate gland development,M1,1,0
1,-5.5,GO:1903578,regulation of ATP metabolic process,M1,1,0
1,-7,M290,PID IL12 STAT4 PATHWAY,M1,1,0
1,-3,GO:0002287,alpha-beta T cell activation involved in immune response,M1,1,0
1,-12,GO:0000075,cell cycle checkpoint signaling,M1,1,0
1,-5.5,M110,PID IL1 PATHWAY,M1,1,0
1,-4.8,GO:0016445,somatic diversification of immunoglobulins,M1,1,0
1,-3.1,GO:0005581,collagen trimer,M1,1,0
1,-3.7,M9815,AKL HTLV1 INFECTION DN,M1,1,0
1,-6.2,M1806,BOCHKIS FOXA2 TARGETS,M1,1,0
1,-18,WP395,IL-4 signaling pathway,M1,1,0
1,-2.4,M4811,GSE27786 BCELL VS ERYTHROBLAST DN,M1,1,0
1,-8.6,GO:0050905,neuromuscular process,M1,1,0
1,-3.5,M5536,TCGA GLIOBLASTOMA COPY NUMBER UP,M1,1,0
1,-12,GO:0098773,skin epidermis development,M1,1,0
1,-6.4,GO:1902807,negative regulation of cell cycle G1/S phase transition,M1,1,0
1,-3.8,M172,GRYDER PAX3FOXO1 TOP ENHANCERS,M1,1,0
1,-4.3,GO:1900034,regulation of cellular response to heat,M1,1,0
1,-5.5,GO:0001673,male germ cell nucleus,M1,1,0
1,-7.9,R-HSA-8940973,RUNX2 regulates osteoblast differentiation,M1,1,0
1,-9.9,M144,PID CERAMIDE PATHWAY,M1,1,0
1,-10,R-HSA-8853659,RET signaling,M1,1,0
1,-4,R-HSA-9675126,Diseases of mitotic cell cycle,M1,1,0
1,-7.6,GO:0008406,gonad development,M1,1,0
1,-3.1,M19261,YAGI AML WITH T 8 21 TRANSLOCATION,M1,1,0
1,-5,hsa05416,Viral myocarditis,M1,1,0
1,-8.2,M34,PID TCR PATHWAY,M1,1,0
1,-7.6,GO:0043525,positive regulation of neuron apoptotic process,M1,1,0
1,-3.4,GO:0000307,cyclin-dependent protein kinase holoenzyme complex,M1,1,0
1,-3.5,R-HSA-9028731,Activated NTRK2 signals through FRS2 and FRS3,M1,1,0
1,-3,M339,GSE7596 AKT TRANSD VS CTRL CD4 TCONV WITH TGFB UP,M1,1,0
1,-12,R-HSA-2424491,DAP12 signaling,M1,1,0
1,-8.5,GO:0042579,microbody,M1,1,0
1,-5.8,M8200,GSE26488 WT VS VP16 TRANSGENIC HDAC7 KO DOUBLE POSITIVE THYMOCYTE UP,M1,1,0
1,-2.4,M8243,GSE27241 CTRL VS DIGOXIN TREATED CD4 TCELL IN TH17 POLARIZING CONDITIONS UP,M1,1,0
1,-5,R-HSA-1483255,PI Metabolism,M1,1,0
1,-2.5,GO:0043537,negative regulation of blood vessel endothelial cell migration,M1,1,0
1,-8.9,M123,MUELLER PLURINET,M1,1,0
1,-3.1,GO:0046434,organophosphate catabolic process,M1,1,0
1,-3.6,GO:0050839,cell adhesion molecule binding,M1,1,0
1,-8.4,GO:0051101,regulation of DNA binding,M1,1,0
1,-2.5,M8672,GSE34156 UNTREATED VS 6H TLR1 TLR2 LIGAND TREATED MONOCYTE UP,M1,1,0
1,-4.1,GO:0140115,export across plasma membrane,M1,1,0
1,-2.5,GO:0030864,cortical actin cytoskeleton,M1,1,0
1,-2.5,GO:0097060,synaptic membrane,M1,1,0
1,-2.7,GO:0032735,positive regulation of interleukin-12 production,M1,1,0
1,-6.1,GO:0007059,chromosome segregation,M1,1,0
1,-2.2,M2073,BAE BRCA1 TARGETS DN,M1,1,0
1,-7.2,GO:0008016,regulation of heart contraction,M1,1,0
1,-17,M276,PID FGF PATHWAY,M1,1,0
1,-6.7,GO:0035137,hindlimb morphogenesis,M1,1,0
1,-6.2,GO:1901655,cellular response to ketone,M1,1,0
1,-2.6,R-HSA-1980143,Signaling by NOTCH1,M1,1,0
1,-5.7,R-HSA-8878171,Transcriptional regulation by RUNX1,M1,1,0
1,-2.2,M269,PID RAS PATHWAY,M1,1,0
1,-4.6,GO:0051640,organelle localization,M1,1,0
1,-3.6,M1859,RHEIN ALL GLUCOCORTICOID THERAPY DN,M1,1,0
1,-5.1,GO:0004536,deoxyribonuclease activity,M1,1,0
1,-6.9,GO:0001216,DNA-binding transcription activator activity,M1,1,0
1,-2.2,GO:1900024,regulation of substrate adhesion-dependent cell spreading,M1,1,0
1,-2.9,GO:0060326,cell chemotaxis,M1,1,0
1,-4.3,GO:0065002,intracellular protein transmembrane transport,M1,1,0
1,-2.2,GO:0031256,leading edge membrane,M1,1,0
1,-6.2,GO:0090316,positive regulation of intracellular protein transport,M1,1,0
1,-2.8,GO:0007595,lactation,M1,1,0
1,-3,M8949,GSE37532 VISCERAL ADIPOSE TISSUE VS LN DERIVED PPARG KO TCONV CD4 TCELL UP,M1,1,0
1,-3.5,GO:0022898,regulation of transmembrane transporter activity,M1,1,0
1,-3.2,GO:0010718,positive regulation of epithelial to mesenchymal transition,M1,1,0
1,-4.4,GO:1903076,regulation of protein localization to plasma membrane,M1,1,0
1,-2.1,M1778,ZHANG GATA6 TARGETS DN,M1,1,0
1,-4.7,M7079,WONG EMBRYONIC STEM CELL CORE,M1,1,0
1,-2.8,R-HSA-6802952,Signaling by BRAF and RAF1 fusions,M1,1,0
1,-3.4,R-HSA-1428517,The citric acid (TCA) cycle and respiratory electron transport,M1,1,0
1,-2.1,M16932,CHIANG LIVER CANCER SUBCLASS PROLIFERATION DN,M1,1,0
1,-8.4,R-HSA-5654689,PI-3K cascade:FGFR1,M1,1,0
1,-2.7,hsa04922,Glucagon signaling pathway,M1,1,0
1,-8.6,GO:0006303,double-strand break repair via nonhomologous end joining,M1,1,0
1,-3.1,GO:0006119,oxidative phosphorylation,M1,1,0
1,-2.1,M9775,HAHTOLA MYCOSIS FUNGOIDES CD4 UP,M1,1,0
1,-2.7,GO:0045814,"negative regulation of gene expression, epigenetic",M1,1,0
1,-10,GO:0050817,coagulation,M1,1,0
1,-3.1,M270,PID MAPK TRK PATHWAY,M1,1,0
1,-9.7,hsa04910,Insulin signaling pathway,M1,1,0
1,-8.7,GO:0019207,kinase regulator activity,M1,1,0
1,-7.3,GO:0031571,mitotic G1 DNA damage checkpoint signaling,M1,1,0
1,-2.1,M4861,VERHAAK AML WITH NPM1 MUTATED UP,M1,1,0
1,-3.5,hsa05030,Cocaine addiction,M1,1,0
1,-2.3,M8890,GSE37301 MULTIPOTENT PROGENITOR VS COMMON LYMPHOID PROGENITOR UP,M1,1,0
1,-22,WP4685,Melanoma,M1,1,0
1,-4.4,WP4655,Cytosolic DNA-sensing pathway,M1,1,0
1,-2.2,GO:0140677,molecular function activator activity,M1,1,0
1,-2.3,M2446,PLASARI TGFB1 TARGETS 10HR DN,M1,1,0
1,-3.3,GO:0051149,positive regulation of muscle cell differentiation,M1,1,0
1,-3,M14344,DASU IL6 SIGNALING UP,M1,1,0
1,-2.5,GO:0046942,carboxylic acid transport,M1,1,0
1,-2.5,M1616,BURTON ADIPOGENESIS 7,M1,1,0
1,-5.8,GO:1900368,regulation of post-transcriptional gene silencing by RNA,M1,1,0
1,-6.1,GO:0032407,MutSalpha complex binding,M1,1,0
1,-2.3,GO:0031113,regulation of microtubule polymerization,M1,1,0
1,-2.7,R-HSA-9656223,Signaling by RAF1 mutants,M1,1,0
1,-4.1,R-HSA-6799198,Complex I biogenesis,M1,1,0
1,-2.4,M4482,GSE22886 NAIVE BCELL VS NEUTROPHIL DN,M1,1,0
1,-2.4,M6053,GSE2770 UNTREATED VS TGFB AND IL12 TREATED ACT CD4 TCELL 6H DN,M1,1,0
1,-8,GO:0048864,stem cell development,M1,1,0
1,-2.3,M1507,ZAMORA NOS2 TARGETS UP,M1,1,0
1,-3,M3629,GSE15930 STIM VS STIM AND IL12 48H CD8 T CELL UP,M1,1,0
1,-11,WP1539,Angiogenesis,M1,1,0
1,-4.3,M5354,FIRESTEIN PROLIFERATION,M1,1,0
1,-3.4,M2840,CHARAFE BREAST CANCER LUMINAL VS BASAL UP,M1,1,0
1,-2.6,R-HSA-9717189,Sensory perception of taste,M1,1,0
1,-3,M7858,GSE23505 UNTREATED VS 4DAY IL6 IL1 TREATED CD4 TCELL UP,M1,1,0
1,-4,GO:0007219,Notch signaling pathway,M1,1,0
1,-3.8,GO:0042775,mitochondrial ATP synthesis coupled electron transport,M1,1,0
1,-6,R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,M1,1,0
1,-2,M4216,GSE17974 IL4 AND ANTI IL12 VS UNTREATED 6H ACT CD4 TCELL UP,M1,1,0
1,-8.3,GO:0070997,neuron death,M1,1,0
1,-4.2,R-HSA-8953750,Transcriptional Regulation by E2F6,M1,1,0
1,-12,GO:0000725,recombinational repair,M1,1,0
1,-4.4,GO:0050982,detection of mechanical stimulus,M1,1,0
1,-2.9,M17428,GAL LEUKEMIC STEM CELL UP,M1,1,0
1,-2.9,CORUM:1111,DNA synthesome complex (17 subunits),M1,1,0
1,-10,GO:0050867,positive regulation of cell activation,M1,1,0
1,-11,GO:1904035,regulation of epithelial cell apoptotic process,M1,1,0
1,-4.2,GO:0003179,heart valve morphogenesis,M1,1,0
1,-3,GO:0045296,cadherin binding,M1,1,0
1,-4.4,M5203,GSE360 L DONOVANI VS B MALAYI LOW DOSE DC UP,M1,1,0
1,-2.8,M1609,LEE CALORIE RESTRICTION NEOCORTEX DN,M1,1,0
1,-4.7,CORUM:5400,BRCC complex,M1,1,0
1,-2.4,M6943,GSE6674 PL2 3 VS ANTI IGM AND CPG STIM BCELL DN,M1,1,0
1,-3.7,M9080,GSE35685 CD34POS CD10NEG CD62LPOS VS CD34POS CD10POS BONE MARROW UP,M1,1,0
1,-2.5,M7885,GSE23925 LIGHT ZONE VS NAIVE BCELL UP,M1,1,0
1,-3.9,GO:0034705,potassium channel complex,M1,1,0
1,-2.2,GO:0001935,endothelial cell proliferation,M1,1,0
1,-3.3,GO:0002762,negative regulation of myeloid leukocyte differentiation,M1,1,0
1,-5.9,GO:0072163,mesonephric epithelium development,M1,1,0
1,-2.9,GO:0061983,meiosis II cell cycle process,M1,1,0
1,-2.4,M7049,GSE15330 LYMPHOID MULTIPOTENT VS GRANULOCYTE MONOCYTE PROGENITOR IKAROS KO DN,M1,1,0
1,-3.5,GO:0051403,stress-activated MAPK cascade,M1,1,0
1,-5.9,GO:1905330,regulation of morphogenesis of an epithelium,M1,1,0
1,-3.2,M737,LIEN BREAST CARCINOMA METAPLASTIC VS DUCTAL DN,M1,1,0
1,-2.8,M2639,GCNP SHH UP EARLY.V1 UP,M1,1,0
1,-5.7,GO:0072091,regulation of stem cell proliferation,M1,1,0
1,-2.7,M14573,BENPORATH NOS TARGETS,M1,1,0
1,-3.5,GO:0021895,cerebral cortex neuron differentiation,M1,1,0
1,-6.4,GO:0005249,voltage-gated potassium channel activity,M1,1,0
1,-2.6,GO:0051972,regulation of telomerase activity,M1,1,0
1,-3.7,GO:0009615,response to virus,M1,1,0
1,-3.1,GO:0098661,inorganic anion transmembrane transport,M1,1,0
1,-3.5,M16845,MYLLYKANGAS AMPLIFICATION HOT SPOT 12,M1,1,0
1,-2.2,R-HSA-4090294,SUMOylation of intracellular receptors,M1,1,0
1,-2,M2758,PTEN DN.V2 DN,M1,1,0
1,-3.9,R-HSA-9013420,RHOU GTPase cycle,M1,1,0
1,-2.6,GO:2000178,negative regulation of neural precursor cell proliferation,M1,1,0
1,-2.3,R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),M1,1,0
1,-3.3,M10236,BORCZUK MALIGNANT MESOTHELIOMA UP,M1,1,0
1,-3.2,M7952,GALLUZZI PREVENT MITOCHONDIAL PERMEABILIZATION,M1,1,0
1,-5.5,GO:0007276,gamete generation,M1,1,0
1,-4.3,M251,PID SYNDECAN 3 PATHWAY,M1,1,0
1,-3,M6453,GSE3039 B2 VS B1 BCELL DN,M1,1,0
1,-3,M1466,AFFAR YY1 TARGETS UP,M1,1,0
1,-2.3,R-HSA-5620971,Pyroptosis,M1,1,0
1,-3,M5565,GSE3982 BASOPHIL VS TH1 DN,M1,1,0
1,-3.8,GO:0003401,axis elongation,M1,1,0
1,-3,M8614,GSE32986 UNSTIM VS CURDLAN HIGHDOSE STIM DC UP,M1,1,0
1,-11,GO:0010389,regulation of G2/M transition of mitotic cell cycle,M1,1,0
1,-6.8,M863,LEI MYB TARGETS,M1,1,0
1,-20,R-HSA-8953897,Cellular responses to stimuli,M1,1,0
1,-2,GO:0031112,positive regulation of microtubule polymerization or depolymerization,M1,1,0
1,-3,GO:0016032,viral process,M1,1,0
1,-2.4,M3865,GSE17721 PAM3CSK4 VS CPG 8H BMDC UP,M1,1,0
1,-3,GO:0032838,plasma membrane bounded cell projection cytoplasm,M1,1,0
1,-5.1,M5567,GSE3982 BASOPHIL VS TH2 DN,M1,1,0
1,-4,GO:1903764,regulation of potassium ion export across plasma membrane,M1,1,0
1,-10,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M1,1,0
1,-3.5,M13283,HSIAO LIVER SPECIFIC GENES,M1,1,0
1,-2.2,M10914,STARK PREFRONTAL CORTEX 22Q11 DELETION DN,M1,1,0
1,-3.2,R-HSA-399955,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,M1,1,0
1,-2.2,GO:0030018,Z disc,M1,1,0
1,-4.1,M13220,OUELLET CULTURED OVARIAN CANCER INVASIVE VS LMP DN,M1,1,0
1,-6.4,GO:0030168,platelet activation,M1,1,0
1,-18,hsa05169,Epstein-Barr virus infection,M1,1,0
1,-9.4,M271,PID PI3K PLC TRK PATHWAY,M1,1,0
1,-16,WP2018,RANKL/RANK signaling pathway,M1,1,0
1,-4.4,M9696,GSE43955 10H VS 30H ACT CD4 TCELL WITH TGFB IL6 UP,M1,1,0
1,-4.9,GO:0010591,regulation of lamellipodium assembly,M1,1,0
1,-11,GO:0001942,hair follicle development,M1,1,0
1,-2.4,M12135,MARTORIATI MDM4 TARGETS NEUROEPITHELIUM DN,M1,1,0
1,-6.4,GO:0002690,positive regulation of leukocyte chemotaxis,M1,1,0
1,-11,GO:0051905,establishment of pigment granule localization,M1,1,0
1,-3.6,GO:0030336,negative regulation of cell migration,M1,1,0
1,-3.6,GO:0004715,non-membrane spanning protein tyrosine kinase activity,M1,1,0
1,-17,WP3932,Focal adhesion: PI3K-Akt-mTOR-signaling pathway,M1,1,0
1,-3.8,GO:0046578,regulation of Ras protein signal transduction,M1,1,0
1,-3.7,M4592,JEON SMAD6 TARGETS UP,M1,1,0
1,-4.1,M15975,LIEN BREAST CARCINOMA METAPLASTIC VS DUCTAL UP,M1,1,0
1,-2.5,M8960,GSE37532 TREG VS TCONV PPARG KO CD4 TCELL FROM LN DN,M1,1,0
1,-4.3,GO:0009259,ribonucleotide metabolic process,M1,1,0
1,-7.3,GO:0071383,cellular response to steroid hormone stimulus,M1,1,0
1,-3,R-HSA-9679506,SARS-CoV Infections,M1,1,0
1,-8.2,GO:0001952,regulation of cell-matrix adhesion,M1,1,0
1,-3.4,GO:0031365,N-terminal protein amino acid modification,M1,1,0
1,-6.2,GO:0044389,ubiquitin-like protein ligase binding,M1,1,0
1,-7.6,R-HSA-9658195,Leishmania infection,M1,1,0
1,-12,GO:0048015,phosphatidylinositol-mediated signaling,M1,1,0
1,-27,GO:0002520,immune system development,M1,1,0
1,-5,WP5200,Dravet syndrome,M1,1,0
1,-5.8,GO:0031252,cell leading edge,M1,1,0
1,-7,GO:0005657,replication fork,M1,1,0
1,-3,M4080,GSE17721 0.5H VS 24H LPS BMDC DN,M1,1,0
1,-2.4,M5167,GSE360 CTRL VS B MALAYI HIGH DOSE MAC DN,M1,1,0
1,-9.9,GO:0051219,phosphoprotein binding,M1,1,0
1,-7.3,R-HSA-5655253,Signaling by FGFR2 in disease,M1,1,0
1,-4.7,GO:0016004,phospholipase activator activity,M1,1,0
1,-9.7,GO:0007031,peroxisome organization,M1,1,0
1,-4.7,GO:0031594,neuromuscular junction,M1,1,0
1,-3.2,GO:0001741,XY body,M1,1,0
1,-3.8,GO:0051893,regulation of focal adhesion assembly,M1,1,0
1,-3.1,GO:0001776,leukocyte homeostasis,M1,1,0
1,-2.4,M4633,GSE24634 IL4 VS CTRL TREATED NAIVE CD4 TCELL DAY5 UP,M1,1,0
1,-8.6,GO:0000723,telomere maintenance,M1,1,0
1,-10,GO:0045930,negative regulation of mitotic cell cycle,M1,1,0
1,-12,GO:0120031,plasma membrane bounded cell projection assembly,M1,1,0
1,-14,R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),M1,1,0
1,-16,R-HSA-74751,Insulin receptor signalling cascade,M1,1,0
1,-7.4,M1587,YIH RESPONSE TO ARSENITE C4,M1,1,0
1,-7.3,R-HSA-9018519,Estrogen-dependent gene expression,M1,1,0
1,-2.6,M2863,KRAS.DF.V1 UP,M1,1,0
1,-2.8,GO:0018107,peptidyl-threonine phosphorylation,M1,1,0
1,-8.7,GO:0051348,negative regulation of transferase activity,M1,1,0
1,-6.6,GO:0051091,positive regulation of DNA-binding transcription factor activity,M1,1,0
1,-2.8,GO:0030512,negative regulation of transforming growth factor beta receptor signaling pathway,M1,1,0
1,-6.6,GO:0030162,regulation of proteolysis,M1,1,0
1,-3.1,M6677,GSE5589 WT VS IL10 KO LPS AND IL10 STIM MACROPHAGE 180MIN DN,M1,1,0
1,-6.4,M17200,SA B CELL RECEPTOR COMPLEXES,M1,1,0
1,-4.4,M9846,GSE46606 IRF4HIGH VS IRF4MID CD40L IL2 IL5 DAY3 STIMULATED BCELL DN,M1,1,0
1,-3.8,M1432,SANSOM APC TARGETS DN,M1,1,0
1,-25,hsa04932,Non-alcoholic fatty liver disease,M1,1,0
1,-2.6,M106,PID HNF3B PATHWAY,M1,1,0
1,-8.4,GO:0015267,channel activity,M1,1,0
1,-2.4,GO:0090023,positive regulation of neutrophil chemotaxis,M1,1,0
1,-3,M3394,GSE14308 NAIVE CD4 TCELL VS NATURAL TREG DN,M1,1,0
1,-7.4,GO:0048660,regulation of smooth muscle cell proliferation,M1,1,0
1,-5.6,GO:0051540,metal cluster binding,M1,1,0
1,-5.4,M2605,ONKEN UVEAL MELANOMA DN,M1,1,0
1,-2,M10292,HONMA DOCETAXEL RESISTANCE,M1,1,0
1,-3.6,M32,PID HDAC CLASSIII PATHWAY,M1,1,0
1,-4.4,M6606,GSE5589 UNSTIM VS 45MIN LPS AND IL6 STIM MACROPHAGE UP,M1,1,0
1,-2.5,M5182,GSE360 DC VS MAC L MAJOR DN,M1,1,0
1,-5.5,GO:0003678,DNA helicase activity,M1,1,0
1,-12,M142,PID AJDISS 2PATHWAY,M1,1,0
1,-3.2,GO:0002931,response to ischemia,M1,1,0
1,-2.4,M14614,SAKAI TUMOR INFILTRATING MONOCYTES UP,M1,1,0
1,-4.3,R-HSA-418990,Adherens junctions interactions,M1,1,0
1,-23,GO:0009314,response to radiation,M1,1,0
1,-4.5,M1286,HOSHIDA LIVER CANCER SUBCLASS S3,M1,1,0
1,-2.2,GO:0016878,acid-thiol ligase activity,M1,1,0
1,-2.6,GO:0046823,negative regulation of nucleocytoplasmic transport,M1,1,0
1,-6.8,GO:0035094,response to nicotine,M1,1,0
1,-8.2,WP5124,Alzheimer's disease,M1,1,0
1,-5.8,GO:0048009,insulin-like growth factor receptor signaling pathway,M1,1,0
1,-3.6,M9788,MOOTHA PGC,M1,1,0
1,-4,WP623,Oxidative phosphorylation,M1,1,0
1,-3,M4668,GSE26669 CD4 VS CD8 TCELL IN MLR UP,M1,1,0
1,-4.5,M201,PID ERBB NETWORK PATHWAY,M1,1,0
1,-2.4,M386,GSE7219 WT VS NIK NFKB2 KO LPS AND ANTI CD40 STIM DC DN,M1,1,0
1,-12,hsa05152,Tuberculosis,M1,1,0
1,-7.5,R-HSA-195258,RHO GTPase Effectors,M1,1,0
1,-4.8,GO:0022834,ligand-gated channel activity,M1,1,0
1,-9.2,GO:0002065,columnar/cuboidal epithelial cell differentiation,M1,1,0
1,-3.4,GO:0005165,neurotrophin receptor binding,M1,1,0
1,-2.2,GO:1903670,regulation of sprouting angiogenesis,M1,1,0
1,-12,hsa04666,Fc gamma R-mediated phagocytosis,M1,1,0
1,-8.3,M4493,REN BOUND BY E2F,M1,1,0
1,-7.3,M125,PID IGF1 PATHWAY,M1,1,0
1,-4.6,M4933,GSE29617 DAY3 VS DAY7 TIV FLU VACCINE PBMC 2008 UP,M1,1,0
1,-3.7,M5221,GSE360 T GONDII VS M TUBERCULOSIS DC DN,M1,1,0
1,-3.4,GO:0015108,chloride transmembrane transporter activity,M1,1,0
1,-3.5,M19025,MOREAUX MULTIPLE MYELOMA BY TACI UP,M1,1,0
1,-5.7,CORUM:2944,Notch1-p56lck-PI3K complex,M1,1,0
1,-14,GO:0048667,cell morphogenesis involved in neuron differentiation,M1,1,0
1,-2.7,GO:0004860,protein kinase inhibitor activity,M1,1,0
1,-3.6,M162,PID RXR VDR PATHWAY,M1,1,0
1,-5.3,GO:0007498,mesoderm development,M1,1,0
1,-2.9,M1124,MCBRYAN PUBERTAL TGFB1 TARGETS UP,M1,1,0
1,-3,M7271,GSE19923 HEB KO VS HEB AND E2A KO DP THYMOCYTE DN,M1,1,0
1,-5.8,GO:0010812,negative regulation of cell-substrate adhesion,M1,1,0
1,-9.6,R-HSA-5637812,Signaling by EGFRvIII in Cancer,M1,1,0
1,-2,M11333,WEIGEL OXIDATIVE STRESS BY TBH AND H2O2,M1,1,0
1,-2.1,M6756,GSE6259 33D1 POS DC VS CD4 TCELL UP,M1,1,0
1,-3.7,GO:0106027,neuron projection organization,M1,1,0
1,-8.1,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M1,1,0
1,-10,GO:0003713,transcription coactivator activity,M1,1,0
1,-11,WP3680,Physico-chemical features and toxicity-associated pathways,M1,1,0
1,-7.4,GO:0070920,regulation of production of small RNA involved in gene silencing by RNA,M1,1,0
1,-5.5,GO:0000228,nuclear chromosome,M1,1,0
1,-5.2,WP4538,Regulatory circuits of the STAT3 signaling pathway,M1,1,0
1,-4.3,M18895,SA TRKA RECEPTOR,M1,1,0
1,-8.6,GO:0022836,gated channel activity,M1,1,0
1,-2.5,M7321,GSE19888 ADENOSINE A3R INH PRETREAT AND ACT BY A3R VS TCELL MEMBRANES ACT MAST CELL DN,M1,1,0
1,-11,GO:0002694,regulation of leukocyte activation,M1,1,0
1,-13,GO:0042063,gliogenesis,M1,1,0
1,-3.1,GO:0033599,regulation of mammary gland epithelial cell proliferation,M1,1,0
1,-7.5,M4008,FARMER BREAST CANCER APOCRINE VS LUMINAL,M1,1,0
1,-3,M8322,GSE28726 NAIVE VS ACTIVATED VA24NEG NKTCELL UP,M1,1,0
1,-2.8,GO:0008301,"DNA binding, bending",M1,1,0
1,-6.3,GO:0008610,lipid biosynthetic process,M1,1,0
1,-3,M2123,HIRSCH CELLULAR TRANSFORMATION SIGNATURE UP,M1,1,0
1,-2.3,R-HSA-432722,Golgi Associated Vesicle Biogenesis,M1,1,0
1,-3.1,R-HSA-4839743,Signaling by CTNNB1 phospho-site mutants,M1,1,0
1,-27,hsa05224,Breast cancer,M1,1,0
1,-2.4,GO:0002708,positive regulation of lymphocyte mediated immunity,M1,1,0
1,-9.3,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M1,1,0
1,-2.7,WP4577,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway,M1,1,0
1,-5.4,GO:0046545,development of primary female sexual characteristics,M1,1,0
1,-11,M15305,PUJANA BRCA CENTERED NETWORK,M1,1,0
1,-4.2,GO:0043235,receptor complex,M1,1,0
1,-3,M5230,GSE360 LOW DOSE B MALAYI VS M TUBERCULOSIS DC DN,M1,1,0
1,-3,GO:0001756,somitogenesis,M1,1,0
1,-2.3,WP4721,Eicosanoid metabolism via lipooxygenases (LOX),M1,1,0
1,-2.8,GO:0032026,response to magnesium ion,M1,1,0
1,-19,GO:0001775,cell activation,M1,1,0
1,-2.3,GO:0060632,regulation of microtubule-based movement,M1,1,0
1,-3.8,WP4479,Supression of HMGB1 mediated inflammation by THBD,M1,1,0
1,-2.3,GO:0050996,positive regulation of lipid catabolic process,M1,1,0
1,-2.3,WP3925,Amino acid metabolism,M1,1,0
1,-4,GO:1905278,positive regulation of epithelial tube formation,M1,1,0
1,-12,hsa04140,Autophagy - animal,M1,1,0
1,-19,M127,PID ERBB1 RECEPTOR PROXIMAL PATHWAY,M1,1,0
1,-3,M9952,GSE41176 WT VS TAK1 KO ANTI IGM STIM BCELL 24H DN,M1,1,0
1,-3,M9627,GSE43956 WT VS SGK1 KO TH17 DIFFERENTIATED CD4 TCELL UP,M1,1,0
1,-2.1,GO:0010664,negative regulation of striated muscle cell apoptotic process,M1,1,0
1,-11,GO:0051875,pigment granule localization,M1,1,0
1,-4,GO:0008366,axon ensheathment,M1,1,0
1,-5.2,GO:0044321,response to leptin,M1,1,0
1,-3.7,GO:1900407,regulation of cellular response to oxidative stress,M1,1,0
1,-2.7,GO:0072593,reactive oxygen species metabolic process,M1,1,0
1,-14,WP364,IL6 signaling pathway,M1,1,0
1,-3.2,GO:0009062,fatty acid catabolic process,M1,1,0
1,-4.4,R-HSA-383280,Nuclear Receptor transcription pathway,M1,1,0
1,-3.3,R-HSA-75153,Apoptotic execution phase,M1,1,0
1,-13,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M1,1,0
1,-4.7,M3278,DE YY1 TARGETS DN,M1,1,0
1,-15,GO:0048514,blood vessel morphogenesis,M1,1,0
1,-2,GO:0030101,natural killer cell activation,M1,1,0
1,-2.5,M6222,GRABARCZYK BCL11B TARGETS UP,M1,1,0
1,-5.7,GO:0000079,regulation of cyclin-dependent protein serine/threonine kinase activity,M1,1,0
1,-7.2,GO:1902893,regulation of miRNA transcription,M1,1,0
1,-2.5,GO:0033260,nuclear DNA replication,M1,1,0
1,-5.6,GO:0097746,blood vessel diameter maintenance,M1,1,0
1,-5.8,GO:0086010,membrane depolarization during action potential,M1,1,0
1,-2.8,GO:0051056,regulation of small GTPase mediated signal transduction,M1,1,0
1,-2.9,GO:0048167,regulation of synaptic plasticity,M1,1,0
1,-2.4,M3939,GSE17721 POLYIC VS CPG 2H BMDC DN,M1,1,0
1,-2.5,M4132,GSE17721 12H VS 24H CPG BMDC UP,M1,1,0
1,-3.7,M5052,GSE30962 ACUTE VS CHRONIC LCMV SECONDARY INF CD8 TCELL DN,M1,1,0
1,-2.7,GO:0000139,Golgi membrane,M1,1,0
1,-11,R-HSA-201556,Signaling by ALK,M1,1,0
1,-6,GO:0032107,regulation of response to nutrient levels,M1,1,0
1,-3.7,GO:0048664,neuron fate determination,M1,1,0
1,-3.2,R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",M1,1,0
1,-2.1,GO:0005903,brush border,M1,1,0
1,-3.2,GO:0048640,negative regulation of developmental growth,M1,1,0
1,-12,GO:1990351,transporter complex,M1,1,0
1,-5.2,GO:0043551,regulation of phosphatidylinositol 3-kinase activity,M1,1,0
1,-7.1,GO:0072009,nephron epithelium development,M1,1,0
1,-4.7,M8512,TSAI RESPONSE TO IONIZING RADIATION,M1,1,0
1,-2.5,M3113,GSE11057 CD4 EFF MEM VS PBMC UP,M1,1,0
1,-3.9,GO:0055069,zinc ion homeostasis,M1,1,0
1,-2.4,M3752,GSE17721 CTRL VS PAM3CSK4 24H BMDC DN,M1,1,0
1,-5.7,R-HSA-1839124,FGFR1 mutant receptor activation,M1,1,0
1,-2.5,M5448,GSE3982 MAST CELL VS CENT MEMORY CD4 TCELL DN,M1,1,0
1,-5.4,WP2857,Mesodermal commitment pathway,M1,1,0
1,-3,M843,STEIN ESRRA TARGETS,M1,1,0
1,-2.8,GO:2000008,regulation of protein localization to cell surface,M1,1,0
1,-2.7,GO:0032495,response to muramyl dipeptide,M1,1,0
1,-17,WP4016,DNA IR-damage and cellular response via ATR,M1,1,0
1,-2.1,M11234,THEILGAARD NEUTROPHIL AT SKIN WOUND DN,M1,1,0
1,-9.5,GO:0090287,regulation of cellular response to growth factor stimulus,M1,1,0
1,-5.7,CORUM:571,p300-CBP-p270 complex,M1,1,0
1,-7.7,GO:0050870,positive regulation of T cell activation,M1,1,0
1,-2.7,M17427,DOANE BREAST CANCER CLASSES UP,M1,1,0
1,-4.7,GO:0006120,"mitochondrial electron transport, NADH to ubiquinone",M1,1,0
1,-4.2,GO:0000019,regulation of mitotic recombination,M1,1,0
1,-14,GO:0046649,lymphocyte activation,M1,1,0
1,-2.8,M1273,SHETH LIVER CANCER VS TXNIP LOSS PAM1,M1,1,0
1,-4.4,M5209,GSE360 L MAJOR VS B MALAYI HIGH DOSE DC UP,M1,1,0
1,-3.4,GO:0051304,chromosome separation,M1,1,0
1,-4.1,M18979,HAMAI APOPTOSIS VIA TRAIL UP,M1,1,0
1,-4.4,R-HSA-1433559,Regulation of KIT signaling,M1,1,0
1,-6.3,M41,PID ER NONGENOMIC PATHWAY,M1,1,0
1,-13,M124,PID CXCR4 PATHWAY,M1,1,0
1,-6.2,GO:0043255,regulation of carbohydrate biosynthetic process,M1,1,0
1,-3.4,M9802,BROWNE HCMV INFECTION 1HR DN,M1,1,0
1,-4.2,GO:0008076,voltage-gated potassium channel complex,M1,1,0
1,-4.6,GO:0043627,response to estrogen,M1,1,0
1,-5.2,GO:0030518,intracellular steroid hormone receptor signaling pathway,M1,1,0
1,-2.7,GO:2000629,negative regulation of miRNA metabolic process,M1,1,0
1,-2.4,GO:0003156,regulation of animal organ formation,M1,1,0
1,-16,R-HSA-9009391,Extra-nuclear estrogen signaling,M1,1,0
1,-6.4,GO:0043401,steroid hormone mediated signaling pathway,M1,1,0
1,-3.6,M14435,TIAN TNF SIGNALING VIA NFKB,M1,1,0
1,-19,hsa04015,Rap1 signaling pathway,M1,1,0
1,-6,R-HSA-112316,Neuronal System,M1,1,0
1,-6.3,M9433,MOOTHA HUMAN MITODB 6 2002,M1,1,0
1,-5.3,GO:0021915,neural tube development,M1,1,0
1,-7.5,M1233,OHM METHYLATED IN ADULT CANCERS,M1,1,0
1,-12,GO:0034762,regulation of transmembrane transport,M1,1,0
1,-4.2,GO:0002020,protease binding,M1,1,0
1,-2.4,GO:0009651,response to salt stress,M1,1,0
1,-3.1,GO:0045943,positive regulation of transcription by RNA polymerase I,M1,1,0
1,-4.6,hsa04921,Oxytocin signaling pathway,M1,1,0
1,-10,M156,PID ECADHERIN NASCENT AJ PATHWAY,M1,1,0
1,-4.5,GO:0014704,intercalated disc,M1,1,0
1,-3.6,GO:1901361,organic cyclic compound catabolic process,M1,1,0
1,-16,R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,M1,1,0
1,-2.2,M19170,MULLIGHAN NPM1 MUTATED SIGNATURE 1 UP,M1,1,0
1,-2.4,GO:0001835,blastocyst hatching,M1,1,0
1,-2.3,GO:0031668,cellular response to extracellular stimulus,M1,1,0
1,-2.8,M768,REN ALVEOLAR RHABDOMYOSARCOMA UP,M1,1,0
1,-2.1,GO:0097061,dendritic spine organization,M1,1,0
1,-10,GO:0034599,cellular response to oxidative stress,M1,1,0
1,-3.3,M8845,CHIN BREAST CANCER COPY NUMBER DN,M1,1,0
1,-6.8,M2700,SMID BREAST CANCER RELAPSE IN BONE DN,M1,1,0
1,-2.3,GO:0048168,regulation of neuronal synaptic plasticity,M1,1,0
1,-9.3,GO:0007093,mitotic cell cycle checkpoint signaling,M1,1,0
1,-4.6,M121,PID MTOR 4PATHWAY,M1,1,0
1,-3,M5699,GSE7460 CTRL VS TGFB TREATED ACT FOXP3 MUT TCONV DN,M1,1,0
1,-3.4,GO:0090049,regulation of cell migration involved in sprouting angiogenesis,M1,1,0
1,-11,GO:0008022,protein C-terminus binding,M1,1,0
1,-3.3,M242,PID AURORA A PATHWAY,M1,1,0
1,-2.6,R-HSA-6802949,Signaling by RAS mutants,M1,1,0
1,-3.4,R-HSA-9755779,SARS-CoV-2 targets host intracellular signalling and regulatory pathways,M1,1,0
1,-3,M4604,GSE24634 TREG VS TCONV POST DAY7 IL4 CONVERSION UP,M1,1,0
1,-3.8,M3837,WEST ADRENOCORTICAL TUMOR DN,M1,1,0
1,-3.7,M3945,GSE17721 POLYIC VS CPG 8H BMDC UP,M1,1,0
1,-2.3,M19341,KRIGE AMINO ACID DEPRIVATION,M1,1,0
1,-3,M3669,GSE16755 CTRL VS IFNA TREATED MAC DN,M1,1,0
1,-6,GO:0015980,energy derivation by oxidation of organic compounds,M1,1,0
1,-2.4,GO:0038179,neurotrophin signaling pathway,M1,1,0
1,-2.3,hsa05410,Hypertrophic cardiomyopathy,M1,1,0
1,-3.6,M20,PID P38 MKK3 6PATHWAY,M1,1,0
1,-8.5,R-HSA-168898,Toll-like Receptor Cascades,M1,1,0
1,-2.1,M1577,BURTON ADIPOGENESIS 3,M1,1,0
1,-11,GO:0036293,response to decreased oxygen levels,M1,1,0
1,-2.5,M7645,GSE22140 GERMFREE VS SPF ARTHRITIC MOUSE CD4 TCELL DN,M1,1,0
1,-3.8,M38972,JINESH BLEBBISHIELD TO IMMUNE CELL FUSION PBSHMS UP,M1,1,0
1,-2.4,M6431,GSE3039 CD4 TCELL VS NKT CELL DN,M1,1,0
1,-2,M86,PID ARF6 PATHWAY,M1,1,0
1,-2.9,GO:0051983,regulation of chromosome segregation,M1,1,0
1,-9.2,M226,PID VEGFR1 PATHWAY,M1,1,0
1,-3.7,CORUM:1252,EBAFa complex,M1,1,0
1,-2.4,M9474,GSE41867 NAIVE VS EFFECTOR CD8 TCELL UP,M1,1,0
1,-7.2,GO:0032200,telomere organization,M1,1,0
1,-5.1,GO:0032099,negative regulation of appetite,M1,1,0
1,-3.9,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M1,1,0
1,-5.9,GO:0071248,cellular response to metal ion,M1,1,0
1,-7,GO:0048738,cardiac muscle tissue development,M1,1,0
1,-9.4,GO:0031903,microbody membrane,M1,1,0
1,-11,GO:0031400,negative regulation of protein modification process,M1,1,0
1,-4.2,GO:0060745,mammary gland branching involved in pregnancy,M1,1,0
1,-2.4,GO:0006959,humoral immune response,M1,1,0
1,-19,GO:0003013,circulatory system process,M1,1,0
1,-11,GO:0022405,hair cycle process,M1,1,0
1,-6.4,GO:0099587,inorganic ion import across plasma membrane,M1,1,0
1,-5.8,GO:1904354,negative regulation of telomere capping,M1,1,0
1,-2.5,GO:0070373,negative regulation of ERK1 and ERK2 cascade,M1,1,0
1,-2,M14590,AIGNER ZEB1 TARGETS,M1,1,0
1,-4.3,GO:0110148,biomineralization,M1,1,0
1,-3,M7028,GSE15330 WT VS IKAROS KO GRANULOCYTE MONOCYTE PROGENITOR DN,M1,1,0
1,-2.2,GO:0045666,positive regulation of neuron differentiation,M1,1,0
1,-3,M4387,GSE2197 IMMUNOSUPPRESSIVE DNA VS UNTREATED IN DC UP,M1,1,0
1,-16,hsa05415,Diabetic cardiomyopathy,M1,1,0
1,-2.3,GO:0010507,negative regulation of autophagy,M1,1,0
1,-3.7,M9572,GSE42021 TREG VS TCONV PLN UP,M1,1,0
1,-4.3,GO:0010975,regulation of neuron projection development,M1,1,0
1,-3.2,M2521,RAO BOUND BY SALL4,M1,1,0
1,-3.5,GO:0016746,acyltransferase activity,M1,1,0
1,-5.4,M6809,GSE7218 UNSTIM VS ANTIGEN STIM THROUGH IGG BCELL UP,M1,1,0
1,-2.3,GO:0042417,dopamine metabolic process,M1,1,0
1,-3.4,CORUM:806,BRM-SIN3A-HDAC complex,M1,1,0
1,-5,GO:0033002,muscle cell proliferation,M1,1,0
1,-3.3,M2965,GSE14415 TCONV VS FOXP3 KO INDUCED TREG DN,M1,1,0
1,-2.3,M9869,SASSON RESPONSE TO FORSKOLIN UP,M1,1,0
1,-3.1,M15606,MARKEY RB1 ACUTE LOF UP,M1,1,0
1,-6.8,R-HSA-5621575,CD209 (DC-SIGN) signaling,M1,1,0
1,-6.4,R-HSA-109581,Apoptosis,M1,1,0
1,-4,GO:0008202,steroid metabolic process,M1,1,0
1,-2.7,M1368,SCHAEFFER SOX9 TARGETS IN PROSTATE DEVELOPMENT UP,M1,1,0
1,-5.1,M4026,GSE17721 POLYIC VS GARDIQUIMOD 8H BMDC UP,M1,1,0
1,-6.5,GO:0050680,negative regulation of epithelial cell proliferation,M1,1,0
1,-11,GO:0097190,apoptotic signaling pathway,M1,1,0
1,-22,GO:0007346,regulation of mitotic cell cycle,M1,1,0
1,-2.2,M13954,NIKOLSKY BREAST CANCER 8Q12 Q22 AMPLICON,M1,1,0
1,-5.8,WP2870,Extracellular vesicle-mediated signaling in recipient cells,M1,1,0
1,-4.6,GO:0030308,negative regulation of cell growth,M1,1,0
1,-2.5,M8736,GSE36888 UNTREATED VS IL2 TREATED TCELL 2H DN,M1,1,0
1,-5.2,GO:0032768,regulation of monooxygenase activity,M1,1,0
1,-3,GO:0090050,positive regulation of cell migration involved in sprouting angiogenesis,M1,1,0
1,-4.1,GO:0044270,cellular nitrogen compound catabolic process,M1,1,0
1,-8.1,R-HSA-373753,Nephrin family interactions,M1,1,0
1,-3,M5613,GSE39820 CTRL VS TGFBETA3 IL6 IL23A CD4 TCELL UP,M1,1,0
1,-7.9,GO:0055065,metal ion homeostasis,M1,1,0
1,-9.5,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M1,1,0
1,-11,GO:0043410,positive regulation of MAPK cascade,M1,1,0
1,-3,M986,SMIRNOV CIRCULATING ENDOTHELIOCYTES IN CANCER UP,M1,1,0
1,-4.4,CORUM:2217,MDC1-MRN-ATM-FANCD2 complex,M1,1,0
1,-11,GO:0071103,DNA conformation change,M1,1,0
1,-4.3,GO:0032970,regulation of actin filament-based process,M1,1,0
1,-4.3,GO:0006474,N-terminal protein amino acid acetylation,M1,1,0
1,-5.4,GO:0003206,cardiac chamber morphogenesis,M1,1,0
1,-3.7,GO:0051153,regulation of striated muscle cell differentiation,M1,1,0
1,-4,M12802,SNIJDERS AMPLIFIED IN HEAD AND NECK TUMORS,M1,1,0
1,-3.3,M2469,KRIEG HYPOXIA NOT VIA KDM3A,M1,1,0
1,-4,R-HSA-1989781,PPARA activates gene expression,M1,1,0
1,-6.1,GO:0047485,protein N-terminus binding,M1,1,0
1,-23,R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,M1,1,0
1,-4.2,R-HSA-1912422,Pre-NOTCH Expression and Processing,M1,1,0
1,-2.4,M5823,BROWNE HCMV INFECTION 1HR UP,M1,1,0
1,-5.4,GO:0097718,disordered domain specific binding,M1,1,0
1,-5.3,GO:0045017,glycerolipid biosynthetic process,M1,1,0
1,-2.5,GO:0009303,rRNA transcription,M1,1,0
1,-8.5,CORUM:433,BASC complex (BRCA1-associated genome surveillance complex),M1,1,0
1,-2.9,WP5174,Ulcerative colitis signaling,M1,1,0
1,-11,R-HSA-9006115,Signaling by NTRK2 (TRKB),M1,1,0
1,-2.8,GO:1902894,negative regulation of miRNA transcription,M1,1,0
1,-3.4,GO:0060333,interferon-gamma-mediated signaling pathway,M1,1,0
1,-4.3,WP4874,CAMKK2 pathway,M1,1,0
1,-3,M2509,ABDELMOHSEN ELAVL4 TARGETS,M1,1,0
1,-2.9,GO:0031100,animal organ regeneration,M1,1,0
1,-2.4,GO:0036473,cell death in response to oxidative stress,M1,1,0
1,-2.4,GO:0051851,modulation by host of symbiont process,M1,1,0
1,-4.5,GO:0060325,face morphogenesis,M1,1,0
1,-11,R-HSA-9607240,FLT3 Signaling,M1,1,0
1,-11,WP4483,"Relationship between inflammation, COX-2 and EGFR",M1,1,0
1,-2.7,WP5066,FOXA2 pathway,M1,1,0
1,-4.2,GO:0033138,positive regulation of peptidyl-serine phosphorylation,M1,1,0
1,-2.8,M2413,PEDERSEN METASTASIS BY ERBB2 ISOFORM 7,M1,1,0
1,-3.7,M8867,GSE37301 COMMON LYMPHOID PROGENITOR VS PRO BCELL DN,M1,1,0
1,-3.3,M2664,AKT UP MTOR DN.V1 DN,M1,1,0
1,-5.3,M2191,SUBTIL PROGESTIN TARGETS,M1,1,0
1,-14,GO:0003012,muscle system process,M1,1,0
1,-2.2,M9729,WIKMAN ASBESTOS LUNG CANCER DN,M1,1,0
1,-2.3,M2637,UEDA CENTRAL CLOCK,M1,1,0
1,-2.4,M8625,GSE32986 CURDLAN LOWDOSE VS GMCSF AND CURDLAN LOWDOSE STIM DC UP,M1,1,0
1,-5,M2431,KAUFFMANN MELANOMA RELAPSE UP,M1,1,0
1,-2.4,M9837,GSE46606 UNSTIM VS CD40L IL2 IL5 3DAY STIMULATED IRF4MID SORTED BCELL DN,M1,1,0
1,-2.4,M7077,GSE14908 RESTING VS HDM STIM CD4 TCELL ATOPIC PATIENT UP,M1,1,0
1,-2,GO:0042056,chemoattractant activity,M1,1,0
1,-4.6,GO:0060219,camera-type eye photoreceptor cell differentiation,M1,1,0
1,-2.3,WP4969,RAS and bradykinin pathways in COVID-19,M1,1,0
1,-4.2,M9483,SUNG METASTASIS STROMA UP,M1,1,0
1,-8.3,WP2064,Neural crest differentiation,M1,1,0
1,-3,M9759,GSE43863 TFH VS LY6C INT CXCR5POS MEMORY CD4 TCELL UP,M1,1,0
1,-6.9,WP422,MAPK cascade,M1,1,0
1,-15,GO:0001934,positive regulation of protein phosphorylation,M1,1,0
1,-2.1,R-HSA-73887,Death Receptor Signalling,M1,1,0
1,-2.3,GO:0007098,centrosome cycle,M1,1,0
1,-3.4,GO:0010575,positive regulation of vascular endothelial growth factor production,M1,1,0
1,-3.1,M5287,GSE36476 CTRL VS TSST ACT 16H MEMORY CD4 TCELL YOUNG UP,M1,1,0
1,-19,R-HSA-9709603,Impaired BRCA2 binding to PALB2,M1,1,0
1,-5.7,R-HSA-5654710,PI-3K cascade:FGFR3,M1,1,0
1,-3.5,GO:0009299,mRNA transcription,M1,1,0
1,-5.5,GO:0051648,vesicle localization,M1,1,0
1,-5.1,M300,GSE10240 CTRL VS IL17 STIM PRIMARY BRONCHIAL EPITHELIAL CELLS UP,M1,1,0
1,-5,GO:0010226,response to lithium ion,M1,1,0
1,-2.7,R-HSA-5663220,RHO GTPases Activate Formins,M1,1,0
1,-3.3,GO:0019199,transmembrane receptor protein kinase activity,M1,1,0
1,-14,hsa04115,p53 signaling pathway,M1,1,0
1,-2.9,R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,M1,1,0
1,-9.7,R-HSA-8878159,Transcriptional regulation by RUNX3,M1,1,0
1,-11,WP4656,Joubert syndrome,M1,1,0
1,-4.4,R-HSA-5660668,CLEC7A/inflammasome pathway,M1,1,0
1,-14,WP5234,Bardet-Biedl syndrome,M1,1,0
1,-3.9,GO:0000795,synaptonemal complex,M1,1,0
1,-5.2,hsa05216,Thyroid cancer,M1,1,0
1,-6,GO:2000696,regulation of epithelial cell differentiation involved in kidney development,M1,1,0
1,-3.5,GO:0030312,external encapsulating structure,M1,1,0
1,-2.2,GO:0000791,euchromatin,M1,1,0
1,-5.4,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M1,1,0
1,-2.4,GO:0032740,positive regulation of interleukin-17 production,M1,1,0
1,-11,WP4754,IL-18 signaling pathway,M1,1,0
1,-4.1,GO:0016358,dendrite development,M1,1,0
1,-12,GO:0010638,positive regulation of organelle organization,M1,1,0
1,-3.1,GO:0001227,"DNA-binding transcription repressor activity, RNA polymerase II-specific",M1,1,0
1,-3,R-HSA-5689901,Metalloprotease DUBs,M1,1,0
1,-7.6,M16488,DING LUNG CANCER MUTATED SIGNIFICANTLY,M1,1,0
1,-9.6,GO:0042391,regulation of membrane potential,M1,1,0
1,-3.4,R-HSA-190373,FGFR1c ligand binding and activation,M1,1,0
1,-2.1,GO:0005525,GTP binding,M1,1,0
1,-2.5,M7035,GSE15330 HSC VS LYMPHOID PRIMED MULTIPOTENT PROGENITOR IKAROS KO DN,M1,1,0
1,-2.4,M17537,JI RESPONSE TO FSH DN,M1,1,0
1,-24,WP2037,Prolactin signaling pathway,M1,1,0
1,-4.5,R-HSA-525793,Myogenesis,M1,1,0
1,-4.7,GO:1905114,cell surface receptor signaling pathway involved in cell-cell signaling,M1,1,0
1,-5.1,CORUM:2470,p130Cas-ER-alpha-cSrc-kinase- PI3-kinase p85-subunit complex,M1,1,0
1,-3,M9639,HAN SATB1 TARGETS UP,M1,1,0
1,-4.4,R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,M1,1,0
1,-3,M9682,GSE43955 1H VS 60H ACT CD4 TCELL WITH TGFB IL6 UP,M1,1,0
1,-2.4,M10688,PAL PRMT5 TARGETS UP,M1,1,0
1,-4.1,M17082,HADDAD T LYMPHOCYTE AND NK PROGENITOR UP,M1,1,0
1,-2.5,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M1,1,0
1,-3.1,R-HSA-5628897,TP53 Regulates Metabolic Genes,M1,1,0
1,-3.7,M5555,GSE3982 BCELL VS TH2 DN,M1,1,0
1,-7.4,hsa05100,Bacterial invasion of epithelial cells,M1,1,0
1,-13,GO:0030029,actin filament-based process,M1,1,0
1,-4.4,WP2435,Quercetin and Nf-kB / AP-1 induced apoptosis,M1,1,0
1,-8.1,GO:0002456,T cell mediated immunity,M1,1,0
1,-3.8,GO:0052812,"phosphatidylinositol-3,4-bisphosphate 5-kinase activity",M1,1,0
1,-2.4,M7211,GSE16266 CTRL VS HEATSHOCK AND LPS STIM MEF UP,M1,1,0
1,-4.4,GO:0032770,positive regulation of monooxygenase activity,M1,1,0
1,-6.8,M12705,SIG CD40PATHWAYMAP,M1,1,0
1,-2.1,R-HSA-193704,p75 NTR receptor-mediated signalling,M1,1,0
1,-7,GO:0007519,skeletal muscle tissue development,M1,1,0
1,-9.6,GO:0070849,response to epidermal growth factor,M1,1,0
1,-12,R-HSA-389357,CD28 dependent PI3K/Akt signaling,M1,1,0
1,-2.1,GO:0071384,cellular response to corticosteroid stimulus,M1,1,0
1,-8.2,GO:0110025,DNA strand resection involved in replication fork processing,M1,1,0
1,-2.5,M5205,GSE360 L DONOVANI VS M TUBERCULOSIS DC UP,M1,1,0
1,-6,R-HSA-69242,S Phase,M1,1,0
1,-2.5,M8404,GSE29949 CD8 NEG DC SPLEEN VS MONOCYTE BONE MARROW UP,M1,1,0
1,-8.9,GO:0061061,muscle structure development,M1,1,0
1,-2.4,M4448,BOYAULT LIVER CANCER SUBCLASS G23 UP,M1,1,0
1,-3.9,GO:0032098,regulation of appetite,M1,1,0
1,-5.1,GO:0072711,cellular response to hydroxyurea,M1,1,0
1,-3.7,M5391,GSE3982 DC VS NEUTROPHIL LPS STIM UP,M1,1,0
1,-5.3,GO:1901522,positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus,M1,1,0
1,-17,R-HSA-5683057,MAPK family signaling cascades,M1,1,0
1,-2.3,GO:0015459,potassium channel regulator activity,M1,1,0
1,-4.9,GO:0001503,ossification,M1,1,0
1,-4,GO:0018958,phenol-containing compound metabolic process,M1,1,0
1,-4.4,M9677,GSE43955 1H VS 20H ACT CD4 TCELL WITH TGFB IL6 DN,M1,1,0
1,-5.1,GO:0050769,positive regulation of neurogenesis,M1,1,0
1,-2.4,M5423,GSE3982 EOSINOPHIL VS TH1 DN,M1,1,0
1,-7.1,M5193,SIG CHEMOTAXIS,M1,1,0
1,-2.4,M9931,GSE41176 UNSTIM VS ANTI IGM STIM TAK1 KO BCELL 6H UP,M1,1,0
1,-3.8,GO:0060117,auditory receptor cell development,M1,1,0
1,-17,WP3646,Hepatitis C and hepatocellular carcinoma,M1,1,0
1,-6.8,WP4300,Extracellular vesicles in the crosstalk of cardiac cells,M1,1,0
1,-3,M5235,GSE360 L DONOVANI VS B MALAYI HIGH DOSE MAC UP,M1,1,0
1,-4,M4780,WANG SMARCE1 TARGETS DN,M1,1,0
1,-3.1,GO:0010765,positive regulation of sodium ion transport,M1,1,0
1,-7.9,GO:0043254,regulation of protein-containing complex assembly,M1,1,0
1,-2.7,M15896,MARTINEZ RB1 AND TP53 TARGETS UP,M1,1,0
1,-4.2,M197,PID HIV NEF PATHWAY,M1,1,0
1,-4.5,R-HSA-5358508,Mismatch Repair,M1,1,0
1,-3.5,GO:0014820,tonic smooth muscle contraction,M1,1,0
1,-2.4,GO:0045649,regulation of macrophage differentiation,M1,1,0
1,-3.2,R-HSA-5696399,Global Genome Nucleotide Excision Repair (GG-NER),M1,1,0
1,-3.2,GO:0010256,endomembrane system organization,M1,1,0
1,-20,R-HSA-9701190,Defective homologous recombination repair (HRR) due to BRCA2 loss of function,M1,1,0
1,-3.1,GO:0004386,helicase activity,M1,1,0
1,-3.4,M6757,GSE6259 33D1 POS DC VS CD4 TCELL DN,M1,1,0
1,-14,WP3959,DNA IR-double strand breaks and cellular response via ATM,M1,1,0
1,-5.1,WP4830,GDNF/RET signaling axis,M1,1,0
1,-4.6,M2652,CYCLIN D1 UP.V1 DN,M1,1,0
1,-8.2,WP1591,Heart development,M1,1,0
1,-39,hsa05200,Pathways in cancer,M1,1,0
1,-4.3,GO:0038083,peptidyl-tyrosine autophosphorylation,M1,1,0
1,-19,GO:0043434,response to peptide hormone,M1,1,0
1,-5.3,GO:0051493,regulation of cytoskeleton organization,M1,1,0
1,-9.1,M12771,SA PTEN PATHWAY,M1,1,0
1,-4.9,GO:0060479,lung cell differentiation,M1,1,0
1,-8.6,GO:0120035,regulation of plasma membrane bounded cell projection organization,M1,1,0
1,-2.4,M8403,GSE29949 CD8 NEG DC SPLEEN VS DC BRAIN DN,M1,1,0
1,-2.1,GO:0046825,regulation of protein export from nucleus,M1,1,0
1,-2.3,M5198,GRAHAM NORMAL QUIESCENT VS NORMAL DIVIDING DN,M1,1,0
1,-2.3,GO:0046889,positive regulation of lipid biosynthetic process,M1,1,0
1,-16,GO:0008015,blood circulation,M1,1,0
1,-10,WP560,TGF-beta receptor signaling,M1,1,0
1,-2.4,M1391,SHIN B CELL LYMPHOMA CLUSTER 7,M1,1,0
1,-4.4,M5201,GSE360 L DONOVANI VS B MALAYI HIGH DOSE DC DN,M1,1,0
1,-10,GO:0010634,positive regulation of epithelial cell migration,M1,1,0
1,-2.5,M9077,GSE35685 CD34POS CD38NEG VS CD34POS CD10POS BONE MARROW UP,M1,1,0
1,-2,GO:0043433,negative regulation of DNA-binding transcription factor activity,M1,1,0
1,-3.9,GO:0099173,postsynapse organization,M1,1,0
1,-3,M3613,GSE15930 NAIVE VS 72H IN VITRO STIM IFNAB CD8 TCELL DN,M1,1,0
1,-2.4,M9764,GSE43863 TH1 VS LY6C INT CXCR5POS EFFECTOR CD4 TCELL UP,M1,1,0
1,-4.3,M17937,NAKAYAMA SOFT TISSUE TUMORS PCA1 DN,M1,1,0
1,-2,M8904,GSE37301 PRO BCELL VS GRANULOCYTE MONOCYTE PROGENITOR UP,M1,1,0
1,-6.2,GO:0007422,peripheral nervous system development,M1,1,0
1,-2.8,M7514,BERENJENO TRANSFORMED BY RHOA DN,M1,1,0
1,-2.8,GO:1904994,regulation of leukocyte adhesion to vascular endothelial cell,M1,1,0
1,-25,hsa05166,Human T-cell leukemia virus 1 infection,M1,1,0
1,-4.4,GO:0003407,neural retina development,M1,1,0
1,-3.2,GO:0006576,cellular biogenic amine metabolic process,M1,1,0
1,-6.6,M8702,DAZARD RESPONSE TO UV NHEK DN,M1,1,0
1,-2.6,M8190,GSE26488 HDAC7 KO VS VP16 TRANSGENIC HDAC7 KO DOUBLE POSITIVE THYMOCYTE UP,M1,1,0
1,-10,R-HSA-5654687,Downstream signaling of activated FGFR1,M1,1,0
1,-2.3,GO:1902175,regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,M1,1,0
1,-2.3,GO:0071229,cellular response to acid chemical,M1,1,0
1,-2.7,GO:0009712,catechol-containing compound metabolic process,M1,1,0
1,-15,R-HSA-9006931,Signaling by Nuclear Receptors,M1,1,0
1,-5.3,GO:0021756,striatum development,M1,1,0
1,-9.9,WP4823,Genes controlling nephrogenesis,M1,1,0
1,-2.4,GO:0030500,regulation of bone mineralization,M1,1,0
1,-4.5,GO:0046631,alpha-beta T cell activation,M1,1,0
1,-12,R-HSA-69473,G2/M DNA damage checkpoint,M1,1,0
1,-3,GO:0032943,mononuclear cell proliferation,M1,1,0
1,-3.4,GO:0033045,regulation of sister chromatid segregation,M1,1,0
1,-3.1,M3472,GSE1460 CD4 THYMOCYTE VS NAIVE CD4 TCELL CORD BLOOD DN,M1,1,0
1,-3.8,GO:0046034,ATP metabolic process,M1,1,0
1,-17,R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),M1,1,0
1,-4,R-HSA-5654706,FRS-mediated FGFR3 signaling,M1,1,0
1,-3.4,GO:0010749,regulation of nitric oxide mediated signal transduction,M1,1,0
1,-13,GO:0001525,angiogenesis,M1,1,0
1,-2.7,GO:0010042,response to manganese ion,M1,1,0
1,-5.1,M9943,GSE41176 WT VS TAK1 KO ANTI IGM STIM BCELL 6H DN,M1,1,0
1,-6.6,GO:0031625,ubiquitin protein ligase binding,M1,1,0
1,-5.2,GO:0010676,positive regulation of cellular carbohydrate metabolic process,M1,1,0
1,-22,WP2374,Oncostatin M signaling pathway,M1,1,0
1,-6.2,GO:0050728,negative regulation of inflammatory response,M1,1,0
1,-8.2,GO:0044774,mitotic DNA integrity checkpoint signaling,M1,1,0
1,-2.4,M4841,GSE27786 CD8 TCELL VS ERYTHROBLAST UP,M1,1,0
1,-2.7,GO:0035173,histone kinase activity,M1,1,0
1,-5.3,GO:0045471,response to ethanol,M1,1,0
1,-5.9,GO:0032147,activation of protein kinase activity,M1,1,0
1,-6.4,R-HSA-9006936,Signaling by TGFB family members,M1,1,0
1,-10,GO:1901991,negative regulation of mitotic cell cycle phase transition,M1,1,0
1,-2.7,GO:1900026,positive regulation of substrate adhesion-dependent cell spreading,M1,1,0
1,-4.6,GO:0051656,establishment of organelle localization,M1,1,0
1,-10,GO:0021543,pallium development,M1,1,0
1,-2.5,GO:0043543,protein acylation,M1,1,0
1,-6.4,GO:1900369,negative regulation of post-transcriptional gene silencing by RNA,M1,1,0
1,-2.4,M291,GSE5503 MLN DC VS PLN DC ACTIVATED ALLOGENIC TCELL DN,M1,1,0
1,-3.5,M789,BROWNE HCMV INFECTION 4HR DN,M1,1,0
1,-5.7,R-HSA-5654733,Negative regulation of FGFR4 signaling,M1,1,0
1,-7,hsa04929,GnRH secretion,M1,1,0
1,-15,GO:0060562,epithelial tube morphogenesis,M1,1,0
1,-2.4,M7132,GSE9960 GRAM POS VS GRAM NEG AND POS SEPSIS PBMC UP,M1,1,0
1,-3,M9186,GSE40274 FOXP3 VS FOXP3 AND GATA1 TRANSDUCED ACTIVATED CD4 TCELL UP,M1,1,0
1,-3.9,R-HSA-9013404,RAC2 GTPase cycle,M1,1,0
1,-4.3,GO:0110020,regulation of actomyosin structure organization,M1,1,0
1,-20,hsa04071,Sphingolipid signaling pathway,M1,1,0
1,-5.7,GO:2000811,negative regulation of anoikis,M1,1,0
1,-3,M9615,GSE42021 CD24HI TREG VS CD24HI TCONV THYMUS UP,M1,1,0
1,-8.8,WP5055,Burn wound healing,M1,1,0
1,-2.5,GO:0043154,negative regulation of cysteine-type endopeptidase activity involved in apoptotic process,M1,1,0
1,-6.4,GO:0051961,negative regulation of nervous system development,M1,1,0
1,-2.3,M6859,GSE7768 OVA ALONE VS OVA WITH MPL IMMUNIZED MOUSE WHOLE SPLEEN 6H DN,M1,1,0
1,-2.1,R-HSA-162906,HIV Infection,M1,1,0
1,-3.2,GO:0070227,lymphocyte apoptotic process,M1,1,0
1,-5.6,GO:0044297,cell body,M1,1,0
1,-3,M6961,GSE7831 1H VS 4H CPG STIM PDC DN,M1,1,0
1,-11,M81,PID CDC42 PATHWAY,M1,1,0
1,-2.2,GO:0035710,"CD4-positive, alpha-beta T cell activation",M1,1,0
1,-4,GO:0045898,regulation of RNA polymerase II transcription preinitiation complex assembly,M1,1,0
1,-4,hsa04723,Retrograde endocannabinoid signaling,M1,1,0
1,-5.6,M16992,ZHANG PROLIFERATING VS QUIESCENT,M1,1,0
1,-9.5,GO:0120039,plasma membrane bounded cell projection morphogenesis,M1,1,0
1,-22,hsa04010,MAPK signaling pathway,M1,1,0
1,-5.7,GO:0018076,N-terminal peptidyl-lysine acetylation,M1,1,0
1,-3.7,M3279,GSE13484 UNSTIM VS YF17D VACCINE STIM PBMC DN,M1,1,0
1,-9.6,hsa05020,Prion disease,M1,1,0
1,-8.4,GO:0009991,response to extracellular stimulus,M1,1,0
1,-21,R-HSA-449147,Signaling by Interleukins,M1,1,0
1,-3,R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,M1,1,0
1,-3,M8964,GSE37532 WT VS PPARG KO VISCERAL ADIPOSE TISSUE TCONV UP,M1,1,0
1,-4.3,R-HSA-432142,Platelet sensitization by LDL,M1,1,0
1,-3.3,M1834,BOQUEST STEM CELL UP,M1,1,0
1,-3.5,WP4534,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms,M1,1,0
1,-11,R-HSA-2871796,FCERI mediated MAPK activation,M1,1,0
1,-3.7,M14371,NAKAMURA TUMOR ZONE PERIPHERAL VS CENTRAL DN,M1,1,0
1,-6.6,GO:0014033,neural crest cell differentiation,M1,1,0
1,-4.1,WP2858,Ectoderm differentiation,M1,1,0
1,-2.6,M2989,GSE13547 WT VS ZFX KO BCELL ANTI IGM STIM 12H UP,M1,1,0
1,-5.7,GO:0060563,neuroepithelial cell differentiation,M1,1,0
1,-3.1,M6190,GSE2124 CTRL VS LYMPHOTOXIN BETA TREATED MLN DN,M1,1,0
1,-6.1,CORUM:570,p300-CBP-p270-SWI/SNF complex,M1,1,0
1,-6.4,GO:0033673,negative regulation of kinase activity,M1,1,0
1,-3.3,GO:0031349,positive regulation of defense response,M1,1,0
1,-9.4,GO:0005778,peroxisomal membrane,M1,1,0
1,-3,M3866,GSE17721 PAM3CSK4 VS CPG 8H BMDC DN,M1,1,0
1,-3.5,M2012,DAVICIONI MOLECULAR ARMS VS ERMS UP,M1,1,0
1,-6.1,GO:1905564,positive regulation of vascular endothelial cell proliferation,M1,1,0
1,-2.9,GO:0003073,regulation of systemic arterial blood pressure,M1,1,0
1,-5.1,GO:0002204,somatic recombination of immunoglobulin genes involved in immune response,M1,1,0
1,-2.4,M2720,CAMP UP.V1 UP,M1,1,0
1,-3,GO:0004707,MAP kinase activity,M1,1,0
1,-16,M48,PID MET PATHWAY,M1,1,0
1,-4.4,GO:0034101,erythrocyte homeostasis,M1,1,0
1,-2.9,R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,M1,1,0
1,-4.7,GO:0051106,positive regulation of DNA ligation,M1,1,0
1,-24,hsa05165,Human papillomavirus infection,M1,1,0
1,-6,GO:0046579,positive regulation of Ras protein signal transduction,M1,1,0
1,-14,WP3972,PDGFR-beta pathway,M1,1,0
1,-6.3,GO:0070372,regulation of ERK1 and ERK2 cascade,M1,1,0
1,-2.3,GO:0000151,ubiquitin ligase complex,M1,1,0
1,-2.4,M5031,GSE30083 SP2 VS SP3 THYMOCYTE UP,M1,1,0
1,-4.3,GO:0071772,response to BMP,M1,1,0
1,-4.9,GO:0009898,cytoplasmic side of plasma membrane,M1,1,0
1,-3.3,CORUM:2639,HES1 promoter-Notch enhancer complex,M1,1,0
1,-10,hsa05130,Pathogenic Escherichia coli infection,M1,1,0
1,-2.8,M17471,SCHUETZ BREAST CANCER DUCTAL INVASIVE UP,M1,1,0
1,-4.5,R-HSA-114452,Activation of BH3-only proteins,M1,1,0
1,-9,GO:0060251,regulation of glial cell proliferation,M1,1,0
1,-2.8,GO:0044000,movement in host,M1,1,0
1,-5.7,GO:0031084,BLOC-2 complex,M1,1,0
1,-11,GO:1901215,negative regulation of neuron death,M1,1,0
1,-2.5,M5184,GSE360 DC VS MAC T GONDII DN,M1,1,0
1,-22,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M1,1,0
1,-3,M6842,GSE7548 DAY7 VS DAY28 PCC IMMUNIZATION CD4 TCELL UP,M1,1,0
1,-2.7,GO:1903978,regulation of microglial cell activation,M1,1,0
1,-2.1,M6739,GSE6259 CD4 TCELL VS CD8 TCELL DN,M1,1,0
1,-4.2,GO:0006977,"DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest",M1,1,0
1,-2.1,GO:0031116,positive regulation of microtubule polymerization,M1,1,0
1,-2.8,GO:2000758,positive regulation of peptidyl-lysine acetylation,M1,1,0
1,-2.2,M6506,DANG MYC TARGETS UP,M1,1,0
1,-11,hsa04650,Natural killer cell mediated cytotoxicity,M1,1,0
1,-11,M288,PID HES HEY PATHWAY,M1,1,0
1,-2.4,M17123,YAGI AML WITH 11Q23 REARRANGED,M1,1,0
1,-2.5,M5008,GSE29618 PRE VS DAY7 POST LAIV FLU VACCINE MDC DN,M1,1,0
1,-2.7,M11238,LINDGREN BLADDER CANCER CLUSTER 3 DN,M1,1,0
1,-3,M4507,GSE22886 TH1 VS TH2 12H ACT UP,M1,1,0
1,-3,GO:0003161,cardiac conduction system development,M1,1,0
1,-2.3,GO:0048333,mesodermal cell differentiation,M1,1,0
1,-3.5,GO:0045669,positive regulation of osteoblast differentiation,M1,1,0
1,-3,M9188,GSE40274 FOXP3 VS FOXP3 AND LEF1 TRANSDUCED ACTIVATED CD4 TCELL DN,M1,1,0
1,-3.5,M2069,BILD MYC ONCOGENIC SIGNATURE,M1,1,0
1,-3.1,GO:0043534,blood vessel endothelial cell migration,M1,1,0
1,-3.6,M3000,GSE13547 CTRL VS ANTI IGM STIM ZFX KO BCELL 2H UP,M1,1,0
1,-5.1,GO:0071456,cellular response to hypoxia,M1,1,0
1,-14,R-HSA-1433557,Signaling by SCF-KIT,M1,1,0
1,-3.1,GO:0009112,nucleobase metabolic process,M1,1,0
1,-2.3,M8994,GSE37533 UNTREATED VS PIOGLIZATONE TREATED CD4 TCELL FOXP3 TRASDUCED CD4 TCELL UP,M1,1,0
1,-3,M8026,GSE16385 ROSIGLITAZONE IL4 VS IL4 ALONE STIM MACROPHAGE 12H UP,M1,1,0
1,-4.4,GO:0005167,neurotrophin TRK receptor binding,M1,1,0
1,-5,M8673,MARTINEZ TP53 TARGETS DN,M1,1,0
1,-2.7,GO:0014074,response to purine-containing compound,M1,1,0
1,-2.7,GO:0022604,regulation of cell morphogenesis,M1,1,0
1,-3.7,M5779,GSE9006 HEALTHY VS TYPE 1 DIABETES PBMC 4MONTH POST DX UP,M1,1,0
1,-4.7,GO:0002039,p53 binding,M1,1,0
1,-13,hsa04062,Chemokine signaling pathway,M1,1,0
1,-17,GO:1901214,regulation of neuron death,M1,1,0
1,-6.3,GO:0070166,enamel mineralization,M1,1,0
1,-2.5,M5013,GSE29618 LAIV VS TIV FLU VACCINE DAY7 BCELL DN,M1,1,0
1,-3.6,GO:1904385,cellular response to angiotensin,M1,1,0
1,-4.8,GO:1904353,regulation of telomere capping,M1,1,0
1,-2.7,WP1982,Sterol regulatory element-binding proteins (SREBP) signaling,M1,1,0
1,-3.2,GO:0048715,negative regulation of oligodendrocyte differentiation,M1,1,0
1,-2.2,R-HSA-933541,TRAF6 mediated IRF7 activation,M1,1,0
1,-5,GO:0072182,regulation of nephron tubule epithelial cell differentiation,M1,1,0
1,-10,R-HSA-389513,CTLA4 inhibitory signaling,M1,1,0
1,-5.2,GO:0040029,epigenetic regulation of gene expression,M1,1,0
1,-4,M15112,WONG MITOCHONDRIA GENE MODULE,M1,1,0
1,-2.1,GO:0035306,positive regulation of dephosphorylation,M1,1,0
1,-2.9,M1951,MEISSNER NPC HCP WITH H3K4ME2,M1,1,0
1,-15,GO:0043523,regulation of neuron apoptotic process,M1,1,0
1,-14,GO:0042770,signal transduction in response to DNA damage,M1,1,0
1,-2.6,GO:0098802,plasma membrane signaling receptor complex,M1,1,0
1,-13,M176,PID FOXM1 PATHWAY,M1,1,0
1,-2.3,GO:0030374,nuclear receptor coactivator activity,M1,1,0
1,-2.4,M9476,GSE41867 NAIVE VS DAY30 LCMV CLONE13 EXHAUSTED CD8 TCELL DN,M1,1,0
1,-2,GO:0071398,cellular response to fatty acid,M1,1,0
1,-30,WP4806,EGFR tyrosine kinase inhibitor resistance,M1,1,0
1,-2.6,WP4535,Envelope proteins and their potential roles in EDMD physiopathology,M1,1,0
1,-4,GO:0060218,hematopoietic stem cell differentiation,M1,1,0
1,-11,WP4549,Fragile X syndrome,M1,1,0
1,-2.7,GO:0051087,chaperone binding,M1,1,0
1,-2.3,WP5097,CCL18 signaling pathway,M1,1,0
1,-3.4,WP2513,Nanoparticle triggered regulated necrosis,M1,1,0
1,-24,GO:0043009,chordate embryonic development,M1,1,0
1,-9.7,R-HSA-5654726,Negative regulation of FGFR1 signaling,M1,1,0
1,-23,GO:0010564,regulation of cell cycle process,M1,1,0
1,-2.5,M8355,GSE28783 ANTI MIR33 VS CTRL ATHEROSCLEROSIS MACROPHAGE DN,M1,1,0
1,-6.4,GO:0048661,positive regulation of smooth muscle cell proliferation,M1,1,0
1,-3,GO:0045144,meiotic sister chromatid segregation,M1,1,0
1,-2.4,M5777,GSE9006 HEALTHY VS TYPE 1 DIABETES PBMC 1MONTH POST DX UP,M1,1,0
1,-2.9,M659,KOBAYASHI EGFR SIGNALING 6HR DN,M1,1,0
1,-4.5,GO:2000378,negative regulation of reactive oxygen species metabolic process,M1,1,0
1,-2.7,WP4249,Hedgehog signaling pathway,M1,1,0
1,-5.1,M8032,GSE16385 IFNG TNF VS UNSTIM MACROPHAGE ROSIGLITAZONE TREATED DN,M1,1,0
1,-4.2,M2323,DORMOY ELAVL1 TARGETS,M1,1,0
1,-2.4,GO:0048799,animal organ maturation,M1,1,0
1,-3,M8855,GSE37301 LYMPHOID PRIMED MPP VS PRO BCELL UP,M1,1,0
1,-3,M7991,GSE25123 ROSIGLITAZONE VS IL4 AND ROSIGLITAZONE STIM PPARG KO MACROPHAGE DAY10 UP,M1,1,0
1,-2.3,GO:0005741,mitochondrial outer membrane,M1,1,0
1,-2.4,M1599,LEE AGING CEREBELLUM UP,M1,1,0
1,-3.5,GO:0060415,muscle tissue morphogenesis,M1,1,0
1,-3,M9666,GSE43955 1H VS 60H ACT CD4 TCELL UP,M1,1,0
1,-4,GO:0005819,spindle,M1,1,0
1,-3.1,M3110,GSE11057 NAIVE CD4 VS PBMC CD4 TCELL DN,M1,1,0
1,-4.9,WP4842,Mammalian disorder of sexual development,M1,1,0
1,-5.3,GO:0060296,regulation of cilium beat frequency involved in ciliary motility,M1,1,0
1,-8.5,GO:0002263,cell activation involved in immune response,M1,1,0
1,-3.1,GO:0055008,cardiac muscle tissue morphogenesis,M1,1,0
1,-3.7,M4963,GSE29618 MONOCYTE VS PDC DAY7 FLU VACCINE UP,M1,1,0
1,-8.6,GO:0019725,cellular homeostasis,M1,1,0
1,-5.1,GO:0033210,leptin-mediated signaling pathway,M1,1,0
1,-13,GO:0061138,morphogenesis of a branching epithelium,M1,1,0
1,-3,M9533,GSE36826 WT VS IL1R KO SKIN STAPH AUREUS INF DN,M1,1,0
1,-4.4,R-HSA-5693548,Sensing of DNA Double Strand Breaks,M1,1,0
1,-4.5,R-HSA-6804758,Regulation of TP53 Activity through Acetylation,M1,1,0
1,-4.2,R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,M1,1,0
1,-5.5,GO:0106310,protein serine kinase activity,M1,1,0
1,-9.8,GO:0070482,response to oxygen levels,M1,1,0
1,-33,WP4263,Pancreatic adenocarcinoma pathway,M1,1,0
1,-2.6,GO:0048634,regulation of muscle organ development,M1,1,0
1,-6.2,GO:0000002,mitochondrial genome maintenance,M1,1,0
1,-3.6,M14127,HELLER HDAC TARGETS SILENCED BY METHYLATION UP,M1,1,0
1,-3,M9751,GSE43863 TFH VS LY6C LOW CXCR5NEG EFFECTOR CD4 TCELL DN,M1,1,0
1,-2.1,R-HSA-373755,Semaphorin interactions,M1,1,0
1,-3.1,M5454,GSE3982 MAST CELL VS TH1 DN,M1,1,0
1,-2.4,M3948,GSE17721 POLYIC VS CPG 12H BMDC UP,M1,1,0
1,-2.5,M8861,GSE37301 LYMPHOID PRIMED MPP VS GRAN MONO PROGENITOR DN,M1,1,0
1,-8.7,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M1,1,0
1,-3.1,GO:0016055,Wnt signaling pathway,M1,1,0
1,-2.1,GO:0021532,neural tube patterning,M1,1,0
1,-3,M2496,PHONG TNF TARGETS UP,M1,1,0
1,-2.5,M4606,GSE24634 TREG VS TCONV POST DAY7 IL4 CONVERSION DN,M1,1,0
1,-2.5,GO:0005884,actin filament,M1,1,0
1,-8.7,R-HSA-1236382,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,M1,1,0
1,-3.2,GO:0034103,regulation of tissue remodeling,M1,1,0
1,-3,M3470,GSE1460 CD4 THYMOCYTE VS NAIVE CD4 TCELL CORD BLOOD UP,M1,1,0
1,-10,GO:0071216,cellular response to biotic stimulus,M1,1,0
1,-7.8,GO:0006325,chromatin organization,M1,1,0
1,-3.1,GO:0045736,negative regulation of cyclin-dependent protein serine/threonine kinase activity,M1,1,0
1,-8.2,GO:0071222,cellular response to lipopolysaccharide,M1,1,0
1,-2.1,GO:0000041,transition metal ion transport,M1,1,0
1,-3.9,GO:0140664,ATP-dependent DNA damage sensor activity,M1,1,0
1,-4.8,GO:0010972,negative regulation of G2/M transition of mitotic cell cycle,M1,1,0
1,-3.9,GO:0098803,respiratory chain complex,M1,1,0
1,-2.4,M4442,GSE22886 NAIVE BCELL VS BM PLASMA CELL UP,M1,1,0
1,-12,hsa04550,Signaling pathways regulating pluripotency of stem cells,M1,1,0
1,-2.4,GO:0001964,startle response,M1,1,0
1,-2.3,M18850,JIANG VHL TARGETS,M1,1,0
1,-4.3,GO:0030307,positive regulation of cell growth,M1,1,0
1,-5.7,WP1403,AMP-activated protein kinase signaling,M1,1,0
1,-5.5,GO:0046622,positive regulation of organ growth,M1,1,0
1,-3.9,GO:0090100,positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M1,1,0
1,-14,WP2586,Aryl hydrocarbon receptor pathway,M1,1,0
1,-4.9,GO:0046546,development of primary male sexual characteristics,M1,1,0
1,-2.2,GO:0002209,behavioral defense response,M1,1,0
1,-2.7,M11620,WIELAND UP BY HBV INFECTION,M1,1,0
1,-4.1,GO:0046390,ribose phosphate biosynthetic process,M1,1,0
1,-11,GO:0042113,B cell activation,M1,1,0
1,-2.4,M19957,FERREIRA EWINGS SARCOMA UNSTABLE VS STABLE UP,M1,1,0
1,-4.5,GO:0070986,left/right axis specification,M1,1,0
1,-2.4,M4838,GSE27786 CD8 TCELL VS NKCELL DN,M1,1,0
1,-2.2,M6716,GSE6092 B BURGDOFERI VS B BURGDORFERI AND IFNG STIM ENDOTHELIAL CELL UP,M1,1,0
1,-2.4,M15592,NGUYEN NOTCH1 TARGETS UP,M1,1,0
1,-2.1,GO:0009914,hormone transport,M1,1,0
1,-8.2,R-HSA-912631,Regulation of signaling by CBL,M1,1,0
1,-5.3,M2324,LEE BMP2 TARGETS UP,M1,1,0
1,-7,GO:0090407,organophosphate biosynthetic process,M1,1,0
1,-4,GO:0006939,smooth muscle contraction,M1,1,0
1,-9.6,GO:0034614,cellular response to reactive oxygen species,M1,1,0
1,-2.3,M945,MOREAUX B LYMPHOCYTE MATURATION BY TACI UP,M1,1,0
1,-2.4,M7640,GSE21360 PRIMARY VS TERTIARY MEMORY CD8 TCELL UP,M1,1,0
1,-2.7,R-HSA-3232118,SUMOylation of transcription factors,M1,1,0
1,-2.9,R-HSA-8934593,Regulation of RUNX1 Expression and Activity,M1,1,0
1,-2.1,M16114,SIMBULAN UV RESPONSE NORMAL DN,M1,1,0
1,-2.8,GO:0006836,neurotransmitter transport,M1,1,0
1,-5.2,M19948,HOQUE METHYLATED IN CANCER,M1,1,0
1,-12,R-HSA-186763,Downstream signal transduction,M1,1,0
1,-6.3,GO:0001953,negative regulation of cell-matrix adhesion,M1,1,0
1,-2.7,M12383,OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL UP,M1,1,0
1,-3.4,GO:1902905,positive regulation of supramolecular fiber organization,M1,1,0
1,-3.1,M5475,GSE3982 DC VS EFF MEMORY CD4 TCELL DN,M1,1,0
1,-7.5,hsa05133,Pertussis,M1,1,0
1,-6.5,M65,PID FRA PATHWAY,M1,1,0
1,-7.8,R-HSA-2990846,SUMOylation,M1,1,0
1,-2.2,GO:0046879,hormone secretion,M1,1,0
1,-2,GO:0032677,regulation of interleukin-8 production,M1,1,0
1,-2.1,R-HSA-5656169,Termination of translesion DNA synthesis,M1,1,0
1,-5,R-HSA-2029481,FCGR activation,M1,1,0
1,-23,GO:0048732,gland development,M1,1,0
1,-4.5,GO:0045737,positive regulation of cyclin-dependent protein serine/threonine kinase activity,M1,1,0
1,-4.2,GO:0016570,histone modification,M1,1,0
1,-9.1,GO:0048593,camera-type eye morphogenesis,M1,1,0
1,-6.5,GO:0051450,myoblast proliferation,M1,1,0
1,-14,GO:0030099,myeloid cell differentiation,M1,1,0
1,-6.4,GO:0002312,B cell activation involved in immune response,M1,1,0
1,-2.3,GO:2000772,regulation of cellular senescence,M1,1,0
1,-4.1,GO:0005901,caveola,M1,1,0
1,-12,WP3611,Photodynamic therapy-induced AP-1 survival signaling,M1,1,0
1,-2.2,GO:0032273,positive regulation of protein polymerization,M1,1,0
1,-3.3,R-HSA-182971,EGFR downregulation,M1,1,0
1,-19,WP382,MAPK signaling pathway,M1,1,0
1,-9.2,R-HSA-5617833,Cilium Assembly,M1,1,0
1,-2.8,GO:0009267,cellular response to starvation,M1,1,0
1,-11,R-HSA-9665348,Signaling by ERBB2 ECD mutants,M1,1,0
1,-5.4,GO:0034505,tooth mineralization,M1,1,0
1,-2.5,M5015,GSE29618 LAIV VS TIV FLU VACCINE DAY7 MONOCYTE UP,M1,1,0
1,-3,GO:0098656,anion transmembrane transport,M1,1,0
1,-3.1,M5253,GSE360 L MAJOR VS M TUBERCULOSIS MAC DN,M1,1,0
1,-3.8,GO:0099177,regulation of trans-synaptic signaling,M1,1,0
1,-4.2,GO:0099106,ion channel regulator activity,M1,1,0
1,-21,R-HSA-9675135,Diseases of DNA repair,M1,1,0
1,-6,GO:0051539,"4 iron, 4 sulfur cluster binding",M1,1,0
1,-2.3,R-HSA-5218859,Regulated Necrosis,M1,1,0
1,-2.6,GO:0042177,negative regulation of protein catabolic process,M1,1,0
1,-4.4,M5165,GSE360 CTRL VS B MALAYI HIGH DOSE MAC UP,M1,1,0
1,-5.7,WP1772,Apoptosis modulation and signaling,M1,1,0
1,-4.2,GO:0071316,cellular response to nicotine,M1,1,0
1,-3.3,GO:0043471,regulation of cellular carbohydrate catabolic process,M1,1,0
1,-4.6,GO:0043405,regulation of MAP kinase activity,M1,1,0
1,-5.1,M2419,WAKABAYASHI ADIPOGENESIS PPARG BOUND 8D,M1,1,0
1,-7.6,GO:0043086,negative regulation of catalytic activity,M1,1,0
1,-3.1,R-HSA-3000171,Non-integrin membrane-ECM interactions,M1,1,0
1,-24,GO:0140297,DNA-binding transcription factor binding,M1,1,0
1,-6.9,GO:0043467,regulation of generation of precursor metabolites and energy,M1,1,0
1,-16,hsa04625,C-type lectin receptor signaling pathway,M1,1,0
1,-2,M19048,RUIZ TNC TARGETS DN,M1,1,0
1,-3.7,M5233,GSE360 L DONOVANI VS T GONDII MAC UP,M1,1,0
1,-2.7,R-HSA-5651801,PCNA-Dependent Long Patch Base Excision Repair,M1,1,0
1,-7.8,CORUM:2815,BRCA1-BARD1-BACH1-DNA damage complex II,M1,1,0
1,-3.2,GO:0086026,atrial cardiac muscle cell to AV node cell signaling,M1,1,0
1,-5.1,GO:2000672,negative regulation of motor neuron apoptotic process,M1,1,0
1,-2.5,R-HSA-195721,Signaling by WNT,M1,1,0
1,-8.3,hsa05146,Amoebiasis,M1,1,0
1,-4.8,GO:0007268,chemical synaptic transmission,M1,1,0
1,-2.5,GO:0140359,ABC-type transporter activity,M1,1,0
1,-3.7,GO:0052813,phosphatidylinositol bisphosphate kinase activity,M1,1,0
1,-4.7,GO:0005242,inward rectifier potassium channel activity,M1,1,0
1,-2,M2666,AKT UP.V1 DN,M1,1,0
1,-4.4,M1945,ISHIDA E2F TARGETS,M1,1,0
1,-8,GO:0014013,regulation of gliogenesis,M1,1,0
1,-4.5,M2905,LEF1 UP.V1 UP,M1,1,0
1,-2.1,GO:0010769,regulation of cell morphogenesis involved in differentiation,M1,1,0
1,-2.8,M3694,LIN MELANOMA COPY NUMBER DN,M1,1,0
1,-6.1,GO:0050957,equilibrioception,M1,1,0
1,-3.7,M3591,GSE15930 NAIVE VS 24H IN VITRO STIM IL12 CD8 TCELL DN,M1,1,0
1,-2.9,R-HSA-1442490,Collagen degradation,M1,1,0
1,-2.8,M12212,WANG ESOPHAGUS CANCER VS NORMAL DN,M1,1,0
1,-3.5,CORUM:2739,FA complex (Fanconi anemia complex),M1,1,0
1,-3.4,M2504,PHONG TNF RESPONSE NOT VIA P38,M1,1,0
1,-9.1,GO:0002027,regulation of heart rate,M1,1,0
1,-7.5,R-HSA-5654716,Downstream signaling of activated FGFR4,M1,1,0
1,-3.6,GO:0051570,regulation of histone H3-K9 methylation,M1,1,0
1,-8.4,GO:0090398,cellular senescence,M1,1,0
1,-2.5,M5632,GSE5463 CTRL VS DEXAMETHASONE TREATED THYMOCYTE DN,M1,1,0
1,-3.1,WP3853,ERK pathway in Huntington's disease,M1,1,0
1,-6.8,GO:0070741,response to interleukin-6,M1,1,0
1,-2.5,M5044,GSE30962 PRIMARY VS SECONDARY CHRONIC LCMV INF CD8 TCELL UP,M1,1,0
1,-2.4,GO:0010823,negative regulation of mitochondrion organization,M1,1,0
1,-13,hsa04024,cAMP signaling pathway,M1,1,0
1,-4.2,GO:0001837,epithelial to mesenchymal transition,M1,1,0
1,-3.7,GO:0008593,regulation of Notch signaling pathway,M1,1,0
1,-2.4,GO:0006633,fatty acid biosynthetic process,M1,1,0
1,-5,GO:0044772,mitotic cell cycle phase transition,M1,1,0
1,-3,GO:1904358,positive regulation of telomere maintenance via telomere lengthening,M1,1,0
1,-5.1,GO:0045190,isotype switching,M1,1,0
1,-3.6,GO:0003254,regulation of membrane depolarization,M1,1,0
1,-6.2,R-HSA-9664407,Parasite infection,M1,1,0
1,-4.7,GO:0033522,histone H2A ubiquitination,M1,1,0
1,-3.3,R-HSA-202670,ERKs are inactivated,M1,1,0
1,-4.5,GO:0035924,cellular response to vascular endothelial growth factor stimulus,M1,1,0
1,-2.5,M15936,NIKOLSKY BREAST CANCER 17Q21 Q25 AMPLICON,M1,1,0
1,-2.4,M5818,GSE9037 WT VS IRAK4 KO LPS 4H STIM BMDM DN,M1,1,0
1,-5.1,GO:0007281,germ cell development,M1,1,0
1,-2.2,GO:1903078,positive regulation of protein localization to plasma membrane,M1,1,0
1,-2.6,GO:0051346,negative regulation of hydrolase activity,M1,1,0
1,-4.5,WP1559,Transcription factors regulate miRNAs related to cardiac hypertrophy,M1,1,0
1,-6.2,GO:0030323,respiratory tube development,M1,1,0
1,-5.1,GO:0032096,negative regulation of response to food,M1,1,0
1,-2.1,M5601,BROWNE HCMV INFECTION 20HR DN,M1,1,0
1,-5,R-HSA-69202,Cyclin E associated events during G1/S transition,M1,1,0
1,-4.4,M9252,GSE20727 ROS INH VS ROS INH AND DNFB ALLERGEN TREATED DC UP,M1,1,0
1,-2.5,M7798,GSE22589 HEALTHY VS SIV INFECTED DC UP,M1,1,0
1,-10,R-HSA-5654696,Downstream signaling of activated FGFR2,M1,1,0
1,-6.3,GO:2000209,regulation of anoikis,M1,1,0
1,-3.1,M177,PID EPHA FWDPATHWAY,M1,1,0
1,-5.4,GO:0006312,mitotic recombination,M1,1,0
1,-4.4,GO:2000116,regulation of cysteine-type endopeptidase activity,M1,1,0
1,-2.9,GO:0035136,forelimb morphogenesis,M1,1,0
1,-2.4,M299,GSE10240 IL22 VS IL17 STIM PRIMARY BRONCHIAL EPITHELIAL CELLS UP,M1,1,0
1,-4.2,GO:0038034,signal transduction in absence of ligand,M1,1,0
1,-21,GO:0001655,urogenital system development,M1,1,0
1,-4.4,R-HSA-8851907,MET activates PI3K/AKT signaling,M1,1,0
1,-7.9,GO:0061337,cardiac conduction,M1,1,0
1,-6.5,WP4331,Neovascularisation processes,M1,1,0
1,-3,M3809,GSE17721 LPS VS POLYIC 6H BMDC DN,M1,1,0
1,-23,hsa05205,Proteoglycans in cancer,M1,1,0
1,-3,M5486,GSE3982 DC VS TH2 DN,M1,1,0
1,-6.7,GO:0035855,megakaryocyte development,M1,1,0
1,-3,M9994,GSE45365 HEALTHY VS MCMV INFECTION BCELL IFNAR KO UP,M1,1,0
1,-4.4,GO:2001243,negative regulation of intrinsic apoptotic signaling pathway,M1,1,0
1,-8.3,GO:0001784,phosphotyrosine residue binding,M1,1,0
1,-8.3,GO:0046530,photoreceptor cell differentiation,M1,1,0
1,-6.2,GO:0046324,regulation of glucose import,M1,1,0
1,-4.4,WP34,Ovarian infertility,M1,1,0
1,-2.4,GO:0010770,positive regulation of cell morphogenesis involved in differentiation,M1,1,0
1,-4.9,GO:0051146,striated muscle cell differentiation,M1,1,0
1,-15,GO:0010035,response to inorganic substance,M1,1,0
1,-8.6,WP4565,Neural crest cell migration in cancer,M1,1,0
1,-4.4,M6779,GSE6681 DELETED FOXP3 VS WT TREG DN,M1,1,0
1,-3,M1613,MILI PSEUDOPODIA CHEMOTAXIS DN,M1,1,0
1,-4.6,M12107,MAHAJAN RESPONSE TO IL1A DN,M1,1,0
1,-3.3,M1291,THEODOROU MAMMARY TUMORIGENESIS,M1,1,0
1,-3.5,GO:0051865,protein autoubiquitination,M1,1,0
1,-3.6,GO:1901861,regulation of muscle tissue development,M1,1,0
1,-2.6,R-HSA-140837,Intrinsic Pathway of Fibrin Clot Formation,M1,1,0
1,-4.1,GO:0006605,protein targeting,M1,1,0
1,-4.2,GO:0070371,ERK1 and ERK2 cascade,M1,1,0
1,-4.2,M16066,SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN DN,M1,1,0
1,-4.2,GO:0016818,"hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides",M1,1,0
1,-2.7,GO:1903579,negative regulation of ATP metabolic process,M1,1,0
1,-3.4,M14151,DEBIASI APOPTOSIS BY REOVIRUS INFECTION UP,M1,1,0
1,-2.7,GO:0031998,regulation of fatty acid beta-oxidation,M1,1,0
1,-6,GO:0007265,Ras protein signal transduction,M1,1,0
1,-9.3,GO:0045859,regulation of protein kinase activity,M1,1,0
1,-4.2,GO:0032205,negative regulation of telomere maintenance,M1,1,0
1,-6.9,GO:0001228,"DNA-binding transcription activator activity, RNA polymerase II-specific",M1,1,0
1,-3,M337,GSE8685 IL15 ACT IL2 STARVED VS IL21 ACT IL2 STARVED CD4 TCELL UP,M1,1,0
1,-2.4,M7209,GSE16266 CTRL VS HEATSHOCK AND LPS STIM MEF DN,M1,1,0
1,-2.8,GO:0060419,heart growth,M1,1,0
1,-2.5,GO:0045730,respiratory burst,M1,1,0
1,-2.2,GO:0015849,organic acid transport,M1,1,0
1,-5,GO:0009896,positive regulation of catabolic process,M1,1,0
1,-11,GO:0048762,mesenchymal cell differentiation,M1,1,0
1,-6.7,GO:0048639,positive regulation of developmental growth,M1,1,0
1,-9.5,M8,PID ENDOTHELIN PATHWAY,M1,1,0
1,-3.6,M15969,VERNELL RETINOBLASTOMA PATHWAY UP,M1,1,0
1,-5.4,GO:0046488,phosphatidylinositol metabolic process,M1,1,0
1,-2.1,R-HSA-73863,RNA Polymerase I Transcription Termination,M1,1,0
1,-6.4,GO:0060967,negative regulation of gene silencing by RNA,M1,1,0
1,-3,M7697,GSE20500 CTRL VS RETINOIC ACID TREATED CD4 TCELL UP,M1,1,0
1,-2.2,GO:2000649,regulation of sodium ion transmembrane transporter activity,M1,1,0
1,-3.1,GO:0110053,regulation of actin filament organization,M1,1,0
1,-2.8,R-HSA-6783310,Fanconi Anemia Pathway,M1,1,0
1,-6.3,GO:0045913,positive regulation of carbohydrate metabolic process,M1,1,0
1,-5.7,M6520,BLALOCK ALZHEIMERS DISEASE INCIPIENT UP,M1,1,0
1,-7.7,GO:0045765,regulation of angiogenesis,M1,1,0
1,-3.3,M3518,WU HBX TARGETS 3 DN,M1,1,0
1,-4.8,GO:0016328,lateral plasma membrane,M1,1,0
1,-6.9,M1167,HUMMERICH SKIN CANCER PROGRESSION UP,M1,1,0
1,-2.5,M6122,BROWNE HCMV INFECTION 20HR UP,M1,1,0
1,-3.4,GO:0042542,response to hydrogen peroxide,M1,1,0
1,-2.2,GO:0010833,telomere maintenance via telomere lengthening,M1,1,0
1,-14,M115,PID REG GR PATHWAY,M1,1,0
1,-3.9,M15491,HAN SATB1 TARGETS DN,M1,1,0
1,-14,GO:0060284,regulation of cell development,M1,1,0
1,-16,M50,PID PTP1B PATHWAY,M1,1,0
1,-5,GO:0061326,renal tubule development,M1,1,0
1,-9.3,GO:0001667,ameboidal-type cell migration,M1,1,0
1,-2.1,GO:1905952,regulation of lipid localization,M1,1,0
1,-6.4,GO:0055067,monovalent inorganic cation homeostasis,M1,1,0
1,-2.9,M9445,GSE24671 CTRL VS BAKIMULC INFECTED MOUSE SPLENOCYTES DN,M1,1,0
1,-3.8,WP1584,Type II diabetes mellitus,M1,1,0
1,-2.3,M2194,OHGUCHI LIVER HNF4A TARGETS DN,M1,1,0
1,-5,GO:0051353,positive regulation of oxidoreductase activity,M1,1,0
1,-9.5,GO:0035825,homologous recombination,M1,1,0
1,-2.9,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M1,1,0
1,-13,M63,PID AVB3 OPN PATHWAY,M1,1,0
1,-2.8,GO:0010719,negative regulation of epithelial to mesenchymal transition,M1,1,0
1,-4.1,R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,M1,1,0
1,-2.3,GO:0014910,regulation of smooth muscle cell migration,M1,1,0
1,-2.7,GO:1903817,negative regulation of voltage-gated potassium channel activity,M1,1,0
1,-5.5,hsa04070,Phosphatidylinositol signaling system,M1,1,0
1,-2,GO:0016242,negative regulation of macroautophagy,M1,1,0
1,-23,WP138,Androgen receptor signaling pathway,M1,1,0
1,-4.3,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M1,1,0
1,-8.7,GO:0002064,epithelial cell development,M1,1,0
1,-3.4,GO:0033327,Leydig cell differentiation,M1,1,0
1,-20,WP4658,Small cell lung cancer,M1,1,0
1,-3.6,GO:0060411,cardiac septum morphogenesis,M1,1,0
1,-2.3,WP2328,Allograft rejection,M1,1,0
1,-17,R-HSA-166520,Signaling by NTRKs,M1,1,0
1,-3,R-HSA-163200,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",M1,1,0
1,-18,GO:0006259,DNA metabolic process,M1,1,0
1,-5.5,GO:0009145,purine nucleoside triphosphate biosynthetic process,M1,1,0
1,-2,GO:0031301,integral component of organelle membrane,M1,1,0
1,-6.5,GO:0030857,negative regulation of epithelial cell differentiation,M1,1,0
1,-21,R-HSA-5633007,Regulation of TP53 Activity,M1,1,0
1,-2.4,M10028,GSE45365 NK CELL VS CD8A DC UP,M1,1,0
1,-2.4,M7020,GSE15330 HSC VS MEGAKARYOCYTE ERYTHROID PROGENITOR IKAROS KO UP,M1,1,0
1,-2.5,M6106,GSE2770 TGFB AND IL4 ACT VS ACT CD4 TCELL 6H UP,M1,1,0
1,-3.8,WP5221,2q11.2 copy number variation syndrome,M1,1,0
1,-3.8,WP5103,Progeria-associated lipodystrophy,M1,1,0
1,-15,hsa04520,Adherens junction,M1,1,0
1,-4.5,M1259,SASAI RESISTANCE TO NEOPLASTIC TRANSFROMATION,M1,1,0
1,-12,M213,PID AR NONGENOMIC PATHWAY,M1,1,0
1,-3.3,GO:0048011,neurotrophin TRK receptor signaling pathway,M1,1,0
1,-8.7,GO:0006289,nucleotide-excision repair,M1,1,0
1,-7.4,GO:0008094,"ATP-dependent activity, acting on DNA",M1,1,0
1,-11,GO:1905515,non-motile cilium assembly,M1,1,0
1,-3.8,GO:0007015,actin filament organization,M1,1,0
1,-2.5,GO:0016895,"exodeoxyribonuclease activity, producing 5'-phosphomonoesters",M1,1,0
1,-12,GO:0010165,response to X-ray,M1,1,0
1,-2.6,GO:0002861,regulation of inflammatory response to antigenic stimulus,M1,1,0
1,-2.9,M6746,GSE6259 FLT3L INDUCED 33D1 POS DC VS CD4 TCELL UP,M1,1,0
1,-15,GO:0043010,camera-type eye development,M1,1,0
1,-4,GO:0000819,sister chromatid segregation,M1,1,0
1,-3.7,M5592,GSE3982 CENT MEMORY CD4 TCELL VS TH2 DN,M1,1,0
1,-4.7,GO:0044770,cell cycle phase transition,M1,1,0
1,-6.1,GO:0098657,import into cell,M1,1,0
1,-2.1,R-HSA-9022692,Regulation of MECP2 expression and activity,M1,1,0
1,-6.1,GO:2000671,regulation of motor neuron apoptotic process,M1,1,0
1,-4.5,GO:0030964,NADH dehydrogenase complex,M1,1,0
1,-3.8,M232,PID ECADHERIN STABILIZATION PATHWAY,M1,1,0
1,-2.7,GO:0097038,perinuclear endoplasmic reticulum,M1,1,0
1,-4.1,R-HSA-1266695,Interleukin-7 signaling,M1,1,0
1,-6.3,M46,PID ATR PATHWAY,M1,1,0
1,-3.7,M9962,GSE45365 WT VS IFNAR KO CD8A DC UP,M1,1,0
1,-4.7,GO:0043620,regulation of DNA-templated transcription in response to stress,M1,1,0
1,-2.4,M14487,HOEGERKORP CD44 TARGETS DIRECT UP,M1,1,0
1,-11,R-HSA-5620922,BBSome-mediated cargo-targeting to cilium,M1,1,0
1,-12,M79,PID TRAIL PATHWAY,M1,1,0
1,-3.7,R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,M1,1,0
1,-2.9,GO:0043369,"CD4-positive or CD8-positive, alpha-beta T cell lineage commitment",M1,1,0
1,-3.8,CORUM:711,Brm-associated complex,M1,1,0
1,-7,GO:0006469,negative regulation of protein kinase activity,M1,1,0
1,-6.5,GO:0060965,negative regulation of miRNA-mediated gene silencing,M1,1,0
1,-3.8,WP4790,FGF23 signaling in hypophosphatemic rickets and related disorders,M1,1,0
1,-3.9,GO:1901293,nucleoside phosphate biosynthetic process,M1,1,0
1,-9.6,R-HSA-5637810,Constitutive Signaling by EGFRvIII,M1,1,0
1,-7.7,GO:0014706,striated muscle tissue development,M1,1,0
1,-3.6,GO:1900076,regulation of cellular response to insulin stimulus,M1,1,0
1,-10,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M1,1,0
1,-5.4,GO:0060749,mammary gland alveolus development,M1,1,0
1,-2.5,M9148,GSE40274 FOXP3 VS FOXP3 AND HELIOS TRANSDUCED ACTIVATED CD4 TCELL UP,M1,1,0
1,-9.9,GO:0043269,regulation of ion transport,M1,1,0
1,-8.4,GO:2001237,negative regulation of extrinsic apoptotic signaling pathway,M1,1,0
1,-6.4,WP4341,"Non-genomic actions of 1,25 dihydroxyvitamin D3",M1,1,0
1,-6.2,GO:0086009,membrane repolarization,M1,1,0
1,-3.2,GO:0031507,heterochromatin formation,M1,1,0
1,-2.5,M9244,GSE20727 CTRL VS ROS INHIBITOR TREATED DC UP,M1,1,0
1,-8.4,M19,PID P73PATHWAY,M1,1,0
1,-4,GO:0017015,regulation of transforming growth factor beta receptor signaling pathway,M1,1,0
1,-4.4,M3627,GSE15930 STIM VS STIM AND TRICHOSTATINA 24H CD8 T CELL UP,M1,1,0
1,-10,GO:0021537,telencephalon development,M1,1,0
1,-8.3,M10508,HARRIS HYPOXIA,M1,1,0
1,-8.6,GO:0033363,secretory granule organization,M1,1,0
1,-2.3,GO:0001843,neural tube closure,M1,1,0
1,-2.5,GO:1903747,regulation of establishment of protein localization to mitochondrion,M1,1,0
1,-21,R-HSA-5693532,DNA Double-Strand Break Repair,M1,1,0
1,-2.9,GO:0004518,nuclease activity,M1,1,0
1,-8,GO:0038093,Fc receptor signaling pathway,M1,1,0
1,-4.7,WP2868,TCA cycle nutrient use and invasiveness of ovarian cancer,M1,1,0
1,-2,M8668,GSE34156 UNTREATED VS 6H NOD2 AND TLR1 TLR2 LIGAND TREATED MONOCYTE UP,M1,1,0
1,-2.6,GO:0032369,negative regulation of lipid transport,M1,1,0
1,-2.8,GO:0002292,T cell differentiation involved in immune response,M1,1,0
1,-5.1,CORUM:4,Multisubunit ACTR coactivator complex,M1,1,0
1,-3.2,M7012,SCHUETZ BREAST CANCER DUCTAL INVASIVE DN,M1,1,0
1,-2.5,GO:0003707,nuclear steroid receptor activity,M1,1,0
1,-3.7,GO:0140612,DNA damage sensor activity,M1,1,0
1,-15,GO:1901990,regulation of mitotic cell cycle phase transition,M1,1,0
1,-6.5,R-HSA-8849470,PTK6 Regulates Cell Cycle,M1,1,0
1,-3.6,GO:0048806,genitalia development,M1,1,0
1,-3.2,R-HSA-397795,G-protein beta:gamma signalling,M1,1,0
1,-2.9,GO:0055078,sodium ion homeostasis,M1,1,0
1,-4.6,GO:1903321,negative regulation of protein modification by small protein conjugation or removal,M1,1,0
1,-2.4,M6866,MISSIAGLIA REGULATED BY METHYLATION DN,M1,1,0
1,-2.4,M9767,GSE43863 TH1 VS LY6C LOW CXCR5NEG EFFECTOR CD4 TCELL UP,M1,1,0
1,-7.7,R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,M1,1,0
1,-2.5,M4744,GSE27786 LSK VS BCELL DN,M1,1,0
1,-2.7,R-HSA-211945,Phase I - Functionalization of compounds,M1,1,0
1,-2.5,M5711,GSE7460 WT VS FOXP3 HET ACT WITH TGFB TCONV UP,M1,1,0
1,-2,GO:0071300,cellular response to retinoic acid,M1,1,0
1,-3,M6661,GSE5589 IL6 KO VS IL10 KO LPS AND IL6 STIM MACROPHAGE 45MIN UP,M1,1,0
1,-2.7,hsa04928,"Parathyroid hormone synthesis, secretion and action",M1,1,0
1,-4.6,GO:0045766,positive regulation of angiogenesis,M1,1,0
1,-4.8,GO:0015276,ligand-gated ion channel activity,M1,1,0
1,-6.2,R-HSA-9664417,Leishmania phagocytosis,M1,1,0
1,-2.1,M10280,ZHAN LATE DIFFERENTIATION GENES UP,M1,1,0
1,-2.8,M1388,SHIN B CELL LYMPHOMA CLUSTER 5,M1,1,0
1,-15,WP5098,T-cell activation SARS-CoV-2,M1,1,0
1,-27,GO:0007423,sensory organ development,M1,1,0
1,-5.4,GO:0006814,sodium ion transport,M1,1,0
1,-2.4,M8037,GSE17301 IFNA2 VS IFNA5 STIM ACD3 ACD28 ACT CD8 TCELL DN,M1,1,0
1,-2.2,GO:0051225,spindle assembly,M1,1,0
1,-6,GO:0060119,inner ear receptor cell development,M1,1,0
1,-3.3,M11893,RAY ALZHEIMERS DISEASE,M1,1,0
1,-3.7,M4613,GSE24634 TEFF VS TCONV DAY3 IN CULTURE UP,M1,1,0
1,-9.3,M2343,FEVR CTNNB1 TARGETS DN,M1,1,0
1,-8.3,GO:0022832,voltage-gated channel activity,M1,1,0
1,-2.7,GO:0036344,platelet morphogenesis,M1,1,0
1,-2.3,M1401,BYSTROEM CORRELATED WITH IL5 DN,M1,1,0
1,-5.9,GO:0001657,ureteric bud development,M1,1,0
1,-4.2,GO:0097192,extrinsic apoptotic signaling pathway in absence of ligand,M1,1,0
1,-3,WP1471,Target of rapamycin signaling,M1,1,0
1,-5.1,M8542,GSE33424 CD161 HIGH VS NEG CD8 TCELL DN,M1,1,0
1,-4.1,M3854,MARTINEZ RB1 AND TP53 TARGETS DN,M1,1,0
1,-6.3,GO:2000679,positive regulation of transcription regulatory region DNA binding,M1,1,0
1,-5.9,GO:0030546,signaling receptor activator activity,M1,1,0
1,-3.4,M10381,CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS DN,M1,1,0
1,-2.9,R-HSA-5620912,Anchoring of the basal body to the plasma membrane,M1,1,0
1,-2.9,M9948,KIM WT1 TARGETS 8HR DN,M1,1,0
1,-3.1,GO:0032409,regulation of transporter activity,M1,1,0
1,-5.4,M19511,WANG CISPLATIN RESPONSE AND XPC UP,M1,1,0
1,-3.4,M38992,MEBARKI HCC PROGENITOR FZD8CRD UP,M1,1,0
1,-14,WP3981,miRNA regulation of prostate cancer signaling pathways,M1,1,0
1,-2.9,GO:0051928,positive regulation of calcium ion transport,M1,1,0
1,-4.9,GO:0034612,response to tumor necrosis factor,M1,1,0
1,-3.1,R-HSA-5358752,CTNNB1 T41 mutants aren't phosphorylated,M1,1,0
1,-5.2,GO:0007131,reciprocal meiotic recombination,M1,1,0
1,-2.4,M3996,JIANG HYPOXIA NORMAL,M1,1,0
1,-2.4,WP5231,Hippocampal synaptogenesis and neurogenesis,M1,1,0
1,-2.5,M3754,GSE17721 CTRL VS CPG 0.5H BMDC UP,M1,1,0
1,-2.4,M5185,GSE360 DC VS MAC B MALAYI HIGH DOSE UP,M1,1,0
1,-2.8,GO:0001502,cartilage condensation,M1,1,0
1,-3.1,M2697,P53 DN.V1 DN,M1,1,0
1,-2.6,M412,GSE11818 WT VS DICER KO TREG UP,M1,1,0
1,-6,GO:0019221,cytokine-mediated signaling pathway,M1,1,0
1,-4.8,R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,M1,1,0
1,-18,WP2526,PDGF pathway,M1,1,0
1,-4.9,M54,PID IL12 2PATHWAY,M1,1,0
1,-2.7,GO:0090201,negative regulation of release of cytochrome c from mitochondria,M1,1,0
1,-2.5,GO:0045582,positive regulation of T cell differentiation,M1,1,0
1,-3,M5219,GSE360 T GONDII VS B MALAYI LOW DOSE DC DN,M1,1,0
1,-14,M141,PID PI3KCI PATHWAY,M1,1,0
1,-2.7,GO:0045663,positive regulation of myoblast differentiation,M1,1,0
1,-3,M3973,GSE17721 PAM3CSK4 VS GADIQUIMOD 8H BMDC DN,M1,1,0
1,-8.5,GO:0007548,sex differentiation,M1,1,0
1,-5,WP5272,LDL- influence on CD14 and TLR4,M1,1,0
1,-5.5,GO:0034774,secretory granule lumen,M1,1,0
1,-4.4,R-HSA-190242,FGFR1 ligand binding and activation,M1,1,0
1,-6.6,M13273,DELYS THYROID CANCER DN,M1,1,0
1,-4.8,GO:0000800,lateral element,M1,1,0
1,-4.7,M2075,WHITFIELD CELL CYCLE S,M1,1,0
1,-2.3,GO:0097472,cyclin-dependent protein kinase activity,M1,1,0
1,-8.8,GO:1902806,regulation of cell cycle G1/S phase transition,M1,1,0
1,-5.1,M7730,GSE21033 3H VS 12H POLYIC STIM DC UP,M1,1,0
1,-5.6,GO:0035150,regulation of tube size,M1,1,0
1,-7.4,GO:0030278,regulation of ossification,M1,1,0
1,-2.2,R-HSA-3000157,Laminin interactions,M1,1,0
1,-4.2,GO:0048144,fibroblast proliferation,M1,1,0
1,-3.3,GO:0007584,response to nutrient,M1,1,0
1,-3.5,M6853,GSE7768 OVA WITH LPS VS OVA WITH MPL IMMUNIZED MOUSE WHOLE SPLEEN 6H UP,M1,1,0
1,-2.7,R-HSA-5675221,Negative regulation of MAPK pathway,M1,1,0
1,-6.6,GO:0035869,ciliary transition zone,M1,1,0
1,-12,R-HSA-8848021,Signaling by PTK6,M1,1,0
1,-4.6,M1871,BENPORATH ES 1,M1,1,0
1,-6.2,WP5205,Clock-controlled autophagy in bone metabolism,M1,1,0
1,-15,R-HSA-109582,Hemostasis,M1,1,0
1,-2.5,M3098,GSE10463 CD40L AND VA347 VS CD40L IN DC UP,M1,1,0
1,-2.8,GO:0008631,intrinsic apoptotic signaling pathway in response to oxidative stress,M1,1,0
1,-7.6,WP581,EPO receptor signaling,M1,1,0
1,-5.8,GO:0010506,regulation of autophagy,M1,1,0
1,-15,GO:0033365,protein localization to organelle,M1,1,0
1,-3.2,GO:0072538,T-helper 17 type immune response,M1,1,0
1,-3.2,GO:1903202,negative regulation of oxidative stress-induced cell death,M1,1,0
1,-3.6,GO:0021795,cerebral cortex cell migration,M1,1,0
1,-3.9,WP5180,DYRK1A,M1,1,0
1,-3.5,R-HSA-376172,DSCAM interactions,M1,1,0
1,-5.9,GO:0004713,protein tyrosine kinase activity,M1,1,0
1,-7.5,M7686,GSE20152 SPHK1 KO VS WT HTNFA OVERXPRESS ANKLE DN,M1,1,0
1,-4,GO:0008013,beta-catenin binding,M1,1,0
1,-11,GO:0016301,kinase activity,M1,1,0
1,-3.7,M6603,GSE5589 UNSTIM VS 45MIN LPS AND IL10 STIM MACROPHAGE DN,M1,1,0
1,-9.5,GO:0030098,lymphocyte differentiation,M1,1,0
1,-7.5,GO:0061351,neural precursor cell proliferation,M1,1,0
1,-3.2,R-HSA-69541,Stabilization of p53,M1,1,0
1,-2.1,R-HSA-9013149,RAC1 GTPase cycle,M1,1,0
1,-2.2,GO:0030665,clathrin-coated vesicle membrane,M1,1,0
1,-25,GO:0048534,hematopoietic or lymphoid organ development,M1,1,0
1,-3.6,hsa04114,Oocyte meiosis,M1,1,0
1,-7.8,GO:0031253,cell projection membrane,M1,1,0
1,-4.4,M4274,GSE18791 CTRL VS NEWCASTLE VIRUS DC 14H UP,M1,1,0
1,-2.3,GO:2000117,negative regulation of cysteine-type endopeptidase activity,M1,1,0
1,-6.5,GO:0055082,cellular chemical homeostasis,M1,1,0
1,-2.6,GO:0031016,pancreas development,M1,1,0
1,-13,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M1,1,0
1,-9.7,GO:0045444,fat cell differentiation,M1,1,0
1,-4.2,R-HSA-9028335,Activated NTRK2 signals through PI3K,M1,1,0
1,-3.5,M10797,AMIT EGF RESPONSE 60 HELA,M1,1,0
1,-2.4,GO:0007435,salivary gland morphogenesis,M1,1,0
1,-3.1,GO:0003376,sphingosine-1-phosphate receptor signaling pathway,M1,1,0
1,-3,M8201,GSE26488 CTRL VS PEPTIDE INJECTION HDAC7 DELTAP TG OT2 THYMOCYTE UP,M1,1,0
1,-3,GO:0051781,positive regulation of cell division,M1,1,0
1,-4.4,GO:0005159,insulin-like growth factor receptor binding,M1,1,0
1,-3.7,M9653,GSE43955 TH0 VS TGFB IL6 IL23 TH17 ACT CD4 TCELL 52H DN,M1,1,0
1,-2.2,M16708,YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 5,M1,1,0
1,-9.3,GO:0000302,response to reactive oxygen species,M1,1,0
1,-3,M3704,GSE17721 CTRL VS LPS 24H BMDC DN,M1,1,0
1,-4.2,WP4321,Thermogenesis,M1,1,0
1,-20,GO:0048729,tissue morphogenesis,M1,1,0
1,-3.3,M393,VANTVEER BREAST CANCER ESR1 UP,M1,1,0
1,-18,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M1,1,0
1,-8.4,M108,PID NETRIN PATHWAY,M1,1,0
1,-3,M7841,GSE24210 CTRL VS IL35 TREATED TCONV CD4 TCELL UP,M1,1,0
1,-5.9,hsa04714,Thermogenesis,M1,1,0
1,-2.4,M7143,GSE12392 CD8A POS VS NEG SPLEEN DC DN,M1,1,0
1,-4.1,M13276,MARZEC IL2 SIGNALING DN,M1,1,0
1,-5.3,hsa03030,DNA replication,M1,1,0
1,-2.1,M2240,JOHNSTONE PARVB TARGETS 3 UP,M1,1,0
1,-3.7,M16424,BERTUCCI INVASIVE CARCINOMA DUCTAL VS LOBULAR UP,M1,1,0
1,-3.5,GO:0019897,extrinsic component of plasma membrane,M1,1,0
1,-2.3,M1851,QI PLASMACYTOMA UP,M1,1,0
1,-2.4,M3631,GSE15930 STIM VS STIM AND IL12 48H CD8 T CELL DN,M1,1,0
1,-8.1,R-HSA-5654727,Negative regulation of FGFR2 signaling,M1,1,0
1,-3.8,CORUM:807,BRG1-associated complex,M1,1,0
1,-2.4,M3411,GSE1432 1H VS 6H IFNG MICROGLIA DN,M1,1,0
1,-7.5,GO:0097651,"phosphatidylinositol 3-kinase complex, class I",M1,1,0
1,-3,M5124,GSE339 CD4POS VS CD4CD8DN DC IN CULTURE DN,M1,1,0
1,-17,GO:0009611,response to wounding,M1,1,0
1,-4.2,R-HSA-438064,Post NMDA receptor activation events,M1,1,0
1,-7.1,WP3982,miRNA regulation of p53 pathway in prostate cancer,M1,1,0
1,-2.6,GO:0019210,kinase inhibitor activity,M1,1,0
1,-3.6,GO:0009581,detection of external stimulus,M1,1,0
1,-2.7,R-HSA-210745,Regulation of gene expression in beta cells,M1,1,0
1,-4.5,GO:0043548,phosphatidylinositol 3-kinase binding,M1,1,0
1,-13,GO:0071478,cellular response to radiation,M1,1,0
1,-2.5,M67,PID ARF6 TRAFFICKING PATHWAY,M1,1,0
1,-3.8,GO:0032391,photoreceptor connecting cilium,M1,1,0
1,-2.7,R-HSA-3928662,EPHB-mediated forward signaling,M1,1,0
1,-5.7,GO:0046854,phosphatidylinositol phosphate biosynthetic process,M1,1,0
1,-4.3,GO:0001541,ovarian follicle development,M1,1,0
1,-2.5,M219,PID HEDGEHOG GLI PATHWAY,M1,1,0
1,-3.3,GO:0004879,nuclear receptor activity,M1,1,0
1,-3.3,GO:0060390,regulation of SMAD protein signal transduction,M1,1,0
1,-2.6,M463,GSE7459 UNTREATED VS IL6 TREATED ACT CD4 TCELL DN,M1,1,0
1,-6.7,GO:0051222,positive regulation of protein transport,M1,1,0
1,-2.5,M3267,GSE13484 3H UNSTIM VS YF17D VACCINE STIM PBMC DN,M1,1,0
1,-2.6,GO:0098719,sodium ion import across plasma membrane,M1,1,0
1,-2.1,GO:0032233,positive regulation of actin filament bundle assembly,M1,1,0
1,-3,M17517,WU HBX TARGETS 2 DN,M1,1,0
1,-3.5,R-HSA-1234158,Regulation of gene expression by Hypoxia-inducible Factor,M1,1,0
1,-11,GO:0048872,homeostasis of number of cells,M1,1,0
1,-4.8,GO:0043409,negative regulation of MAPK cascade,M1,1,0
1,-13,GO:0043588,skin development,M1,1,0
1,-6.7,R-HSA-1250196,SHC1 events in ERBB2 signaling,M1,1,0
1,-2.6,GO:0010830,regulation of myotube differentiation,M1,1,0
1,-2.1,M5884,NABA CORE MATRISOME,M1,1,0
1,-11,M100,PID SHP2 PATHWAY,M1,1,0
1,-2.3,M5649,GSE6269 HEALTHY VS STAPH PNEUMO INF PBMC DN,M1,1,0
1,-8.5,GO:0048066,developmental pigmentation,M1,1,0
1,-3,R-HSA-6798695,Neutrophil degranulation,M1,1,0
1,-3.7,M6468,GSE3039 CD4 TCELL VS B1 BCELL DN,M1,1,0
1,-5,GO:0002320,lymphoid progenitor cell differentiation,M1,1,0
1,-12,hsa04213,Longevity regulating pathway - multiple species,M1,1,0
1,-4.6,GO:0005942,phosphatidylinositol 3-kinase complex,M1,1,0
1,-3.3,GO:0110110,positive regulation of animal organ morphogenesis,M1,1,0
1,-12,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M1,1,0
1,-2.6,R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,M1,1,0
1,-3.3,GO:0010447,response to acidic pH,M1,1,0
1,-4.9,GO:0007528,neuromuscular junction development,M1,1,0
1,-3,M4650,GSE25087 TREG VS TCONV ADULT UP,M1,1,0
1,-9.5,GO:0055123,digestive system development,M1,1,0
1,-4.2,M4913,IZADPANAH STEM CELL ADIPOSE VS BONE DN,M1,1,0
1,-3.2,M18789,LY AGING OLD DN,M1,1,0
1,-2.8,GO:0006284,base-excision repair,M1,1,0
1,-2.9,GO:0007135,meiosis II,M1,1,0
1,-3,M7532,GSE21546 WT VS SAP1A KO ANTI CD3 STIM DP THYMOCYTES DN,M1,1,0
1,-2.4,M3035,GOLDRATH NAIVE VS EFF CD8 TCELL UP,M1,1,0
1,-3,GO:0120032,regulation of plasma membrane bounded cell projection assembly,M1,1,0
1,-3,M7782,GSE20754 WT VS TCF1 KO MEMORY CD8 TCELL DN,M1,1,0
1,-4,GO:0009205,purine ribonucleoside triphosphate metabolic process,M1,1,0
1,-3.1,GO:0046651,lymphocyte proliferation,M1,1,0
1,-2.4,WP3658,Wnt/beta-catenin signaling pathway in leukemia,M1,1,0
1,-2.9,GO:0035065,regulation of histone acetylation,M1,1,0
1,-6.2,M10961,GOZGIT ESR1 TARGETS DN,M1,1,0
1,-6.7,GO:0086011,membrane repolarization during action potential,M1,1,0
1,-3.8,GO:0006268,DNA unwinding involved in DNA replication,M1,1,0
1,-4.7,M1399,KHETCHOUMIAN TRIM24 TARGETS UP,M1,1,0
1,-4.5,R-HSA-75892,Platelet Adhesion to exposed collagen,M1,1,0
1,-8.1,GO:0007368,determination of left/right symmetry,M1,1,0
1,-3,GO:0042093,T-helper cell differentiation,M1,1,0
1,-3.6,GO:0042445,hormone metabolic process,M1,1,0
1,-9.9,GO:0034330,cell junction organization,M1,1,0
1,-11,GO:0045005,DNA-templated DNA replication maintenance of fidelity,M1,1,0
1,-9.6,R-HSA-69236,G1 Phase,M1,1,0
1,-12,M214,PID ERBB1 INTERNALIZATION PATHWAY,M1,1,0
1,-8.3,WP3863,T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection,M1,1,0
1,-2,R-HSA-1296065,Inwardly rectifying K+ channels,M1,1,0
1,-10,GO:0003697,single-stranded DNA binding,M1,1,0
1,-3,M3204,GSE12845 PRE GC VS DARKZONE GC TONSIL BCELL DN,M1,1,0
1,-4.6,GO:0061005,cell differentiation involved in kidney development,M1,1,0
1,-3,GO:0140299,small molecule sensor activity,M1,1,0
1,-20,GO:0071363,cellular response to growth factor stimulus,M1,1,0
1,-3,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M1,1,0
1,-3.5,GO:0045747,positive regulation of Notch signaling pathway,M1,1,0
1,-9.5,GO:0035107,appendage morphogenesis,M1,1,0
1,-3,M6488,GSE4748 CTRL VS CYANOBACTERIUM LPSLIKE STIM DC 1H DN,M1,1,0
1,-5,GO:0018209,peptidyl-serine modification,M1,1,0
1,-3.1,R-HSA-382551,Transport of small molecules,M1,1,0
1,-3.5,WP1541,Energy metabolism,M1,1,0
1,-7.8,R-HSA-9006335,Signaling by Erythropoietin,M1,1,0
1,-4.6,R-HSA-3371453,Regulation of HSF1-mediated heat shock response,M1,1,0
1,-17,GO:0072001,renal system development,M1,1,0
1,-20,GO:0006281,DNA repair,M1,1,0
1,-3.1,GO:0048484,enteric nervous system development,M1,1,0
1,-8.2,R-HSA-9707616,Heme signaling,M1,1,0
1,-10,GO:0009411,response to UV,M1,1,0
1,-4.4,GO:0032095,regulation of response to food,M1,1,0
1,-2.4,M3998,GSE17721 LPS VS CPG 6H BMDC UP,M1,1,0
1,-4.8,GO:0098916,anterograde trans-synaptic signaling,M1,1,0
1,-2.5,M10031,GSE45365 NK CELL VS BCELL UP,M1,1,0
1,-4.4,GO:0060420,regulation of heart growth,M1,1,0
1,-4.1,WP3850,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling,M1,1,0
1,-3.4,GO:1903533,regulation of protein targeting,M1,1,0
1,-2.6,GO:0046849,bone remodeling,M1,1,0
1,-4.9,GO:0008584,male gonad development,M1,1,0
1,-12,WP2516,ATM signaling pathway,M1,1,0
1,-2.4,M4366,GSE20715 0H VS 24H OZONE LUNG UP,M1,1,0
1,-3.8,M13910,CLIMENT BREAST CANCER COPY NUMBER UP,M1,1,0
1,-2.7,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M1,1,0
1,-7.6,M253,BONOME OVARIAN CANCER SURVIVAL SUBOPTIMAL DEBULKING,M1,1,0
1,-2.4,M9956,GSE45365 NK CELL VS CD11B DC MCMV INFECTION UP,M1,1,0
1,-6.5,WP5269,Genetic causes of porto-sinusoidal vascular disease,M1,1,0
1,-5.8,M5883,NABA SECRETED FACTORS,M1,1,0
1,-2.8,WP384,Apoptosis modulation by HSP70,M1,1,0
1,-2.5,M6275,GSE2585 CD80 HIGH VS LOW AIRE KO MTEC DN,M1,1,0
1,-11,GO:2001234,negative regulation of apoptotic signaling pathway,M1,1,0
1,-3.6,GO:0001906,cell killing,M1,1,0
1,-2.6,GO:0016571,histone methylation,M1,1,0
1,-2.7,M9016,PROVENZANI METASTASIS DN,M1,1,0
1,-9.6,GO:0001508,action potential,M1,1,0
1,-14,GO:0001701,in utero embryonic development,M1,1,0
1,-4.4,M2502,PHONG TNF RESPONSE VIA P38 PARTIAL,M1,1,0
1,-2.7,GO:0042098,T cell proliferation,M1,1,0
1,-15,M19387,TCGA GLIOBLASTOMA MUTATED,M1,1,0
1,-2.3,GO:0002699,positive regulation of immune effector process,M1,1,0
1,-5.1,GO:0010717,regulation of epithelial to mesenchymal transition,M1,1,0
1,-2.1,M8792,GSE37605 FOXP3 FUSION GFP VS IRES GFP TREG C57BL6 UP,M1,1,0
1,-3.6,GO:0051881,regulation of mitochondrial membrane potential,M1,1,0
1,-3.7,M6511,GSE4984 LPS VS VEHICLE CTRL TREATED DC DN,M1,1,0
1,-2.5,M8103,GSE19941 UNSTIM VS LPS STIM IL10 KO NFKBP50 KO MACROPHAGE UP,M1,1,0
1,-2.6,GO:0120161,regulation of cold-induced thermogenesis,M1,1,0
1,-4.3,M9911,WOO LIVER CANCER RECURRENCE DN,M1,1,0
1,-2.7,GO:0060396,growth hormone receptor signaling pathway,M1,1,0
1,-8.3,GO:1903522,regulation of blood circulation,M1,1,0
1,-5.5,GO:0060688,regulation of morphogenesis of a branching structure,M1,1,0
1,-12,GO:0086001,cardiac muscle cell action potential,M1,1,0
1,-3.2,GO:0016053,organic acid biosynthetic process,M1,1,0
1,-3.1,M9192,CHARAFE BREAST CANCER LUMINAL VS MESENCHYMAL DN,M1,1,0
1,-14,GO:0045786,negative regulation of cell cycle,M1,1,0
1,-14,GO:0006468,protein phosphorylation,M1,1,0
1,-4.1,R-HSA-9703465,Signaling by FLT3 fusion proteins,M1,1,0
1,-2.4,GO:0009994,oocyte differentiation,M1,1,0
1,-8.1,M136,PID FOXO PATHWAY,M1,1,0
1,-14,WP4536,Genes related to primary cilium development (based on CRISPR),M1,1,0
1,-3.1,M8424,GSE30153 LUPUS VS HEALTHY DONOR BCELL DN,M1,1,0
1,-3,M8429,GSE23321 CD8 STEM CELL MEMORY VS EFFECTOR MEMORY CD8 TCELL UP,M1,1,0
1,-3.6,R-HSA-5696397,Gap-filling DNA repair synthesis and ligation in GG-NER,M1,1,0
1,-15,GO:0048562,embryonic organ morphogenesis,M1,1,0
1,-6.5,GO:0051046,regulation of secretion,M1,1,0
1,-4.8,M2491,BRIDEAU IMPRINTED GENES,M1,1,0
1,-13,M167,PID AP1 PATHWAY,M1,1,0
1,-22,WP3303,RAC1/PAK1/p38/MMP2 pathway,M1,1,0
1,-3.2,GO:1904044,response to aldosterone,M1,1,0
1,-3.9,GO:0021885,forebrain cell migration,M1,1,0
1,-2.6,GO:0010821,regulation of mitochondrion organization,M1,1,0
1,-3.8,GO:0042773,ATP synthesis coupled electron transport,M1,1,0
1,-10,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M1,1,0
1,-2.4,M3527,GSE15324 NAIVE VS ACTIVATED ELF4 KO CD8 TCELL DN,M1,1,0
1,-3.4,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M1,1,0
1,-4.7,M2342,FEVR CTNNB1 TARGETS UP,M1,1,0
1,-5.3,R-HSA-5218921,VEGFR2 mediated cell proliferation,M1,1,0
1,-3,M4599,GSE24634 TREG VS TCONV POST DAY3 IL4 CONVERSION UP,M1,1,0
1,-4.2,GO:1990414,replication-born double-strand break repair via sister chromatid exchange,M1,1,0
1,-5.1,M15411,BARIS THYROID CANCER DN,M1,1,0
1,-3.5,hsa04974,Protein digestion and absorption,M1,1,0
1,-6.4,GO:0035637,multicellular organismal signaling,M1,1,0
1,-2.9,M1492,BRUNO HEMATOPOIESIS,M1,1,0
1,-3.3,GO:0018205,peptidyl-lysine modification,M1,1,0
1,-2.3,GO:0097553,calcium ion transmembrane import into cytosol,M1,1,0
1,-2.4,M8765,GSE34515 CD16 POS MONOCYTE VS DC UP,M1,1,0
1,-2.9,GO:0071468,cellular response to acidic pH,M1,1,0
1,-5,GO:0030198,extracellular matrix organization,M1,1,0
1,-2.4,GO:0090288,negative regulation of cellular response to growth factor stimulus,M1,1,0
1,-2.4,M5602,GSE39820 CTRL VS IL1B IL6 IL23A CD4 TCELL UP,M1,1,0
1,-10,WP3929,Chemokine signaling pathway,M1,1,0
1,-5.1,CORUM:964,BRCA1-RAD50-MRE11-NBS1 complex,M1,1,0
1,-10,WP3594,Circadian rhythm genes,M1,1,0
1,-4.5,GO:0060389,pathway-restricted SMAD protein phosphorylation,M1,1,0
1,-4.9,GO:0019827,stem cell population maintenance,M1,1,0
1,-2.3,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M1,1,0
1,-3.3,GO:0021591,ventricular system development,M1,1,0
1,-2,M2885,KRAS.600.LUNG.BREAST UP.V1 DN,M1,1,0
1,-2.3,GO:0003338,metanephros morphogenesis,M1,1,0
1,-2.7,M1463,TIEN INTESTINE PROBIOTICS 24HR UP,M1,1,0
1,-6.3,WP4871,Kisspeptin/kisspeptin receptor system in the ovary,M1,1,0
1,-2.4,M5066,GSE31082 DP VS CD8 SP THYMOCYTE UP,M1,1,0
1,-26,WP4155,Endometrial cancer,M1,1,0
1,-7.2,GO:0001895,retina homeostasis,M1,1,0
1,-3.7,M9770,GSE43863 TFH VS LY6C INT CXCR5POS EFFECTOR CD4 TCELL UP,M1,1,0
1,-6.7,R-HSA-430116,GP1b-IX-V activation signalling,M1,1,0
1,-10,GO:0032869,cellular response to insulin stimulus,M1,1,0
1,-15,GO:0003015,heart process,M1,1,0
1,-2.4,M4893,GSE28237 EARLY VS LATE GC BCELL UP,M1,1,0
1,-3.9,GO:0051047,positive regulation of secretion,M1,1,0
1,-3,M7440,GSE21670 TGFB VS IL6 TREATED CD4 TCELL DN,M1,1,0
1,-8.2,R-HSA-9665686,Signaling by ERBB2 TMD/JMD mutants,M1,1,0
1,-5.2,GO:0140527,reciprocal homologous recombination,M1,1,0
1,-4.9,GO:0008080,N-acetyltransferase activity,M1,1,0
1,-2.7,M2948,SESTO RESPONSE TO UV C8,M1,1,0
1,-10,GO:0007599,hemostasis,M1,1,0
1,-4.2,CORUM:1189,DNA double-strand break end-joining complex,M1,1,0
1,-14,GO:0060537,muscle tissue development,M1,1,0
1,-3.6,R-HSA-445989,TAK1-dependent IKK and NF-kappa-B activation,M1,1,0
1,-6.6,M9419,GSE39556 CD8A DC VS NK CELL MOUSE 3H POST POLYIC INJ UP,M1,1,0
1,-2.3,GO:0045861,negative regulation of proteolysis,M1,1,0
1,-10,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M1,1,0
1,-10,GO:0007601,visual perception,M1,1,0
1,-23,GO:0030097,hemopoiesis,M1,1,0
1,-2.2,R-HSA-9013423,RAC3 GTPase cycle,M1,1,0
1,-5.3,M10237,RODRIGUES THYROID CARCINOMA ANAPLASTIC UP,M1,1,0
1,-10,GO:1903037,regulation of leukocyte cell-cell adhesion,M1,1,0
1,-6.6,GO:0030111,regulation of Wnt signaling pathway,M1,1,0
1,-3.7,M7050,GSE15330 HSC VS LYMPHOID PRIMED MULTIPOTENT PROGENITOR IKAROS KO UP,M1,1,0
1,-18,R-HSA-9704646,Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function,M1,1,0
1,-3.1,M5215,GSE360 T GONDII VS B MALAYI HIGH DOSE DC UP,M1,1,0
1,-11,GO:0007389,pattern specification process,M1,1,0
1,-5.9,R-HSA-8863795,Downregulation of ERBB2 signaling,M1,1,0
1,-2.8,GO:0035014,phosphatidylinositol 3-kinase regulator activity,M1,1,0
1,-2.7,M2391,WANG THOC1 TARGETS DN,M1,1,0
1,-2.9,GO:0030224,monocyte differentiation,M1,1,0
1,-7,GO:1902895,positive regulation of miRNA transcription,M1,1,0
1,-3.4,M8519,DAVICIONI MOLECULAR ARMS VS ERMS DN,M1,1,0
1,-5,R-HSA-6802957,Oncogenic MAPK signaling,M1,1,0
1,-4,GO:0042473,outer ear morphogenesis,M1,1,0
1,-4.3,M9143,FRIDMAN SENESCENCE UP,M1,1,0
1,-3.2,WP5113,Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway,M1,1,0
1,-3.6,M8795,CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS UP,M1,1,0
1,-2.2,GO:0032091,negative regulation of protein binding,M1,1,0
1,-2.1,M3026,CHUNG BLISTER CYTOTOXICITY UP,M1,1,0
1,-3.9,GO:0061318,renal filtration cell differentiation,M1,1,0
1,-3,GO:0070603,SWI/SNF superfamily-type complex,M1,1,0
1,-3.5,CORUM:803,BRG1-SIN3A-HDAC containing SWI/SNF remodeling complex I,M1,1,0
1,-5.9,R-HSA-5653656,Vesicle-mediated transport,M1,1,0
1,-7.4,GO:0071345,cellular response to cytokine stimulus,M1,1,0
1,-10,GO:0010595,positive regulation of endothelial cell migration,M1,1,0
1,-4.2,WP2813,Mammary gland development pathway - Embryonic development (Stage 1 of 4),M1,1,0
1,-2.1,M1785,POS HISTAMINE RESPONSE NETWORK,M1,1,0
1,-3,M4593,GSE24634 NAIVE CD4 TCELL VS DAY7 IL4 CONV TREG DN,M1,1,0
1,-3.4,GO:0090737,telomere maintenance via telomere trimming,M1,1,0
1,-3.3,GO:0060295,regulation of cilium movement involved in cell motility,M1,1,0
1,-3.9,GO:0098858,actin-based cell projection,M1,1,0
1,-11,GO:0061448,connective tissue development,M1,1,0
1,-3.3,GO:0048644,muscle organ morphogenesis,M1,1,0
1,-5.7,GO:0030674,protein-macromolecule adaptor activity,M1,1,0
1,-4.4,M9754,GSE43863 LY6C INT CXCR5POS VS LY6C LOW CXCR5NEG EFFECTOR CD4 TCELL UP,M1,1,0
1,-6.4,GO:0033500,carbohydrate homeostasis,M1,1,0
1,-5.5,GO:0030316,osteoclast differentiation,M1,1,0
1,-14,WP707,DNA damage response,M1,1,0
1,-5.1,GO:0051341,regulation of oxidoreductase activity,M1,1,0
1,-2.4,M3628,GSE15930 STIM VS STIM AND TRICHOSTATINA 24H CD8 T CELL DN,M1,1,0
1,-2.3,GO:0070293,renal absorption,M1,1,0
1,-2.7,GO:0017145,stem cell division,M1,1,0
1,-2,GO:1903580,positive regulation of ATP metabolic process,M1,1,0
1,-6.2,GO:0090132,epithelium migration,M1,1,0
1,-2.2,GO:0060261,positive regulation of transcription initiation by RNA polymerase II,M1,1,0
1,-2.6,M5542,SATO SILENCED EPIGENETICALLY IN PANCREATIC CANCER,M1,1,0
1,-6.6,GO:0022408,negative regulation of cell-cell adhesion,M1,1,0
1,-2.4,GO:0071622,regulation of granulocyte chemotaxis,M1,1,0
1,-5.5,GO:0022843,voltage-gated cation channel activity,M1,1,0
1,-9.5,R-HSA-375165,NCAM signaling for neurite out-growth,M1,1,0
1,-4.3,GO:1902911,protein kinase complex,M1,1,0
1,-3.5,GO:0019233,sensory perception of pain,M1,1,0
1,-11,GO:0060173,limb development,M1,1,0
1,-15,GO:0008285,negative regulation of cell population proliferation,M1,1,0
1,-6.8,GO:0007405,neuroblast proliferation,M1,1,0
1,-2.4,M5369,POOLA INVASIVE BREAST CANCER UP,M1,1,0
1,-2.3,GO:0032330,regulation of chondrocyte differentiation,M1,1,0
1,-7.8,GO:0009799,specification of symmetry,M1,1,0
1,-2.6,GO:0051000,positive regulation of nitric-oxide synthase activity,M1,1,0
1,-5.7,GO:0038128,ERBB2 signaling pathway,M1,1,0
1,-2.5,GO:0005782,peroxisomal matrix,M1,1,0
1,-4.6,GO:0014015,positive regulation of gliogenesis,M1,1,0
1,-3.2,GO:0048070,regulation of developmental pigmentation,M1,1,0
1,-2.5,M5561,GSE3982 BASOPHIL VS NKCELL UP,M1,1,0
1,-2.4,M3514,GSE14769 40MIN VS 360MIN LPS BMDM UP,M1,1,0
1,-7,R-HSA-69206,G1/S Transition,M1,1,0
1,-4.9,GO:0071887,leukocyte apoptotic process,M1,1,0
1,-8.8,GO:0043470,regulation of carbohydrate catabolic process,M1,1,0
1,-3.1,GO:0046883,regulation of hormone secretion,M1,1,0
1,-3.9,WP4884,Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex,M1,1,0
1,-16,GO:0003007,heart morphogenesis,M1,1,0
1,-4.9,GO:0033135,regulation of peptidyl-serine phosphorylation,M1,1,0
1,-2.7,GO:0043621,protein self-association,M1,1,0
1,-4,GO:1902903,regulation of supramolecular fiber organization,M1,1,0
1,-4.5,M8737,GSE36888 UNTREATED VS IL2 TREATED STAT5 AB KNOCKIN TCELL 6H UP,M1,1,0
1,-2.4,GO:0033233,regulation of protein sumoylation,M1,1,0
1,-10,GO:0001221,transcription coregulator binding,M1,1,0
1,-18,GO:0031175,neuron projection development,M1,1,0
1,-3.4,M13867,ONDER CDH1 TARGETS 2 UP,M1,1,0
1,-12,GO:0048017,inositol lipid-mediated signaling,M1,1,0
1,-4.4,M9967,GSE45365 HEALTHY VS MCMV INFECTION CD8A DC UP,M1,1,0
1,-9.9,GO:0061008,hepaticobiliary system development,M1,1,0
1,-3.8,R-HSA-5696400,Dual Incision in GG-NER,M1,1,0
1,-5.8,GO:0007568,aging,M1,1,0
1,-2.1,M2901,KRAS.PROSTATE UP.V1 DN,M1,1,0
1,-2.3,GO:0034698,response to gonadotropin,M1,1,0
1,-18,WP4946,"DNA repair pathways, full network",M1,1,0
1,-4.4,M7658,GSE19401 NAIVE VS IMMUNIZED MOUSE PLN FOLLICULAR DC DN,M1,1,0
1,-4.1,GO:0060977,coronary vasculature morphogenesis,M1,1,0
1,-2.1,GO:0018394,peptidyl-lysine acetylation,M1,1,0
1,-2.6,GO:0045089,positive regulation of innate immune response,M1,1,0
1,-2.7,GO:0090090,negative regulation of canonical Wnt signaling pathway,M1,1,0
1,-5,GO:0016922,nuclear receptor binding,M1,1,0
1,-4.6,R-HSA-446652,Interleukin-1 family signaling,M1,1,0
1,-5.3,R-HSA-5654688,SHC-mediated cascade:FGFR1,M1,1,0
1,-2.5,M1977,ONO AML1 TARGETS UP,M1,1,0
1,-17,hsa05162,Measles,M1,1,0
1,-2.5,GO:0045776,negative regulation of blood pressure,M1,1,0
1,-3.1,M19016,GAZDA DIAMOND BLACKFAN ANEMIA ERYTHROID DN,M1,1,0
1,-7.8,M1529,SA G1 AND S PHASES,M1,1,0
1,-4.3,M1361,DAZARD RESPONSE TO UV SCC UP,M1,1,0
1,-3.8,hsa04934,Cushing syndrome,M1,1,0
1,-3.5,GO:0031012,extracellular matrix,M1,1,0
1,-3.1,hsa04512,ECM-receptor interaction,M1,1,0
1,-8.8,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M1,1,0
1,-3.1,GO:0071675,regulation of mononuclear cell migration,M1,1,0
1,-3.7,M9135,GSE40274 CTRL VS FOXP3 TRANSDUCED ACTIVATED CD4 TCELL UP,M1,1,0
1,-3.9,M4665,BAELDE DIABETIC NEPHROPATHY DN,M1,1,0
1,-5,M1106,GRAESSMANN RESPONSE TO MC AND DOXORUBICIN UP,M1,1,0
1,-2.4,CORUM:5233,TNF-alpha/NF-kappa B signaling complex 5,M1,1,0
1,-3.3,M244,SMID BREAST CANCER RELAPSE IN BRAIN DN,M1,1,0
1,-8.5,M9577,MOOTHA MITOCHONDRIA,M1,1,0
1,-5.8,GO:0015399,primary active transmembrane transporter activity,M1,1,0
1,-4.1,M13327,VANHARANTA UTERINE FIBROID WITH 7Q DELETION DN,M1,1,0
1,-5.6,GO:0016538,cyclin-dependent protein serine/threonine kinase regulator activity,M1,1,0
1,-2.7,GO:0060561,apoptotic process involved in morphogenesis,M1,1,0
1,-3.9,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M1,1,0
1,-10,WP3844,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities,M1,1,0
1,-3.2,GO:0032946,positive regulation of mononuclear cell proliferation,M1,1,0
1,-4.2,GO:0042310,vasoconstriction,M1,1,0
1,-3,M4529,GSE22886 NAIVE CD4 TCELL VS 48H ACT TH2 DN,M1,1,0
1,-2.1,GO:0090183,regulation of kidney development,M1,1,0
1,-12,GO:0000077,DNA damage checkpoint signaling,M1,1,0
1,-2.4,M2733,NOJIMA SFRP2 TARGETS DN,M1,1,0
1,-4.9,GO:0044843,cell cycle G1/S phase transition,M1,1,0
1,-5,M12498,UEDA PERIFERAL CLOCK,M1,1,0
1,-2.8,M2510,ZHANG RESPONSE TO CANTHARIDIN DN,M1,1,0
1,-3.5,M18761,SMITH LIVER CANCER,M1,1,0
1,-3.7,M4584,GSE24142 ADULT VS FETAL DN3 THYMOCYTE UP,M1,1,0
1,-10,GO:0048839,inner ear development,M1,1,0
1,-4.3,GO:0070665,positive regulation of leukocyte proliferation,M1,1,0
1,-3.4,M18757,ONDER CDH1 TARGETS 1 UP,M1,1,0
1,-3,GO:0032731,positive regulation of interleukin-1 beta production,M1,1,0
1,-5.1,GO:0048512,circadian behavior,M1,1,0
1,-4.7,R-HSA-1650814,Collagen biosynthesis and modifying enzymes,M1,1,0
1,-4.2,GO:0010484,H3 histone acetyltransferase activity,M1,1,0
1,-2.6,GO:0001818,negative regulation of cytokine production,M1,1,0
1,-5.1,R-HSA-112315,Transmission across Chemical Synapses,M1,1,0
1,-2.5,M7549,GSE21546 UNSTIM VS ANTI CD3 STIM DP THYMOCYTES DN,M1,1,0
1,-15,M10,PID BCR 5PATHWAY,M1,1,0
1,-3.7,GO:0014003,oligodendrocyte development,M1,1,0
1,-2,GO:0005539,glycosaminoglycan binding,M1,1,0
1,-2.2,R-HSA-8943724,Regulation of PTEN gene transcription,M1,1,0
1,-5.6,GO:0035296,regulation of tube diameter,M1,1,0
1,-2.9,GO:0001101,response to acid chemical,M1,1,0
1,-3.7,M6352,GSE3720 VD1 VS VD2 GAMMADELTA TCELL WITH LPS STIM UP,M1,1,0
1,-8.2,GO:0006631,fatty acid metabolic process,M1,1,0
1,-3.8,CORUM:710,Brg1-associated complex I,M1,1,0
1,-2.7,GO:0110149,regulation of biomineralization,M1,1,0
1,-4.1,hsa05017,Spinocerebellar ataxia,M1,1,0
1,-3.4,WP3849,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ,M1,1,0
1,-3.7,M11865,BRUNEAU SEPTATION VENTRICULAR,M1,1,0
1,-2.9,GO:0060973,cell migration involved in heart development,M1,1,0
1,-2.5,M10277,MULLIGHAN NPM1 SIGNATURE 3 UP,M1,1,0
1,-4.8,WP2814,Mammary gland development pathway - Puberty (Stage 2 of 4),M1,1,0
1,-9,GO:0007409,axonogenesis,M1,1,0
1,-3.4,GO:0090312,positive regulation of protein deacetylation,M1,1,0
1,-2.2,GO:0080171,lytic vacuole organization,M1,1,0
1,-2.8,GO:0021549,cerebellum development,M1,1,0
1,-15,GO:0030335,positive regulation of cell migration,M1,1,0
1,-5.3,R-HSA-5673000,RAF activation,M1,1,0
1,-4.2,R-HSA-881907,Gastrin-CREB signalling pathway via PKC and MAPK,M1,1,0
1,-2.7,M9003,GSE37533 UNTREATED VS PIOGLIZATONE TREATED CD4 TCELL PPARG2 AND FOXP3 TRASDUCED UP,M1,1,0
1,-5.5,M240,PID SYNDECAN 2 PATHWAY,M1,1,0
1,-5.6,GO:0050885,neuromuscular process controlling balance,M1,1,0
1,-11,GO:0006351,DNA-templated transcription,M1,1,0
1,-3.8,GO:0060982,coronary artery morphogenesis,M1,1,0
1,-8.5,GO:0050801,ion homeostasis,M1,1,0
1,-11,hsa04613,Neutrophil extracellular trap formation,M1,1,0
1,-22,WP2828,Bladder cancer,M1,1,0
1,-3.1,M1902,SCHRAETS MLL TARGETS UP,M1,1,0
1,-8.7,GO:0045936,negative regulation of phosphate metabolic process,M1,1,0
1,-2.1,GO:0005604,basement membrane,M1,1,0
1,-4.4,R-HSA-210744,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,M1,1,0
1,-16,WP2032,Thyroid stimulating hormone (TSH) signaling pathway,M1,1,0
1,-5.3,GO:0070192,chromosome organization involved in meiotic cell cycle,M1,1,0
1,-7.2,GO:0060090,molecular adaptor activity,M1,1,0
1,-11,R-HSA-9664565,Signaling by ERBB2 KD Mutants,M1,1,0
1,-5,GO:0022900,electron transport chain,M1,1,0
1,-5.8,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M1,1,0
1,-5.5,WP1742,TP53 network,M1,1,0
1,-3.1,GO:0002763,positive regulation of myeloid leukocyte differentiation,M1,1,0
1,-2.9,GO:0031663,lipopolysaccharide-mediated signaling pathway,M1,1,0
1,-3.6,GO:0003208,cardiac ventricle morphogenesis,M1,1,0
1,-4.8,R-HSA-69563,p53-Dependent G1 DNA Damage Response,M1,1,0
1,-2.3,GO:1901017,negative regulation of potassium ion transmembrane transporter activity,M1,1,0
1,-3.6,GO:0016601,Rac protein signal transduction,M1,1,0
1,-9.3,GO:0031329,regulation of cellular catabolic process,M1,1,0
1,-2.5,M5289,GSE36476 CTRL VS TSST ACT 40H MEMORY CD4 TCELL YOUNG UP,M1,1,0
1,-3,M5490,WELCSH BRCA1 TARGETS UP,M1,1,0
1,-3.3,M1409,PEART HDAC PROLIFERATION CLUSTER UP,M1,1,0
1,-2.9,M5657,GSE6269 FLU VS STREP PNEUMO INF PBMC UP,M1,1,0
1,-2.4,M8842,GSE37301 MULTIPOTENT PROGENITOR VS COMMON LYMPHOID PROGENITOR DN,M1,1,0
1,-6.3,GO:0048709,oligodendrocyte differentiation,M1,1,0
1,-2.9,M6851,GSE7768 OVA ALONE VS OVA WITH LPS IMMUNIZED MOUSE WHOLE SPLEEN 6H UP,M1,1,0
1,-8.7,hsa04923,Regulation of lipolysis in adipocytes,M1,1,0
1,-11,M143,PID IL2 PI3K PATHWAY,M1,1,0
1,-3,M7293,GSE18893 TCONV VS TREG 2H CULTURE DN,M1,1,0
1,-2.4,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M1,1,0
1,-2.7,M17287,LIU SOX4 TARGETS DN,M1,1,0
1,-2.2,M2981,GSE13547 2H VS 12 H ANTI IGM STIM BCELL UP,M1,1,0
1,-3.8,R-HSA-5654712,FRS-mediated FGFR4 signaling,M1,1,0
1,-12,GO:1901988,negative regulation of cell cycle phase transition,M1,1,0
1,-3,GO:0043393,regulation of protein binding,M1,1,0
1,-2.2,M6659,FULCHER INFLAMMATORY RESPONSE LECTIN VS LPS UP,M1,1,0
1,-9.3,GO:1903706,regulation of hemopoiesis,M1,1,0
1,-2.5,GO:0051495,positive regulation of cytoskeleton organization,M1,1,0
1,-2.1,M10243,FLECHNER PBL KIDNEY TRANSPLANT REJECTED VS OK UP,M1,1,0
1,-21,GO:0061629,RNA polymerase II-specific DNA-binding transcription factor binding,M1,1,0
1,-6.7,M14665,SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN UP,M1,1,0
1,-2.9,GO:0043923,positive regulation by host of viral transcription,M1,1,0
1,-4.4,GO:0035725,sodium ion transmembrane transport,M1,1,0
1,-6,GO:0006091,generation of precursor metabolites and energy,M1,1,0
1,-3.9,GO:0060993,kidney morphogenesis,M1,1,0
1,-3.9,GO:0035902,response to immobilization stress,M1,1,0
1,-2,M6813,IVANOVA HEMATOPOIESIS STEM CELL,M1,1,0
1,-2.4,M3573,GSE15750 WT VS TRAF6KO DAY10 EFF CD8 TCELL UP,M1,1,0
1,-4.2,GO:0019693,ribose phosphate metabolic process,M1,1,0
1,-4.5,GO:0048706,embryonic skeletal system development,M1,1,0
1,-5.2,M2388,BYSTRYKH HEMATOPOIESIS STEM CELL QTL TRANS,M1,1,0
1,-2,GO:0032784,regulation of DNA-templated transcription elongation,M1,1,0
1,-2.5,M9306,GSE40685 TREG VS FOXP3 KO TREG PRECURSOR UP,M1,1,0
1,-15,M183,PID IL6 7 PATHWAY,M1,1,0
1,-3.8,R-HSA-8876493,InlA-mediated entry of Listeria monocytogenes into host cells,M1,1,0
1,-2.3,GO:0031110,regulation of microtubule polymerization or depolymerization,M1,1,0
1,-5.4,M12522,CREIGHTON ENDOCRINE THERAPY RESISTANCE 1,M1,1,0
1,-2.1,GO:0003158,endothelium development,M1,1,0
1,-2.6,WP3599,Transcription factor regulation in adipogenesis,M1,1,0
1,-9.3,WP205,IL-7 signaling pathway,M1,1,0
1,-8.3,GO:0031647,regulation of protein stability,M1,1,0
1,-2.3,M252,PID IL8 CXCR1 PATHWAY,M1,1,0
1,-4.6,GO:1904018,positive regulation of vasculature development,M1,1,0
1,-5.3,M19693,DAZARD RESPONSE TO UV NHEK UP,M1,1,0
1,-2.6,GO:0061437,renal system vasculature development,M1,1,0
1,-4.7,GO:0045670,regulation of osteoclast differentiation,M1,1,0
1,-5.3,GO:0007626,locomotory behavior,M1,1,0
1,-3.1,GO:0090571,RNA polymerase II transcription repressor complex,M1,1,0
1,-6.7,GO:0055075,potassium ion homeostasis,M1,1,0
1,-2.7,GO:1900274,regulation of phospholipase C activity,M1,1,0
1,-2.7,M2772,ESC V6.5 UP LATE.V1 UP,M1,1,0
1,-3,M7335,GSE19888 CTRL VS TCELL MEMBRANES ACT MAST CELL PRETREAT A3R INH UP,M1,1,0
1,-2.5,M5579,GSE3982 EFF MEMORY CD4 TCELL VS TH1 DN,M1,1,0
1,-6.4,GO:1904951,positive regulation of establishment of protein localization,M1,1,0
1,-5.1,M5150,GSE360 CTRL VS B MALAYI HIGH DOSE DC UP,M1,1,0
1,-4.8,hsa05321,Inflammatory bowel disease,M1,1,0
1,-13,GO:0043549,regulation of kinase activity,M1,1,0
1,-4.4,GO:0045639,positive regulation of myeloid cell differentiation,M1,1,0
1,-4.3,WP3859,TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition,M1,1,0
1,-3,GO:2001240,negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,M1,1,0
1,-5.9,GO:0060964,regulation of miRNA-mediated gene silencing,M1,1,0
1,-2.3,GO:0061919,process utilizing autophagic mechanism,M1,1,0
1,-3,GO:0051282,regulation of sequestering of calcium ion,M1,1,0
1,-4.7,M6267,ZAIDI OSTEOBLAST TRANSCRIPTION FACTORS,M1,1,0
1,-18,GO:0071375,cellular response to peptide hormone stimulus,M1,1,0
1,-3.1,WP4786,Type I collagen synthesis in the context of osteogenesis imperfecta,M1,1,0
1,-2.4,M6942,GSE6674 PL2 3 VS ANTI IGM AND CPG STIM BCELL UP,M1,1,0
1,-2.4,M7042,GSE15330 GRANULOCYTE MONOCYTE PROGENITOR VS PRO BCELL DN,M1,1,0
1,-3.8,GO:0010517,regulation of phospholipase activity,M1,1,0
1,-6.6,M5156,GSE360 CTRL VS M TUBERCULOSIS DC DN,M1,1,0
1,-11,GO:0032496,response to lipopolysaccharide,M1,1,0
1,-13,WP4481,Resistin as a regulator of inflammation,M1,1,0
1,-2.5,M8289,GSE23114 WT VS SLE2C1 MOUSE SPLEEN B1A BCELL DN,M1,1,0
1,-2.5,M8140,GSE25846 IL10 POS VS NEG CD8 TCELL DAY7 POST CORONAVIRUS BRAIN UP,M1,1,0
1,-3,M5228,GSE360 HIGH DOSE B MALAYI VS M TUBERCULOSIS DC DN,M1,1,0
1,-3,GO:0090520,sphingolipid mediated signaling pathway,M1,1,0
1,-2.5,M8443,GSE46468 LUNG INNATE LYMPHOID CELL VS SPLEEN CD4 TCELL UP,M1,1,0
1,-4.5,GO:0046903,secretion,M1,1,0
1,-2.5,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M1,1,0
1,-4.7,M190,PID TCR JNK PATHWAY,M1,1,0
1,-3.7,M9556,BANDRES RESPONSE TO CARMUSTIN MGMT 48HR DN,M1,1,0
1,-34,WP710,DNA damage response (only ATM dependent),M1,1,0
1,-2.1,GO:1903900,regulation of viral life cycle,M1,1,0
1,-6.3,GO:0004674,protein serine/threonine kinase activity,M1,1,0
1,-2.6,GO:0030742,GTP-dependent protein binding,M1,1,0
1,-2.5,GO:0046850,regulation of bone remodeling,M1,1,0
1,-2.5,M2155,MCBRYAN PUBERTAL BREAST 6 7WK UP,M1,1,0
1,-2.1,R-HSA-8986944,Transcriptional Regulation by MECP2,M1,1,0
1,-3.2,GO:0003180,aortic valve morphogenesis,M1,1,0
1,-7.9,M268,PID S1P S1P2 PATHWAY,M1,1,0
1,-4.3,GO:0048010,vascular endothelial growth factor receptor signaling pathway,M1,1,0
1,-3.2,GO:0003014,renal system process,M1,1,0
1,-4.1,M17788,LINDGREN BLADDER CANCER CLUSTER 1 DN,M1,1,0
1,-3.3,GO:0072503,cellular divalent inorganic cation homeostasis,M1,1,0
1,-6.5,R-HSA-9603381,Activated NTRK3 signals through PI3K,M1,1,0
1,-9.4,R-HSA-194315,Signaling by Rho GTPases,M1,1,0
1,-9,GO:0006941,striated muscle contraction,M1,1,0
1,-2.3,WP3869,Cannabinoid receptor signaling,M1,1,0
1,-9.9,GO:0042303,molting cycle,M1,1,0
1,-5.1,CORUM:3062,"RNA polymerase II complex, (CBP, RPBI, PCAF, BAF47), chromatin structure modifying",M1,1,0
1,-2.2,M178,CROMER TUMORIGENESIS UP,M1,1,0
1,-2.6,GO:0032069,regulation of nuclease activity,M1,1,0
1,-8.4,GO:0055080,cation homeostasis,M1,1,0
1,-2.7,GO:1901681,sulfur compound binding,M1,1,0
1,-3,M5229,GSE360 LOW DOSE B MALAYI VS M TUBERCULOSIS DC UP,M1,1,0
1,-3.2,M2632,E2F1 UP.V1 UP,M1,1,0
1,-5.6,GO:0032944,regulation of mononuclear cell proliferation,M1,1,0
1,-13,R-HSA-912446,Meiotic recombination,M1,1,0
1,-2,GO:0034399,nuclear periphery,M1,1,0
1,-4,GO:0006975,DNA damage induced protein phosphorylation,M1,1,0
1,-9.1,R-HSA-180292,GAB1 signalosome,M1,1,0
1,-2.4,WP5183,SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction,M1,1,0
1,-4.3,M113,PID NFAT 3PATHWAY,M1,1,0
1,-3,M3892,GSE17721 CPG VS GARDIQUIMOD 8H BMDC UP,M1,1,0
1,-4.2,GO:0003279,cardiac septum development,M1,1,0
1,-8.9,GO:0072006,nephron development,M1,1,0
1,-8.1,GO:0050931,pigment cell differentiation,M1,1,0
1,-4.5,GO:0005779,integral component of peroxisomal membrane,M1,1,0
1,-12,GO:0007173,epidermal growth factor receptor signaling pathway,M1,1,0
1,-2.2,M7632,GSE21360 NAIVE VS SECONDARY MEMORY CD8 TCELL DN,M1,1,0
1,-2.5,M5599,GSE39820 CTRL VS IL1B IL6 CD4 TCELL UP,M1,1,0
1,-2.5,M8581,GSE26030 UNSTIM VS RESTIM TH17 DAY5 POST POLARIZATION DN,M1,1,0
1,-10,GO:0000278,mitotic cell cycle,M1,1,0
1,-20,GO:0070848,response to growth factor,M1,1,0
1,-2.4,M9422,GSE33292 WT VS TCF1 KO DN3 THYMOCYTE DN,M1,1,0
1,-7.2,M16,PID INSULIN PATHWAY,M1,1,0
1,-6.3,R-HSA-199991,Membrane Trafficking,M1,1,0
1,-7.5,GO:2000630,positive regulation of miRNA metabolic process,M1,1,0
1,-3.4,GO:0061307,cardiac neural crest cell differentiation involved in heart development,M1,1,0
1,-7.5,R-HSA-198203,PI3K/AKT activation,M1,1,0
1,-2.7,GO:0008340,determination of adult lifespan,M1,1,0
1,-3.3,GO:2000615,regulation of histone H3-K9 acetylation,M1,1,0
1,-5.3,R-HSA-74749,Signal attenuation,M1,1,0
1,-3.2,GO:0034391,regulation of smooth muscle cell apoptotic process,M1,1,0
1,-3.7,M8407,GSE29949 CD8 POS DC SPLEEN VS DC BRAIN UP,M1,1,0
1,-7.7,GO:0060306,regulation of membrane repolarization,M1,1,0
1,-3.2,M5275,OSMAN BLADDER CANCER UP,M1,1,0
1,-4,GO:0010626,negative regulation of Schwann cell proliferation,M1,1,0
1,-3.3,CORUM:189,BAF complex,M1,1,0
1,-2.4,M624,HOLLERN EMT BREAST TUMOR DN,M1,1,0
1,-17,WP2203,Thymic stromal lymphopoietin (TSLP) signaling pathway,M1,1,0
1,-14,GO:0071479,cellular response to ionizing radiation,M1,1,0
1,-3.5,R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,M1,1,0
1,-2.1,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M1,1,0
1,-4.8,R-HSA-1358803,Downregulation of ERBB2:ERBB3 signaling,M1,1,0
1,-2.1,M1125,MCBRYAN PUBERTAL TGFB1 TARGETS DN,M1,1,0
1,-9.2,GO:0042326,negative regulation of phosphorylation,M1,1,0
1,-2.8,GO:0055076,transition metal ion homeostasis,M1,1,0
1,-7.8,M6303,SCHEIDEREIT IKK INTERACTING PROTEINS,M1,1,0
1,-5.3,GO:0031058,positive regulation of histone modification,M1,1,0
1,-8,GO:0034765,regulation of ion transmembrane transport,M1,1,0
1,-9.7,M233,PID EPO PATHWAY,M1,1,0
1,-2.1,M5775,BROWNE HCMV INFECTION 12HR DN,M1,1,0
1,-7.2,M76,PID P38 ALPHA BETA PATHWAY,M1,1,0
1,-3.7,GO:0060260,regulation of transcription initiation by RNA polymerase II,M1,1,0
1,-19,GO:0048871,multicellular organismal homeostasis,M1,1,0
1,-2.7,GO:0007589,body fluid secretion,M1,1,0
1,-3.4,GO:0045667,regulation of osteoblast differentiation,M1,1,0
1,-2.2,M1636,YIH RESPONSE TO ARSENITE C3,M1,1,0
1,-2.1,GO:0035115,embryonic forelimb morphogenesis,M1,1,0
1,-10,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M1,1,0
1,-2.6,GO:0001618,virus receptor activity,M1,1,0
1,-4.1,M8637,STREICHER LSM1 TARGETS DN,M1,1,0
1,-3.5,GO:0072522,purine-containing compound biosynthetic process,M1,1,0
1,-4.3,WP3676,BDNF-TrkB signaling,M1,1,0
1,-4.6,M1410,SCHLOSSER SERUM RESPONSE DN,M1,1,0
1,-5.3,GO:0016303,1-phosphatidylinositol-3-kinase activity,M1,1,0
1,-2.1,M14670,DING LUNG CANCER EXPRESSION BY COPY NUMBER,M1,1,0
1,-2.5,GO:0010633,negative regulation of epithelial cell migration,M1,1,0
1,-10,GO:0070252,actin-mediated cell contraction,M1,1,0
1,-3.9,GO:0007063,regulation of sister chromatid cohesion,M1,1,0
1,-18,WP437,EGF/EGFR signaling pathway,M1,1,0
1,-7.6,hsa04912,GnRH signaling pathway,M1,1,0
1,-2.6,WP2877,Vitamin D receptor pathway,M1,1,0
1,-3,M6936,GSE6674 CPG VS PL2 3 STIM BCELL UP,M1,1,0
1,-8.8,GO:0006935,chemotaxis,M1,1,0
1,-4.8,GO:0000226,microtubule cytoskeleton organization,M1,1,0
1,-8.6,GO:0030856,regulation of epithelial cell differentiation,M1,1,0
1,-3.8,GO:0051924,regulation of calcium ion transport,M1,1,0
1,-5.6,GO:0098727,maintenance of cell number,M1,1,0
1,-8.6,GO:0002366,leukocyte activation involved in immune response,M1,1,0
1,-8.5,GO:0002696,positive regulation of leukocyte activation,M1,1,0
1,-2.1,GO:0042267,natural killer cell mediated cytotoxicity,M1,1,0
1,-5,WP5083,Neuroinflammation and glutamatergic signaling,M1,1,0
1,-7,R-HSA-8941326,RUNX2 regulates bone development,M1,1,0
1,-4.4,M6158,GSE1740 MCSF VS MCSF AND IFNG DAY2 DERIVED MACROPHAGE WITH IFNA STIM UP,M1,1,0
1,-13,GO:0045787,positive regulation of cell cycle,M1,1,0
1,-3.4,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M1,1,0
1,-2.1,M16584,LIU BREAST CANCER,M1,1,0
1,-26,hsa04917,Prolactin signaling pathway,M1,1,0
1,-2.5,M4525,GSE22886 NAIVE CD4 TCELL VS 48H ACT TH1 DN,M1,1,0
1,-10,M295,SIG PIP3 SIGNALING IN CARDIAC MYOCTES,M1,1,0
1,-3,GO:0046683,response to organophosphorus,M1,1,0
1,-3.1,M10276,LEE NEURAL CREST STEM CELL DN,M1,1,0
1,-5.8,M19529,RODRIGUES THYROID CARCINOMA ANAPLASTIC DN,M1,1,0
1,-14,GO:0014065,phosphatidylinositol 3-kinase signaling,M1,1,0
1,-3.7,M6045,GSE2770 UNTREATED VS IL12 TREATED ACT CD4 TCELL 48H DN,M1,1,0
1,-4.9,GO:0044853,plasma membrane raft,M1,1,0
1,-7.8,R-HSA-2029485,Role of phospholipids in phagocytosis,M1,1,0
1,-3.9,M6386,CREIGHTON ENDOCRINE THERAPY RESISTANCE 4,M1,1,0
1,-4.7,GO:0045862,positive regulation of proteolysis,M1,1,0
1,-3.5,GO:1903055,positive regulation of extracellular matrix organization,M1,1,0
1,-2.4,M8058,GSE24726 WT VS E2 22 KO PDC DAY4 POST DELETION DN,M1,1,0
1,-3.2,GO:0046394,carboxylic acid biosynthetic process,M1,1,0
1,-3.5,GO:0070231,T cell apoptotic process,M1,1,0
1,-3,M8297,GSE23114 PERITONEAL CAVITY B1A BCELL VS SPLEEN BCELL DN,M1,1,0
1,-3.8,GO:0071897,DNA biosynthetic process,M1,1,0
1,-4.4,M5173,GSE360 DC VS MAC DN,M1,1,0
1,-8.7,GO:0010563,negative regulation of phosphorus metabolic process,M1,1,0
1,-5.3,GO:0010572,positive regulation of platelet activation,M1,1,0
1,-8.8,GO:0072073,kidney epithelium development,M1,1,0
1,-2.4,M9765,GSE43863 TH1 VS LY6C INT CXCR5POS EFFECTOR CD4 TCELL DN,M1,1,0
1,-11,GO:1902495,transmembrane transporter complex,M1,1,0
1,-3.1,R-HSA-4791275,Signaling by WNT in cancer,M1,1,0
1,-3.5,GO:0005247,voltage-gated chloride channel activity,M1,1,0
1,-5.5,GO:0005251,delayed rectifier potassium channel activity,M1,1,0
1,-3.7,M9325,MCMURRAY TP53 HRAS COOPERATION RESPONSE DN,M1,1,0
1,-3.1,M44,PID HIF2PATHWAY,M1,1,0
1,-4.2,M210,PID IL8 CXCR2 PATHWAY,M1,1,0
1,-2.7,GO:1903427,negative regulation of reactive oxygen species biosynthetic process,M1,1,0
1,-12,GO:1903131,mononuclear cell differentiation,M1,1,0
1,-7.5,M9689,GSE43955 10H VS 30H ACT CD4 TCELL UP,M1,1,0
1,-3.1,GO:0004714,transmembrane receptor protein tyrosine kinase activity,M1,1,0
1,-3.4,GO:0072310,glomerular epithelial cell development,M1,1,0
1,-7.3,GO:0071364,cellular response to epidermal growth factor stimulus,M1,1,0
1,-2.3,M6110,BLALOCK ALZHEIMERS DISEASE INCIPIENT DN,M1,1,0
1,-11,GO:0098655,cation transmembrane transport,M1,1,0
1,-10,WP4217,Ebola virus infection in host,M1,1,0
1,-2.5,M3436,GSE1460 INTRATHYMIC T PROGENITOR VS DP THYMOCYTE UP,M1,1,0
1,-2.5,M7568,GSE21927 SPLEEN VS BONE MARROW MONOCYTE BALBC DN,M1,1,0
1,-13,WP2572,Primary focal segmental glomerulosclerosis (FSGS),M1,1,0
1,-3.1,M7715,FERRANDO T ALL WITH MLL ENL FUSION DN,M1,1,0
1,-9.8,GO:1903047,mitotic cell cycle process,M1,1,0
1,-5.8,R-HSA-3371556,Cellular response to heat stress,M1,1,0
1,-5.1,M5197,GSE360 L DONOVANI VS B MALAYI HIGH DOSE DC UP,M1,1,0
1,-10,GO:0034464,BBSome,M1,1,0
1,-3,M9833,GSE46606 UNSTIM VS CD40L IL2 IL5 1DAY STIMULATED IRF4MID SORTED BCELL UP,M1,1,0
1,-23,hsa04066,HIF-1 signaling pathway,M1,1,0
1,-18,WP23,B cell receptor signaling pathway,M1,1,0
1,-11,WP4566,Translation inhibitors in chronically activated PDGFRA cells,M1,1,0
1,-35,GO:0008283,cell population proliferation,M1,1,0
1,-19,hsa04926,Relaxin signaling pathway,M1,1,0
1,-6.5,M3686,SA REG CASCADE OF CYCLIN EXPR,M1,1,0
1,-3.7,M8850,GSE37301 MULTIPOTENT PROGENITOR VS RAG2 KO NK CELL UP,M1,1,0
1,-3.2,GO:0035060,brahma complex,M1,1,0
1,-6.1,M11011,ASTON MAJOR DEPRESSIVE DISORDER DN,M1,1,0
1,-2.5,M7522,GSE21546 WT VS SAP1A KO AND ELK1 KO ANTI CD3 STIM DP THYMOCYTES DN,M1,1,0
1,-9.2,GO:1902105,regulation of leukocyte differentiation,M1,1,0
1,-3.7,M4369,GSE20715 0H VS 48H OZONE LUNG DN,M1,1,0
1,-5,GO:0008589,regulation of smoothened signaling pathway,M1,1,0
1,-6,GO:0032535,regulation of cellular component size,M1,1,0
1,-5,GO:0090311,regulation of protein deacetylation,M1,1,0
1,-4.5,M2726,RAF UP.V1 DN,M1,1,0
1,-3.4,GO:0061308,cardiac neural crest cell development involved in heart development,M1,1,0
1,-3,M7762,GSE22935 WT VS MYD88 KO MACROPHAGE DN,M1,1,0
1,-3,M6249,GSE22601 DOUBLE POSITIVE VS CD8 SINGLE POSITIVE THYMOCYTE DN,M1,1,0
1,-2.7,GO:0050999,regulation of nitric-oxide synthase activity,M1,1,0
1,-2.4,M7911,GSE16385 UNTREATED VS 12H ROSIGLITAZONE IL4 TREATED MACROPHAGE UP,M1,1,0
1,-3.4,M2796,CRX NRL DN.V1 UP,M1,1,0
1,-5.6,GO:0031490,chromatin DNA binding,M1,1,0
1,-2.4,M9667,GSE43955 TGFB IL6 VS TGFB IL6 IL23 TH17 ACT CD4 TCELL 52H UP,M1,1,0
1,-2.3,GO:1900087,positive regulation of G1/S transition of mitotic cell cycle,M1,1,0
1,-4.5,GO:0015453,oxidoreduction-driven active transmembrane transporter activity,M1,1,0
1,-15,hsa04210,Apoptosis,M1,1,0
1,-4.4,M5300,GSE36476 CTRL VS TSST ACT 40H MEMORY CD4 TCELL OLD DN,M1,1,0
1,-20,R-HSA-9675136,Diseases of DNA Double-Strand Break Repair,M1,1,0
1,-7.2,WP5101,Congenital generalized lipodystrophy,M1,1,0
1,-4.5,GO:0042826,histone deacetylase binding,M1,1,0
1,-2.4,GO:0015103,inorganic anion transmembrane transporter activity,M1,1,0
1,-5.6,GO:0051057,positive regulation of small GTPase mediated signal transduction,M1,1,0
1,-3,M5815,GSE9037 WT VS IRAK4 KO LPS 1H STIM BMDM UP,M1,1,0
1,-2.4,GO:0048641,regulation of skeletal muscle tissue development,M1,1,0
1,-4.1,R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,M1,1,0
1,-2.1,M453,MURAKAMI UV RESPONSE 6HR UP,M1,1,0
1,-8.5,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M1,1,0
1,-12,GO:0061458,reproductive system development,M1,1,0
1,-2.1,M1417,JECHLINGER EPITHELIAL TO MESENCHYMAL TRANSITION DN,M1,1,0
1,-3,GO:0003231,cardiac ventricle development,M1,1,0
1,-7.4,GO:0034702,ion channel complex,M1,1,0
1,-3,GO:0060033,anatomical structure regression,M1,1,0
1,-3.7,M8383,GSE22025 UNTREATED VS TGFB1 AND PROGESTERONE TREATED CD4 TCELL UP,M1,1,0
1,-5.1,GO:0070532,BRCA1-B complex,M1,1,0
1,-13,M266,PID NCADHERIN PATHWAY,M1,1,0
1,-2.5,GO:0055081,anion homeostasis,M1,1,0
1,-2.7,GO:0002042,cell migration involved in sprouting angiogenesis,M1,1,0
1,-5.4,M88,PID CD8 TCR PATHWAY,M1,1,0
1,-9.1,GO:0033674,positive regulation of kinase activity,M1,1,0
1,-3.2,R-HSA-198323,AKT phosphorylates targets in the cytosol,M1,1,0
1,-12,GO:0048608,reproductive structure development,M1,1,0
1,-7.3,M55,PID S1P S1P3 PATHWAY,M1,1,0
1,-3,M6476,GSE3039 ALPHAALPHA VS ALPHABETA CD8 TCELL UP,M1,1,0
1,-2.3,GO:0051262,protein tetramerization,M1,1,0
1,-3,GO:0099568,cytoplasmic region,M1,1,0
1,-6.8,M1885,YOSHIMURA MAPK8 TARGETS DN,M1,1,0
1,-8.9,R-HSA-210993,Tie2 Signaling,M1,1,0
1,-5.1,GO:0090497,mesenchymal cell migration,M1,1,0
1,-3.6,R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,M1,1,0
1,-9.6,GO:0030048,actin filament-based movement,M1,1,0
1,-3,M4150,GSE17721 12H VS 24H GARDIQUIMOD BMDC DN,M1,1,0
1,-12,GO:1902749,regulation of cell cycle G2/M phase transition,M1,1,0
1,-6.4,M99,PID TXA2PATHWAY,M1,1,0
1,-3.4,GO:0043124,negative regulation of I-kappaB kinase/NF-kappaB signaling,M1,1,0
1,-3.2,GO:0009636,response to toxic substance,M1,1,0
1,-2.3,GO:0007254,JNK cascade,M1,1,0
1,-14,hsa03460,Fanconi anemia pathway,M1,1,0
1,-9,M9575,WAKASUGI HAVE ZNF143 BINDING SITES,M1,1,0
1,-5.1,GO:0071559,response to transforming growth factor beta,M1,1,0
1,-5.3,WP3657,Hematopoietic stem cell gene regulation by GABP alpha/beta complex,M1,1,0
1,-2.5,M5526,GSE3982 NEUTROPHIL VS EFF MEMORY CD4 TCELL UP,M1,1,0
1,-2.7,M1347,SCHAEFFER PROSTATE DEVELOPMENT 6HR DN,M1,1,0
1,-11,GO:0072663,establishment of protein localization to peroxisome,M1,1,0
1,-3.4,GO:0046425,regulation of receptor signaling pathway via JAK-STAT,M1,1,0
1,-3,M3619,GSE15930 NAIVE VS 72H IN VITRO STIM TRICHOSTATINA CD8 TCELL DN,M1,1,0
1,-18,R-HSA-5693554,Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA),M1,1,0
1,-2.6,R-HSA-212165,Epigenetic regulation of gene expression,M1,1,0
1,-3,WP4928,MAPK pathway in congenital thyroid cancer,M1,1,0
1,-41,WP2261,Glioblastoma signaling pathways,M1,1,0
1,-3.7,M8576,GSE26030 UNSTIM VS RESTIM TH1 DAY15 POST POLARIZATION DN,M1,1,0
1,-2,WP4542,Leukocyte-intrinsic Hippo pathway functions,M1,1,0
1,-4.1,GO:0052742,phosphatidylinositol kinase activity,M1,1,0
1,-2.1,GO:0042755,eating behavior,M1,1,0
1,-6.2,GO:0030055,cell-substrate junction,M1,1,0
1,-3.1,GO:0051170,import into nucleus,M1,1,0
1,-3.4,GO:0070633,transepithelial transport,M1,1,0
1,-7.4,GO:0017053,transcription repressor complex,M1,1,0
1,-2.2,GO:0005764,lysosome,M1,1,0
1,-7.4,M12717,LOPES METHYLATED IN COLON CANCER DN,M1,1,0
1,-8.8,GO:0045177,apical part of cell,M1,1,0
1,-2.9,GO:0070064,proline-rich region binding,M1,1,0
1,-7,M70,PID PS1 PATHWAY,M1,1,0
1,-3.1,M11288,SCHLESINGER METHYLATED DE NOVO IN CANCER,M1,1,0
1,-2.4,M9650,GSE43955 TH0 VS TGFB IL6 TH17 ACT CD4 TCELL 30H DN,M1,1,0
1,-3,M11788,CLASPER LYMPHATIC VESSELS DURING METASTASIS DN,M1,1,0
1,-3.8,CORUM:555,BAF complex,M1,1,0
1,-3,M7353,GSE19888 ADENOSINE A3R INH PRETREAT AND ACT BY A3R VS A3R INH AND TCELL MEMBRANES ACT MAST CELL DN,M1,1,0
1,-6.5,R-HSA-5654693,FRS-mediated FGFR1 signaling,M1,1,0
1,-4,CORUM:564,BAF complex,M1,1,0
1,-2.1,GO:0001569,branching involved in blood vessel morphogenesis,M1,1,0
1,-5.8,hsa04530,Tight junction,M1,1,0
1,-4.7,GO:0071681,cellular response to indole-3-methanol,M1,1,0
1,-4,GO:0060428,lung epithelium development,M1,1,0
1,-4.4,M5347,GSE37416 0H VS 12H F TULARENSIS LVS NEUTROPHIL UP,M1,1,0
1,-12,WP1530,miRNA regulation of DNA damage response,M1,1,0
1,-5.7,GO:0060147,regulation of post-transcriptional gene silencing,M1,1,0
1,-3.1,GO:0032872,regulation of stress-activated MAPK cascade,M1,1,0
1,-2.2,hsa01523,Antifolate resistance,M1,1,0
1,-2.9,M2026,NAKAMURA ADIPOGENESIS LATE UP,M1,1,0
1,-3.2,M2151,DUTERTRE ESTRADIOL RESPONSE 6HR UP,M1,1,0
1,-6.5,GO:0045216,cell-cell junction organization,M1,1,0
1,-9.1,GO:0010959,regulation of metal ion transport,M1,1,0
1,-3.6,GO:0010799,regulation of peptidyl-threonine phosphorylation,M1,1,0
1,-8.3,WP186,Homologous recombination,M1,1,0
1,-3.4,GO:0010800,positive regulation of peptidyl-threonine phosphorylation,M1,1,0
1,-11,R-HSA-6804757,Regulation of TP53 Degradation,M1,1,0
1,-2.8,GO:0043267,negative regulation of potassium ion transport,M1,1,0
1,-7,GO:0006110,regulation of glycolytic process,M1,1,0
1,-16,WP75,Toll-like receptor signaling pathway,M1,1,0
1,-3.1,GO:1901380,negative regulation of potassium ion transmembrane transport,M1,1,0
1,-2.4,M7423,GSE16450 CTRL VS IFNA 6H STIM MATURE NEURON CELL LINE DN,M1,1,0
1,-2.1,GO:0030332,cyclin binding,M1,1,0
1,-8.5,GO:0003151,outflow tract morphogenesis,M1,1,0
1,-3.3,M5520,TCGA GLIOBLASTOMA COPY NUMBER DN,M1,1,0
1,-8.3,hsa04930,Type II diabetes mellitus,M1,1,0
1,-6.9,GO:0099622,cardiac muscle cell membrane repolarization,M1,1,0
1,-2.6,GO:0072329,monocarboxylic acid catabolic process,M1,1,0
1,-2.3,M12225,PICCALUGA ANGIOIMMUNOBLASTIC LYMPHOMA UP,M1,1,0
1,-3.4,M2208,CARD MIR302A TARGETS,M1,1,0
1,-9.5,GO:0090066,regulation of anatomical structure size,M1,1,0
1,-12,GO:0098660,inorganic ion transmembrane transport,M1,1,0
1,-5.8,GO:0051668,localization within membrane,M1,1,0
1,-3.9,GO:0099086,synaptonemal structure,M1,1,0
1,-6.4,R-HSA-9700206,Signaling by ALK in cancer,M1,1,0
1,-2.4,GO:0044088,regulation of vacuole organization,M1,1,0
1,-4.2,R-HSA-6802953,RAS signaling downstream of NF1 loss-of-function variants,M1,1,0
1,-2.9,M1897,RASHI RESPONSE TO IONIZING RADIATION 1,M1,1,0
1,-3.7,M7950,GSE25088 ROSIGLITAZONE VS IL4 AND ROSIGLITAZONE STIM STAT6 KO MACROPHAGE DAY10 DN,M1,1,0
1,-2.2,R-HSA-2173795,Downregulation of SMAD2/3:SMAD4 transcriptional activity,M1,1,0
1,-3.1,M5344,GSE37416 0H VS 6H F TULARENSIS LVS NEUTROPHIL UP,M1,1,0
1,-6.9,GO:0086013,membrane repolarization during cardiac muscle cell action potential,M1,1,0
1,-3.7,M5268,GSE360 LOW DOSE B MALAYI VS M TUBERCULOSIS MAC DN,M1,1,0
1,-2.5,R-HSA-5627123,RHO GTPases activate PAKs,M1,1,0
1,-3.6,R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,M1,1,0
1,-4.7,M1744,MARSON BOUND BY E2F4 UNSTIMULATED,M1,1,0
1,-4.4,R-HSA-157118,Signaling by NOTCH,M1,1,0
1,-9.1,M26,PID NFKAPPAB ATYPICAL PATHWAY,M1,1,0
1,-6.7,M13984,MARZEC IL2 SIGNALING UP,M1,1,0
1,-9.9,WP231,TNF-alpha signaling pathway,M1,1,0
1,-7.3,GO:1990204,oxidoreductase complex,M1,1,0
1,-4.4,M3877,GSE17721 CPG VS GARDIQUIMOD 0.5H BMDC DN,M1,1,0
1,-6.4,M2961,GSE14415 NATURAL TREG VS TCONV DN,M1,1,0
1,-8.6,GO:0032392,DNA geometric change,M1,1,0
1,-4.6,WP176,Folate metabolism,M1,1,0
1,-4.8,M14601,CAIRO HEPATOBLASTOMA UP,M1,1,0
1,-2.9,R-HSA-421270,Cell-cell junction organization,M1,1,0
1,-2.3,GO:0044030,regulation of DNA methylation,M1,1,0
1,-2.5,M8636,GSE32986 CURDLAN HIGHDOSE VS GMCSF AND CURDLAN HIGHDOSE STIM DC UP,M1,1,0
1,-9.5,GO:0051347,positive regulation of transferase activity,M1,1,0
1,-3.8,M174,PID UPA UPAR PATHWAY,M1,1,0
1,-4.7,GO:0009925,basal plasma membrane,M1,1,0
1,-3.5,GO:0005201,extracellular matrix structural constituent,M1,1,0
1,-3.7,M5186,GSE360 DC VS MAC B MALAYI HIGH DOSE DN,M1,1,0
1,-3,R-HSA-391160,Signal regulatory protein family interactions,M1,1,0
1,-2.3,R-HSA-8941858,Regulation of RUNX3 expression and activity,M1,1,0
1,-11,GO:0000165,MAPK cascade,M1,1,0
1,-6,GO:0062014,negative regulation of small molecule metabolic process,M1,1,0
1,-5.5,GO:0043268,positive regulation of potassium ion transport,M1,1,0
1,-15,GO:0019901,protein kinase binding,M1,1,0
1,-18,R-HSA-9709570,Impaired BRCA2 binding to RAD51,M1,1,0
1,-7.3,GO:0099623,regulation of cardiac muscle cell membrane repolarization,M1,1,0
1,-3.3,GO:0002791,regulation of peptide secretion,M1,1,0
1,-2.4,M3968,GSE17721 PAM3CSK4 VS GADIQUIMOD 4H BMDC UP,M1,1,0
1,-6.9,GO:0048546,digestive tract morphogenesis,M1,1,0
1,-4.1,GO:0030534,adult behavior,M1,1,0
1,-2.1,GO:0072686,mitotic spindle,M1,1,0
1,-2.4,M10575,DACOSTA UV RESPONSE VIA ERCC3 XPCS DN,M1,1,0
1,-4.4,M3078,GSE10325 CD4 TCELL VS MYELOID UP,M1,1,0
1,-4.4,M8330,GSE24574 NAIVE VS TCONV CD4 TCELL DN,M1,1,0
1,-4.6,GO:0150116,regulation of cell-substrate junction organization,M1,1,0
1,-2.6,M2684,ATF2 UP.V1 DN,M1,1,0
1,-3,GO:1904356,regulation of telomere maintenance via telomere lengthening,M1,1,0
1,-6.6,GO:0060538,skeletal muscle organ development,M1,1,0
1,-24,M9150,GRESHOCK CANCER COPY NUMBER UP,M1,1,0
1,-8.7,GO:0062012,regulation of small molecule metabolic process,M1,1,0
1,-13,GO:0030031,cell projection assembly,M1,1,0
1,-6.1,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M1,1,0
1,-2.7,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M1,1,0
1,-3.4,hsa04371,Apelin signaling pathway,M1,1,0
1,-2.5,M3111,GSE11057 EFF MEM VS CENT MEM CD4 TCELL UP,M1,1,0
1,-2.5,GO:0051701,biological process involved in interaction with host,M1,1,0
1,-6,GO:0097623,potassium ion export across plasma membrane,M1,1,0
1,-3.8,GO:1905314,semi-lunar valve development,M1,1,0
1,-4.3,WP4949,16p11.2 proximal deletion syndrome,M1,1,0
1,-6.5,M196,PID IL23 PATHWAY,M1,1,0
1,-2.5,M4069,GSE17721 0.5H VS 12H LPS BMDC DN,M1,1,0
1,-10,M11171,DACOSTA UV RESPONSE VIA ERCC3 UP,M1,1,0
1,-2.4,M17466,SANA TNF SIGNALING UP,M1,1,0
1,-3.5,GO:0021548,pons development,M1,1,0
1,-2.4,M8596,GSE27859 DC VS CD11C INT F480 INT DC UP,M1,1,0
1,-18,R-HSA-9704331,Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function,M1,1,0
1,-2.4,M7174,GSE17186 CD21LOW VS CD21HIGH TRANSITIONAL BCELL DN,M1,1,0
1,-8.4,GO:0030522,intracellular receptor signaling pathway,M1,1,0
1,-4,CORUM:434,BASC (Ab 80) complex (BRCA1-associated genome surveillance complex),M1,1,0
1,-2.9,R-HSA-1369062,ABC transporters in lipid homeostasis,M1,1,0
1,-2.5,M8339,GSE24574 BCL6 LOW TFH VS NAIVE CD4 TCELL DN,M1,1,0
1,-4,GO:0007597,"blood coagulation, intrinsic pathway",M1,1,0
1,-3,GO:0007631,feeding behavior,M1,1,0
1,-6.7,M5214,GSE360 L MAJOR VS M TUBERCULOSIS DC DN,M1,1,0
1,-2.3,M5661,GSE6269 E COLI VS STREP PNEUMO INF PBMC UP,M1,1,0
1,-10,M72,PID NECTIN PATHWAY,M1,1,0
1,-3.7,GO:0043587,tongue morphogenesis,M1,1,0
1,-3.3,GO:0008296,3'-5'-exodeoxyribonuclease activity,M1,1,0
1,-3,M3084,GSE10325 LUPUS CD4 TCELL VS LUPUS BCELL UP,M1,1,0
1,-2.2,R-HSA-8874081,MET activates PTK2 signaling,M1,1,0
1,-8.7,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M1,1,0
1,-5.3,GO:0022412,cellular process involved in reproduction in multicellular organism,M1,1,0
1,-3.6,GO:0051169,nuclear transport,M1,1,0
1,-3.7,R-HSA-9617629,Regulation of FOXO transcriptional activity by acetylation,M1,1,0
1,-5.3,hsa05168,Herpes simplex virus 1 infection,M1,1,0
1,-3.6,GO:0034212,peptide N-acetyltransferase activity,M1,1,0
1,-4.3,M15193,GRUETZMANN PANCREATIC CANCER UP,M1,1,0
1,-12,R-HSA-1500620,Meiosis,M1,1,0
1,-3,GO:0046935,1-phosphatidylinositol-3-kinase regulator activity,M1,1,0
1,-2.5,GO:0006694,steroid biosynthetic process,M1,1,0
1,-9.4,GO:0090399,replicative senescence,M1,1,0
1,-2.5,GO:0033628,regulation of cell adhesion mediated by integrin,M1,1,0
1,-3.5,WP4147,PTF1A related regulatory pathway,M1,1,0
1,-2.5,M9195,GSE40441 NRP1 POS INDUCED TREG VS NRP1 NEG NATURAL TREG DN,M1,1,0
1,-2.4,M4754,GSE27786 LSK VS NKTCELL UP,M1,1,0
1,-3.8,GO:0002218,activation of innate immune response,M1,1,0
1,-7.3,GO:0001890,placenta development,M1,1,0
1,-2.4,M15484,ONDER CDH1 SIGNALING VIA CTNNB1,M1,1,0
1,-3.6,GO:0034706,sodium channel complex,M1,1,0
1,-2.4,GO:0042133,neurotransmitter metabolic process,M1,1,0
1,-16,GO:0050679,positive regulation of epithelial cell proliferation,M1,1,0
1,-2.6,M128,PID TNF PATHWAY,M1,1,0
1,-4.6,GO:1901976,regulation of cell cycle checkpoint,M1,1,0
1,-2.3,M9102,GSE40274 CTRL VS FOXP3 AND EOS TRANSDUCED ACTIVATED CD4 TCELL UP,M1,1,0
1,-3,GO:0140678,molecular function inhibitor activity,M1,1,0
1,-3.7,M15031,STREICHER LSM1 TARGETS UP,M1,1,0
1,-5.2,M8235,GSE27241 WT VS RORGT KO TH17 POLARIZED CD4 TCELL UP,M1,1,0
1,-3,GO:0031966,mitochondrial membrane,M1,1,0
1,-4.5,GO:0061982,meiosis I cell cycle process,M1,1,0
1,-18,hsa04370,VEGF signaling pathway,M1,1,0
1,-16,M91,PID TCPTP PATHWAY,M1,1,0
1,-9.4,WP4673,Male infertility,M1,1,0
1,-2.7,GO:0060716,labyrinthine layer blood vessel development,M1,1,0
1,-5.8,GO:0016407,acetyltransferase activity,M1,1,0
1,-3.7,M9621,GSE27434 WT VS DNMT1 KO TREG DN,M1,1,0
1,-2.9,R-HSA-73933,Resolution of Abasic Sites (AP sites),M1,1,0
1,-3.3,GO:0060674,placenta blood vessel development,M1,1,0
1,-2.3,GO:0005080,protein kinase C binding,M1,1,0
1,-2.1,GO:1903052,positive regulation of proteolysis involved in protein catabolic process,M1,1,0
1,-3.8,R-HSA-212718,EGFR interacts with phospholipase C-gamma,M1,1,0
1,-5.2,GO:0005975,carbohydrate metabolic process,M1,1,0
1,-2.2,M3732,SIMBULAN UV RESPONSE IMMORTALIZED DN,M1,1,0
1,-3,M1320,INGRAM SHH TARGETS UP,M1,1,0
1,-2.3,GO:0090175,regulation of establishment of planar polarity,M1,1,0
1,-9.7,M239,PID A6B1 A6B4 INTEGRIN PATHWAY,M1,1,0
1,-3.1,M2445,PLASARI TGFB1 TARGETS 10HR UP,M1,1,0
1,-8.5,R-HSA-451927,Interleukin-2 family signaling,M1,1,0
1,-2.4,GO:2000278,regulation of DNA biosynthetic process,M1,1,0
1,-9.7,WP5072,Modulators of TCR signaling and T cell activation,M1,1,0
1,-6.8,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M1,1,0
1,-3,M7650,GSE22140 HEALTHY VS ARTHRITIC MOUSE CD4 TCELL UP,M1,1,0
1,-3.6,GO:0097731,9+0 non-motile cilium,M1,1,0
1,-3.7,M5638,GSE5960 TH1 VS ANERGIC TH1 DN,M1,1,0
1,-2.9,WP4301,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells,M1,1,0
1,-3,M7649,GSE22140 GERMFREE VS SPF ARTHRITIC MOUSE CD4 TCELL UP,M1,1,0
1,-3,GO:0002293,alpha-beta T cell differentiation involved in immune response,M1,1,0
1,-8.3,R-HSA-1226099,Signaling by FGFR in disease,M1,1,0
1,-13,R-HSA-190236,Signaling by FGFR,M1,1,0
1,-3.8,GO:0090665,glycoprotein complex,M1,1,0
1,-3.7,GO:0045664,regulation of neuron differentiation,M1,1,0
1,-3,GO:0045651,positive regulation of macrophage differentiation,M1,1,0
1,-2.5,M5426,GSE3982 MAST CELL VS DC UP,M1,1,0
1,-8.8,GO:0070533,BRCA1-C complex,M1,1,0
1,-4.4,GO:1905477,positive regulation of protein localization to membrane,M1,1,0
1,-12,GO:0009791,post-embryonic development,M1,1,0
1,-3.6,GO:0016574,histone ubiquitination,M1,1,0
1,-5,M4023,FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR UP,M1,1,0
1,-4.2,GO:0052547,regulation of peptidase activity,M1,1,0
1,-2.2,GO:0045807,positive regulation of endocytosis,M1,1,0
1,-8.9,M5652,FARMER BREAST CANCER BASAL VS LULMINAL,M1,1,0
1,-2.4,GO:0071684,organism emergence from protective structure,M1,1,0
1,-7.4,R-HSA-8878166,Transcriptional regulation by RUNX2,M1,1,0
1,-4,GO:0007272,ensheathment of neurons,M1,1,0
1,-8.6,M207,PID RETINOIC ACID PATHWAY,M1,1,0
1,-3.7,GO:2001026,regulation of endothelial cell chemotaxis,M1,1,0
1,-27,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M1,1,0
1,-4.2,GO:0009260,ribonucleotide biosynthetic process,M1,1,0
1,-5.3,GO:0036092,phosphatidylinositol-3-phosphate biosynthetic process,M1,1,0
1,-6.4,GO:0042593,glucose homeostasis,M1,1,0
1,-3,M3843,GSE17721 POLYIC VS PAM3CSK4 16H BMDC DN,M1,1,0
1,-4.4,M9779,GSE44649 NAIVE VS ACTIVATED CD8 TCELL DN,M1,1,0
1,-4.7,WP4758,Nephrotic syndrome,M1,1,0
1,-2.4,M9550,GSE41978 WT VS ID2 KO AND BIM KO KLRG1 LOW EFFECTOR CD8 TCELL UP,M1,1,0
1,-6.6,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M1,1,0
1,-2.4,GO:0034243,regulation of transcription elongation by RNA polymerase II,M1,1,0
1,-5.7,GO:0001823,mesonephros development,M1,1,0
1,-2.2,GO:0055074,calcium ion homeostasis,M1,1,0
1,-5.8,GO:0086012,membrane depolarization during cardiac muscle cell action potential,M1,1,0
1,-4.8,GO:1902750,negative regulation of cell cycle G2/M phase transition,M1,1,0
1,-2.5,GO:1901863,positive regulation of muscle tissue development,M1,1,0
1,-7.6,CORUM:2920,Respiratory chain complex I (lambda subunit) mitochondrial,M1,1,0
1,-2.1,GO:0042886,amide transport,M1,1,0
1,-18,WP286,IL-3 signaling pathway,M1,1,0
1,-2.2,GO:0034446,substrate adhesion-dependent cell spreading,M1,1,0
1,-5.4,M9880,ABRAHAM ALPC VS MULTIPLE MYELOMA DN,M1,1,0
1,-3.5,GO:0032760,positive regulation of tumor necrosis factor production,M1,1,0
1,-6.2,GO:0002562,somatic diversification of immune receptors via germline recombination within a single locus,M1,1,0
1,-2.5,M5145,GSE360 CTRL VS L MAJOR DC UP,M1,1,0
1,-2.4,GO:0010463,mesenchymal cell proliferation,M1,1,0
1,-4.7,R-HSA-418885,DCC mediated attractive signaling,M1,1,0
1,-15,GO:0006310,DNA recombination,M1,1,0
1,-5,GO:0035004,phosphatidylinositol 3-kinase activity,M1,1,0
1,-3.7,M6722,GSE6259 FLT3L INDUCED VS WT SPLENIC DC 33D1 POS DN,M1,1,0
1,-3,M6146,GSE1112 OT1 VS HY CD8AB THYMOCYTE RTOC CULTURE DN,M1,1,0
1,-10,CORUM:6163,BBSome,M1,1,0
1,-5.3,GO:1902743,regulation of lamellipodium organization,M1,1,0
1,-13,GO:0010942,positive regulation of cell death,M1,1,0
1,-5.1,WP5118,SMC1/SMC3 role in DNA damage - Cornelia de Lange Syndrome,M1,1,0
1,-2.8,GO:0015698,inorganic anion transport,M1,1,0
1,-3.9,R-HSA-8876198,RAB GEFs exchange GTP for GDP on RABs,M1,1,0
1,-6.6,GO:0050778,positive regulation of immune response,M1,1,0
1,-3.2,M4065,ZHU CMV 24 HR DN,M1,1,0
1,-4.2,R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,M1,1,0
1,-4.5,GO:0006753,nucleoside phosphate metabolic process,M1,1,0
1,-12,GO:0009612,response to mechanical stimulus,M1,1,0
1,-3.7,M2157,DUTERTRE ESTRADIOL RESPONSE 24HR DN,M1,1,0
1,-2.9,R-HSA-9664433,Leishmania parasite growth and survival,M1,1,0
1,-17,GO:0001568,blood vessel development,M1,1,0
1,-2.6,GO:0035162,embryonic hemopoiesis,M1,1,0
1,-8.8,GO:0042330,taxis,M1,1,0
1,-6.3,M17923,BOQUEST STEM CELL CULTURED VS FRESH UP,M1,1,0
1,-2.1,GO:0003382,epithelial cell morphogenesis,M1,1,0
1,-11,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M1,1,0
1,-4.3,GO:0003356,regulation of cilium beat frequency,M1,1,0
1,-6.4,R-HSA-4839726,Chromatin organization,M1,1,0
1,-5.4,M6807,GSE7218 IGM VS IGG SIGNAL THGOUGH ANTIGEN BCELL UP,M1,1,0
1,-4.1,R-HSA-5696398,Nucleotide Excision Repair,M1,1,0
1,-7.9,GO:0001819,positive regulation of cytokine production,M1,1,0
1,-3.4,M1820,MATZUK CENTRAL FOR FEMALE FERTILITY,M1,1,0
1,-12,WP5144,NRP1-triggered signaling pathways in pancreatic cancer,M1,1,0
1,-2,M2693,P53 DN.V2 DN,M1,1,0
1,-2.1,GO:0044091,membrane biogenesis,M1,1,0
1,-2.3,GO:0007431,salivary gland development,M1,1,0
1,-31,M15356,PUJANA BREAST CANCER LIT INT NETWORK,M1,1,0
1,-4.1,GO:0036303,lymph vessel morphogenesis,M1,1,0
1,-4.3,GO:0030291,protein serine/threonine kinase inhibitor activity,M1,1,0
1,-3.1,M2725,MEK UP.V1 UP,M1,1,0
1,-2.4,GO:0071467,cellular response to pH,M1,1,0
1,-5,GO:0046474,glycerophospholipid biosynthetic process,M1,1,0
1,-23,hsa04722,Neurotrophin signaling pathway,M1,1,0
1,-2.5,GO:0050770,regulation of axonogenesis,M1,1,0
1,-4.1,M17742,SMITH TERT TARGETS UP,M1,1,0
1,-3.8,WP5039,SARS-CoV-2 innate immunity evasion and cell-specific immune response,M1,1,0
1,-2.6,R-HSA-3108214,SUMOylation of DNA damage response and repair proteins,M1,1,0
1,-2.4,M5995,GSE411 100MIN VS 400MIN IL6 STIM SOCS3 KO MACROPHAGE DN,M1,1,0
1,-3.7,M5256,GSE360 T GONDII VS B MALAYI LOW DOSE MAC UP,M1,1,0
1,-3,M5159,GSE360 CTRL VS L DONOVANI MAC DN,M1,1,0
1,-6.2,M159,PID AMB2 NEUTROPHILS PATHWAY,M1,1,0
1,-14,M2,PID SMAD2 3NUCLEAR PATHWAY,M1,1,0
1,-4.1,GO:0042552,myelination,M1,1,0
1,-8.8,GO:0098771,inorganic ion homeostasis,M1,1,0
1,-2.2,M4752,WATANABE RECTAL CANCER RADIOTHERAPY RESPONSIVE DN,M1,1,0
1,-3,M6839,GSE7548 NAIVE VS DAY28 PCC IMMUNIZATION CD4 TCELL UP,M1,1,0
1,-2.3,M17299,CHARAFE BREAST CANCER LUMINAL VS MESENCHYMAL UP,M1,1,0
1,-21,GO:0001501,skeletal system development,M1,1,0
1,-5.3,GO:0099536,synaptic signaling,M1,1,0
1,-20,GO:0071214,cellular response to abiotic stimulus,M1,1,0
1,-2.5,M2477,ALFANO MYC TARGETS,M1,1,0
1,-6.9,GO:0030850,prostate gland development,M1,1,0
1,-3.1,GO:0001217,DNA-binding transcription repressor activity,M1,1,0
1,-3.7,M6131,GSE2770 IL12 AND TGFB ACT VS ACT CD4 TCELL 48H UP,M1,1,0
1,-3.7,M7366,GSE20198 UNTREATED VS IFNA TREATED ACT CD4 TCELL UP,M1,1,0
1,-8.7,GO:0071695,anatomical structure maturation,M1,1,0
1,-5,GO:0008137,NADH dehydrogenase (ubiquinone) activity,M1,1,0
1,-2.4,M1770,GAZIN EPIGENETIC SILENCING BY KRAS,M1,1,0
1,-2.3,M2765,ESC J1 UP LATE.V1 DN,M1,1,0
1,-8.3,GO:0031344,regulation of cell projection organization,M1,1,0
1,-3.3,M15565,ZHU CMV 24 HR UP,M1,1,0
1,-6.5,GO:0043560,insulin receptor substrate binding,M1,1,0
1,-2.5,M4727,GSE2706 LPS VS R848 AND LPS 8H STIM DC UP,M1,1,0
1,-3.2,M64,PID S1P S1P4 PATHWAY,M1,1,0
1,-8.3,WP4496,Signal transduction through IL1R,M1,1,0
1,-14,M94,PID FAS PATHWAY,M1,1,0
1,-8.9,GO:0008630,intrinsic apoptotic signaling pathway in response to DNA damage,M1,1,0
1,-2.5,GO:0000794,condensed nuclear chromosome,M1,1,0
1,-4.7,M2511,ZHANG ADIPOGENESIS BY BMP7,M1,1,0
1,-6,WP314,Fas ligand pathway and stress induction of heat shock proteins,M1,1,0
1,-3.5,M11250,FRASOR RESPONSE TO SERM OR FULVESTRANT DN,M1,1,0
1,-2.4,M3638,GSE15930 STIM VS STIM AND TRICHOSTATINA 48H CD8 T CELL DN,M1,1,0
1,-3.8,GO:0035518,histone H2A monoubiquitination,M1,1,0
1,-6.4,R-HSA-5357801,Programmed Cell Death,M1,1,0
1,-7.3,WP5053,Development of ureteric collection system,M1,1,0
1,-3.2,GO:0060675,ureteric bud morphogenesis,M1,1,0
1,-2.5,GO:0042311,vasodilation,M1,1,0
1,-2.5,M4434,GSE22886 NAIVE VS IGM MEMORY BCELL UP,M1,1,0
1,-8.5,GO:0035113,embryonic appendage morphogenesis,M1,1,0
1,-7.1,GO:0010675,regulation of cellular carbohydrate metabolic process,M1,1,0
1,-2.6,GO:0035020,regulation of Rac protein signal transduction,M1,1,0
1,-2.5,M9590,GSE42021 CD24INT VS CD24LOW TREG THYMUS DN,M1,1,0
1,-3.6,GO:0000018,regulation of DNA recombination,M1,1,0
1,-6.4,GO:0002449,lymphocyte mediated immunity,M1,1,0
1,-10,WP254,Apoptosis,M1,1,0
1,-6.8,WP4970,Galanin receptor pathway,M1,1,0
1,-3.8,R-HSA-9668250,Defective factor IX causes hemophilia B,M1,1,0
1,-5.1,GO:0038108,negative regulation of appetite by leptin-mediated signaling pathway,M1,1,0
1,-9.4,GO:0048858,cell projection morphogenesis,M1,1,0
1,-4.2,GO:1902106,negative regulation of leukocyte differentiation,M1,1,0
1,-12,hsa05131,Shigellosis,M1,1,0
1,-4,GO:0008361,regulation of cell size,M1,1,0
1,-11,GO:0006298,mismatch repair,M1,1,0
1,-2.3,GO:0045069,regulation of viral genome replication,M1,1,0
1,-8.9,R-HSA-1368082,RORA activates gene expression,M1,1,0
1,-6.7,GO:0060324,face development,M1,1,0
1,-2.6,M2630,E2F1 UP.V1 DN,M1,1,0
1,-8.7,WP4352,Ciliary landscape,M1,1,0
1,-16,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M1,1,0
1,-4.4,GO:0031346,positive regulation of cell projection organization,M1,1,0
1,-6.1,M33,PID GLYPICAN 1PATHWAY,M1,1,0
1,-5.7,GO:0032299,ribonuclease H2 complex,M1,1,0
1,-3.9,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M1,1,0
1,-10,GO:0045494,photoreceptor cell maintenance,M1,1,0
1,-9.1,GO:0032438,melanosome organization,M1,1,0
1,-4.4,GO:0045671,negative regulation of osteoclast differentiation,M1,1,0
1,-2.5,M5877,GSE9988 ANTI TREM1 AND LPS VS CTRL TREATED MONOCYTES DN,M1,1,0
1,-9,GO:0031667,response to nutrient levels,M1,1,0
1,-5,GO:0031295,T cell costimulation,M1,1,0
1,-2.5,M4063,GSE17721 LPS VS GARDIQUIMOD 24H BMDC UP,M1,1,0
1,-5.1,GO:0097730,non-motile cilium,M1,1,0
1,-2.7,GO:0071548,response to dexamethasone,M1,1,0
1,-2.9,GO:2000144,positive regulation of DNA-templated transcription initiation,M1,1,0
1,-2.2,WP4752,Base excision repair,M1,1,0
1,-6.5,GO:0030318,melanocyte differentiation,M1,1,0
1,-3.7,M3005,NABA COLLAGENS,M1,1,0
1,-4,GO:0061733,peptide-lysine-N-acetyltransferase activity,M1,1,0
1,-9.8,GO:0034764,positive regulation of transmembrane transport,M1,1,0
1,-2.8,GO:0030104,water homeostasis,M1,1,0
1,-3.6,GO:0048232,male gamete generation,M1,1,0
1,-2.7,M2293,PASINI SUZ12 TARGETS DN,M1,1,0
1,-8.5,GO:1903232,melanosome assembly,M1,1,0
1,-4.4,M6802,GSE6875 TCONV VS FOXP3 KO TREG DN,M1,1,0
1,-4.6,GO:0048844,artery morphogenesis,M1,1,0
1,-11,WP313,Hepatocyte growth factor receptor signaling,M1,1,0
1,-3.3,R-HSA-5658623,FGFRL1 modulation of FGFR1 signaling,M1,1,0
1,-5.1,M9744,GSE43863 DAY6 EFF VS DAY150 MEM TH1 CD4 TCELL DN,M1,1,0
1,-8.5,R-HSA-5693606,DNA Double Strand Break Response,M1,1,0
1,-2.2,M6721,GSE6259 FLT3L INDUCED VS WT SPLENIC DC 33D1 POS UP,M1,1,0
1,-11,M14072,WINTER HYPOXIA METAGENE,M1,1,0
1,-2,GO:1903305,regulation of regulated secretory pathway,M1,1,0
1,-4.3,WP408,Oxidative stress response,M1,1,0
1,-3.4,M2868,TBK1.DN.48HRS DN,M1,1,0
1,-2.7,GO:0060078,regulation of postsynaptic membrane potential,M1,1,0
1,-2.5,M8507,GSE23568 CTRL VS ID3 TRANSDUCED CD8 TCELL DN,M1,1,0
1,-5.9,GO:0072164,mesonephric tubule development,M1,1,0
1,-2,M2648,CYCLIN D1 KE .V1 UP,M1,1,0
1,-7.3,GO:0060541,respiratory system development,M1,1,0
1,-2.9,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M1,1,0
1,-7.6,R-HSA-8853884,Transcriptional Regulation by VENTX,M1,1,0
1,-6.7,M2125,CHICAS RB1 TARGETS SENESCENT,M1,1,0
1,-2.5,M3441,GSE1460 INTRATHYMIC T PROGENITOR VS NAIVE CD4 TCELL CORD BLOOD UP,M1,1,0
1,-18,hsa04380,Osteoclast differentiation,M1,1,0
1,-4.4,M3028,KAECH DAY8 EFF VS MEMORY CD8 TCELL DN,M1,1,0
1,-2.4,GO:0051209,release of sequestered calcium ion into cytosol,M1,1,0
1,-2.2,GO:0016342,catenin complex,M1,1,0
1,-9,M278,PID RAC1 PATHWAY,M1,1,0
1,-2.6,M19439,DOANE BREAST CANCER ESR1 UP,M1,1,0
1,-2.3,M12701,MARTINEZ RB1 TARGETS DN,M1,1,0
1,-3.4,GO:0010826,negative regulation of centrosome duplication,M1,1,0
1,-7.6,GO:0086008,voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization,M1,1,0
1,-21,hsa04012,ErbB signaling pathway,M1,1,0
1,-7.3,GO:0070663,regulation of leukocyte proliferation,M1,1,0
1,-3.9,GO:0035051,cardiocyte differentiation,M1,1,0
1,-5.3,GO:0009201,ribonucleoside triphosphate biosynthetic process,M1,1,0
1,-22,hsa05226,Gastric cancer,M1,1,0
1,-8.1,WP3612,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling,M1,1,0
1,-3.1,GO:0033028,myeloid cell apoptotic process,M1,1,0
1,-2.5,M4502,GAL LEUKEMIC STEM CELL DN,M1,1,0
1,-12,GO:0050953,sensory perception of light stimulus,M1,1,0
1,-3.7,GO:0033034,positive regulation of myeloid cell apoptotic process,M1,1,0
1,-3.4,GO:0090263,positive regulation of canonical Wnt signaling pathway,M1,1,0
1,-4.4,GO:1901992,positive regulation of mitotic cell cycle phase transition,M1,1,0
1,-3.8,R-HSA-2428933,SHC-related events triggered by IGF1R,M1,1,0
1,-7.2,GO:0014032,neural crest cell development,M1,1,0
1,-2.5,M7458,GSE21670 UNTREATED VS IL6 TREATED STAT3 KO CD4 TCELL DN,M1,1,0
1,-3.4,GO:0004861,cyclin-dependent protein serine/threonine kinase inhibitor activity,M1,1,0
1,-2.6,GO:0050806,positive regulation of synaptic transmission,M1,1,0
1,-18,GO:0050678,regulation of epithelial cell proliferation,M1,1,0
1,-5.9,M27,BENPORATH MYC TARGETS WITH EBOX,M1,1,0
1,-8.3,GO:0005244,voltage-gated ion channel activity,M1,1,0
1,-6.3,R-HSA-5654700,FRS-mediated FGFR2 signaling,M1,1,0
1,-2.3,GO:0050714,positive regulation of protein secretion,M1,1,0
1,-6.6,GO:0050921,positive regulation of chemotaxis,M1,1,0
1,-23,hsa05163,Human cytomegalovirus infection,M1,1,0
1,-16,GO:0048863,stem cell differentiation,M1,1,0
1,-3.3,GO:0030177,positive regulation of Wnt signaling pathway,M1,1,0
1,-3.2,GO:0071599,otic vesicle development,M1,1,0
1,-3.3,GO:0001946,lymphangiogenesis,M1,1,0
1,-3.1,M1904,SCHRAETS MLL TARGETS DN,M1,1,0
1,-2.9,M2962,GSE14415 ACT VS CTRL NATURAL TREG DN,M1,1,0
1,-8,GO:0031082,BLOC complex,M1,1,0
1,-2.5,M17856,MULLIGHAN MLL SIGNATURE 1 UP,M1,1,0
1,-5.4,GO:0018105,peptidyl-serine phosphorylation,M1,1,0
1,-2.1,GO:0032259,methylation,M1,1,0
1,-2.5,M8302,GSE26727 WT VS KLF2 KO LPS STIM MACROPHAGE DN,M1,1,0
1,-5.4,M17646,JAIN NFKB SIGNALING,M1,1,0
1,-2.7,GO:0032993,protein-DNA complex,M1,1,0
1,-6,GO:0018212,peptidyl-tyrosine modification,M1,1,0
1,-4.7,GO:0048663,neuron fate commitment,M1,1,0
1,-3,M9322,GSE11961 MARGINAL ZONE BCELL VS PLASMA CELL DAY7 UP,M1,1,0
1,-4,GO:2000351,regulation of endothelial cell apoptotic process,M1,1,0
1,-19,GO:0090596,sensory organ morphogenesis,M1,1,0
1,-3.7,M5242,GSE360 L DONOVANI VS M TUBERCULOSIS MAC DN,M1,1,0
1,-6.5,M1810,DAZARD UV RESPONSE CLUSTER G6,M1,1,0
1,-3,M9649,GSE43955 TH0 VS TGFB IL6 TH17 ACT CD4 TCELL 30H UP,M1,1,0
1,-13,GO:1900180,regulation of protein localization to nucleus,M1,1,0
1,-3.3,M1757,SANSOM APC TARGETS REQUIRE MYC,M1,1,0
1,-5.4,WP5114,Nucleotide excision repair in xeroderma pigmentosum,M1,1,0
1,-9.9,R-HSA-1236394,Signaling by ERBB4,M1,1,0
1,-16,R-HSA-388841,Costimulation by the CD28 family,M1,1,0
1,-23,GO:0009792,embryo development ending in birth or egg hatching,M1,1,0
1,-2.9,GO:0048645,animal organ formation,M1,1,0
1,-3.3,GO:1903201,regulation of oxidative stress-induced cell death,M1,1,0
1,-2.1,M18517,MATSUDA NATURAL KILLER DIFFERENTIATION,M1,1,0
1,-27,GO:0009725,response to hormone,M1,1,0
1,-3.7,GO:0032070,regulation of deoxyribonuclease activity,M1,1,0
1,-2.4,M8217,GSE27670 CTRL VS LMP1 TRANSDUCED GC BCELL DN,M1,1,0
1,-4.8,WP4753,Nucleotide excision repair,M1,1,0
1,-2,M6819,GSE7509 UNSTIM VS TNFA IL1B IL6 PGE STIM DC UP,M1,1,0
1,-4.4,hsa04728,Dopaminergic synapse,M1,1,0
1,-8.5,M45,PID CD40 PATHWAY,M1,1,0
1,-5.2,GO:1990391,DNA repair complex,M1,1,0
1,-3.2,M8124,SMID BREAST CANCER BASAL UP,M1,1,0
1,-3.8,GO:0030218,erythrocyte differentiation,M1,1,0
1,-2.1,M7127,GSE9960 HEALTHY VS SEPSIS PBMC DN,M1,1,0
1,-3,M17261,KAYO AGING MUSCLE DN,M1,1,0
1,-12,GO:0000724,double-strand break repair via homologous recombination,M1,1,0
1,-2.8,GO:0031234,extrinsic component of cytoplasmic side of plasma membrane,M1,1,0
1,-6.6,M2368,GOBERT OLIGODENDROCYTE DIFFERENTIATION UP,M1,1,0
1,-4.7,GO:0046890,regulation of lipid biosynthetic process,M1,1,0
1,-13,GO:0071396,cellular response to lipid,M1,1,0
1,-9.8,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M1,1,0
1,-2.5,M5849,GSE9988 ANTI TREM1 VS ANTI TREM1 AND LPS MONOCYTE DN,M1,1,0
1,-2.4,M19766,WU SILENCED BY METHYLATION IN BLADDER CANCER,M1,1,0
1,-6.4,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M1,1,0
1,-6.1,GO:0090734,site of DNA damage,M1,1,0
1,-2.2,GO:0060395,SMAD protein signal transduction,M1,1,0
1,-4.4,M9568,GSE41978 ID2 KO VS BIM KO KLRG1 LOW EFFECTOR CD8 TCELL UP,M1,1,0
1,-2.4,M4531,GSE22886 UNSTIM VS IL2 STIM NKCELL DN,M1,1,0
1,-2.4,GO:0035591,signaling adaptor activity,M1,1,0
1,-9.4,GO:0010810,regulation of cell-substrate adhesion,M1,1,0
1,-3.1,M14591,WEIGEL OXIDATIVE STRESS RESPONSE,M1,1,0
1,-2.2,M6100,SENESE HDAC1 TARGETS DN,M1,1,0
1,-2.2,GO:0070664,negative regulation of leukocyte proliferation,M1,1,0
1,-28,GO:0048568,embryonic organ development,M1,1,0
1,-2.4,GO:0006111,regulation of gluconeogenesis,M1,1,0
1,-2.4,M7208,GSE18203 CTRL VS INTRATUMORAL CPG INJ MC38 TUMOR DN,M1,1,0
1,-17,R-HSA-5685942,HDR through Homologous Recombination (HRR),M1,1,0
1,-12,GO:0043583,ear development,M1,1,0
1,-12,hsa04630,JAK-STAT signaling pathway,M1,1,0
1,-2.8,M1780,MCGOWAN RSP6 TARGETS UP,M1,1,0
1,-4,M18264,MOOTHA VOXPHOS,M1,1,0
1,-2.2,GO:1901798,positive regulation of signal transduction by p53 class mediator,M1,1,0
1,-3.7,M4670,GSE26669 CD4 VS CD8 TCELL IN MLR DN,M1,1,0
1,-3.1,M2402,KOHOUTEK CCNT2 TARGETS,M1,1,0
1,-2.6,GO:2000756,regulation of peptidyl-lysine acetylation,M1,1,0
1,-20,GO:0007420,brain development,M1,1,0
1,-6.5,GO:0031348,negative regulation of defense response,M1,1,0
1,-2.3,M14539,BERTUCCI MEDULLARY VS DUCTAL BREAST CANCER UP,M1,1,0
1,-2.6,M1676,SHEN SMARCA2 TARGETS DN,M1,1,0
1,-2.7,GO:0022616,DNA strand elongation,M1,1,0
1,-9.4,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M1,1,0
1,-3.9,GO:0062013,positive regulation of small molecule metabolic process,M1,1,0
1,-2.3,GO:1902115,regulation of organelle assembly,M1,1,0
1,-5.5,GO:0007292,female gamete generation,M1,1,0
1,-3.5,WP2035,Follicle stimulating hormone (FSH) signaling pathway,M1,1,0
1,-7.6,GO:1903799,negative regulation of miRNA maturation,M1,1,0
1,-9.9,WP2355,Corticotropin-releasing hormone signaling pathway,M1,1,0
1,-3.8,M9642,GALLUZZI PERMEABILIZE MITOCHONDRIA,M1,1,0
1,-3.5,GO:0010624,regulation of Schwann cell proliferation,M1,1,0
1,-4.7,M13251,BROWNE HCMV INFECTION 14HR DN,M1,1,0
1,-3.2,R-HSA-447115,Interleukin-12 family signaling,M1,1,0
1,-15,R-HSA-5654736,Signaling by FGFR1,M1,1,0
1,-22,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M1,1,0
1,-2.4,GO:1903020,positive regulation of glycoprotein metabolic process,M1,1,0
1,-2.3,GO:0051438,regulation of ubiquitin-protein transferase activity,M1,1,0
1,-3.1,GO:0051785,positive regulation of nuclear division,M1,1,0
1,-3.2,R-HSA-6804759,Regulation of TP53 Activity through Association with Co-factors,M1,1,0
1,-2.3,GO:0010811,positive regulation of cell-substrate adhesion,M1,1,0
1,-3.7,M9665,GSE43955 1H VS 42H ACT CD4 TCELL DN,M1,1,0
1,-5.3,GO:0015079,potassium ion transmembrane transporter activity,M1,1,0
1,-4.4,M6667,GSE5589 IL6 KO VS IL10 KO LPS STIM MACROPHAGE 180MIN DN,M1,1,0
1,-3.7,M5746,GSE7852 LN VS THYMUS TCONV DN,M1,1,0
1,-5.1,GO:0032388,positive regulation of intracellular transport,M1,1,0
1,-18,hsa05225,Hepatocellular carcinoma,M1,1,0
1,-2.6,M452,GSE12963 UNINF VS ENV AND NEF DEFICIENT HIV1 INF CD4 TCELL DN,M1,1,0
1,-6.2,GO:0044325,transmembrane transporter binding,M1,1,0
1,-2.4,M7308,GSE18893 TCONV VS TREG 24H TNF STIM UP,M1,1,0
1,-2.1,WP3971,OSX and miRNAs in tooth development,M1,1,0
1,-4,GO:1904892,regulation of receptor signaling pathway via STAT,M1,1,0
1,-11,GO:0032774,RNA biosynthetic process,M1,1,0
1,-6,GO:0035116,embryonic hindlimb morphogenesis,M1,1,0
1,-8.4,GO:0044089,positive regulation of cellular component biogenesis,M1,1,0
1,-3,M8682,GSE34156 UNTREATED VS 24H NOD2 LIGAND TREATED MONOCYTE DN,M1,1,0
1,-2,GO:0006874,cellular calcium ion homeostasis,M1,1,0
1,-2.1,GO:0007617,mating behavior,M1,1,0
1,-3.3,GO:0042771,intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,M1,1,0
1,-4.9,GO:0005996,monosaccharide metabolic process,M1,1,0
1,-2.3,GO:0009952,anterior/posterior pattern specification,M1,1,0
1,-3.3,M1550,SIMBULAN PARP1 TARGETS UP,M1,1,0
1,-4.7,GO:0032886,regulation of microtubule-based process,M1,1,0
1,-6.5,GO:0003002,regionalization,M1,1,0
1,-6.3,GO:2000027,regulation of animal organ morphogenesis,M1,1,0
1,-2.6,hsa04971,Gastric acid secretion,M1,1,0
1,-15,M261,PID P53 REGULATION PATHWAY,M1,1,0
1,-4.4,M3418,GSE14350 TREG VS TEFF DN,M1,1,0
1,-4.9,GO:0060512,prostate gland morphogenesis,M1,1,0
1,-6.9,GO:0007062,sister chromatid cohesion,M1,1,0
1,-2.1,hsa04916,Melanogenesis,M1,1,0
1,-2.6,M211,PID HEDGEHOG 2PATHWAY,M1,1,0
1,-3,GO:1904427,positive regulation of calcium ion transmembrane transport,M1,1,0
1,-3.1,GO:0061512,protein localization to cilium,M1,1,0
1,-4.6,GO:0001570,vasculogenesis,M1,1,0
1,-9.7,GO:0042803,protein homodimerization activity,M1,1,0
1,-10,GO:0003684,damaged DNA binding,M1,1,0
1,-2.4,M17951,NAKAYAMA SOFT TISSUE TUMORS PCA1 UP,M1,1,0
1,-12,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M1,1,0
1,-9.3,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M1,1,0
1,-7,R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,M1,1,0
1,-3.7,M3328,GSE14000 TRANSLATED RNA VS MRNA 4H LPS DC UP,M1,1,0
1,-2.2,M3335,HELLER HDAC TARGETS UP,M1,1,0
1,-18,WP1971,Integrated cancer pathway,M1,1,0
1,-2.4,M6263,GSE8835 HEALTHY VS CLL CD8 TCELL DN,M1,1,0
1,-16,R-HSA-5693568,Resolution of D-loop Structures through Holliday Junction Intermediates,M1,1,0
1,-4.6,GO:0072507,divalent inorganic cation homeostasis,M1,1,0
1,-2.8,M6909,GSE9509 10MIN VS 30MIN LPS AND IL10 STIM IL10 KO MACROPHAGE UP,M1,1,0
1,-3.8,GO:0046628,positive regulation of insulin receptor signaling pathway,M1,1,0
1,-3.9,M2107,KIM BIPOLAR DISORDER OLIGODENDROCYTE DENSITY CORR UP,M1,1,0
1,-2.3,M2386,GILDEA METASTASIS,M1,1,0
1,-4.2,WP2272,Pathogenic Escherichia coli infection,M1,1,0
1,-5,GO:0060736,prostate gland growth,M1,1,0
1,-2.3,M6297,GSE1925 CTRL VS IFNG PRIMED MACROPHAGE 3H IFNG STIM DN,M1,1,0
1,-2.8,R-HSA-174414,Processive synthesis on the C-strand of the telomere,M1,1,0
1,-2.9,GO:0038065,collagen-activated signaling pathway,M1,1,0
1,-3,M8496,GSE29164 UNTREATED VS CD8 TCELL TREATED MELANOMA DAY7 DN,M1,1,0
1,-2.4,M7300,BLUM RESPONSE TO SALIRASIB UP,M1,1,0
1,-4.7,WP2873,Aryl hydrocarbon receptor pathway,M1,1,0
1,-3,M9031,GSE33162 UNTREATED VS 4H LPS STIM HDAC3 HET MACROPHAGE DN,M1,1,0
1,-3.3,M17557,DANG MYC TARGETS DN,M1,1,0
1,-7.9,WP4877,Host-pathogen interaction of human coronaviruses - MAPK signaling,M1,1,0
1,-12,GO:0006260,DNA replication,M1,1,0
1,-2.3,M256,PID TAP63 PATHWAY,M1,1,0
1,-4,GO:1903707,negative regulation of hemopoiesis,M1,1,0
1,-4.5,GO:0016323,basolateral plasma membrane,M1,1,0
1,-17,GO:0001944,vasculature development,M1,1,0
1,-2.2,GO:0005793,endoplasmic reticulum-Golgi intermediate compartment,M1,1,0
1,-12,GO:0048754,branching morphogenesis of an epithelial tube,M1,1,0
1,-5.6,GO:1904029,regulation of cyclin-dependent protein kinase activity,M1,1,0
1,-21,GO:0043473,pigmentation,M1,1,0
1,-2.7,GO:0043277,apoptotic cell clearance,M1,1,0
1,-2.4,M5979,GSE369 PRE VS POST IL6 INJECTION IFNG WT LIVER UP,M1,1,0
1,-4.4,GO:0072175,epithelial tube formation,M1,1,0
1,-2.5,GO:0140272,exogenous protein binding,M1,1,0
1,-3.3,CORUM:3066,"RNA polymerase II complex, chromatin structure modifying",M1,1,0
1,-3.5,WP111,Electron transport chain: OXPHOS system in mitochondria,M1,1,0
1,-2.8,GO:0072079,nephron tubule formation,M1,1,0
1,-5.7,GO:0045178,basal part of cell,M1,1,0
1,-5.1,CORUM:248,BRAFT complex,M1,1,0
1,-4.4,GO:0070469,respirasome,M1,1,0
1,-3,GO:0002028,regulation of sodium ion transport,M1,1,0
1,-2.3,GO:0090329,regulation of DNA-templated DNA replication,M1,1,0
1,-15,R-HSA-2428924,IGF1R signaling cascade,M1,1,0
1,-4.2,GO:0031060,regulation of histone methylation,M1,1,0
1,-4,GO:0055023,positive regulation of cardiac muscle tissue growth,M1,1,0
1,-4.2,GO:0071542,dopaminergic neuron differentiation,M1,1,0
1,-3.6,GO:1900078,positive regulation of cellular response to insulin stimulus,M1,1,0
1,-4.4,GO:0005788,endoplasmic reticulum lumen,M1,1,0
1,-4.4,M8415,GSE29949 CD8 POS DC SPLEEN VS MONOCYTE BONE MARROW DN,M1,1,0
1,-4.2,GO:0032231,regulation of actin filament bundle assembly,M1,1,0
1,-9.1,hsa04920,Adipocytokine signaling pathway,M1,1,0
1,-3.1,R-HSA-68962,Activation of the pre-replicative complex,M1,1,0
1,-8.3,M2156,DUTERTRE ESTRADIOL RESPONSE 24HR UP,M1,1,0
1,-4,WP4191,Caloric restriction and aging,M1,1,0
1,-12,GO:0010632,regulation of epithelial cell migration,M1,1,0
1,-3.8,GO:0098609,cell-cell adhesion,M1,1,0
1,-5.4,R-HSA-5654720,PI-3K cascade:FGFR4,M1,1,0
1,-4.5,M8708,GSE30971 CTRL VS LPS STIM MACROPHAGE WBP7 HET 2H UP,M1,1,0
1,-4.4,M3577,GSE15750 DAY6 VS DAY10 EFF CD8 TCELL UP,M1,1,0
1,-4.5,M346,LIN MELANOMA COPY NUMBER UP,M1,1,0
1,-2.4,GO:0050851,antigen receptor-mediated signaling pathway,M1,1,0
1,-2.3,GO:0030136,clathrin-coated vesicle,M1,1,0
1,-9.9,hsa05171,Coronavirus disease - COVID-19,M1,1,0
1,-3.6,GO:0043281,regulation of cysteine-type endopeptidase activity involved in apoptotic process,M1,1,0
1,-2.6,GO:0021536,diencephalon development,M1,1,0
1,-2.2,GO:0030225,macrophage differentiation,M1,1,0
1,-4.7,R-HSA-180336,SHC1 events in EGFR signaling,M1,1,0
1,-4.4,WP1533,Vitamin B12 metabolism,M1,1,0
1,-7.2,GO:1990573,potassium ion import across plasma membrane,M1,1,0
1,-6.2,GO:0046620,regulation of organ growth,M1,1,0
1,-5.8,WP5119,NIPBL role in DNA damage - Cornelia de Lange syndrome,M1,1,0
1,-4,CORUM:1251,BAF complex,M1,1,0
1,-2.6,GO:1900015,regulation of cytokine production involved in inflammatory response,M1,1,0
1,-3.3,GO:0002757,immune response-activating signal transduction,M1,1,0
1,-5.9,GO:0060425,lung morphogenesis,M1,1,0
1,-4.2,R-HSA-9032500,Activated NTRK2 signals through FYN,M1,1,0
1,-4.8,R-HSA-9012999,RHO GTPase cycle,M1,1,0
1,-2,GO:0031644,regulation of nervous system process,M1,1,0
1,-2.1,GO:0030514,negative regulation of BMP signaling pathway,M1,1,0
1,-3.1,R-HSA-5339716,Signaling by GSK3beta mutants,M1,1,0
1,-2.6,GO:0004712,protein serine/threonine/tyrosine kinase activity,M1,1,0
1,-4.2,GO:0014068,positive regulation of phosphatidylinositol 3-kinase signaling,M1,1,0
1,-3,M12139,GALE APL WITH FLT3 MUTATED DN,M1,1,0
1,-3.9,M2984,GSE13547 CTRL VS ANTI IGM STIM BCELL 12H UP,M1,1,0
1,-9.9,hsa04150,mTOR signaling pathway,M1,1,0
1,-7.1,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M1,1,0
1,-4.7,WP4541,Hippo-Merlin signaling dysregulation,M1,1,0
1,-6.9,M101,PID HDAC CLASSI PATHWAY,M1,1,0
1,-2.7,GO:0001726,ruffle,M1,1,0
1,-6,M195,PID CMYB PATHWAY,M1,1,0
1,-3.4,GO:0090656,t-circle formation,M1,1,0
1,-2.4,GO:0034707,chloride channel complex,M1,1,0
1,-2.2,GO:0030199,collagen fibril organization,M1,1,0
1,-2.5,M5252,GSE360 L MAJOR VS M TUBERCULOSIS MAC UP,M1,1,0
1,-8.3,GO:0002244,hematopoietic progenitor cell differentiation,M1,1,0
1,-2.4,M8631,GSE32986 CURDLAN HIGHDOSE VS GMCSF AND CURDLAN HIGHDOSE STIM DC DN,M1,1,0
1,-3.1,M5553,GSE3982 BCELL VS TH1 DN,M1,1,0
1,-4.4,GO:0006820,anion transport,M1,1,0
1,-3.1,M17749,DORN ADENOVIRUS INFECTION 12HR DN,M1,1,0
1,-4.4,R-HSA-3000178,ECM proteoglycans,M1,1,0
1,-2.6,M13763,RADAEVA RESPONSE TO IFNA1 UP,M1,1,0
1,-2.1,GO:0045648,positive regulation of erythrocyte differentiation,M1,1,0
1,-3.7,M3640,GSE15930 STIM VS STIM AND IL12 72H CD8 T CELL DN,M1,1,0
1,-2.9,R-HSA-5689896,Ovarian tumor domain proteases,M1,1,0
1,-6.7,WP400,p38 MAPK signaling pathway,M1,1,0
1,-6.4,R-HSA-3247509,Chromatin modifying enzymes,M1,1,0
1,-4.5,GO:0005747,mitochondrial respiratory chain complex I,M1,1,0
1,-4.4,GO:0004468,"lysine N-acetyltransferase activity, acting on acetyl phosphate as donor",M1,1,0
1,-2.8,GO:2001235,positive regulation of apoptotic signaling pathway,M1,1,0
1,-4.7,R-HSA-5358606,Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),M1,1,0
1,-14,R-HSA-76002,"Platelet activation, signaling and aggregation",M1,1,0
1,-3.6,GO:0009141,nucleoside triphosphate metabolic process,M1,1,0
1,-20,GO:0001654,eye development,M1,1,0
1,-5.1,GO:0060740,prostate gland epithelium morphogenesis,M1,1,0
1,-2.3,GO:0032878,regulation of establishment or maintenance of cell polarity,M1,1,0
1,-13,WP3931,Embryonic stem cell pluripotency pathways,M1,1,0
1,-12,GO:0098797,plasma membrane protein complex,M1,1,0
1,-4.4,GO:0070875,positive regulation of glycogen metabolic process,M1,1,0
1,-10,hsa04659,Th17 cell differentiation,M1,1,0
1,-7.3,GO:0042306,regulation of protein import into nucleus,M1,1,0
1,-5.7,GO:0061371,determination of heart left/right asymmetry,M1,1,0
1,-2.8,M8666,GSE34156 UNTREATED VS 6H NOD2 LIGAND TREATED MONOCYTE DN,M1,1,0
1,-6.8,GO:0006886,intracellular protein transport,M1,1,0
1,-3.9,GO:0016887,ATP hydrolysis activity,M1,1,0
1,-2.1,R-HSA-15869,Metabolism of nucleotides,M1,1,0
1,-2.3,WP3851,TLR4 signaling and tolerance,M1,1,0
1,-3.7,GO:0007127,meiosis I,M1,1,0
1,-5.1,CORUM:654,BLOC1-BLOC2 complex,M1,1,0
1,-2.2,M16431,DEURIG T CELL PROLYMPHOCYTIC LEUKEMIA UP,M1,1,0
1,-2.1,GO:0014020,primary neural tube formation,M1,1,0
1,-2.1,GO:0048524,positive regulation of viral process,M1,1,0
1,-17,GO:0045596,negative regulation of cell differentiation,M1,1,0
1,-20,M164,PID ERBB1 DOWNSTREAM PATHWAY,M1,1,0
1,-2.7,GO:0032986,protein-DNA complex disassembly,M1,1,0
1,-6.3,GO:0140657,ATP-dependent activity,M1,1,0
1,-2,M3100,GSE10856 CTRL VS TNFRSF6B IN MACROPHAGE UP,M1,1,0
1,-3.7,M4925,STEARMAN LUNG CANCER EARLY VS LATE UP,M1,1,0
1,-2.3,GO:1901983,regulation of protein acetylation,M1,1,0
1,-6.4,WP4540,Hippo signaling regulation pathways,M1,1,0
1,-19,GO:0048598,embryonic morphogenesis,M1,1,0
1,-2.7,GO:0071378,cellular response to growth hormone stimulus,M1,1,0
1,-5.1,M8448,BENPORATH PRC2 TARGETS,M1,1,0
1,-4.9,GO:0060148,positive regulation of post-transcriptional gene silencing,M1,1,0
1,-2.2,WP2533,Glycerophospholipid biosynthetic pathway,M1,1,0
1,-13,WP5074,Kallmann syndrome,M1,1,0
1,-3.2,GO:0045348,positive regulation of MHC class II biosynthetic process,M1,1,0
1,-5.1,GO:0032404,mismatch repair complex binding,M1,1,0
1,-4.5,GO:0045132,meiotic chromosome segregation,M1,1,0
1,-8.5,GO:0030326,embryonic limb morphogenesis,M1,1,0
1,-4.2,GO:0060627,regulation of vesicle-mediated transport,M1,1,0
1,-2,M1267,HOWLIN PUBERTAL MAMMARY GLAND,M1,1,0
1,-2.4,M2456,WANG MLL TARGETS,M1,1,0
1,-4.3,WP2864,Apoptosis-related network due to altered Notch3 in ovarian cancer,M1,1,0
1,-2.4,GO:0002639,positive regulation of immunoglobulin production,M1,1,0
1,-2.5,M4017,GSE17721 POLYIC VS GARDIQUIMOD 1H BMDC DN,M1,1,0
1,-2.1,M15346,LEE LIVER CANCER E2F1 DN,M1,1,0
1,-7,GO:0050900,leukocyte migration,M1,1,0
1,-15,GO:0008544,epidermis development,M1,1,0
1,-8.2,GO:0001754,eye photoreceptor cell differentiation,M1,1,0
1,-5.9,GO:0014066,regulation of phosphatidylinositol 3-kinase signaling,M1,1,0
1,-7.1,GO:0045931,positive regulation of mitotic cell cycle,M1,1,0
1,-2.6,GO:0060976,coronary vasculature development,M1,1,0
1,-2,M11513,SARRIO EPITHELIAL MESENCHYMAL TRANSITION DN,M1,1,0
1,-9.9,GO:0060047,heart contraction,M1,1,0
1,-5.1,GO:0007264,small GTPase mediated signal transduction,M1,1,0
1,-4.8,M19541,REN ALVEOLAR RHABDOMYOSARCOMA DN,M1,1,0
1,-8,R-HSA-1280218,Adaptive Immune System,M1,1,0
1,-3.7,M4607,GSE24634 TREG VS TCONV POST DAY10 IL4 CONVERSION UP,M1,1,0
1,-2.2,GO:0045621,positive regulation of lymphocyte differentiation,M1,1,0
1,-4.4,M6996,GSE5503 LIVER DC VS SPLEEN DC ACTIVATED ALLOGENIC TCELL UP,M1,1,0
1,-4.8,R-HSA-8847993,ERBB2 Activates PTK6 Signaling,M1,1,0
1,-5,GO:0048708,astrocyte differentiation,M1,1,0
1,-4.5,GO:1903426,regulation of reactive oxygen species biosynthetic process,M1,1,0
1,-4.5,M18219,BREUHAHN GROWTH FACTOR SIGNALING IN LIVER CANCER,M1,1,0
1,-2,GO:1901224,positive regulation of NIK/NF-kappaB signaling,M1,1,0
1,-3.7,M6785,GSE3203 HEALTHY VS INFLUENZA INFECTED LN BCELL UP,M1,1,0
1,-6.8,R-HSA-373752,Netrin-1 signaling,M1,1,0
1,-4,M2001,WU CELL MIGRATION,M1,1,0
1,-2.7,M10739,CROONQUIST NRAS SIGNALING DN,M1,1,0
1,-3,GO:0009308,amine metabolic process,M1,1,0
1,-11,hsa04152,AMPK signaling pathway,M1,1,0
1,-5.2,WP4482,Vitamin D in inflammatory diseases,M1,1,0
1,-3,M3790,GSE17721 CTRL VS GARDIQUIMOD 8H BMDC DN,M1,1,0
1,-8.3,M13522,DACOSTA UV RESPONSE VIA ERCC3 COMMON DN,M1,1,0
1,-2.4,M10828,SHEPARD CRASH AND BURN MUTANT UP,M1,1,0
1,-8.3,R-HSA-6796648,TP53 Regulates Transcription of DNA Repair Genes,M1,1,0
1,-3.3,CORUM:1005,RC complex during G2/M-phase of cell cycle,M1,1,0
1,-3.1,M9167,ROZANOV MMP14 TARGETS SUBSET,M1,1,0
1,-3.6,GO:0001091,RNA polymerase II general transcription initiation factor binding,M1,1,0
1,-3,M5803,GSE9037 CTRL VS LPS 4H STIM BMDM UP,M1,1,0
1,-3,R-HSA-176187,Activation of ATR in response to replication stress,M1,1,0
1,-6,WP2583,T cell receptor and co-stimulatory signaling,M1,1,0
1,-3.7,M8597,GSE27859 DC VS CD11C INT F480 HI MACROPHAGE UP,M1,1,0
1,-4.4,CORUM:5197,PTIP-DNA damage response complex,M1,1,0
1,-2.2,M1461,PETROVA ENDOTHELIUM LYMPHATIC VS BLOOD UP,M1,1,0
1,-4.6,R-HSA-5218920,VEGFR2 mediated vascular permeability,M1,1,0
1,-5.8,R-HSA-9661069,"Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)",M1,1,0
1,-3.4,M19875,SENGUPTA NASOPHARYNGEAL CARCINOMA UP,M1,1,0
1,-6.2,M16381,SCHLOSSER SERUM RESPONSE UP,M1,1,0
1,-3,M6639,GSE5589 WT VS IL6 KO LPS STIM MACROPHAGE 45MIN DN,M1,1,0
1,-2.4,GO:0050886,endocrine process,M1,1,0
1,-5.4,R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,M1,1,0
1,-2.9,WP2447,Amyotrophic lateral sclerosis (ALS),M1,1,0
1,-6.4,GO:0042692,muscle cell differentiation,M1,1,0
1,-2.4,M1107,GRAESSMANN RESPONSE TO MC AND DOXORUBICIN DN,M1,1,0
1,-10,GO:0001666,response to hypoxia,M1,1,0
1,-5.5,GO:0048147,negative regulation of fibroblast proliferation,M1,1,0
1,-3.2,GO:0050777,negative regulation of immune response,M1,1,0
1,-5.3,GO:0000014,single-stranded DNA endodeoxyribonuclease activity,M1,1,0
1,-3.7,M53,PID INTEGRIN3 PATHWAY,M1,1,0
1,-4.4,M4760,GSE27786 LSK VS NEUTROPHIL UP,M1,1,0
1,-2.5,M8717,GSE30971 CTRL VS LPS STIM MACROPHAGE WBP7 KO 4H DN,M1,1,0
1,-9.7,GO:0051223,regulation of protein transport,M1,1,0
1,-4.4,GO:0051105,regulation of DNA ligation,M1,1,0
1,-3.8,WP4357,NRF2-ARE regulation,M1,1,0
1,-23,hsa05223,Non-small cell lung cancer,M1,1,0
1,-2.9,GO:0008201,heparin binding,M1,1,0
1,-5.5,M11318,MITSIADES RESPONSE TO APLIDIN DN,M1,1,0
1,-3.2,M14973,SENESE HDAC1 TARGETS UP,M1,1,0
1,-2.2,GO:0042116,macrophage activation,M1,1,0
1,-5.1,CORUM:2551,"PDGFRA-PLC-gamma-1-PI3K-SHP-2 complex, PDGF stimulated",M1,1,0
1,-2.5,GO:0032412,regulation of ion transmembrane transporter activity,M1,1,0
1,-4.7,M153,PID P75 NTR PATHWAY,M1,1,0
1,-6,GO:0090130,tissue migration,M1,1,0
1,-15,R-HSA-5684996,MAPK1/MAPK3 signaling,M1,1,0
1,-2.8,GO:0030178,negative regulation of Wnt signaling pathway,M1,1,0
1,-2.1,GO:0031333,negative regulation of protein-containing complex assembly,M1,1,0
1,-10,hsa04611,Platelet activation,M1,1,0
1,-36,hsa01522,Endocrine resistance,M1,1,0
1,-4.4,M6244,OHM EMBRYONIC CARCINOMA UP,M1,1,0
1,-4.6,GO:0090150,establishment of protein localization to membrane,M1,1,0
1,-5.6,GO:0051099,positive regulation of binding,M1,1,0
1,-2.7,GO:0055064,chloride ion homeostasis,M1,1,0
1,-4.2,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M1,1,0
1,-5.1,R-HSA-2586552,Signaling by Leptin,M1,1,0
1,-2.8,GO:0003352,regulation of cilium movement,M1,1,0
1,-8,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M1,1,0
1,-3,M7168,GSE17186 CD21LOW VS CD21HIGH TRANSITIONAL BCELL UP,M1,1,0
1,-3.5,CORUM:5177,"Polycystin-1 multiprotein complex (ACTN1, CDH1, SRC, JUP, VCL, CTNNB1, PXN, BCAR1, PKD1, PTK2, TLN1)",M1,1,0
1,-19,M122,PID IL2 1PATHWAY,M1,1,0
1,-3,M5607,GSE39820 CTRL VS TGFBETA1 IL6 IL23A CD4 TCELL UP,M1,1,0
1,-3,GO:2000106,regulation of leukocyte apoptotic process,M1,1,0
1,-8.3,GO:0042471,ear morphogenesis,M1,1,0
1,-4.5,M3362,MARKS HDAC TARGETS DN,M1,1,0
1,-4.1,M939,HADDAD B LYMPHOCYTE PROGENITOR,M1,1,0
1,-14,M13,PID ERBB4 PATHWAY,M1,1,0
1,-9.1,GO:0040011,locomotion,M1,1,0
1,-2,R-HSA-3781865,Diseases of glycosylation,M1,1,0
1,-4.6,GO:0060711,labyrinthine layer development,M1,1,0
1,-7.5,M6060,GSE2770 IL12 VS TGFB AND IL12 TREATED ACT CD4 TCELL 6H DN,M1,1,0
1,-3,GO:0004519,endonuclease activity,M1,1,0
1,-2.4,GO:0051283,negative regulation of sequestering of calcium ion,M1,1,0
1,-16,WP2324,AGE/RAGE pathway,M1,1,0
1,-11,R-HSA-422475,Axon guidance,M1,1,0
1,-2.1,hsa04215,Apoptosis - multiple species,M1,1,0
1,-3.6,hsa04137,Mitophagy - animal,M1,1,0
1,-7.7,GO:0009913,epidermal cell differentiation,M1,1,0
1,-3.9,GO:0009199,ribonucleoside triphosphate metabolic process,M1,1,0
1,-2.3,M1037,KANG DOXORUBICIN RESISTANCE UP,M1,1,0
1,-2.3,GO:0060795,cell fate commitment involved in formation of primary germ layer,M1,1,0
1,-4.4,M4645,GSE25087 FETAL VS ADULT TCONV UP,M1,1,0
1,-19,GO:0051054,positive regulation of DNA metabolic process,M1,1,0
1,-4.5,GO:0008217,regulation of blood pressure,M1,1,0
1,-4.8,M5493,WNT SIGNALING,M1,1,0
1,-2.9,GO:0007249,I-kappaB kinase/NF-kappaB signaling,M1,1,0
1,-2.1,GO:0032481,positive regulation of type I interferon production,M1,1,0
1,-4.7,M8526,CHEN LUNG CANCER SURVIVAL,M1,1,0
1,-3.1,GO:0198738,cell-cell signaling by wnt,M1,1,0
1,-4.4,R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,M1,1,0
1,-5.7,M7995,HOSHIDA LIVER CANCER SUBCLASS S2,M1,1,0
1,-4.6,R-HSA-8957322,Metabolism of steroids,M1,1,0
1,-2.1,GO:0030511,positive regulation of transforming growth factor beta receptor signaling pathway,M1,1,0
1,-19,hsa05222,Small cell lung cancer,M1,1,0
1,-20,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,M1,1,0
1,-6.6,GO:0051703,biological process involved in intraspecies interaction between organisms,M1,1,0
1,-9.4,GO:0051098,regulation of binding,M1,1,0
1,-2.7,GO:2000036,regulation of stem cell population maintenance,M1,1,0
1,-2.3,GO:0005923,bicellular tight junction,M1,1,0
1,-2.7,GO:2001056,positive regulation of cysteine-type endopeptidase activity,M1,1,0
1,-2.1,GO:0002712,regulation of B cell mediated immunity,M1,1,0
1,-7.1,M2574,LIM MAMMARY STEM CELL DN,M1,1,0
1,-2.3,M2309,AZARE NEOPLASTIC TRANSFORMATION BY STAT3 UP,M1,1,0
1,-7.8,GO:0071219,cellular response to molecule of bacterial origin,M1,1,0
1,-2.2,GO:0098552,side of membrane,M1,1,0
1,-3,M4810,GSE27786 BCELL VS ERYTHROBLAST UP,M1,1,0
1,-14,GO:0040017,positive regulation of locomotion,M1,1,0
1,-2,M13133,BYSTRYKH HEMATOPOIESIS STEM CELL AND BRAIN QTL CIS,M1,1,0
1,-24,GO:0007167,enzyme-linked receptor protein signaling pathway,M1,1,0
1,-18,WP4223,Ras signaling,M1,1,0
1,-2.4,GO:0045686,negative regulation of glial cell differentiation,M1,1,0
1,-3.3,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M1,1,0
1,-2.4,M6930,GSE6674 ANTI IGM VS PL2 3 STIM BCELL UP,M1,1,0
1,-10,GO:0062197,cellular response to chemical stress,M1,1,0
1,-3.7,hsa04020,Calcium signaling pathway,M1,1,0
1,-4.7,GO:0016491,oxidoreductase activity,M1,1,0
1,-5.3,CORUM:86,NUMAC complex (nucleosomal methylation activator complex),M1,1,0
1,-3,M3950,GSE17721 POLYIC VS CPG 16H BMDC UP,M1,1,0
1,-6,GO:0014014,negative regulation of gliogenesis,M1,1,0
1,-5.1,WP262,Ebstein-Barr virus LMP1 signaling,M1,1,0
1,-8.6,M257,PID EPHRINB REV PATHWAY,M1,1,0
1,-3.8,GO:0048845,venous blood vessel morphogenesis,M1,1,0
1,-3.3,GO:0051059,NF-kappaB binding,M1,1,0
1,-4.7,M198,PID SYNDECAN 1 PATHWAY,M1,1,0
1,-7.8,M9884,BRUNEAU HEART GREAT VESSELS AND VALVULOGENESIS,M1,1,0
1,-9.2,GO:0035994,response to muscle stretch,M1,1,0
1,-5,GO:0045229,external encapsulating structure organization,M1,1,0
1,-5.1,M5617,GSE39820 TGFBETA1 IL6 VS TGFBETA1 IL6 IL23A TREATED CD4 TCELL UP,M1,1,0
1,-3.7,M8405,GSE29949 MICROGLIA VS DC BRAIN DN,M1,1,0
1,-2.4,GO:0050792,regulation of viral process,M1,1,0
1,-5.3,hsa04390,Hippo signaling pathway,M1,1,0
1,-2.6,GO:0051444,negative regulation of ubiquitin-protein transferase activity,M1,1,0
1,-3.7,M5183,GSE360 DC VS MAC T GONDII UP,M1,1,0
1,-4.8,R-HSA-6782135,Dual incision in TC-NER,M1,1,0
1,-2.4,M3584,GSE15767 MED VS SCS MAC LN UP,M1,1,0
1,-5.3,CORUM:2904,"Respiratory chain complex I (intermediate VII/650kD), mitochondrial",M1,1,0
1,-3.3,WP1434,Osteopontin signaling,M1,1,0
1,-2.4,WP2249,Metastatic brain tumor,M1,1,0
1,-4.4,GO:0071680,response to indole-3-methanol,M1,1,0
1,-12,hsa04725,Cholinergic synapse,M1,1,0
1,-8,GO:0006282,regulation of DNA repair,M1,1,0
1,-2.1,GO:0061041,regulation of wound healing,M1,1,0
1,-3,M8729,AMIT EGF RESPONSE 480 HELA,M1,1,0
1,-9.2,GO:0070201,regulation of establishment of protein localization,M1,1,0
1,-6,GO:0009895,negative regulation of catabolic process,M1,1,0
1,-7.3,M8156,BENPORATH CYCLING GENES,M1,1,0
1,-7.8,R-HSA-5654708,Downstream signaling of activated FGFR3,M1,1,0
1,-4.6,GO:0048477,oogenesis,M1,1,0
1,-12,GO:0015919,peroxisomal membrane transport,M1,1,0
1,-6.7,M5264,GSE360 HIGH DOSE B MALAYI VS M TUBERCULOSIS MAC DN,M1,1,0
1,-3.3,GO:0090087,regulation of peptide transport,M1,1,0
1,-3.4,GO:0060043,regulation of cardiac muscle cell proliferation,M1,1,0
1,-7.6,WP3969,H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity,M1,1,0
1,-7.4,GO:1905475,regulation of protein localization to membrane,M1,1,0
1,-6.4,GO:0071901,negative regulation of protein serine/threonine kinase activity,M1,1,0
1,-8.2,GO:0043535,regulation of blood vessel endothelial cell migration,M1,1,0
1,-2.2,M1428,SANSOM APC TARGETS UP,M1,1,0
1,-12,GO:0051276,chromosome organization,M1,1,0
1,-4.5,WP2855,Dopaminergic neurogenesis,M1,1,0
1,-3.7,M12824,SHEDDEN LUNG CANCER GOOD SURVIVAL A4,M1,1,0
1,-13,R-HSA-109704,PI3K Cascade,M1,1,0
1,-2.6,M8570,DOANE BREAST CANCER ESR1 DN,M1,1,0
1,-3.5,M3654,THUM SYSTOLIC HEART FAILURE UP,M1,1,0
1,-5.6,GO:0051536,iron-sulfur cluster binding,M1,1,0
1,-2.9,GO:0060571,morphogenesis of an epithelial fold,M1,1,0
1,-3.7,GO:0032956,regulation of actin cytoskeleton organization,M1,1,0
1,-2.9,R-HSA-2033519,Activated point mutants of FGFR2,M1,1,0
1,-9.8,GO:0098662,inorganic cation transmembrane transport,M1,1,0
1,-9.2,GO:0021700,developmental maturation,M1,1,0
1,-2.2,M8881,GSE37301 HEMATOPOIETIC STEM CELL VS CD4 TCELL UP,M1,1,0
1,-4.4,M9750,GSE43863 TFH VS LY6C LOW CXCR5NEG EFFECTOR CD4 TCELL UP,M1,1,0
1,-2.1,GO:0042626,ATPase-coupled transmembrane transporter activity,M1,1,0
1,-3.9,GO:0034440,lipid oxidation,M1,1,0
1,-4.8,GO:0003954,NADH dehydrogenase activity,M1,1,0
1,-3.7,M8274,GSE21063 CTRL VS ANTI IGM STIM BCELL NFATC1 KO 8H DN,M1,1,0
1,-3.8,R-HSA-442755,Activation of NMDA receptors and postsynaptic events,M1,1,0
1,-11,GO:0019903,protein phosphatase binding,M1,1,0
1,-3,GO:0043517,"positive regulation of DNA damage response, signal transduction by p53 class mediator",M1,1,0
1,-2.1,GO:0045070,positive regulation of viral genome replication,M1,1,0
1,-4.5,GO:0060840,artery development,M1,1,0
1,-2.1,M2854,STK33 NOMO DN,M1,1,0
1,-4.4,WP4705,Pathways of nucleic acid metabolism and innate immune sensing,M1,1,0
1,-8,M2993,GSE13547 CTRL VS ANTI IGM STIM BCELL 2H UP,M1,1,0
1,-3,M8081,GSE23502 BM VS COLON TUMOR HDC KO MYELOID DERIVED SUPPRESSOR CELL DN,M1,1,0
1,-3.1,GO:0019646,aerobic electron transport chain,M1,1,0
1,-2.5,GO:0031648,protein destabilization,M1,1,0
1,-3,M7273,GSE19923 WT VS HEB AND E2A KO DP THYMOCYTE UP,M1,1,0
1,-7.5,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M1,1,0
1,-9.1,GO:0043270,positive regulation of ion transport,M1,1,0
1,-7.2,GO:0042472,inner ear morphogenesis,M1,1,0
1,-10,GO:0001656,metanephros development,M1,1,0
1,-5.7,GO:0032206,positive regulation of telomere maintenance,M1,1,0
1,-8.5,GO:0044773,mitotic DNA damage checkpoint signaling,M1,1,0
1,-2.3,M215,LIU VAV3 PROSTATE CARCINOGENESIS UP,M1,1,0
1,-5.8,GO:0030219,megakaryocyte differentiation,M1,1,0
1,-8.7,GO:0043388,positive regulation of DNA binding,M1,1,0
1,-6,R-HSA-1963640,GRB2 events in ERBB2 signaling,M1,1,0
1,-5.6,GO:0043542,endothelial cell migration,M1,1,0
1,-4.9,R-HSA-933542,TRAF6 mediated NF-kB activation,M1,1,0
1,-6.5,CORUM:244,BRAFT complex,M1,1,0
1,-9.7,GO:0060348,bone development,M1,1,0
1,-9.5,GO:0060155,platelet dense granule organization,M1,1,0
1,-2.1,GO:0002705,positive regulation of leukocyte mediated immunity,M1,1,0
1,-5.6,GO:0051053,negative regulation of DNA metabolic process,M1,1,0
1,-3,GO:0032421,stereocilium bundle,M1,1,0
1,-5.7,GO:0072331,signal transduction by p53 class mediator,M1,1,0
1,-10,GO:0031347,regulation of defense response,M1,1,0
1,-3,M5303,GSE36476 CTRL VS TSST ACT 72H MEMORY CD4 TCELL OLD DN,M1,1,0
1,-3.1,GO:0051494,negative regulation of cytoskeleton organization,M1,1,0
1,-8,GO:0007517,muscle organ development,M1,1,0
1,-3.2,WP5192,Modulation of PI3K-Akt-mTOR signaling by bioactive sphingolipids,M1,1,0
1,-3.9,GO:2000112,regulation of cellular macromolecule biosynthetic process,M1,1,0
1,-6.7,GO:0001938,positive regulation of endothelial cell proliferation,M1,1,0
1,-2.3,GO:2000781,positive regulation of double-strand break repair,M1,1,0
1,-2.5,GO:0030666,endocytic vesicle membrane,M1,1,0
1,-4,M10702,JAEGER METASTASIS DN,M1,1,0
1,-3.2,GO:0072171,mesonephric tubule morphogenesis,M1,1,0
1,-4.5,GO:0031231,intrinsic component of peroxisomal membrane,M1,1,0
1,-4.4,M13108,LI WILMS TUMOR VS FETAL KIDNEY 1 DN,M1,1,0
1,-10,R-HSA-1500931,Cell-Cell communication,M1,1,0
1,-2.5,M6787,SCIBETTA KDM5B TARGETS DN,M1,1,0
1,-2.3,GO:0042594,response to starvation,M1,1,0
1,-3,M6090,GSE2770 UNTREATED VS IL12 TREATED ACT CD4 TCELL 2H UP,M1,1,0
1,-4.6,GO:1903046,meiotic cell cycle process,M1,1,0
1,-6.7,GO:0005158,insulin receptor binding,M1,1,0
1,-7.6,GO:1903798,regulation of miRNA maturation,M1,1,0
1,-5.9,GO:0050920,regulation of chemotaxis,M1,1,0
1,-8.7,GO:0032989,cellular component morphogenesis,M1,1,0
1,-2.7,M2451,PLASARI TGFB1 SIGNALING VIA NFIC 1HR DN,M1,1,0
1,-14,hsa05230,Central carbon metabolism in cancer,M1,1,0
1,-6.8,M15626,OUYANG PROSTATE CANCER PROGRESSION UP,M1,1,0
1,-11,M222,PID CXCR3 PATHWAY,M1,1,0
1,-4.6,GO:0031331,positive regulation of cellular catabolic process,M1,1,0
1,-8.8,GO:1901216,positive regulation of neuron death,M1,1,0
1,-3.1,GO:0006206,pyrimidine nucleobase metabolic process,M1,1,0
1,-3.2,M1195,PATIL LIVER CANCER,M1,1,0
1,-6.4,GO:0030902,hindbrain development,M1,1,0
1,-11,GO:0010594,regulation of endothelial cell migration,M1,1,0
1,-9.8,GO:0010001,glial cell differentiation,M1,1,0
1,-3,GO:0005068,transmembrane receptor protein tyrosine kinase adaptor activity,M1,1,0
1,-6.2,GO:2000001,regulation of DNA damage checkpoint,M1,1,0
1,-3,M8545,GSE33425 CD161 HIGH VS INT CD8 TCELL DN,M1,1,0
1,-3.3,GO:0000803,sex chromosome,M1,1,0
1,-6.7,GO:0050808,synapse organization,M1,1,0
1,-3.8,GO:0003925,G protein activity,M1,1,0
1,-5.6,M10351,BUYTAERT PHOTODYNAMIC THERAPY STRESS DN,M1,1,0
1,-4,M1515,JOSEPH RESPONSE TO SODIUM BUTYRATE DN,M1,1,0
1,-2.6,M5311,HOSHIDA LIVER CANCER SUBCLASS S1,M1,1,0
1,-11,GO:0051249,regulation of lymphocyte activation,M1,1,0
1,-2.1,GO:0097529,myeloid leukocyte migration,M1,1,0
1,-21,hsa05417,Lipid and atherosclerosis,M1,1,0
1,-14,GO:0048592,eye morphogenesis,M1,1,0
1,-4.5,M1493,NIKOLSKY BREAST CANCER 11Q12 Q14 AMPLICON,M1,1,0
1,-18,R-HSA-1640170,Cell Cycle,M1,1,0
1,-2.3,M8182,GSE25677 R848 VS MPL AND R848 STIM BCELL DN,M1,1,0
1,-11,GO:1903829,positive regulation of protein localization,M1,1,0
1,-3.5,hsa04064,NF-kappa B signaling pathway,M1,1,0
1,-14,R-HSA-1227986,Signaling by ERBB2,M1,1,0
1,-6.7,GO:0042462,eye photoreceptor cell development,M1,1,0
1,-6,GO:0031952,regulation of protein autophosphorylation,M1,1,0
1,-14,R-HSA-112399,IRS-mediated signalling,M1,1,0
1,-6.4,GO:0072089,stem cell proliferation,M1,1,0
1,-2.1,M374,GSE11386 NAIVE VS MEMORY BCELL UP,M1,1,0
1,-5.2,GO:0036064,ciliary basal body,M1,1,0
1,-11,M7955,SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES,M1,1,0
1,-4.4,M9062,GSE32034 LY6C HIGH VS LOW ROSIGLIZATONE TREATED MONOCYTE DN,M1,1,0
1,-2,M2674,PGF UP.V1 UP,M1,1,0
1,-6.3,R-HSA-76009,Platelet Aggregation (Plug Formation),M1,1,0
1,-20,GO:0104004,cellular response to environmental stimulus,M1,1,0
1,-3.4,GO:0050852,T cell receptor signaling pathway,M1,1,0
1,-2.7,M2670,MTOR UP.V1 DN,M1,1,0
1,-2.2,GO:0099565,"chemical synaptic transmission, postsynaptic",M1,1,0
1,-3.8,GO:0001838,embryonic epithelial tube formation,M1,1,0
1,-4.4,M8308,GSE28726 NAIVE CD4 TCELL VS NAIVE VA24NEG NKTCELL UP,M1,1,0
1,-3.4,R-HSA-2672351,Stimuli-sensing channels,M1,1,0
1,-4.3,GO:0006349,regulation of gene expression by genomic imprinting,M1,1,0
1,-2.3,GO:0016363,nuclear matrix,M1,1,0
1,-2.4,M15927,RODRIGUES DCC TARGETS DN,M1,1,0
1,-20,GO:0003682,chromatin binding,M1,1,0
1,-2.8,M8578,GSE26030 UNSTIM VS RESTIM TH17 DAY15 POST POLARIZATION UP,M1,1,0
1,-8.3,GO:0015318,inorganic molecular entity transmembrane transporter activity,M1,1,0
1,-3.7,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M1,1,0
1,-3,GO:0051177,meiotic sister chromatid cohesion,M1,1,0
1,-4.1,WP3287,Overview of nanoparticle effects,M1,1,0
1,-2.4,M4503,GSE22886 NAIVE CD4 TCELL VS DC DN,M1,1,0
1,-7.2,R-HSA-450341,Activation of the AP-1 family of transcription factors,M1,1,0
1,-2.6,M1488,HANSON HRAS SIGNALING VIA NFKB,M1,1,0
1,-2.1,GO:0005635,nuclear envelope,M1,1,0
1,-3.7,GO:0045840,positive regulation of mitotic nuclear division,M1,1,0
1,-8.8,M5825,VART KSHV INFECTION ANGIOGENIC MARKERS DN,M1,1,0
1,-13,hsa04072,Phospholipase D signaling pathway,M1,1,0
1,-4.2,M19630,ZHU CMV ALL UP,M1,1,0
1,-2.9,GO:0044214,spanning component of plasma membrane,M1,1,0
1,-2.8,M14877,BASAKI YBX1 TARGETS DN,M1,1,0
1,-3.3,GO:1902260,negative regulation of delayed rectifier potassium channel activity,M1,1,0
1,-3.3,GO:0032148,activation of protein kinase B activity,M1,1,0
1,-6.3,GO:0042307,positive regulation of protein import into nucleus,M1,1,0
1,-2.7,GO:0006584,catecholamine metabolic process,M1,1,0
1,-2.5,GO:0008360,regulation of cell shape,M1,1,0
1,-2.4,M5973,GSE369 PRE VS POST IL6 INJECTION IFNG KO LIVER UP,M1,1,0
1,-5.1,GO:0021766,hippocampus development,M1,1,0
1,-9.3,GO:0022612,gland morphogenesis,M1,1,0
1,-3.8,GO:1990858,cellular response to lectin,M1,1,0
1,-6,GO:0071805,potassium ion transmembrane transport,M1,1,0
1,-6,GO:0001947,heart looping,M1,1,0
1,-4,GO:0032981,mitochondrial respiratory chain complex I assembly,M1,1,0
1,-14,R-HSA-2559583,Cellular Senescence,M1,1,0
1,-3.7,GO:0060972,left/right pattern formation,M1,1,0
1,-7.3,R-HSA-6806834,Signaling by MET,M1,1,0
1,-6.3,GO:0006338,chromatin remodeling,M1,1,0
1,-8.1,M11951,HINATA NFKB TARGETS KERATINOCYTE UP,M1,1,0
1,-6.1,R-HSA-2426168,Activation of gene expression by SREBF (SREBP),M1,1,0
1,-4.9,GO:0043266,regulation of potassium ion transport,M1,1,0
1,-2.6,GO:0002637,regulation of immunoglobulin production,M1,1,0
1,-4.4,M6280,GSE2585 THYMIC MACROPHAGE VS MTEC DN,M1,1,0
1,-3,GO:0070873,regulation of glycogen metabolic process,M1,1,0
1,-4.3,GO:1904031,positive regulation of cyclin-dependent protein kinase activity,M1,1,0
1,-6.3,GO:0014009,glial cell proliferation,M1,1,0
1,-2.7,M11166,IVANOVA HEMATOPOIESIS LATE PROGENITOR,M1,1,0
1,-4.8,GO:0005912,adherens junction,M1,1,0
1,-2.9,GO:0008308,voltage-gated anion channel activity,M1,1,0
1,-3,GO:0032387,negative regulation of intracellular transport,M1,1,0
1,-9.7,GO:0140097,"catalytic activity, acting on DNA",M1,1,0
1,-2.5,M9989,GSE45365 WT VS IFNAR KO BCELL MCMV INFECTION DN,M1,1,0
1,-4.4,M2802,RB P107 DN.V1 UP,M1,1,0
1,-7.3,GO:0061180,mammary gland epithelium development,M1,1,0
1,-5.9,GO:0001708,cell fate specification,M1,1,0
1,-2.2,M16639,KOKKINAKIS METHIONINE DEPRIVATION 48HR DN,M1,1,0
1,-3.7,M7993,GSE16385 ROSIGLITAZONE IFNG TNF VS IL4 STIM MACROPHAGE DN,M1,1,0
1,-3.1,GO:0006473,protein acetylation,M1,1,0
1,-3,R-HSA-9007101,Rab regulation of trafficking,M1,1,0
1,-2.8,GO:0045124,regulation of bone resorption,M1,1,0
1,-4,GO:0002697,regulation of immune effector process,M1,1,0
1,-3.5,R-HSA-611105,Respiratory electron transport,M1,1,0
1,-2,R-HSA-9645723,Diseases of programmed cell death,M1,1,0
1,-4.6,GO:0034976,response to endoplasmic reticulum stress,M1,1,0
1,-10,WP4747,Netrin-UNC5B signaling pathway,M1,1,0
1,-5.5,hsa04261,Adrenergic signaling in cardiomyocytes,M1,1,0
1,-2.4,M4506,GSE22886 NAIVE CD4 TCELL VS MONOCYTE DN,M1,1,0
1,-4.1,WP4478,LTF danger signal response pathway,M1,1,0
1,-4.4,WP2839,Hair follicle development: organogenesis - part 2 of 3,M1,1,0
1,-15,GO:0045321,leukocyte activation,M1,1,0
1,-4.9,GO:0097447,dendritic tree,M1,1,0
1,-4.9,GO:0010660,regulation of muscle cell apoptotic process,M1,1,0
1,-5.2,GO:0016655,"oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor",M1,1,0
1,-5.6,GO:0051899,membrane depolarization,M1,1,0
1,-3.3,GO:0002274,myeloid leukocyte activation,M1,1,0
1,-3.5,M17183,BENPORATH OCT4 TARGETS,M1,1,0
1,-3.3,R-HSA-171007,p38MAPK events,M1,1,0
1,-3.4,GO:0045685,regulation of glial cell differentiation,M1,1,0
1,-3.8,GO:0006265,DNA topological change,M1,1,0
1,-6.4,GO:0005261,cation channel activity,M1,1,0
1,-2.7,GO:0008347,glial cell migration,M1,1,0
1,-4.4,M6978,GSE8621 UNSTIM VS LPS PRIMED UNSTIM MACROPHAGE UP,M1,1,0
1,-2.8,GO:0032733,positive regulation of interleukin-10 production,M1,1,0
1,-15,GO:0043408,regulation of MAPK cascade,M1,1,0
1,-3.1,R-HSA-918233,TRAF3-dependent IRF activation pathway,M1,1,0
1,-4.4,M3580,GSE15750 DAY6 VS DAY10 TRAF6KO EFF CD8 TCELL UP,M1,1,0
1,-4.5,R-HSA-9674555,Signaling by CSF3 (G-CSF),M1,1,0
1,-3.2,CORUM:1230,WINAC complex,M1,1,0
1,-2.4,GO:0035330,regulation of hippo signaling,M1,1,0
1,-3.1,M8284,GSE23114 WT VS SLE2C1 MOUSE PERITONEAL CAVITY B1A BCELL UP,M1,1,0
1,-4,GO:0042129,regulation of T cell proliferation,M1,1,0
1,-4.8,GO:0060441,epithelial tube branching involved in lung morphogenesis,M1,1,0
1,-6.2,GO:0008543,fibroblast growth factor receptor signaling pathway,M1,1,0
1,-3.2,GO:0097049,motor neuron apoptotic process,M1,1,0
1,-2.5,GO:0031907,microbody lumen,M1,1,0
1,-2.3,GO:0035914,skeletal muscle cell differentiation,M1,1,0
1,-4.8,GO:0097110,scaffold protein binding,M1,1,0
1,-2.4,M7786,GSE23695 CD57 POS VS NEG NK CELL DN,M1,1,0
1,-2.5,M9214,GSE40666 WT VS STAT1 KO CD8 TCELL WITH IFNA STIM 90MIN UP,M1,1,0
1,-3.8,GO:0060444,branching involved in mammary gland duct morphogenesis,M1,1,0
1,-2.2,M83,PID CDC42 REG PATHWAY,M1,1,0
1,-5.9,GO:0007411,axon guidance,M1,1,0
1,-2.7,M10454,MCLACHLAN DENTAL CARIES UP,M1,1,0
1,-3.7,M6272,GSE2585 CTEC VS THYMIC DC DN,M1,1,0
1,-3,M9256,GSE20727 DNFB ALLERGEN VS ROS INH AND DNFB ALLERGEN TREATED DC DN,M1,1,0
1,-2.4,M5099,GSE3337 CTRL VS 4H IFNG IN CD8POS DC DN,M1,1,0
1,-2.5,M8788,GSE36891 UNSTIM VS PAM TLR2 STIM PERITONEAL MACROPHAGE DN,M1,1,0
1,-4.5,GO:0031214,biomineral tissue development,M1,1,0
1,-2.6,M442,GSE12839 CTRL VS IL12 TREATED PBMC UP,M1,1,0
1,-3.6,GO:0045980,negative regulation of nucleotide metabolic process,M1,1,0
1,-3.2,GO:0071674,mononuclear cell migration,M1,1,0
1,-9.8,GO:0060048,cardiac muscle contraction,M1,1,0
1,-2.4,R-HSA-1538133,G0 and Early G1,M1,1,0
1,-3.9,R-HSA-1474290,Collagen formation,M1,1,0
1,-4.4,GO:0014855,striated muscle cell proliferation,M1,1,0
1,-4.5,R-HSA-6785631,ERBB2 Regulates Cell Motility,M1,1,0
1,-3.9,M4203,LASTOWSKA NEUROBLASTOMA COPY NUMBER UP,M1,1,0
1,-22,hsa04664,Fc epsilon RI signaling pathway,M1,1,0
1,-2.4,M8993,GSE37533 UNTREATED VS PIOGLIZATONE TREATED CD4 TCELL PPARG2 AND FOXP3 TRASDUCED DN,M1,1,0
1,-2.4,M8099,GSE24972 MARGINAL ZONE BCELL VS FOLLICULAR BCELL IRF8 KO UP,M1,1,0
1,-2.6,GO:0046718,viral entry into host cell,M1,1,0
1,-3.1,M1098,GRAESSMANN APOPTOSIS BY SERUM DEPRIVATION DN,M1,1,0
1,-5.9,GO:0002764,immune response-regulating signaling pathway,M1,1,0
1,-20,R-HSA-2262752,Cellular responses to stress,M1,1,0
1,-5.5,GO:0090575,RNA polymerase II transcription regulator complex,M1,1,0
1,-3.3,GO:0006821,chloride transport,M1,1,0
1,-6.7,M206,PID PDGFRA PATHWAY,M1,1,0
1,-2.5,M3474,GSE1460 CD4 THYMOCYTE VS NAIVE CD4 TCELL ADULT BLOOD UP,M1,1,0
1,-6.3,M135,PID IL5 PATHWAY,M1,1,0
1,-9,GO:0002285,lymphocyte activation involved in immune response,M1,1,0
1,-7,M200,PID ERA GENOMIC PATHWAY,M1,1,0
1,-3.2,GO:0070141,response to UV-A,M1,1,0
1,-3.1,M14340,FUJII YBX1 TARGETS DN,M1,1,0
1,-2.4,M3623,GSE15930 STIM VS STIM AND IFNAB 24H CD8 T CELL UP,M1,1,0
1,-3,M6640,GSE5589 WT VS IL6 KO LPS AND IL10 STIM MACROPHAGE 45MIN UP,M1,1,0
1,-2.7,R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,M1,1,0
1,-3,M8600,GSE27859 DC VS CD11C INT F480 INT DC DN,M1,1,0
1,-3,M16050,KAYO AGING MUSCLE UP,M1,1,0
1,-4.8,GO:0060191,regulation of lipase activity,M1,1,0
1,-4.2,GO:0042733,embryonic digit morphogenesis,M1,1,0
1,-3.2,WP3414,Initiation of transcription and translation elongation at the HIV-1 LTR,M1,1,0
1,-2.7,M6728,GSE6259 33D1 POS VS DEC205 POS FLT3L INDUCED SPLENIC DC DN,M1,1,0
1,-2.5,M3401,GSE1432 CTRL VS IFNG 1H MICROGLIA DN,M1,1,0
1,-3.7,M4018,GSE17721 POLYIC VS GARDIQUIMOD 2H BMDC UP,M1,1,0
1,-19,R-HSA-5685938,HDR through Single Strand Annealing (SSA),M1,1,0
1,-7.8,R-HSA-202733,Cell surface interactions at the vascular wall,M1,1,0
1,-11,GO:0007605,sensory perception of sound,M1,1,0
1,-5,GO:2000637,positive regulation of miRNA-mediated gene silencing,M1,1,0
1,-4.7,GO:0006650,glycerophospholipid metabolic process,M1,1,0
1,-5.5,GO:0019217,regulation of fatty acid metabolic process,M1,1,0
1,-5.3,GO:0031334,positive regulation of protein-containing complex assembly,M1,1,0
1,-2,GO:0031023,microtubule organizing center organization,M1,1,0
1,-2.3,M7669,LEE TARGETS OF PTCH1 AND SUFU UP,M1,1,0
1,-2.9,R-HSA-9031628,NGF-stimulated transcription,M1,1,0
1,-18,M166,PID ATF2 PATHWAY,M1,1,0
1,-7.2,M16909,PARENT MTOR SIGNALING UP,M1,1,0
1,-3.2,GO:0060416,response to growth hormone,M1,1,0
1,-2.6,GO:0061440,kidney vasculature development,M1,1,0
1,-5.4,GO:1901379,regulation of potassium ion transmembrane transport,M1,1,0
1,-2.4,R-HSA-8854691,Interleukin-20 family signaling,M1,1,0
1,-2.6,M6755,GSE6259 33D1 POS DC VS BCELL DN,M1,1,0
1,-7.9,GO:0046822,regulation of nucleocytoplasmic transport,M1,1,0
1,-12,M13537,KOKKINAKIS METHIONINE DEPRIVATION 48HR UP,M1,1,0
1,-2.6,GO:0030501,positive regulation of bone mineralization,M1,1,0
1,-5.1,GO:0072080,nephron tubule development,M1,1,0
1,-24,hsa05218,Melanoma,M1,1,0
1,-2.9,M2847,SIRNA EIF4GI UP,M1,1,0
1,-2.5,WP4925,Unfolded protein response,M1,1,0
1,-11,WP4298,Acute viral myocarditis,M1,1,0
1,-13,WP195,IL-1 signaling pathway,M1,1,0
1,-2.5,GO:0048599,oocyte development,M1,1,0
1,-2.9,GO:0002363,alpha-beta T cell lineage commitment,M1,1,0
1,-5.2,GO:1901796,regulation of signal transduction by p53 class mediator,M1,1,0
1,-4.5,GO:0045333,cellular respiration,M1,1,0
1,-2.4,GO:0010656,negative regulation of muscle cell apoptotic process,M1,1,0
1,-16,R-HSA-389356,CD28 co-stimulation,M1,1,0
1,-3.3,GO:0006978,"DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator",M1,1,0
1,-3.9,WP474,Endochondral ossification,M1,1,0
1,-19,GO:0000904,cell morphogenesis involved in differentiation,M1,1,0
1,-2.5,GO:0005248,voltage-gated sodium channel activity,M1,1,0
1,-3,M9171,GSE40277 EOS AND LEF1 TRANSDUCED VS CTRL CD4 TCELL UP,M1,1,0
1,-2.2,M2584,KAAB HEART ATRIUM VS VENTRICLE DN,M1,1,0
1,-4.7,GO:0043125,ErbB-3 class receptor binding,M1,1,0
1,-3.9,GO:0009144,purine nucleoside triphosphate metabolic process,M1,1,0
1,-2.4,M8319,GSE28726 NAIVE VS ACTIVATED NKTCELL DN,M1,1,0
1,-3.3,GO:0098531,ligand-activated transcription factor activity,M1,1,0
1,-13,GO:0071407,cellular response to organic cyclic compound,M1,1,0
1,-2.2,GO:0007040,lysosome organization,M1,1,0
1,-3.5,M7363,ELVIDGE HYPOXIA UP,M1,1,0
1,-10,hsa04914,Progesterone-mediated oocyte maturation,M1,1,0
1,-2.5,M1436,GUO HEX TARGETS UP,M1,1,0
1,-2.7,GO:0060252,positive regulation of glial cell proliferation,M1,1,0
1,-5,GO:0061311,cell surface receptor signaling pathway involved in heart development,M1,1,0
1,-8.3,GO:1904036,negative regulation of epithelial cell apoptotic process,M1,1,0
1,-2.5,M7551,GSE21546 WT VS ELK1 KO ANTI CD3 STIM DP THYMOCYTES DN,M1,1,0
1,-29,R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",M1,1,0
1,-3.4,GO:1904707,positive regulation of vascular associated smooth muscle cell proliferation,M1,1,0
1,-10,M18811,PUJANA XPRSS INT NETWORK,M1,1,0
1,-5.1,GO:0038189,neuropilin signaling pathway,M1,1,0
1,-2.9,GO:0043020,NADPH oxidase complex,M1,1,0
1,-2.3,M15676,BECKER TAMOXIFEN RESISTANCE DN,M1,1,0
1,-4.5,GO:0003714,transcription corepressor activity,M1,1,0
1,-2.8,GO:0017080,sodium channel regulator activity,M1,1,0
1,-3,M5997,GSE411 100MIN VS 400MIN IL6 STIM MACROPHAGE UP,M1,1,0
1,-6.1,M2645,HINATA NFKB IMMU INF,M1,1,0
1,-11,GO:0045785,positive regulation of cell adhesion,M1,1,0
1,-5.8,GO:0070851,growth factor receptor binding,M1,1,0
1,-2,GO:0008514,organic anion transmembrane transporter activity,M1,1,0
1,-2.2,GO:0060606,tube closure,M1,1,0
1,-3.1,M119,PID ERB GENOMIC PATHWAY,M1,1,0
1,-19,WP69,T-cell receptor signaling pathway,M1,1,0
1,-2.8,R-HSA-3928664,Ephrin signaling,M1,1,0
1,-3.4,GO:0031098,stress-activated protein kinase signaling cascade,M1,1,0
1,-3,GO:0046320,regulation of fatty acid oxidation,M1,1,0
1,-2.6,GO:0030520,intracellular estrogen receptor signaling pathway,M1,1,0
1,-5.9,GO:0048873,homeostasis of number of cells within a tissue,M1,1,0
1,-2.9,CORUM:1099,DNA synthesome complex (17 subunits),M1,1,0
1,-8.5,WP3927,BMP signaling in eyelid development,M1,1,0
1,-12,WP236,Adipogenesis,M1,1,0
1,-2.4,M6556,GSE5679 CTRL VS RARA AGONIST AM580 TREATED DC DN,M1,1,0
1,-3,hsa05323,Rheumatoid arthritis,M1,1,0
1,-4.1,GO:2000736,regulation of stem cell differentiation,M1,1,0
1,-4.4,WP4838,Regucalcin in proximal tubule epithelial kidney cells,M1,1,0
1,-7,R-HSA-9707564,Cytoprotection by HMOX1,M1,1,0
1,-11,WP5130,Th17 cell differentiation pathway,M1,1,0
1,-2.5,M9599,GSE42021 TCONV PLN VS CD24HI TCONV THYMUS DN,M1,1,0
1,-2.7,GO:0072012,glomerulus vasculature development,M1,1,0
1,-4.1,GO:0060323,head morphogenesis,M1,1,0
1,-8.1,GO:0030879,mammary gland development,M1,1,0
1,-5.8,GO:0007224,smoothened signaling pathway,M1,1,0
1,-9.2,GO:0002252,immune effector process,M1,1,0
1,-3.2,GO:0048710,regulation of astrocyte differentiation,M1,1,0
1,-3.5,M1246,LI WILMS TUMOR VS FETAL KIDNEY 2 DN,M1,1,0
1,-2.4,M4021,GSE17721 POLYIC VS GARDIQUIMOD 4H BMDC UP,M1,1,0
1,-2.3,M12892,SMID BREAST CANCER LUMINAL B UP,M1,1,0
1,-3.3,GO:0150117,positive regulation of cell-substrate junction organization,M1,1,0
1,-3.1,GO:1904030,negative regulation of cyclin-dependent protein kinase activity,M1,1,0
1,-5.2,GO:0140352,export from cell,M1,1,0
1,-7.8,GO:0032508,DNA duplex unwinding,M1,1,0
1,-2.4,GO:0005179,hormone activity,M1,1,0
1,-2.5,GO:0003016,respiratory system process,M1,1,0
1,-5.3,M6175,CAIRO LIVER DEVELOPMENT DN,M1,1,0
1,-2.2,GO:0043368,positive T cell selection,M1,1,0
1,-4,GO:0097435,supramolecular fiber organization,M1,1,0
1,-11,GO:0033044,regulation of chromosome organization,M1,1,0
1,-5.7,M1949,MEISSNER NPC HCP WITH H3K4ME2 AND H3K27ME3,M1,1,0
1,-2.8,GO:1901617,organic hydroxy compound biosynthetic process,M1,1,0
1,-3.7,M5885,NABA MATRISOME ASSOCIATED,M1,1,0
1,-13,GO:2001020,regulation of response to DNA damage stimulus,M1,1,0
1,-5.8,GO:0006006,glucose metabolic process,M1,1,0
1,-2.3,GO:2000648,positive regulation of stem cell proliferation,M1,1,0
1,-3,M1571,YAMAZAKI TCEB3 TARGETS DN,M1,1,0
1,-4,M422,GSE9946 IMMATURE VS PROSTAGLANDINE2 TREATED MATURE DC DN,M1,1,0
1,-3,M9586,GSE42021 CD24HI VS CD24INT TREG THYMUS DN,M1,1,0
1,-2.2,GO:0044282,small molecule catabolic process,M1,1,0
1,-4.1,M1120,JOHANSSON GLIOMAGENESIS BY PDGFB UP,M1,1,0
1,-3.1,M4283,GSE18791 CTRL VS NEWCASTLE VIRUS DC 18H UP,M1,1,0
1,-4.3,M6154,MAHAJAN RESPONSE TO IL1A UP,M1,1,0
1,-24,WP4666,Hepatitis B infection,M1,1,0
1,-12,GO:0043068,positive regulation of programmed cell death,M1,1,0
1,-3.3,GO:0044409,entry into host,M1,1,0
1,-18,R-HSA-5693616,Presynaptic phase of homologous DNA pairing and strand exchange,M1,1,0
1,-12,M82,PID RET PATHWAY,M1,1,0
1,-3.1,GO:0070302,regulation of stress-activated protein kinase signaling cascade,M1,1,0
1,-9.4,GO:0072594,establishment of protein localization to organelle,M1,1,0
1,-9.3,R-HSA-177929,Signaling by EGFR,M1,1,0
1,-7.4,GO:0045309,protein phosphorylated amino acid binding,M1,1,0
1,-3.2,M134,PID TCR RAS PATHWAY,M1,1,0
1,-2.5,M4415,GSE22886 NAIVE TCELL VS NKCELL DN,M1,1,0
1,-3.1,M8326,GSE24574 BCL6 HIGH TFH VS NAIVE CD4 TCELL UP,M1,1,0
1,-7.8,GO:0010639,negative regulation of organelle organization,M1,1,0
1,-6.3,GO:0070102,interleukin-6-mediated signaling pathway,M1,1,0
1,-2.4,R-HSA-9705683,SARS-CoV-2-host interactions,M1,1,0
1,-2.5,M6514,GSE5542 UNTREATED VS IFNA TREATED EPITHELIAL CELLS 6H UP,M1,1,0
1,-7.5,R-HSA-1592230,Mitochondrial biogenesis,M1,1,0
1,-11,R-HSA-453279,Mitotic G1 phase and G1/S transition,M1,1,0
1,-29,WP4674,Head and neck squamous cell carcinoma,M1,1,0
1,-10,hsa04110,Cell cycle,M1,1,0
1,-2.5,GO:0005254,chloride channel activity,M1,1,0
1,-4.4,GO:0016447,somatic recombination of immunoglobulin gene segments,M1,1,0
1,-3.5,M18562,MANALO HYPOXIA DN,M1,1,0
1,-5.3,GO:0035861,site of double-strand break,M1,1,0
1,-2.3,GO:0046966,nuclear thyroid hormone receptor binding,M1,1,0
1,-6.6,M1831,MATZUK SPERMATOCYTE,M1,1,0
1,-2.4,M5623,GSE39820 TGFBETA1 VS TGFBETA3 IN IL6 TREATED CD4 TCELL UP,M1,1,0
1,-3.7,M9597,GSE42021 CD24INT VS CD24LOW TCONV THYMUS DN,M1,1,0
1,-3.6,WP2878,PPAR-alpha pathway,M1,1,0
1,-2.5,M7925,GSE16385 IFNG TNF VS IL4 STIM MACROPHAGE ROSIGLITAZONE TREATED DN,M1,1,0
1,-4.7,M19779,FARMER BREAST CANCER CLUSTER 6,M1,1,0
1,-3.7,M5251,GSE360 L MAJOR VS B MALAYI LOW DOSE MAC DN,M1,1,0
1,-3.3,GO:2000108,positive regulation of leukocyte apoptotic process,M1,1,0
1,-2.3,M8215,IVANOVA HEMATOPOIESIS STEM CELL AND PROGENITOR,M1,1,0
1,-3.7,M2066,WHITFIELD CELL CYCLE LITERATURE,M1,1,0
1,-4.9,GO:0046486,glycerolipid metabolic process,M1,1,0
1,-2.4,M4763,GSE27786 LSK VS MONO MAC UP,M1,1,0
1,-4.8,GO:0048857,neural nucleus development,M1,1,0
1,-6.8,WP2637,Interleukin-1 (IL-1) structural pathway,M1,1,0
1,-3.2,WP4022,Pyrimidine metabolism,M1,1,0
1,-7.5,R-HSA-912526,Interleukin receptor SHC signaling,M1,1,0
1,-2.6,GO:1902459,positive regulation of stem cell population maintenance,M1,1,0
1,-4.3,WP4880,Host-pathogen interaction of human coronaviruses - interferon induction,M1,1,0
1,-2.5,GO:0010952,positive regulation of peptidase activity,M1,1,0
1,-3.4,M18491,STEIN ESRRA TARGETS UP,M1,1,0
1,-21,R-HSA-1280215,Cytokine Signaling in Immune system,M1,1,0
1,-4.1,M6694,GSE3920 UNTREATED VS IFNB TREATED ENDOTHELIAL CELL DN,M1,1,0
1,-2.3,GO:0007043,cell-cell junction assembly,M1,1,0
1,-3.9,hsa04623,Cytosolic DNA-sensing pathway,M1,1,0
1,-5.4,M4987,KIM WT1 TARGETS 12HR DN,M1,1,0
1,-4.7,GO:0009055,electron transfer activity,M1,1,0
1,-2.5,GO:0005125,cytokine activity,M1,1,0
1,-3.2,GO:1901343,negative regulation of vasculature development,M1,1,0
1,-2.2,GO:0018393,internal peptidyl-lysine acetylation,M1,1,0
1,-3,M8113,GSE19941 UNSTIM VS LPS AND IL10 STIM IL10 KO NFKBP50 KO MACROPHAGE DN,M1,1,0
1,-6.5,GO:0097186,amelogenesis,M1,1,0
1,-4,GO:0000405,bubble DNA binding,M1,1,0
1,-2.6,GO:0051769,regulation of nitric-oxide synthase biosynthetic process,M1,1,0
1,-4.4,CORUM:435,BASC (Ab 81) complex (BRCA1-associated genome surveillance complex),M1,1,0
1,-3.8,GO:0030145,manganese ion binding,M1,1,0
1,-18,hsa05219,Bladder cancer,M1,1,0
1,-34,WP4659,Gastrin signaling pathway,M1,1,0
1,-4.3,WP4872,MAP3K1 role in promoting and blocking gonadal determination,M1,1,0
1,-5.6,GO:0051897,positive regulation of protein kinase B signaling,M1,1,0
1,-9.4,GO:0030217,T cell differentiation,M1,1,0
1,-3,M4188,GSE17974 CTRL VS ACT IL4 AND ANTI IL12 4H CD4 TCELL DN,M1,1,0
1,-2.3,M14507,CHARAFE BREAST CANCER LUMINAL VS BASAL DN,M1,1,0
1,-2.3,GO:0070169,positive regulation of biomineral tissue development,M1,1,0
1,-23,hsa05135,Yersinia infection,M1,1,0
1,-2.4,GO:0007585,respiratory gaseous exchange by respiratory system,M1,1,0
1,-4.4,GO:0006909,phagocytosis,M1,1,0
1,-3.6,M170,KOKKINAKIS METHIONINE DEPRIVATION 96HR DN,M1,1,0
1,-2,M3346,RODRIGUES NTN1 AND DCC TARGETS,M1,1,0
1,-9.1,GO:0045927,positive regulation of growth,M1,1,0
1,-2.6,M7570,GSE21927 BALBC VS C57BL6 MONOCYTE SPLEEN DN,M1,1,0
1,-6.1,GO:0002262,myeloid cell homeostasis,M1,1,0
1,-2.5,M2105,KIM ALL DISORDERS OLIGODENDROCYTE NUMBER CORR UP,M1,1,0
1,-12,GO:0097305,response to alcohol,M1,1,0
1,-3.1,GO:0051604,protein maturation,M1,1,0
1,-5.5,GO:0005267,potassium channel activity,M1,1,0
1,-2.7,R-HSA-190241,FGFR2 ligand binding and activation,M1,1,0
1,-7.3,GO:0046686,response to cadmium ion,M1,1,0
1,-19,R-HSA-5693579,Homologous DNA Pairing and Strand Exchange,M1,1,0
1,-4.1,GO:0006882,cellular zinc ion homeostasis,M1,1,0
1,-4.6,M2244,BRUINS UVC RESPONSE VIA TP53 GROUP B,M1,1,0
1,-3.2,GO:0010518,positive regulation of phospholipase activity,M1,1,0
1,-5.4,R-HSA-202424,Downstream TCR signaling,M1,1,0
1,-5.3,GO:0010827,regulation of glucose transmembrane transport,M1,1,0
1,-24,GO:0071417,cellular response to organonitrogen compound,M1,1,0
1,-4.3,M3645,DELYS THYROID CANCER UP,M1,1,0
1,-2.2,GO:0044458,motile cilium assembly,M1,1,0
1,-3.8,GO:0090109,regulation of cell-substrate junction assembly,M1,1,0
1,-4,GO:0043139,5'-3' DNA helicase activity,M1,1,0
1,-5.4,GO:1902107,positive regulation of leukocyte differentiation,M1,1,0
1,-3.5,R-HSA-351906,Apoptotic cleavage of cell adhesion  proteins,M1,1,0
1,-4.3,GO:0055086,nucleobase-containing small molecule metabolic process,M1,1,0
1,-4.3,M12602,WOO LIVER CANCER RECURRENCE UP,M1,1,0
1,-2.2,M12707,MILI PSEUDOPODIA HAPTOTAXIS UP,M1,1,0
1,-4.2,GO:0008654,phospholipid biosynthetic process,M1,1,0
1,-7.8,GO:0019216,regulation of lipid metabolic process,M1,1,0
1,-3,M5814,GSE9037 WT VS IRAK4 KO BMDM DN,M1,1,0
1,-2.4,M5582,GSE3982 EFF MEMORY CD4 TCELL VS TH2 DN,M1,1,0
1,-11,R-HSA-5693607,Processing of DNA double-strand break ends,M1,1,0
1,-2.8,WP1433,Nucleotide-binding oligomerization domain (NOD) pathway,M1,1,0
1,-5.3,GO:0030971,receptor tyrosine kinase binding,M1,1,0
1,-7.6,R-HSA-1251932,PLCG1 events in ERBB2 signaling,M1,1,0
1,-20,M193,PID NEPHRIN NEPH1 PATHWAY,M1,1,0
1,-4.4,WP399,Wnt signaling pathway and pluripotency,M1,1,0
1,-3.3,GO:0008353,RNA polymerase II CTD heptapeptide repeat kinase activity,M1,1,0
1,-2.4,M6634,GSE5589 LPS VS LPS AND IL10 STIM IL10 KO MACROPHAGE 180MIN DN,M1,1,0
1,-4.8,M18,PID INTEGRIN1 PATHWAY,M1,1,0
1,-15,R-HSA-2428928,IRS-related events triggered by IGF1R,M1,1,0
1,-3.1,M17268,SAMOLS TARGETS OF KHSV MIRNAS DN,M1,1,0
1,-18,R-HSA-9701193,Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function,M1,1,0
1,-4.9,GO:0060042,retina morphogenesis in camera-type eye,M1,1,0
1,-2.3,M5312,CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS CDC25 DN,M1,1,0
1,-2.4,M5722,GSE7764 NKCELL VS SPLENOCYTE DN,M1,1,0
1,-2.5,M4523,GSE22886 NAIVE CD4 TCELL VS 12H ACT TH1 DN,M1,1,0
1,-4.3,GO:0071773,cellular response to BMP stimulus,M1,1,0
1,-10,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M1,1,0
1,-2.4,M8986,GSE37534 GW1929 VS PIOGLITAZONE TREATED CD4 TCELL PPARG1 FOXP3 TRANSDUCED DN,M1,1,0
1,-2.1,WP727,Monoamine transport,M1,1,0
1,-11,WP3915,Angiopoietin-like protein 8 regulatory pathway,M1,1,0
1,-3.6,GO:0002703,regulation of leukocyte mediated immunity,M1,1,0
1,-2.5,GO:0034620,cellular response to unfolded protein,M1,1,0
1,-2.8,GO:0021953,central nervous system neuron differentiation,M1,1,0
1,-3.1,M360,GSE7568 CTRL VS 3H TGFB TREATED MACROPHAGES WITH IL4 AND DEXAMETHASONE UP,M1,1,0
1,-3.8,GO:0060065,uterus development,M1,1,0
1,-3.2,GO:1990776,response to angiotensin,M1,1,0
1,-2.5,M7843,GSE24210 IL35 TREATED VS RESTING TREG DN,M1,1,0
1,-2.7,GO:0070167,regulation of biomineral tissue development,M1,1,0
1,-13,GO:2001233,regulation of apoptotic signaling pathway,M1,1,0
1,-3.7,M7177,GSE17186 NAIVE VS CD21LOW TRANSITIONAL BCELL CORD BLOOD DN,M1,1,0
1,-11,WP2446,Retinoblastoma gene in cancer,M1,1,0
1,-2.6,M37,PID NFKAPPAB CANONICAL PATHWAY,M1,1,0
1,-2.2,GO:0007565,female pregnancy,M1,1,0
1,-2.5,M5867,GSE9988 LOW LPS VS CTRL TREATED MONOCYTE UP,M1,1,0
1,-2.9,WP4225,Pyrimidine metabolism and related diseases,M1,1,0
1,-2.3,M2367,PURBEY TARGETS OF CTBP1 NOT SATB1 DN,M1,1,0
1,-14,GO:0038127,ERBB signaling pathway,M1,1,0
1,-4.1,M2259,KIM GLIS2 TARGETS UP,M1,1,0
1,-3.7,M9383,GSE28737 WT VS BCL6 HET FOLLICULAR BCELL DN,M1,1,0
1,-2.6,M4077,FOURNIER ACINAR DEVELOPMENT LATE 2,M1,1,0
1,-2.5,M5384,GSE3982 MEMORY CD4 TCELL VS BCELL UP,M1,1,0
1,-2.4,M5808,GSE9037 CTRL VS LPS 1H STIM IRAK4 KO BMDM DN,M1,1,0
1,-19,GO:0033059,cellular pigmentation,M1,1,0
1,-9.1,GO:0022409,positive regulation of cell-cell adhesion,M1,1,0
1,-2.7,R-HSA-5250913,Positive epigenetic regulation of rRNA expression,M1,1,0
1,-4.6,M761,FLORIO NEOCORTEX BASAL RADIAL GLIA DN,M1,1,0
1,-12,WP2036,TNF-related weak inducer of apoptosis (TWEAK) signaling pathway,M1,1,0
1,-3.1,R-HSA-5358751,CTNNB1 S45 mutants aren't phosphorylated,M1,1,0
1,-4.5,GO:0052548,regulation of endopeptidase activity,M1,1,0
1,-3.4,M163,PID LIS1 PATHWAY,M1,1,0
1,-3.1,M1950,MEISSNER BRAIN HCP WITH H3K4ME2 AND H3K27ME3,M1,1,0
1,-6.9,GO:0097191,extrinsic apoptotic signaling pathway,M1,1,0
1,-3.2,GO:0086014,atrial cardiac muscle cell action potential,M1,1,0
1,-2.1,GO:0035967,cellular response to topologically incorrect protein,M1,1,0
1,-4.4,M10861,LI PROSTATE CANCER EPIGENETIC,M1,1,0
1,-6.1,GO:0018108,peptidyl-tyrosine phosphorylation,M1,1,0
1,-4.5,GO:0060603,mammary gland duct morphogenesis,M1,1,0
1,-4.7,CORUM:2224,MSH2/6-BLM-p53-RAD51 complex,M1,1,0
1,-6.7,M3898,ENK UV RESPONSE KERATINOCYTE DN,M1,1,0
1,-10,GO:0050863,regulation of T cell activation,M1,1,0
1,-7.4,GO:0016324,apical plasma membrane,M1,1,0
1,-2.9,GO:0070828,heterochromatin organization,M1,1,0
1,-5.9,M8377,GSE22025 UNTREATED VS PROGESTERONE TREATED CD4 TCELL UP,M1,1,0
1,-2.6,GO:0046916,cellular transition metal ion homeostasis,M1,1,0
1,-2.6,M1456,PARK HSC AND MULTIPOTENT PROGENITORS,M1,1,0
1,-2.1,GO:0045143,homologous chromosome segregation,M1,1,0
1,-2.4,GO:0010043,response to zinc ion,M1,1,0
1,-8.1,GO:0040014,regulation of multicellular organism growth,M1,1,0
1,-3.1,M9440,DUTTA APOPTOSIS VIA NFKB,M1,1,0
1,-4.4,WP3943,Robo4 and VEGF signaling pathways crosstalk,M1,1,0
1,-2.3,M2568,ALTEMEIER RESPONSE TO LPS WITH MECHANICAL VENTILATION,M1,1,0
1,-3.7,M6481,GSE4748 CTRL VS LPS STIM DC 3H DN,M1,1,0
1,-3.6,GO:0006913,nucleocytoplasmic transport,M1,1,0
1,-3.6,WP4906,3q29 copy number variation syndrome,M1,1,0
1,-3.2,GO:0016525,negative regulation of angiogenesis,M1,1,0
1,-18,GO:0010212,response to ionizing radiation,M1,1,0
1,-2.1,GO:1902624,positive regulation of neutrophil migration,M1,1,0
1,-3.1,GO:0002821,positive regulation of adaptive immune response,M1,1,0
1,-4.2,WP2942,DDX1 as a regulatory component of the Drosha microprocessor,M1,1,0
1,-2.7,M18685,ZHOU INFLAMMATORY RESPONSE LIVE UP,M1,1,0
1,-3.8,M2059,FERRANDO HOX11 NEIGHBORS,M1,1,0
1,-3.2,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M1,1,0
1,-7.9,GO:0097193,intrinsic apoptotic signaling pathway,M1,1,0
1,-3,M5257,GSE360 T GONDII VS B MALAYI LOW DOSE MAC DN,M1,1,0
1,-3.3,R-HSA-983712,Ion channel transport,M1,1,0
1,-2.4,GO:0008306,associative learning,M1,1,0
1,-19,GO:0006302,double-strand break repair,M1,1,0
1,-3.1,M9804,GSE45382 UNTREATED VS TGFB TREATED MACROPHAGES DN,M1,1,0
1,-3.8,WP5046,NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence,M1,1,0
1,-2.3,M1414,MAGRANGEAS MULTIPLE MYELOMA IGG VS IGA DN,M1,1,0
1,-30,GO:0007507,heart development,M1,1,0
1,-2.9,GO:0097479,synaptic vesicle localization,M1,1,0
1,-14,M160,PID AVB3 INTEGRIN PATHWAY,M1,1,0
1,-17,R-HSA-8939211,ESR-mediated signaling,M1,1,0
1,-7.7,hsa04670,Leukocyte transendothelial migration,M1,1,0
1,-4.3,GO:0140013,meiotic nuclear division,M1,1,0
1,-2,GO:0002833,positive regulation of response to biotic stimulus,M1,1,0
1,-5,GO:0042169,SH2 domain binding,M1,1,0
1,-9.7,GO:0010038,response to metal ion,M1,1,0
1,-2.5,M2800,RB DN.V1 UP,M1,1,0
1,-3.7,M5191,GSE360 DC VS MAC M TUBERCULOSIS DN,M1,1,0
1,-24,R-HSA-9006925,Intracellular signaling by second messengers,M1,1,0
1,-7.7,GO:0051402,neuron apoptotic process,M1,1,0
1,-2.4,M5108,GSE339 CD4POS VS CD8POS DC UP,M1,1,0
1,-4.7,R-HSA-69615,G1/S DNA Damage Checkpoints,M1,1,0
1,-2.1,M1955,MIKKELSEN MCV6 ICP WITH H3K4ME3 AND H3K27ME3,M1,1,0
1,-12,GO:0001763,morphogenesis of a branching structure,M1,1,0
1,-7.2,GO:0071480,cellular response to gamma radiation,M1,1,0
1,-2.7,M6718,GSE6092 IFNG VS IFNG AND B BURGDORFERI INF ENDOTHELIAL CELL UP,M1,1,0
1,-3,M4527,GSE22886 NAIVE CD4 TCELL VS 12H ACT TH2 DN,M1,1,0
1,-4.7,GO:1904705,regulation of vascular associated smooth muscle cell proliferation,M1,1,0
1,-4.9,WP5222,2q13 copy number variation syndrome,M1,1,0
1,-4.8,GO:0071806,protein transmembrane transport,M1,1,0
1,-6.2,GO:0060113,inner ear receptor cell differentiation,M1,1,0
1,-6.1,GO:0010907,positive regulation of glucose metabolic process,M1,1,0
1,-3.8,R-HSA-419037,NCAM1 interactions,M1,1,0
1,-2.5,M7670,GSE19401 UNSTIM VS PAM2CSK4 STIM FOLLICULAR DC UP,M1,1,0
1,-2.1,WP2884,NRF2 pathway,M1,1,0
1,-6.9,R-HSA-5655291,Signaling by FGFR4 in disease,M1,1,0
1,-9.8,GO:0086005,ventricular cardiac muscle cell action potential,M1,1,0
1,-2.8,GO:0036297,interstrand cross-link repair,M1,1,0
1,-3.3,GO:0033688,regulation of osteoblast proliferation,M1,1,0
1,-2.2,WP3858,Toll-like receptor signaling related to MyD88,M1,1,0
1,-13,GO:0006936,muscle contraction,M1,1,0
1,-2.4,M6265,GSE2585 CTEC VS MTEC THYMUS UP,M1,1,0
1,-2.4,M6955,GSE7831 UNSTIM VS INFLUENZA STIM PDC 4H UP,M1,1,0
1,-2.4,M118,PID INTEGRIN A9B1 PATHWAY,M1,1,0
1,-2.7,R-HSA-5654719,SHC-mediated cascade:FGFR4,M1,1,0
1,-13,WP2795,Cardiac hypertrophic response,M1,1,0
1,-3.7,GO:0140092,bBAF complex,M1,1,0
1,-3.3,WP5102,Familial partial lipodystrophy,M1,1,0
1,-2.7,M9005,GSE38696 LIGHT ZONE VS DARK ZONE BCELL UP,M1,1,0
1,-3.9,WP4808,Endochondral ossification with skeletal dysplasias,M1,1,0
1,-4,GO:0010310,regulation of hydrogen peroxide metabolic process,M1,1,0
1,-3.2,GO:0120305,regulation of pigmentation,M1,1,0
1,-5.3,GO:0006661,phosphatidylinositol biosynthetic process,M1,1,0
1,-4.3,M1719,LEIN CHOROID PLEXUS MARKERS,M1,1,0
1,-3.2,GO:0042772,"DNA damage response, signal transduction resulting in transcription",M1,1,0
1,-3.1,GO:0048678,response to axon injury,M1,1,0
1,-8,GO:0001933,negative regulation of protein phosphorylation,M1,1,0
1,-4.4,M5196,GSE360 L DONOVANI VS T GONDII DC DN,M1,1,0
1,-13,GO:0050878,regulation of body fluid levels,M1,1,0
1,-7.5,GO:0032835,glomerulus development,M1,1,0
1,-5.4,WP3286,Copper homeostasis,M1,1,0
1,-3,GO:1903828,negative regulation of protein localization,M1,1,0
1,-2.4,M7232,GSE19198 1H VS 6H IL21 TREATED TCELL DN,M1,1,0
1,-18,hsa03440,Homologous recombination,M1,1,0
1,-5.5,GO:0045637,regulation of myeloid cell differentiation,M1,1,0
1,-4.7,GO:0031954,positive regulation of protein autophosphorylation,M1,1,0
1,-10,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M1,1,0
1,-2.3,M14036,TONKS TARGETS OF RUNX1 RUNX1T1 FUSION MONOCYTE DN,M1,1,0
1,-2.2,GO:0008045,motor neuron axon guidance,M1,1,0
1,-3.9,M14555,ZHU CMV ALL DN,M1,1,0
1,-8.2,GO:0032102,negative regulation of response to external stimulus,M1,1,0
1,-2.7,GO:0061333,renal tubule morphogenesis,M1,1,0
1,-2.3,R-HSA-5250924,B-WICH complex positively regulates rRNA expression,M1,1,0
1,-2.5,GO:0002347,response to tumor cell,M1,1,0
1,-2,GO:1904377,positive regulation of protein localization to cell periphery,M1,1,0
1,-2.5,M5548,GSE3982 BCELL VS NKCELL DN,M1,1,0
1,-2.3,GO:0043122,regulation of I-kappaB kinase/NF-kappaB signaling,M1,1,0
1,-4.8,GO:0045580,regulation of T cell differentiation,M1,1,0
1,-3.5,CORUM:2948,"Respiratory chain complex I (incomplete intermediate), mitochondrial",M1,1,0
1,-9.9,WP3995,Prion disease pathway,M1,1,0
1,-2.2,M336,VILLANUEVA LIVER CANCER KRT19 UP,M1,1,0
1,-2.2,R-HSA-8866654,E3 ubiquitin ligases ubiquitinate target proteins,M1,1,0
1,-2.7,GO:0051602,response to electrical stimulus,M1,1,0
1,-2.2,M11472,RIZKI TUMOR INVASIVENESS 3D DN,M1,1,0
1,-2.7,M14636,OUYANG PROSTATE CANCER PROGRESSION DN,M1,1,0
1,-4.9,GO:0030003,cellular cation homeostasis,M1,1,0
1,-2.1,GO:0031102,neuron projection regeneration,M1,1,0
1,-9.6,R-HSA-69231,Cyclin D associated events in G1,M1,1,0
1,-3.7,GO:0032291,axon ensheathment in central nervous system,M1,1,0
1,-2.5,M6015,GSE2770 UNTREATED VS TGFB AND IL4 TREATED ACT CD4 TCELL 2H DN,M1,1,0
1,-14,GO:0070925,organelle assembly,M1,1,0
1,-2.5,M18855,VECCHI GASTRIC CANCER EARLY UP,M1,1,0
1,-4.4,WP363,Wnt signaling pathway,M1,1,0
1,-6,GO:0010828,positive regulation of glucose transmembrane transport,M1,1,0
1,-12,GO:0060485,mesenchyme development,M1,1,0
1,-2.8,GO:1902176,negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,M1,1,0
1,-30,hsa04068,FoxO signaling pathway,M1,1,0
1,-2.9,GO:0045922,negative regulation of fatty acid metabolic process,M1,1,0
1,-5.4,GO:0019318,hexose metabolic process,M1,1,0
1,-11,M187,PID TRKR PATHWAY,M1,1,0
1,-3.5,R-HSA-9634285,Constitutive Signaling by Overexpressed ERBB2,M1,1,0
1,-12,GO:0043574,peroxisomal transport,M1,1,0
1,-9.1,WP4829,mBDNF and proBDNF regulation of GABA neurotransmission,M1,1,0
1,-9.6,GO:0061564,axon development,M1,1,0
1,-5.5,WP722,Serotonin HTR1 group and FOS pathway,M1,1,0
1,-6.7,GO:0033146,regulation of intracellular estrogen receptor signaling pathway,M1,1,0
1,-2.7,GO:0055083,monovalent inorganic anion homeostasis,M1,1,0
1,-4.6,GO:0034703,cation channel complex,M1,1,0
1,-2.2,M10279,HORIUCHI WTAP TARGETS DN,M1,1,0
1,-3.5,M1865,WANG TUMOR INVASIVENESS UP,M1,1,0
1,-4.7,GO:1990782,protein tyrosine kinase binding,M1,1,0
1,-3.7,GO:0060491,regulation of cell projection assembly,M1,1,0
1,-4.4,GO:2000142,regulation of DNA-templated transcription initiation,M1,1,0
1,-7,R-HSA-450294,MAP kinase activation,M1,1,0
1,-11,GO:0031570,DNA integrity checkpoint signaling,M1,1,0
1,-2.9,M4995,LINDGREN BLADDER CANCER CLUSTER 2B,M1,1,0
1,-3,GO:0003176,aortic valve development,M1,1,0
1,-3.3,GO:0016788,"hydrolase activity, acting on ester bonds",M1,1,0
1,-4.2,GO:0044320,cellular response to leptin stimulus,M1,1,0
1,-8.8,GO:0051251,positive regulation of lymphocyte activation,M1,1,0
1,-6.7,GO:0071774,response to fibroblast growth factor,M1,1,0
1,-3,M7259,GSE18281 PERIMEDULLARY CORTICAL REGION VS WHOLE MEDULLA THYMUS UP,M1,1,0
1,-4.8,WP4329,miRNAs involvement in the immune response in sepsis,M1,1,0
1,-5.2,hsa05202,Transcriptional misregulation in cancer,M1,1,0
1,-2.7,GO:0001832,blastocyst growth,M1,1,0
1,-7,M8626,SIG BCR SIGNALING PATHWAY,M1,1,0
1,-10,GO:0071241,cellular response to inorganic substance,M1,1,0
1,-3.7,GO:0022010,central nervous system myelination,M1,1,0
1,-3.2,GO:0007612,learning,M1,1,0
1,-2.1,M7536,GSE21546 UNSTIM VS ANTI CD3 STIM SAP1A KO DP THYMOCYTES DN,M1,1,0
1,-2.5,M5103,YAGI AML FAB MARKERS,M1,1,0
1,-4.4,R-HSA-9634635,Estrogen-stimulated signaling through PRKCZ,M1,1,0
1,-3.1,M9747,GSE43863 DAY6 EFF VS DAY150 MEM TFH CD4 TCELL DN,M1,1,0
1,-6.3,M29,SHEN SMARCA2 TARGETS UP,M1,1,0
1,-14,WP366,TGF-beta signaling pathway,M1,1,0
1,-3.7,M8418,GSE29949 DC BRAIN VS MONOCYTE BONE MARROW UP,M1,1,0
1,-10,hsa05164,Influenza A,M1,1,0
1,-4.1,GO:1903053,regulation of extracellular matrix organization,M1,1,0
1,-6.1,GO:0045121,membrane raft,M1,1,0
1,-2,GO:0042887,amide transmembrane transporter activity,M1,1,0
1,-2.7,GO:1904894,positive regulation of receptor signaling pathway via STAT,M1,1,0
1,-2.1,GO:1901981,phosphatidylinositol phosphate binding,M1,1,0
1,-4.4,M3446,GSE1460 INTRATHYMIC T PROGENITOR VS NAIVE CD4 TCELL ADULT BLOOD UP,M1,1,0
1,-3.4,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M1,1,0
1,-4.5,GO:0060602,branch elongation of an epithelium,M1,1,0
1,-3.7,M5144,GSE360 CTRL VS L DONOVANI DC DN,M1,1,0
1,-3.7,M5838,GSE9650 EXHAUSTED VS MEMORY CD8 TCELL UP,M1,1,0
1,-2.4,M2804,HAHTOLA CTCL CUTANEOUS,M1,1,0
1,-3.7,M5247,GSE360 L MAJOR VS B MALAYI HIGH DOSE MAC UP,M1,1,0
1,-3.3,GO:0051702,biological process involved in interaction with symbiont,M1,1,0
1,-3.6,GO:0033108,mitochondrial respiratory chain complex assembly,M1,1,0
1,-5.9,GO:0003955,NAD(P)H dehydrogenase (quinone) activity,M1,1,0
1,-12,WP49,IL-2 signaling pathway,M1,1,0
1,-11,M285,PID HNF3A PATHWAY,M1,1,0
1,-4.2,M2257,SONG TARGETS OF IE86 CMV PROTEIN,M1,1,0
1,-7.5,GO:0090068,positive regulation of cell cycle process,M1,1,0
1,-3.9,GO:0004520,endodeoxyribonuclease activity,M1,1,0
1,-2,GO:0014904,myotube cell development,M1,1,0
1,-3.7,M8332,GSE24574 BCL6 LOW TFH VS TCONV CD4 TCELL DN,M1,1,0
1,-3.2,R-HSA-216083,Integrin cell surface interactions,M1,1,0
1,-3.2,WP5265,Neurogenesis regulation in the olfactory epithelium,M1,1,0
1,-4.2,R-HSA-3214858,RMTs methylate histone arginines,M1,1,0
1,-2.4,GO:0031103,axon regeneration,M1,1,0
1,-3.7,GO:0010171,body morphogenesis,M1,1,0
1,-9.8,R-HSA-2172127,DAP12 interactions,M1,1,0
1,-2.6,M13944,GOZGIT ESR1 TARGETS UP,M1,1,0
1,-6.2,GO:0016444,somatic cell DNA recombination,M1,1,0
1,-3.4,WP5191,Resolvin E1 and resolvin D1 signaling pathways promoting inflammation resolution,M1,1,0
1,-13,M237,PID VEGFR1 2 PATHWAY,M1,1,0
1,-3.9,GO:0051591,response to cAMP,M1,1,0
1,-5.3,GO:0035850,epithelial cell differentiation involved in kidney development,M1,1,0
1,-15,GO:0060249,anatomical structure homeostasis,M1,1,0
1,-3.2,GO:0050796,regulation of insulin secretion,M1,1,0
1,-2.5,M2724,MEK UP.V1 DN,M1,1,0
1,-2.2,GO:0010464,regulation of mesenchymal cell proliferation,M1,1,0
1,-23,hsa04919,Thyroid hormone signaling pathway,M1,1,0
1,-3.1,GO:0046700,heterocycle catabolic process,M1,1,0
1,-10,R-HSA-5654743,Signaling by FGFR4,M1,1,0
1,-14,GO:2000147,positive regulation of cell motility,M1,1,0
1,-30,M175,PID ERBB2 ERBB3 PATHWAY,M1,1,0
1,-4.1,GO:0001755,neural crest cell migration,M1,1,0
1,-3.8,GO:1990840,response to lectin,M1,1,0
1,-2.4,M6959,GSE7831 CPG VS INFLUENZA STIM PDC 4H DN,M1,1,0
1,-3.3,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M1,1,0
1,-3.3,M5149,MARTINELLI IMMATURE NEUTROPHIL DN,M1,1,0
1,-5.3,GO:0070374,positive regulation of ERK1 and ERK2 cascade,M1,1,0
1,-2.8,M8779,LI LUNG CANCER,M1,1,0
1,-2.2,GO:0009266,response to temperature stimulus,M1,1,0
1,-3.3,GO:0045815,epigenetic maintenance of chromatin in transcription-competent conformation,M1,1,0
1,-13,GO:0048638,regulation of developmental growth,M1,1,0
1,-6.5,GO:0050768,negative regulation of neurogenesis,M1,1,0
1,-10,GO:0044782,cilium organization,M1,1,0
1,-2.3,M2010,MIKKELSEN NPC HCP WITH H3K4ME3 AND H3K27ME3,M1,1,0
1,-3.1,R-HSA-5358747,CTNNB1 S33 mutants aren't phosphorylated,M1,1,0
1,-3.5,GO:0015986,proton motive force-driven ATP synthesis,M1,1,0
1,-6.5,GO:0032355,response to estradiol,M1,1,0
1,-7.9,WP1528,Physiological and pathological hypertrophy of the heart,M1,1,0
1,-9.7,GO:2000045,regulation of G1/S transition of mitotic cell cycle,M1,1,0
1,-3.2,GO:0034504,protein localization to nucleus,M1,1,0
1,-3.9,WP3298,Melatonin metabolism and effects,M1,1,0
1,-4.6,hsa03420,Nucleotide excision repair,M1,1,0
1,-2.8,M3284,KUMAR TARGETS OF MLL AF9 FUSION,M1,1,0
1,-5.8,hsa04973,Carbohydrate digestion and absorption,M1,1,0
1,-4.7,GO:0010971,positive regulation of G2/M transition of mitotic cell cycle,M1,1,0
1,-11,GO:0016773,"phosphotransferase activity, alcohol group as acceptor",M1,1,0
1,-5.1,M7041,GSE15330 GRANULOCYTE MONOCYTE PROGENITOR VS PRO BCELL UP,M1,1,0
1,-2.1,hsa03250,Viral life cycle - HIV-1,M1,1,0
1,-3.6,GO:0009582,detection of abiotic stimulus,M1,1,0
1,-5.1,WP4585,Cancer immunotherapy by PD-1 blockade,M1,1,0
1,-8.5,R-HSA-9711123,Cellular response to chemical stress,M1,1,0
1,-20,M11563,KAUFFMANN DNA REPAIR GENES,M1,1,0
1,-3.9,GO:0030509,BMP signaling pathway,M1,1,0
1,-3,M7976,GSE25123 CTRL VS IL4 STIM PPARG KO MACROPHAGE DN,M1,1,0
1,-6.7,R-HSA-389359,CD28 dependent Vav1 pathway,M1,1,0
1,-3,M6406,GSE8921 UNSTIM 0H VS TLR1 2 STIM MONOCYTE 12H UP,M1,1,0
1,-18,GO:0080135,regulation of cellular response to stress,M1,1,0
1,-4.4,CORUM:2817,BRCA1-BARD1-BACH1-DNA damage complex I,M1,1,0
1,-7.8,R-HSA-1643713,Signaling by EGFR in Cancer,M1,1,0
1,-15,WP127,IL-5 signaling pathway,M1,1,0
1,-3.6,GO:1904950,negative regulation of establishment of protein localization,M1,1,0
1,-10,GO:0086091,regulation of heart rate by cardiac conduction,M1,1,0
1,-4.4,WP2253,Pilocytic astrocytoma,M1,1,0
1,-5.2,GO:0002437,inflammatory response to antigenic stimulus,M1,1,0
1,-5,GO:0000082,G1/S transition of mitotic cell cycle,M1,1,0
1,-3.5,hsa00562,Inositol phosphate metabolism,M1,1,0
1,-2.2,GO:0001099,basal RNA polymerase II transcription machinery binding,M1,1,0
1,-5.5,R-HSA-2559585,Oncogene Induced Senescence,M1,1,0
1,-3.3,WP5224,2q37 copy number variation syndrome,M1,1,0
1,-2.4,GO:2000773,negative regulation of cellular senescence,M1,1,0
1,-2.8,GO:0072088,nephron epithelium morphogenesis,M1,1,0
1,-2,R-HSA-8856828,Clathrin-mediated endocytosis,M1,1,0
1,-6.2,GO:0030183,B cell differentiation,M1,1,0
1,-6.2,WP5115,Network map of SARS-CoV-2 signaling pathway,M1,1,0
1,-7.2,GO:0010720,positive regulation of cell development,M1,1,0
1,-3.5,R-HSA-354192,Integrin signaling,M1,1,0
1,-2.6,GO:0048169,regulation of long-term neuronal synaptic plasticity,M1,1,0
1,-4.9,GO:0060487,lung epithelial cell differentiation,M1,1,0
1,-3.1,R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,M1,1,0
1,-2.7,M8591,GSE27859 CD11C INT F480 HI MACROPHAGE VS CD11C ING F480 INT DC UP,M1,1,0
1,-2.4,GO:0098800,inner mitochondrial membrane protein complex,M1,1,0
1,-4.6,GO:0099537,trans-synaptic signaling,M1,1,0
1,-3.8,GO:0008625,extrinsic apoptotic signaling pathway via death domain receptors,M1,1,0
1,-3.3,GO:0030510,regulation of BMP signaling pathway,M1,1,0
1,-3.1,M6226,GSE22601 DOUBLE NEGATIVE VS DOUBLE POSITIVE THYMOCYTE UP,M1,1,0
1,-3.5,GO:0032836,glomerular basement membrane development,M1,1,0
1,-4.6,GO:0045834,positive regulation of lipid metabolic process,M1,1,0
1,-2.4,R-HSA-5619507,Activation of HOX genes during differentiation,M1,1,0
1,-2.6,GO:1905818,regulation of chromosome separation,M1,1,0
1,-6.4,R-HSA-6783589,Interleukin-6 family signaling,M1,1,0
1,-2.8,GO:0030858,positive regulation of epithelial cell differentiation,M1,1,0
1,-11,hsa05010,Alzheimer disease,M1,1,0
1,-3.6,GO:1902476,chloride transmembrane transport,M1,1,0
1,-11,GO:0042476,odontogenesis,M1,1,0
1,-12,R-HSA-194138,Signaling by VEGF,M1,1,0
1,-2,M130,FISCHER G2 M CELL CYCLE,M1,1,0
1,-3.9,GO:0043296,apical junction complex,M1,1,0
1,-6.8,GO:0042461,photoreceptor cell development,M1,1,0
1,-6.6,GO:0002683,negative regulation of immune system process,M1,1,0
1,-4.8,M28,PID IL4 2PATHWAY,M1,1,0
1,-3.2,M1666,BURTON ADIPOGENESIS 9,M1,1,0
1,-2.2,hsa00190,Oxidative phosphorylation,M1,1,0
1,-3.7,R-HSA-982772,Growth hormone receptor signaling,M1,1,0
1,-8,WP4582,Cancer immunotherapy by CTLA4 blockade,M1,1,0
1,-5.1,CORUM:202,BRCA1-RAD50-MRE11-NBS1 complex,M1,1,0
1,-3.8,WP3624,Lung fibrosis,M1,1,0
1,-3.6,GO:1904996,positive regulation of leukocyte adhesion to vascular endothelial cell,M1,1,0
1,-19,hsa05211,Renal cell carcinoma,M1,1,0
1,-2.4,GO:0007140,male meiotic nuclear division,M1,1,0
1,-2.6,GO:0000242,pericentriolar material,M1,1,0
1,-6.9,WP4018,Clear cell renal cell carcinoma pathways,M1,1,0
1,-2.2,GO:0045638,negative regulation of myeloid cell differentiation,M1,1,0
1,-3.9,GO:0043618,regulation of transcription from RNA polymerase II promoter in response to stress,M1,1,0
1,-3.1,M8380,GSE22025 TGFB1 VS TGFB1 AND PROGESTERONE TREATED CD4 TCELL UP,M1,1,0
1,-7.8,GO:0010721,negative regulation of cell development,M1,1,0
1,-10,R-HSA-166166,MyD88-independent TLR4 cascade,M1,1,0
1,-5.7,GO:0036294,cellular response to decreased oxygen levels,M1,1,0
1,-14,GO:0048545,response to steroid hormone,M1,1,0
1,-2.8,M10480,GU PDEF TARGETS DN,M1,1,0
1,-7.2,GO:0003018,vascular process in circulatory system,M1,1,0
1,-5.4,GO:1903708,positive regulation of hemopoiesis,M1,1,0
1,-9.9,GO:2001236,regulation of extrinsic apoptotic signaling pathway,M1,1,0
1,-2.4,M4948,GSE29618 MONOCYTE VS MDC UP,M1,1,0
1,-11,GO:1900182,positive regulation of protein localization to nucleus,M1,1,0
1,-2.4,GO:1901985,positive regulation of protein acetylation,M1,1,0
1,-2.4,GO:0051894,positive regulation of focal adhesion assembly,M1,1,0
1,-5.8,GO:0030545,signaling receptor regulator activity,M1,1,0
1,-19,hsa05142,Chagas disease,M1,1,0
1,-3.9,M2848,HOXA9 DN.V1 DN,M1,1,0
1,-4.4,GO:0001913,T cell mediated cytotoxicity,M1,1,0
1,-11,M12313,KOKKINAKIS METHIONINE DEPRIVATION 96HR UP,M1,1,0
1,-2.5,GO:0030295,protein kinase activator activity,M1,1,0
1,-2.4,M9122,GSE40274 FOXP3 VS FOXP3 AND EOS TRANSDUCED ACTIVATED CD4 TCELL DN,M1,1,0
1,-6.6,M9410,GSE39556 UNTREATED VS 3H POLYIC INJ MOUSE NK CELL UP,M1,1,0
1,-4.5,hsa05016,Huntington disease,M1,1,0
1,-2.9,M8937,GSE37532 TREG VS TCONV CD4 TCELL FROM VISCERAL ADIPOSE TISSUE DN,M1,1,0
1,-11,GO:0022404,molting cycle process,M1,1,0
1,-6,GO:0032104,regulation of response to extracellular stimulus,M1,1,0
1,-2.9,GO:0007369,gastrulation,M1,1,0
1,-2.1,hsa03410,Base excision repair,M1,1,0
1,-2,GO:0080008,Cul4-RING E3 ubiquitin ligase complex,M1,1,0
1,-3.1,M2698,P53 DN.V1 UP,M1,1,0
1,-2.1,GO:0010977,negative regulation of neuron projection development,M1,1,0
1,-3.4,M2009,MIKKELSEN NPC HCP WITH H3K27ME3,M1,1,0
1,-25,WP673,ErbB signaling pathway,M1,1,0
1,-6.6,R-HSA-448424,Interleukin-17 signaling,M1,1,0
1,-2.5,M7255,GSE18281 SUBCAPSULAR CORTICAL REGION VS WHOLE MEDULLA THYMUS DN,M1,1,0
1,-2.3,M6332,GSE3565 DUSP1 VS WT SPLENOCYTES POST LPS INJECTION UP,M1,1,0
1,-2.7,M2273,ZHU SKIL TARGETS UP,M1,1,0
1,-4,M6641,BROWNE HCMV INFECTION 18HR DN,M1,1,0
1,-4.3,GO:0045778,positive regulation of ossification,M1,1,0
1,-5.3,GO:0009755,hormone-mediated signaling pathway,M1,1,0
1,-3.2,R-HSA-1251985,Nuclear signaling by ERBB4,M1,1,0
1,-3.4,M2573,LIM MAMMARY STEM CELL UP,M1,1,0
1,-2,GO:0030888,regulation of B cell proliferation,M1,1,0
1,-4.8,R-HSA-6782210,Gap-filling DNA repair synthesis and ligation in TC-NER,M1,1,0
1,-5.9,GO:0006754,ATP biosynthetic process,M1,1,0
1,-6.9,GO:0048538,thymus development,M1,1,0
1,-5.8,GO:0006873,cellular ion homeostasis,M1,1,0
1,-2.5,M12391,DAUER STAT3 TARGETS UP,M1,1,0
1,-3.6,GO:0055010,ventricular cardiac muscle tissue morphogenesis,M1,1,0
1,-6.7,R-HSA-5655332,Signaling by FGFR3 in disease,M1,1,0
1,-2.8,GO:0010762,regulation of fibroblast migration,M1,1,0
1,-2.8,GO:0150077,regulation of neuroinflammatory response,M1,1,0
1,-4.4,M7651,GSE22140 HEALTHY VS ARTHRITIC MOUSE CD4 TCELL DN,M1,1,0
1,-14,M6752,TENEDINI MEGAKARYOCYTE MARKERS,M1,1,0
1,-2.6,GO:0032890,regulation of organic acid transport,M1,1,0
1,-3.7,GO:0006644,phospholipid metabolic process,M1,1,0
1,-2.4,GO:0010662,regulation of striated muscle cell apoptotic process,M1,1,0
1,-2,GO:1902742,apoptotic process involved in development,M1,1,0
1,-3,M8569,GSE26030 UNSTIM VS RESTIM TH1 DAY15 POST POLARIZATION UP,M1,1,0
1,-2.4,R-HSA-392451,G beta:gamma signalling through PI3Kgamma,M1,1,0
1,-5,GO:0003264,regulation of cardioblast proliferation,M1,1,0
1,-3.2,GO:0002758,innate immune response-activating signal transduction,M1,1,0
1,-12,GO:1901654,response to ketone,M1,1,0
1,-3.8,R-HSA-388396,GPCR downstream signalling,M1,1,0
1,-2.8,GO:0016064,immunoglobulin mediated immune response,M1,1,0
1,-6.7,GO:0003143,embryonic heart tube morphogenesis,M1,1,0
1,-7,GO:0001558,regulation of cell growth,M1,1,0
1,-16,R-HSA-9669938,Signaling by KIT in disease,M1,1,0
1,-3.1,GO:0032212,positive regulation of telomere maintenance via telomerase,M1,1,0
1,-3.7,M8567,GSE26030 UNSTIM VS RESTIM TH1 DAY5 POST POLARIZATION UP,M1,1,0
1,-3.4,M7725,GSE21033 1H VS 12H POLYIC STIM DC UP,M1,1,0
1,-3.7,CORUM:808,BRM-associated complex,M1,1,0
1,-2.2,M4308,SATO SILENCED BY METHYLATION IN PANCREATIC CANCER 1,M1,1,0
1,-2.1,GO:0051651,maintenance of location in cell,M1,1,0
1,-3,M8690,GSE34156 NOD2 LIGAND VS TLR1 TLR2 LIGAND 6H TREATED MONOCYTE UP,M1,1,0
1,-15,GO:0040008,regulation of growth,M1,1,0
1,-3.2,hsa05134,Legionellosis,M1,1,0
1,-3.7,GO:0002360,T cell lineage commitment,M1,1,0
1,-2.4,M4056,GSE17721 LPS VS GARDIQUIMOD 8H BMDC UP,M1,1,0
1,-3.3,M1612,BURTON ADIPOGENESIS 1,M1,1,0
1,-4.4,M9687,GSE43955 10H VS 60H ACT CD4 TCELL WITH TGFB IL6 DN,M1,1,0
1,-3.2,GO:0003229,ventricular cardiac muscle tissue development,M1,1,0
1,-5,GO:0072710,response to hydroxyurea,M1,1,0
1,-2.5,M6338,GSE3720 UNSTIM VS LPS STIM VD2 GAMMADELTA TCELL DN,M1,1,0
1,-14,M184,PID ECADHERIN KERATINOCYTE PATHWAY,M1,1,0
1,-2.4,R-HSA-110373,Resolution of AP sites via the multiple-nucleotide patch replacement pathway,M1,1,0
1,-4,M3155,GRAHAM CML DIVIDING VS NORMAL QUIESCENT UP,M1,1,0
1,-2.3,GO:0030968,endoplasmic reticulum unfolded protein response,M1,1,0
1,-3.1,M8431,GSE23321 CENTRAL MEMORY VS NAIVE CD8 TCELL DN,M1,1,0
1,-2.7,GO:0045911,positive regulation of DNA recombination,M1,1,0
1,-3,M5206,GSE360 L DONOVANI VS M TUBERCULOSIS DC DN,M1,1,0
1,-4.5,GO:0044291,cell-cell contact zone,M1,1,0
1,-5,hsa05022,Pathways of neurodegeneration - multiple diseases,M1,1,0
1,-6.7,R-HSA-5685939,HDR through MMEJ (alt-NHEJ),M1,1,0
1,-2.1,GO:0080164,regulation of nitric oxide metabolic process,M1,1,0
1,-3.5,GO:2000737,negative regulation of stem cell differentiation,M1,1,0
1,-5.9,GO:0097485,neuron projection guidance,M1,1,0
1,-3.4,GO:0090102,cochlea development,M1,1,0
1,-2,CORUM:3055,Nop56p-associated pre-rRNA complex,M1,1,0
1,-3.7,GO:0014824,artery smooth muscle contraction,M1,1,0
1,-2.7,GO:0042789,mRNA transcription by RNA polymerase II,M1,1,0
1,-6,GO:0032881,regulation of polysaccharide metabolic process,M1,1,0
1,-6.7,R-HSA-210990,PECAM1 interactions,M1,1,0
1,-3.2,GO:0031397,negative regulation of protein ubiquitination,M1,1,0
1,-24,WP306,Focal adhesion,M1,1,0
1,-5.5,GO:0007005,mitochondrion organization,M1,1,0
1,-2.8,GO:0031093,platelet alpha granule lumen,M1,1,0
1,-9.8,hsa04360,Axon guidance,M1,1,0
1,-6.6,GO:0035176,social behavior,M1,1,0
1,-2.4,M2218,BOYAULT LIVER CANCER SUBCLASS G123 DN,M1,1,0
1,-5.3,GO:0060768,regulation of epithelial cell proliferation involved in prostate gland development,M1,1,0
1,-13,GO:0086003,cardiac muscle cell contraction,M1,1,0
1,-7.2,M17115,SCHEIDEREIT IKK TARGETS,M1,1,0
1,-4.1,GO:1903320,regulation of protein modification by small protein conjugation or removal,M1,1,0
1,-9.2,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M1,1,0
1,-2.3,M5888,RASHI RESPONSE TO IONIZING RADIATION 2,M1,1,0
1,-4,GO:0001505,regulation of neurotransmitter levels,M1,1,0
1,-3.1,M7319,GSE19888 ADENOSINE A3R ACT VS TCELL MEMBRANES ACT AND A3R INH PRETREAT IN MAST CELL DN,M1,1,0
1,-13,WP51,Regulation of actin cytoskeleton,M1,1,0
1,-2.1,GO:0035909,aorta morphogenesis,M1,1,0
1,-2.5,M11064,HALMOS CEBPA TARGETS UP,M1,1,0
1,-4,GO:1905276,regulation of epithelial tube formation,M1,1,0
1,-2.3,GO:0004693,cyclin-dependent protein serine/threonine kinase activity,M1,1,0
1,-3.5,WP4312,Rett syndrome causing genes,M1,1,0
1,-3.6,M1597,BURTON ADIPOGENESIS PEAK AT 2HR,M1,1,0
1,-9.5,GO:0035108,limb morphogenesis,M1,1,0
1,-9.8,GO:0032401,establishment of melanosome localization,M1,1,0
1,-4.3,GO:0033032,regulation of myeloid cell apoptotic process,M1,1,0
1,-3.7,M1928,MIKKELSEN PARTIALLY REPROGRAMMED TO PLURIPOTENCY,M1,1,0
1,-2.9,CORUM:7581,ESR1-TRAP/Mediator coactivator-complex,M1,1,0
1,-2.1,R-HSA-5576892,Phase 0 - rapid depolarisation,M1,1,0
1,-3,M2520,RAO BOUND BY SALL4 ISOFORM B,M1,1,0
1,-11,M281,PID FAK PATHWAY,M1,1,0
1,-3.1,M5217,GSE360 T GONDII VS B MALAYI LOW DOSE DC UP,M1,1,0
1,-3.4,R-HSA-5688426,Deubiquitination,M1,1,0
1,-6,GO:0060828,regulation of canonical Wnt signaling pathway,M1,1,0
1,-3.7,M9922,GSE41176 UNSTIM VS ANTI IGM STIM BCELL 6H UP,M1,1,0
1,-32,WP4262,Breast cancer pathway,M1,1,0
1,-2,M8244,BROCKE APOPTOSIS REVERSED BY IL6,M1,1,0
1,-4.1,GO:2000136,regulation of cell proliferation involved in heart morphogenesis,M1,1,0
1,-5.3,CORUM:238,SWI-SNF chromatin remodeling-related-BRCA1 complex,M1,1,0
1,-2.4,M2110,KIM ALL DISORDERS CALB1 CORR UP,M1,1,0
1,-2.8,GO:1902305,regulation of sodium ion transmembrane transport,M1,1,0
1,-3.4,GO:0001325,formation of extrachromosomal circular DNA,M1,1,0
1,-5.3,CORUM:6247,BBS-chaperonin complex,M1,1,0
1,-9.8,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M1,1,0
1,-2.5,R-HSA-9663891,Selective autophagy,M1,1,0
1,-2,M6738,GSE6259 CD4 TCELL VS CD8 TCELL UP,M1,1,0
1,-5.1,M7707,GSE20500 CTRL VS RARA ANTAGONIST TREATED CD4 TCELL DN,M1,1,0
1,-7.2,GO:0050727,regulation of inflammatory response,M1,1,0
1,-11,GO:0006979,response to oxidative stress,M1,1,0
1,-22,GO:0032870,cellular response to hormone stimulus,M1,1,0
1,-3.1,R-HSA-111447,Activation of BAD and translocation to mitochondria,M1,1,0
1,-3.2,M16189,BERENJENO TRANSFORMED BY RHOA UP,M1,1,0
1,-5.4,GO:0034767,positive regulation of ion transmembrane transport,M1,1,0
1,-2.6,R-HSA-9649948,Signaling downstream of RAS mutants,M1,1,0
1,-3.8,R-HSA-198753,ERK/MAPK targets,M1,1,0
1,-6,M1387,SHIN B CELL LYMPHOMA CLUSTER 3,M1,1,0
1,-4,GO:0016331,morphogenesis of embryonic epithelium,M1,1,0
1,-2.5,GO:0061053,somite development,M1,1,0
1,-3,M7752,GSE22935 UNSTIM VS 12H MBOVIS BCG STIM MACROPHAGE UP,M1,1,0
1,-4.7,GO:0002052,positive regulation of neuroblast proliferation,M1,1,0
1,-7.4,GO:0097306,cellular response to alcohol,M1,1,0
1,-25,GO:0035239,tube morphogenesis,M1,1,0
1,-3.5,GO:0030100,regulation of endocytosis,M1,1,0
1,-2.5,M8180,SAKAI TUMOR INFILTRATING MONOCYTES DN,M1,1,0
1,-6.9,GO:2000134,negative regulation of G1/S transition of mitotic cell cycle,M1,1,0
1,-4.8,M17079,VECCHI GASTRIC CANCER ADVANCED VS EARLY UP,M1,1,0
1,-6.5,WP4919,Neuroinflammation,M1,1,0
1,-2.5,M34034,DESERT STEM CELL HEPATOCELLULAR CARCINOMA SUBCLASS UP,M1,1,0
1,-14,R-HSA-114604,GPVI-mediated activation cascade,M1,1,0
1,-6.3,GO:0000722,telomere maintenance via recombination,M1,1,0
1,-2,M8231,HEIDENBLAD AMPLICON 12P11 12 UP,M1,1,0
1,-4.7,R-HSA-170834,Signaling by TGF-beta Receptor Complex,M1,1,0
1,-4.9,M9946,LU TUMOR ANGIOGENESIS UP,M1,1,0
1,-3,GO:0072378,"blood coagulation, fibrin clot formation",M1,1,0
1,-5.1,M7683,GSE20152 SPHK1 KO VS HTNFA OVEREXPRESS ANKLE DN,M1,1,0
1,-15,GO:0019900,kinase binding,M1,1,0
1,-8,GO:0001889,liver development,M1,1,0
1,-2.9,GO:0010965,regulation of mitotic sister chromatid separation,M1,1,0
1,-2.9,GO:0033151,V(D)J recombination,M1,1,0
1,-3.2,GO:0044106,cellular amine metabolic process,M1,1,0
1,-2.4,M9051,GSE34006 A2AR KO VS A2AR AGONIST TREATED TREG UP,M1,1,0
1,-5.8,M5101,GSE3337 CTRL VS 16H IFNG IN CD8POS DC DN,M1,1,0
1,-2.4,M5506,GSE3982 MAC VS CENT MEMORY CD4 TCELL UP,M1,1,0
1,-6.5,R-HSA-1660499,Synthesis of PIPs at the plasma membrane,M1,1,0
1,-3.1,M1453,NADLER HYPERGLYCEMIA AT OBESITY,M1,1,0
1,-3.8,CORUM:566,BAF complex,M1,1,0
1,-6.6,M8389,GSE29949 MICROGLIA BRAIN VS MONOCYTE BONE MARROW DN,M1,1,0
1,-2,GO:0002228,natural killer cell mediated immunity,M1,1,0
1,-5.9,GO:0002067,glandular epithelial cell differentiation,M1,1,0
1,-2,GO:0048536,spleen development,M1,1,0
1,-5,GO:0001909,leukocyte mediated cytotoxicity,M1,1,0
1,-3.5,GO:0021892,cerebral cortex GABAergic interneuron differentiation,M1,1,0
1,-4.5,WP550,Biogenic amine synthesis,M1,1,0
1,-8.9,WP2643,Nanoparticle-mediated activation of receptor signaling,M1,1,0
1,-2.6,M3045,CHEMNITZ RESPONSE TO PROSTAGLANDIN E2 UP,M1,1,0
1,-4.4,M8371,GSE22025 UNTREATED VS TGFB1 TREATED CD4 TCELL UP,M1,1,0
1,-2.6,M2853,STK33 DN,M1,1,0
1,-13,R-HSA-74752,Signaling by Insulin receptor,M1,1,0
1,-5.1,CORUM:6653,EP300-KAT2B-TBX5-WWTR1 complex,M1,1,0
1,-2.9,GO:1904949,ATPase complex,M1,1,0
1,-4,GO:1900125,regulation of hyaluronan biosynthetic process,M1,1,0
1,-5.1,M8538,GSE33374 CD8 ALPHAALPHA VS ALPHABETA CD161 HIGH TCELL UP,M1,1,0
1,-4.1,M2122,VERHAAK GLIOBLASTOMA MESENCHYMAL,M1,1,0
1,-3.7,M5189,GSE360 DC VS MAC M TUBERCULOSIS UP,M1,1,0
1,-14,WP481,Insulin signaling,M1,1,0
1,-3.4,GO:0030258,lipid modification,M1,1,0
1,-6.6,GO:0033143,regulation of intracellular steroid hormone receptor signaling pathway,M1,1,0
1,-5.2,GO:0140640,"catalytic activity, acting on a nucleic acid",M1,1,0
1,-2.1,M2641,GCNP SHH UP LATE.V1 UP,M1,1,0
1,-6.4,GO:0045088,regulation of innate immune response,M1,1,0
1,-4.3,GO:0060229,lipase activator activity,M1,1,0
1,-2.5,M3448,GSE1460 INTRATHYMIC T PROGENITOR VS NAIVE CD4 TCELL ADULT BLOOD DN,M1,1,0
1,-2.3,M2777,AMIT SERUM RESPONSE 240 MCF10A,M1,1,0
1,-4.8,GO:0031294,lymphocyte costimulation,M1,1,0
1,-4.9,GO:0046824,positive regulation of nucleocytoplasmic transport,M1,1,0
1,-3.1,M8859,GSE37301 LYMPHOID PRIMED MPP VS CD4 TCELL DN,M1,1,0
1,-2.8,GO:2000779,regulation of double-strand break repair,M1,1,0
1,-3.7,GO:0002819,regulation of adaptive immune response,M1,1,0
1,-6.5,GO:1902282,voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization,M1,1,0
1,-12,GO:0035050,embryonic heart tube development,M1,1,0
1,-2.2,GO:0001098,basal transcription machinery binding,M1,1,0
1,-2.4,M4124,GSE17721 0.5H VS 4H CPG BMDC UP,M1,1,0
1,-4.6,M15510,NUNODA RESPONSE TO DASATINIB IMATINIB UP,M1,1,0
1,-8.7,R-HSA-5637815,Signaling by Ligand-Responsive EGFR Variants in Cancer,M1,1,0
1,-26,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M1,1,0
1,-5.1,R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,M1,1,0
1,-2.4,M9549,GSE41978 WT VS ID2 KO KLRG1 LOW EFFECTOR CD8 TCELL DN,M1,1,0
1,-5,GO:1903800,positive regulation of miRNA maturation,M1,1,0
1,-4,GO:0032680,regulation of tumor necrosis factor production,M1,1,0
1,-5.6,R-HSA-112411,MAPK1 (ERK2) activation,M1,1,0
1,-5.1,R-HSA-5654699,SHC-mediated cascade:FGFR2,M1,1,0
1,-2.7,M5316,MODY HIPPOCAMPUS PRENATAL,M1,1,0
1,-6,GO:1990841,promoter-specific chromatin binding,M1,1,0
1,-3.3,GO:0005979,regulation of glycogen biosynthetic process,M1,1,0
1,-5.8,M5801,GSE9037 CTRL VS LPS 1H STIM BMDM DN,M1,1,0
1,-5.5,GO:0071260,cellular response to mechanical stimulus,M1,1,0
1,-4.2,M249,PID PI3KCI AKT PATHWAY,M1,1,0
1,-2.9,GO:0032587,ruffle membrane,M1,1,0
1,-4.7,GO:0031099,regeneration,M1,1,0
1,-6.6,hsa04657,IL-17 signaling pathway,M1,1,0
1,-3.3,GO:1902019,regulation of cilium-dependent cell motility,M1,1,0
1,-6.4,GO:0032885,regulation of polysaccharide biosynthetic process,M1,1,0
1,-11,hsa04936,Alcoholic liver disease,M1,1,0
1,-3.7,GO:0042176,regulation of protein catabolic process,M1,1,0
1,-4.3,GO:0014829,vascular associated smooth muscle contraction,M1,1,0
1,-4.9,GO:1900370,positive regulation of post-transcriptional gene silencing by RNA,M1,1,0
1,-3,M9787,GSE42724 B1 BCELL VS PLASMABLAST UP,M1,1,0
1,-3.4,GO:0008509,anion transmembrane transporter activity,M1,1,0
1,-3.8,R-HSA-2179392,EGFR Transactivation by Gastrin,M1,1,0
1,-2.4,M8548,GSE33425 CD8 ALPHAALPHA VS ALPHABETA CD161 HIGH TCELL DN,M1,1,0
1,-4.7,GO:1990779,glycoprotein Ib-IX-V complex,M1,1,0
1,-3,M3429,GSE1448 CTRL VS ANTI VBETA5 DP THYMOCYTE DN,M1,1,0
1,-2.6,GO:0010560,positive regulation of glycoprotein biosynthetic process,M1,1,0
1,-2.7,GO:0072028,nephron morphogenesis,M1,1,0
1,-17,GO:0001822,kidney development,M1,1,0
1,-2.4,GO:2000114,regulation of establishment of cell polarity,M1,1,0
1,-9.3,GO:0033157,regulation of intracellular protein transport,M1,1,0
1,-12,M258,PID BARD1 PATHWAY,M1,1,0
1,-7.3,GO:0005216,ion channel activity,M1,1,0
1,-2.9,GO:1902099,regulation of metaphase/anaphase transition of cell cycle,M1,1,0
1,-2.5,M3493,GSE14769 UNSTIM VS 40MIN LPS BMDM UP,M1,1,0
1,-2.6,M12804,LE EGR2 TARGETS UP,M1,1,0
1,-2.7,GO:0001046,core promoter sequence-specific DNA binding,M1,1,0
1,-11,GO:0072662,protein localization to peroxisome,M1,1,0
1,-4.7,M366,LANDIS ERBB2 BREAST TUMORS 324 UP,M1,1,0
1,-5,GO:0051117,ATPase binding,M1,1,0
1,-3.3,GO:0030595,leukocyte chemotaxis,M1,1,0
1,-2.3,GO:0031091,platelet alpha granule,M1,1,0
1,-3,GO:0048008,platelet-derived growth factor receptor signaling pathway,M1,1,0
1,-2.3,GO:0060021,roof of mouth development,M1,1,0
1,-3.7,M6630,GSE5589 LPS VS LPS AND IL10 STIM IL10 KO MACROPHAGE 45MIN DN,M1,1,0
1,-3.4,WP5121,Sphingolipid metabolism in senescence,M1,1,0
1,-19,hsa05203,Viral carcinogenesis,M1,1,0
1,-11,hsa04146,Peroxisome,M1,1,0
1,-3.7,M3756,GSE17721 CTRL VS CPG 1H BMDC UP,M1,1,0
1,-2.1,M377,GSE7219 WT VS NIK NFKB2 KO DC UP,M1,1,0
1,-3.3,R-HSA-9013694,Signaling by NOTCH4,M1,1,0
1,-6.1,GO:0021544,subpallium development,M1,1,0
1,-3.7,GO:0086065,cell communication involved in cardiac conduction,M1,1,0
1,-4,GO:0010257,NADH dehydrogenase complex assembly,M1,1,0
1,-3.3,M7577,ACEVEDO LIVER CANCER DN,M1,1,0
1,-2.4,M9085,GSE40274 CTRL VS IRF4 TRANSDUCED ACTIVATED CD4 TCELL UP,M1,1,0
1,-2.6,GO:0002700,regulation of production of molecular mediator of immune response,M1,1,0
1,-3.1,GO:0043596,nuclear replication fork,M1,1,0
1,-8.1,GO:0035264,multicellular organism growth,M1,1,0
1,-4.9,GO:0016410,N-acyltransferase activity,M1,1,0
1,-4.4,M18635,CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN,M1,1,0
1,-2.6,M2643,RAPA EARLY UP.V1 DN,M1,1,0
1,-5.7,CORUM:6946,BARD1u2013BRCA1u2013RAD51 complex,M1,1,0
1,-6.7,WP2290,RalA downstream regulated genes,M1,1,0
1,-8.5,GO:0000781,"chromosome, telomeric region",M1,1,0
1,-11,GO:0031297,replication fork processing,M1,1,0
1,-6.3,GO:1902692,regulation of neuroblast proliferation,M1,1,0
1,-2.4,M302,GSE10240 CTRL VS IL22 STIM PRIMARY BRONCHIAL EPITHELIAL CELLS UP,M1,1,0
1,-6,GO:0042490,mechanoreceptor differentiation,M1,1,0
1,-3.1,WP4584,Biomarkers for pyrimidine metabolism disorders,M1,1,0
1,-7.8,GO:0008324,cation transmembrane transporter activity,M1,1,0
1,-3.1,GO:0086066,atrial cardiac muscle cell to AV node cell communication,M1,1,0
1,-6.8,GO:0048471,perinuclear region of cytoplasm,M1,1,0
1,-4.5,GO:0090101,negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M1,1,0
1,-2.7,GO:0007416,synapse assembly,M1,1,0
1,-2.3,WP5036,Angiotensin II receptor type 1 pathway,M1,1,0
1,-2.4,M16740,GRADE COLON AND RECTAL CANCER UP,M1,1,0
1,-2.1,GO:0032653,regulation of interleukin-10 production,M1,1,0
1,-2.9,M5636,LEE LIVER CANCER MYC E2F1 DN,M1,1,0
1,-5.7,GO:0031056,regulation of histone modification,M1,1,0
1,-5.4,GO:0035270,endocrine system development,M1,1,0
1,-7.5,GO:0045137,development of primary sexual characteristics,M1,1,0
1,-2.3,M2915,GSE13522 WT VS IFNG KO SKING T CRUZI Y STRAIN INF DN,M1,1,0
1,-21,GO:0002009,morphogenesis of an epithelium,M1,1,0
1,-3.7,M5041,GSE30962 PRIMARY VS SECONDARY ACUTE LCMV INF CD8 TCELL UP,M1,1,0
1,-2.5,M5511,GSE3982 MAC VS TH1 DN,M1,1,0
1,-2.8,GO:0036003,positive regulation of transcription from RNA polymerase II promoter in response to stress,M1,1,0
1,-24,hsa04218,Cellular senescence,M1,1,0
1,-3,GO:0071565,nBAF complex,M1,1,0
1,-5.1,CORUM:2905,"Respiratory chain complex I (intermediate), mitochondrial",M1,1,0
1,-6.5,GO:0061515,myeloid cell development,M1,1,0
1,-8.8,GO:0032386,regulation of intracellular transport,M1,1,0
1,-16,R-HSA-1852241,Organelle biogenesis and maintenance,M1,1,0
1,-8.1,GO:0043073,germ cell nucleus,M1,1,0
1,-3.7,M8688,GSE34156 NOD2 LIGAND VS NOD2 AND TLR1 TLR2 LIGAND 6H TREATED MONOCYTE DN,M1,1,0
1,-4.1,R-HSA-416476,G alpha (q) signalling events,M1,1,0
1,-26,hsa05208,Chemical carcinogenesis - reactive oxygen species,M1,1,0
1,-3.7,M3459,GSE1460 DP THYMOCYTE VS NAIVE CD4 TCELL CORD BLOOD UP,M1,1,0
1,-19,GO:0048880,sensory system development,M1,1,0
1,-3.3,GO:0036038,MKS complex,M1,1,0
1,-2.8,R-HSA-9755511,KEAP1-NFE2L2 pathway,M1,1,0
1,-2.6,GO:0031968,organelle outer membrane,M1,1,0
1,-2.9,WP3413,NOTCH1 regulation of endothelial cell calcification,M1,1,0
1,-2.8,GO:0048771,tissue remodeling,M1,1,0
1,-2.9,GO:0099068,postsynapse assembly,M1,1,0
1,-2.5,M4005,GSE17721 LPS VS CPG 12H BMDC UP,M1,1,0
1,-7.9,GO:0060307,regulation of ventricular cardiac muscle cell membrane repolarization,M1,1,0
1,-3.3,GO:0060221,retinal rod cell differentiation,M1,1,0
1,-5,GO:0042491,inner ear auditory receptor cell differentiation,M1,1,0
1,-18,hsa05170,Human immunodeficiency virus 1 infection,M1,1,0
1,-12,M9516,PUJANA BRCA2 PCC NETWORK,M1,1,0
1,-2.1,GO:0006066,alcohol metabolic process,M1,1,0
1,-3,GO:1990403,embryonic brain development,M1,1,0
1,-3.7,M7655,GSE22196 HEALTHY VS OBESE MOUSE SKIN GAMMADELTA TCELL UP,M1,1,0
1,-12,GO:0002237,response to molecule of bacterial origin,M1,1,0
1,-23,WP4255,Non-small cell lung cancer,M1,1,0
1,-4.4,GO:1905562,regulation of vascular endothelial cell proliferation,M1,1,0
1,-3,M2024,NAKAMURA ADIPOGENESIS EARLY UP,M1,1,0
1,-11,hsa05120,Epithelial cell signaling in Helicobacter pylori infection,M1,1,0
1,-3,GO:0032655,regulation of interleukin-12 production,M1,1,0
1,-7.5,R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,M1,1,0
1,-11,WP4787,Osteoblast differentiation and related diseases,M1,1,0
1,-3.7,GO:0045058,T cell selection,M1,1,0
1,-2.2,M8599,CHIARADONNA NEOPLASTIC TRANSFORMATION KRAS CDC25 UP,M1,1,0
1,-2,GO:1903749,positive regulation of establishment of protein localization to mitochondrion,M1,1,0
1,-14,WP61,Notch signaling pathway,M1,1,0
1,-3,M8495,GSE29164 DAY3 VS DAY7 CD8 TCELL AND IL12 TREATED MELANOMA UP,M1,1,0
1,-4,GO:0016747,"acyltransferase activity, transferring groups other than amino-acyl groups",M1,1,0
1,-2.7,GO:0031669,cellular response to nutrient levels,M1,1,0
1,-3.5,R-HSA-1296071,Potassium Channels,M1,1,0
1,-2.2,GO:0061098,positive regulation of protein tyrosine kinase activity,M1,1,0
1,-2.5,M3467,GSE1460 DP THYMOCYTE VS THYMIC STROMAL CELL UP,M1,1,0
1,-10,GO:2000377,regulation of reactive oxygen species metabolic process,M1,1,0
1,-3.5,R-HSA-73762,RNA Polymerase I Transcription Initiation,M1,1,0
1,-2.6,GO:1900543,negative regulation of purine nucleotide metabolic process,M1,1,0
1,-3.6,GO:0048701,embryonic cranial skeleton morphogenesis,M1,1,0
1,-7.1,GO:0008286,insulin receptor signaling pathway,M1,1,0
1,-4.4,R-HSA-9673221,Defective F9 activation,M1,1,0
1,-15,GO:0042060,wound healing,M1,1,0
1,-5,R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,M1,1,0
1,-2.4,M3839,GSE17721 POLYIC VS PAM3CSK4 8H BMDC DN,M1,1,0
1,-4.4,M5204,GSE360 L DONOVANI VS B MALAYI LOW DOSE DC DN,M1,1,0
1,-2.1,M8241,GSE27241 WT CTRL VS DIGOXIN TREATED RORGT KO CD4 TCELL IN TH17 POLARIZING CONDITIONS DN,M1,1,0
1,-7.8,M274,PID LYMPH ANGIOGENESIS PATHWAY,M1,1,0
1,-7.6,GO:2001022,positive regulation of response to DNA damage stimulus,M1,1,0
1,-3,M4041,GSE17721 LPS VS GARDIQUIMOD 1H BMDC DN,M1,1,0
1,-4.1,GO:0009953,dorsal/ventral pattern formation,M1,1,0
1,-4.3,GO:0051412,response to corticosterone,M1,1,0
1,-3.5,M7140,ZHOU INFLAMMATORY RESPONSE FIMA UP,M1,1,0
1,-12,GO:0004672,protein kinase activity,M1,1,0
1,-6.3,GO:0032570,response to progesterone,M1,1,0
1,-2.3,R-HSA-442742,CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling,M1,1,0
1,-2.2,M2133,QI HYPOXIA,M1,1,0
1,-8.9,GO:2000177,regulation of neural precursor cell proliferation,M1,1,0
1,-11,WP712,Estrogen signaling pathway,M1,1,0
1,-11,GO:0048736,appendage development,M1,1,0
1,-2.9,M4288,SARRIO EPITHELIAL MESENCHYMAL TRANSITION UP,M1,1,0
1,-7.6,GO:0048469,cell maturation,M1,1,0
1,-5.5,M273,PID EPHA2 FWD PATHWAY,M1,1,0
1,-7.1,M13678,JEON SMAD6 TARGETS DN,M1,1,0
1,-4.4,M2135,LUI THYROID CANCER CLUSTER 1,M1,1,0
1,-28,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M1,1,0
1,-14,GO:0048145,regulation of fibroblast proliferation,M1,1,0
1,-2.9,R-HSA-5654704,SHC-mediated cascade:FGFR3,M1,1,0
1,-4.2,GO:0002088,lens development in camera-type eye,M1,1,0
1,-2.1,M23,PID WNT NONCANONICAL PATHWAY,M1,1,0
1,-6.9,M2310,DANG REGULATED BY MYC DN,M1,1,0
1,-4.7,GO:1901989,positive regulation of cell cycle phase transition,M1,1,0
1,-3.7,GO:0015629,actin cytoskeleton,M1,1,0
1,-4,GO:0032071,regulation of endodeoxyribonuclease activity,M1,1,0
1,-2.1,GO:0048566,embryonic digestive tract development,M1,1,0
1,-3.4,GO:0045475,locomotor rhythm,M1,1,0
1,-10,GO:0002573,myeloid leukocyte differentiation,M1,1,0
1,-6.2,GO:0046873,metal ion transmembrane transporter activity,M1,1,0
1,-4.8,WP5198,Inflammatory bowel disease signaling,M1,1,0
1,-3,M5174,GSE360 DC VS MAC L DONOVANI UP,M1,1,0
1,-8.6,R-HSA-69278,"Cell Cycle, Mitotic",M1,1,0
1,-3.3,GO:0140666,annealing activity,M1,1,0
1,-2.3,GO:0110151,positive regulation of biomineralization,M1,1,0
1,-4.4,CORUM:3061,"RNA polymerase II complex (CBP, PCAF, RPB1, BAF47, CYCC, CDK8), chromatin structure modifying",M1,1,0
1,-5.7,WP1992,Genes targeted by miRNAs in adipocytes,M1,1,0
1,-15,GO:0002521,leukocyte differentiation,M1,1,0
1,-2,R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,M1,1,0
1,-2.4,GO:1901888,regulation of cell junction assembly,M1,1,0
1,-2.6,GO:0002526,acute inflammatory response,M1,1,0
1,-2.5,M7585,TURASHVILI BREAST DUCTAL CARCINOMA VS DUCTAL NORMAL UP,M1,1,0
1,-2.3,GO:0042759,long-chain fatty acid biosynthetic process,M1,1,0
1,-16,R-HSA-5693537,Resolution of D-Loop Structures,M1,1,0
1,-4.7,GO:0046632,alpha-beta T cell differentiation,M1,1,0
1,-12,GO:0086002,cardiac muscle cell action potential involved in contraction,M1,1,0
1,-10,GO:0005911,cell-cell junction,M1,1,0
1,-2.4,M7896,GSE16385 ROSIGLITAZONE VS UNTREATED IFNG TNF STIM MACROPHAGE DN,M1,1,0
1,-5.5,GO:0001936,regulation of endothelial cell proliferation,M1,1,0
1,-3.1,R-HSA-5358749,CTNNB1 S37 mutants aren't phosphorylated,M1,1,0
1,-3.7,GO:2000048,negative regulation of cell-cell adhesion mediated by cadherin,M1,1,0
1,-4.7,R-HSA-3134973,LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,M1,1,0
1,-2.9,GO:0060263,regulation of respiratory burst,M1,1,0
1,-4.4,M9570,GSE42021 TREG PLN VS TREG PRECURSORS THYMUS DN,M1,1,0
1,-9.4,R-HSA-1963642,PI3K events in ERBB2 signaling,M1,1,0
1,-3,GO:0034393,positive regulation of smooth muscle cell apoptotic process,M1,1,0
1,-14,GO:0030900,forebrain development,M1,1,0
1,-4.6,GO:0009117,nucleotide metabolic process,M1,1,0
1,-12,WP2431,Spinal cord injury,M1,1,0
1,-2.1,M15664,ROSTY CERVICAL CANCER PROLIFERATION CLUSTER,M1,1,0
1,-4.8,GO:1905953,negative regulation of lipid localization,M1,1,0
1,-2.4,M3954,GSE17721 POLYIC VS CPG 24H BMDC DN,M1,1,0
1,-2.5,M7252,GSE18281 CORTICAL VS MEDULLARY THYMOCYTE UP,M1,1,0
1,-4.3,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,M1,1,0
1,-2.4,M303,GSE10240 CTRL VS IL17 AND IL22 STIM PRIMARY BRONCHIAL EPITHELIAL CELLS UP,M1,1,0
1,-5.8,GO:0051650,establishment of vesicle localization,M1,1,0
1,-6.8,GO:0005929,cilium,M1,1,0
1,-3.2,GO:0061043,regulation of vascular wound healing,M1,1,0
1,-2.1,R-HSA-174417,Telomere C-strand (Lagging Strand) Synthesis,M1,1,0
1,-4.7,CORUM:2922,"LAT-PLC-gamma-1-p85-GRB2-SOS signaling complex, C305 activated",M1,1,0
